

APPROVED DRUG PRODUCTS


With Therapeutic Equivalence Evaluations



The "Orange Book"

FDA data supplied by [DrugPatentWatch.com](https://www.drugpatentwatch.com)

**CUMULATIVE
SUPPLEMENT 10
OCTOBER 2013**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

33rd EDITION

Department of Health and Human Services

**Food and Drug Administration
Center for Drug Evaluation and Research
Office of Generic Drugs**

2013

Prepared By
Office of Generic Drugs
Center for Drug Evaluation and Research
Food and Drug Administration

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

33rd EDITION

Cumulative Supplement 10

October 2013

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION.....	iii
1.1 How to use the Cumulative Supplement	iii
1.2 Cumulative Supplement Content	iv
1.3 Applicant Name Changes	v
1.4 Levothyroxine Sodium.....	v
1.5 Availability of the Edition.....	vi
1.6 Report of Counts for the Prescription Drug Product List.....	vii
1.7 Cumulative Supplement Legend	viii
 DRUG PRODUCT LISTS	
Prescription Drug Product List	1-1
OTC Drug Product List	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List.....	3-1
Orphan Product Designations and Approvals List	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution	5-1
 PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

33rd EDITION

**CUMULATIVE SUPPLEMENT 10
October 2013**

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 30th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; over-the-counter (OTC) drug products that require approved applications as a condition of marketing; drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 32nd Edition List will then be added to the "Discontinued Drug Product List" appearing in the 33rd Edition. The current Edition Section 2., How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - o Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
 - o Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).
- New Drug Application (NDA) approvals appear in the CS month they were approved.

- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at drugproducts@fda.hhs.gov. Send Changes by FAX: 240-276-8974; mail to:

FDA/CDER Orange Book Staff
Office of Generic Drugs, HFD-610
7620 Standish Place
Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

FORMER APPLICANT NAME
(FORMER ABBREVIATED NAME)

NEW APPLICANT NAME
(NEW ABBREVIATED NAME)

BIONICHE PHARMA USA LLC
(BIONICHE PHARMA USA)

MYLAN INSTITUTIONAL LLC
(MYLAN LLC)

BOCA PHARMACAL INC
(BOCA PHARMA)

BOCA PHARMACAL LLC
(BOCA PHARMA LLC)

1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 76187) and Levo-T (Alara NDA 21342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets. Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 76187), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbott NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210), Levothyroxine Sodium (Mylan ANDA 076187), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 76187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levotheroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Potency	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	76187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	21301	001
SYNTHROID	ABBOTT	0.025MG	AB1	21402	001
LEVO-T	ALARA PHARM	0.025MG	AB1	21342	001
SYNTHROID	ABBOTT	0.025MG	AB2	21402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	76187	001
LEVO-T	ALARA PHARM	0.025MG	AB2	21342	001
UNITHROID	STEVENS J	0.025MG	AB2	21210	001
LEVOXYL	KUNG PHARMS	0.025MG	AB3	21301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	21342	001
UNITHROID	STEVENS J	0.025MG	AB3	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	76187	001
LEVOTHYROXINE SODIUM	MERCK KGAA	0.025MG	AB3	76752	001
LEVOTHROID	LLOYD	0.025MG	AB4	21116	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	76187	001

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <http://www.fda.gov/opacom/morechoices/fdaforms/default.html>.

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2012) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST
COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2012</u>	<u>MAR 2013</u>	<u>JUN 2013</u>	<u>SEPT 2013</u>	<u>DEC 2013</u>
DRUG PRODUCTS LISTED	15343	15445	15408	15472	
SINGLE SOURCE	2400 (15.9%)	2467 (16.0%)	2440 (15.8%)	2502 (16.2%)	
MULTISOURCE	12825 (83.6%)	12900 (83.5%)	12890 (83.7%)	12970 (83.8%)	
THERAPEUTICALLY EQUIVALENT	12683 (82.7%)	12758 (82.6%)	12750 (82.7%)	12827 (82.9%)	
NOT THERAPEUTICALLY EQUIVALENT	142 (0.9%)	142 (0.9%)	140 (0.9%)	143 (0.9%)	
EXCEPTIONS ¹	78 (0.5%)	78 (0.5%)	78 (0.5%)	78 (0.5%)	
NEW MOLECULAR ENTITIES APPROVED	17	9	5	8	
NUMBER OF APPLICANTS	835	844	841	832	

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.

CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

ABACAVIR SULFATE

TABLET;ORAL						
ABACAVIR SULFATE						
AB	HETERO LABS LTD III EQ 300MG BASE	A091560	001	Sep 13, 2013	Aug	NEWA

ACAMPROSATE CALCIUM

TABLET, DELAYED RELEASE;ORAL						
ACAMPROSATE CALCIUM						
AB	GLENMARK GENERICS 333MG	A202229	001	Jul 16, 2013	Jul	NEWA
CAMPRAL						
AB	+ FOREST LABS 333MG	N021431	001	Jul 29, 2004	Jul	CFTG

ACARBOSE

TABLET;ORAL						
ACARBOSE						
AB	VIRTUS PHARM 25MG	A091343	001	Oct 17, 2013	Sep	NEWA
AB	50MG	A091343	002	Oct 17, 2013	Sep	NEWA
AB	100MG	A091343	003	Oct 17, 2013	Sep	NEWA

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE;ORAL						
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE						
	@ WEST WARD 500MG;50MG;40MG	A040261	001	Oct 28, 1998	Jul	DISC
ESGIC-PLUS						
+	MIKART 500MG;50MG;40MG	A040085	001	Mar 28, 1996	Jul	CTEC
TABLET;ORAL						
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE						
	@ MIRROR PHARMS LLC 500MG;50MG;40MG	A040883	001	Dec 23, 2008	Feb	DISC
	@ WEST WARD 500MG;50MG;40MG	A040336	001	Aug 18, 1999	Aug	DISC

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE;ORAL						
ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE						
	@ MIKART 356.4MG;30MG;16MG	A040109	001	Aug 26, 1997	Feb	DISC
	@ WRASER PHARMS LLC 356.4MG;30MG;16MG	A040688	001	Apr 03, 2007	Jun	DISC
TABLET;ORAL						
ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE						
	@ BOCA PHARMA 712.8MG;60MG;32MG	A040701	001	Apr 03, 2007	Jun	DISC
	@ MIKART 712.8MG;60MG;32MG	A040316	001	Apr 28, 1999	Feb	DISC

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET;ORAL						
ACETAMINOPHEN AND CODEINE PHOSPHATE						
AA	AUROLIFE PHARMA LLC 300MG;15MG	A202800	001	Apr 15, 2013	Apr	NEWA
AA	300MG;30MG	A202800	002	Apr 15, 2013	Apr	NEWA
AA	300MG;60MG	A202800	003	Apr 15, 2013	Apr	NEWA
	@ MIKART 300MG;30MG	A089238	001	Feb 25, 1986	Jun	DISC
	@ 650MG;30MG	A089231	001	Mar 03, 1986	Feb	DISC
	@ 650MG;60MG	A089363	001	Sep 09, 1991	Feb	DISC

ACETAMINOPHEN; HYDROCODONE BITARTRATE

CAPSULE;ORAL						
HYDROCODONE BITARTRATE AND ACETAMINOPHEN						
	@ MIKART 500MG;5MG	A081067	001	Nov 30, 1989	Feb	DISC
	@ 500MG;5MG	A089008	001	Feb 21, 1986	Jun	DISC
SOLUTION;ORAL						
HYDROCODONE BITARTRATE AND ACETAMINOPHEN						
AA	PAI 325MG/15ML;7.5MG/15ML	A040838	001	May 10, 2013	Apr	NEWA
TABLET;ORAL						
HYDROCODONE BITARTRATE AND ACETAMINOPHEN						
AA	CARACO 325MG;5MG	A090118	001	Dec 23, 2008	May	CAHN
AA	325MG;7.5MG	A090118	002	Dec 23, 2008	May	CAHN
AA	325MG;10MG	A090118	003	Dec 23, 2008	May	CAHN
AA	500MG;5MG	A090265	001	Dec 23, 2008	May	CAHN
AA	500MG;7.5MG	A090265	002	Dec 23, 2008	May	CAHN
AA	500MG;10MG	A090265	003	Dec 23, 2008	May	CAHN
AA	650MG;7.5MG	A090380	001	Dec 23, 2008	Jun	CAHN
AA	650MG;10MG	A090380	002	Dec 23, 2008	Jun	CAHN
AA	660MG;10MG	A090380	003	Dec 23, 2008	Jun	CAHN

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA		750MG; 7.5MG	A090380	004	Dec 23, 2008	Jun CAHN
	+	MIKART	A040846	001	Jun 09, 2010	Jul CRLD
	@	500MG; 2.5MG	A089698	001	Aug 25, 1989	Feb DISC
	@	650MG; 5MG	A040849	001	Jun 09, 2010	Feb DISC
AA		TRIS PHARMA INC	A202214	001	Mar 27, 2013	Mar NEWA
AA		325MG; 7.5MG	A202214	002	Mar 27, 2013	Mar NEWA
AA		325MG; 10MG	A202214	003	Mar 27, 2013	Mar NEWA

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

OXYCODONE AND ACETAMINOPHEN

AA		ACTAVIS ELIZABETH	A201447	001	Apr 12, 2013	Apr NEWA
AA		325MG; 5MG	A201447	002	Apr 12, 2013	Apr NEWA
AA		325MG; 7.5MG	A201447	003	Apr 12, 2013	Apr NEWA
AA		325MG; 10MG	A201447	004	Apr 12, 2013	Apr NEWA
AA		AUROLIFE PHARMA LLC	A201972	001	Jul 15, 2013	Jul NEWA
AA		325MG; 5MG	A201972	002	Jul 15, 2013	Jul NEWA
AA		325MG; 7.5MG	A201972	003	Jul 15, 2013	Jul NEWA
AA		325MG; 10MG	A201972	004	Jul 15, 2013	Jul NEWA
	@	MIKART	A040679	001	May 16, 2006	Jul DISC
AA		VINTAGE PHARMS	A090733	001	Jul 11, 2013	Jul NEWA
AA		325MG; 7.5MG	A090734	001	Jul 11, 2013	Jul NEWA
AA		325MG; 10MG	A090734	002	Jul 11, 2013	Jul NEWA
		ROXICET 5/500				
	@	ROXANE	A089775	001	Jan 12, 1989	Aug DISC

ACETAZOLAMIDE

TABLET; ORAL

ACETAZOLAMIDE

	@	WATSON LABS	A088882	001	Oct 22, 1985	Jan DISC
--	---	-------------	---------	-----	--------------	----------

ACETAZOLAMIDE SODIUM

INJECTABLE; INJECTION

ACETAZOLAMIDE SODIUM

AP		SAGENT AGILA	EQ 500MG BASE/VIAL	A200880	001	May 09, 2012	Jan CAHN
----	--	--------------	--------------------	---------	-----	--------------	----------

ACITRETIN

CAPSULE; ORAL

ACITRETIN

AB	BARR LABS INC	10MG	A091455	001	Apr 04, 2013	Mar NEWA
AB		25MG	A091455	002	Apr 04, 2013	Mar NEWA
AB	TEVA PHARMS USA	17.5MG	A202897	001	Apr 04, 2013	Mar NEWA
AB		22.5MG	A202897	002	Apr 04, 2013	Mar NEWA
	SORIATANE					
AB	STIEFEL LABS INC	10MG	N019821	001	Oct 28, 1996	Mar CFTG
AB		17.5MG	N019821	003	Aug 06, 2009	Mar CFTG
AB		22.5MG	N019821	004	Aug 06, 2009	Mar CFTG
AB	+	25MG	N019821	002	Oct 28, 1996	Mar CFTG

ACRIVASTINE; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE; ORAL

SEMPREX-D

	+	ACTIENT PHARMS	8MG; 60MG	N019806	001	Mar 25, 1994	May CAHN
--	---	----------------	-----------	---------	-----	--------------	----------

ACYCLOVIR

CAPSULE; ORAL

ACYCLOVIR

	@	MYLAN	200MG	A074977	001	Apr 13, 1998	Aug DISC
	@	WATSON LABS	200MG	A075101	001	Apr 15, 1998	Sep DISC

CREAM; TOPICAL

ZOVIRAX

	+	VALEANT BERMUDA	5%	N021478	001	Dec 30, 2002	Jul CAHN
--	---	-----------------	----	---------	-----	--------------	----------

OINTMENT; TOPICAL

ACYCLOVIR

AB		MYLAN PHARMS INC	5%	A202459	001	Apr 03, 2013	Mar NEWA
		ZOVIRAX					
AB	+	VALEANT BERMUDA	5%	N018604	001	Mar 29, 1982	May CAHN
AB	+	VALEANT INTL	5%	N018604	001	Mar 29, 1982	Mar CFTG

ACYCLOVIRSUSPENSION; ORAL
ZOVIRAX

AB	+	DELCOR ASSET	200MG/5ML	N019909	001	Dec 22, 1989	Jun CAHN
----	---	--------------	-----------	---------	-----	--------------	----------

TABLET; BUCCAL
SITAVIG

@ BIOALLIANCE PHARMA

50MG

N203791 001 Apr 12, 2013 Sep DISC

+

50MG

N203791 001 Apr 12, 2013 Apr NEWA

TABLET; ORAL

ACYCLOVIR

>A>	AB		CADILA PHARMS LTD	400MG	A202168	001	Nov 15, 2013	Oct NEWA
-----	----	--	-------------------	-------	---------	-----	--------------	----------

>A>	AB			800MG	A202168	002	Nov 15, 2013	Oct NEWA
-----	----	--	--	-------	---------	-----	--------------	----------

>A>	AB		HETERO LABS LTD V	400MG	A203834	001	Oct 29, 2013	Oct NEWA
-----	----	--	-------------------	-------	---------	-----	--------------	----------

>A>	AB			800MG	A203834	002	Oct 29, 2013	Oct NEWA
-----	----	--	--	-------	---------	-----	--------------	----------

@ MYLAN

400MG

A074976 001 Apr 13, 1998 Aug DISC

@

800MG

A074976 002 Apr 13, 1998 Aug DISC

ACYCLOVIR SODIUM

INJECTABLE; INJECTION

ACYCLOVIR SODIUM

AP		AUROBINDO PHARMA LTD	EQ 50MG BASE/ML	A203701	001	Oct 11, 2013	Sep NEWA
----	--	----------------------	-----------------	---------	-----	--------------	----------

ACYCLOVIR; HYDROCORTISONE

CREAM; TOPICAL

XERESE

+ VALEANT BERMUDA

5%;1%

N022436 001 Jul 31, 2009 Apr CAHN

ADEFOVIR DIPIVOXIL

TABLET; ORAL

ADEFOVIR DIPIVOXIL

AB		SIGMAPHARM LABS LLC	10MG	A202051	001	Aug 29, 2013	Aug NEWA
----	--	---------------------	------	---------	-----	--------------	----------

HEPSERA

AB	+	GILEAD	10MG	N021449	001	Sep 20, 2002	Aug CFTG
----	---	--------	------	---------	-----	--------------	----------

ADENOSINE

INJECTABLE; INJECTION

ADENOSCAN

AP	+	ASTELLAS	3MG/ML	N020059	001	May 18, 1995	Aug CTEC
----	---	----------	--------	---------	-----	--------------	----------

ADENOSINE

@ TEVA PHARMS USA

3MG/ML

A076564 001 Jun 16, 2004 Apr CAHN

AP			3MG/ML	A077425	001	Aug 29, 2013	Aug NEWA
----	--	--	--------	---------	-----	--------------	----------

@

3MG/ML

A078676 001 Jul 31, 2008 Apr CAHN

AFATINIB DIMALEATE

TABLET; ORAL

GILOTRIF

BOEHRINGER INGELHEIM

EQ 20MG BASE

N201292 001 Jul 12, 2013 Jul NEWA

EQ 30MG BASE

N201292 002 Jul 12, 2013 Jul NEWA

+

EQ 40MG BASE

N201292 003 Jul 12, 2013 Jul NEWA

ALBENDAZOLE

TABLET; ORAL

ALBENZA

+ AMEDRA PHARMS

200MG

N020666 001 Jun 11, 1996 Feb CAHN

ALBUTEROL SULFATE

AEROSOL, METERED; INHALATION

PROAIR HFA

BX	+	TEVA BRANDED PHARM	EQ 0.09MG BASE/INH	N021457	001	Oct 29, 2004	Apr CAHN
----	---	--------------------	--------------------	---------	-----	--------------	----------

VENTOLIN HFA

BX	+	GLAXO GRP LTD	EQ 0.09MG BASE/INH	N020983	001	Apr 19, 2001	May CAHN
----	---	---------------	--------------------	---------	-----	--------------	----------

SOLUTION; INHALATION

ALBUTEROL SULFATE

@ APOTEX INC

EQ 0.021% BASE

A078623 001 Apr 05, 2010 Apr DISC

@

EQ 0.042% BASE

A078623 002 Apr 05, 2010 Apr DISC

@

EQ 0.083% BASE

A075717 001 Feb 02, 2007 Apr DISC

@

EQ 0.5% BASE

A076391 001 Apr 01, 2003 Apr DISC

AN	+	MYLAN SPECLT	EQ 0.083% BASE	A072652	001	Feb 21, 1992	Jan CAHN
----	---	--------------	----------------	---------	-----	--------------	----------

@ WOCKHARDT EU OPERATN

EQ 0.083% BASE

A075394 001 Nov 22, 1999 Mar DISC

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

SOLUTION; INHALATION

ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE

	@ APOTEX INC	EQ 0.083% BASE;0.017%	A077117	001	Dec 31, 2007	Apr DISC
AN	CIPLA LTD	EQ 0.083% BASE;0.017%	A077559	001	Dec 31, 2007	Aug CAHN

ALENDRONATE SODIUM

SOLUTION; ORAL

ALENDRONATE SODIUM

AA	ROXANE	EQ 70MG BASE/75ML	A090520	001	Feb 25, 2013	Feb NEWA
	FOSAMAX					
AA	+ MERCK	EQ 70MG BASE/75ML	N021575	001	Sep 17, 2003	Feb CFTG

TABLET; ORAL

ALENDRONATE SODIUM

AB	CIPLA LTD	EQ 5MG BASE	A076768	001	Aug 04, 2008	Jul CAHN
AB		EQ 10MG BASE	A076768	002	Aug 04, 2008	Jul CAHN
AB		EQ 35MG BASE	A076768	003	Aug 04, 2008	Jul CAHN
AB		EQ 40MG BASE	A076768	004	Aug 04, 2008	Jul CAHN
AB		EQ 70MG BASE	A076768	005	Aug 04, 2008	Jul CAHN
	@ MYLAN	EQ 35MG BASE	A078638	001	Aug 04, 2008	Aug DISC
	@	EQ 70MG BASE	A078638	002	Aug 04, 2008	Aug DISC

ALFUZOSIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

UROXATRAL

AB	+ COVIS PHARMA SARL	10MG	N021287	001	Jun 12, 2003	Apr CAHN
----	---------------------	------	---------	-----	--------------	----------

ALLOPURINOL

TABLET; ORAL

ALLOPURINOL

AB	ACCORD HLTHCARE	100MG	A203154	001	May 06, 2013	Apr NEWA
AB		300MG	A203154	002	May 06, 2013	Apr NEWA

ALOGLIPTIN BENZOATE

TABLET; ORAL

NESINA

TAKEDA PHARMS USA

EQ 6.25MG BASE

N022271 001 Jan 25, 2013 Jan NEWA

EQ 12.5MG BASE

N022271 002 Jan 25, 2013 Jan NEWA

+ EQ 25MG BASE

N022271 003 Jan 25, 2013 Jan NEWA

ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

KAZANO

+ TAKEDA PHARMS USA

EQ 12.5MG BASE;1GM

N203414 002 Jan 25, 2013 Jan NEWA

EQ 12.5MG BASE;500MG

N203414 001 Jan 25, 2013 Jan NEWA

ALOGLIPTIN BENZOATE; PIOGLITAZONE

TABLET; ORAL

OSEN

TAKEDA PHARMS USA

EQ 12.5MG BASE;15MG

N022426 004 Jan 25, 2013 Jan NEWA

EQ 12.5MG BASE;30MG

N022426 005 Jan 25, 2013 Jan NEWA

EQ 12.5MG BASE;45MG

N022426 006 Jan 25, 2013 Jan NEWA

EQ 25MG BASE;15MG

N022426 001 Jan 25, 2013 Jan NEWA

EQ 25MG BASE;30MG

N022426 002 Jan 25, 2013 Jan NEWA

+ EQ 25MG BASE;45MG

N022426 003 Jan 25, 2013 Jan NEWA

ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

OSEN

TAKEDA PHARMS USA

EQ 12.5MG BASE;EQ 15MG BASE

N022426 004 Jan 25, 2013 Feb CAIN

EQ 12.5MG BASE;EQ 30MG BASE

N022426 005 Jan 25, 2013 Feb CAIN

EQ 12.5MG BASE;EQ 45MG BASE

N022426 006 Jan 25, 2013 Feb CAIN

EQ 25MG BASE;EQ 15MG BASE

N022426 001 Jan 25, 2013 Feb CAIN

EQ 25MG BASE;EQ 30MG BASE

N022426 002 Jan 25, 2013 Feb CAIN

+ EQ 25MG BASE;EQ 45MG BASE

N022426 003 Jan 25, 2013 Feb CAIN

ALPRAZOLAM

TABLET, EXTENDED RELEASE; ORAL

ALPRAZOLAM

@ TEVA PHARMS USA

0.5MG

A077979 001 Feb 28, 2007 Jun DISC

@ 1MG

A077979 002 Feb 28, 2007 Jun DISC

ALPRAZOLAM

TABLET, EXTENDED RELEASE; ORAL
ALPRAZOLAM

@	2MG	A077979	003	Feb 28, 2007	Jun DISC
@	3MG	A077979	004	Feb 28, 2007	Jun DISC

ALPROSTADIL

INJECTABLE; INJECTION
ALPROSTADIL

AP	TEVA PHARMS USA	0.5MG/ML	A075196	001	Apr 30, 1999	Apr CAHN
----	-----------------	----------	---------	-----	--------------	----------

AMIKACIN SULFATE

INJECTABLE; INJECTION
AMIKACIN SULFATE

@	HOSPIRA	EQ 250MG BASE/ML	A063264	001	Nov 30, 1994	Mar DISC
@	TEVA PHARMS USA	EQ 50MG BASE/ML	A064045	001	Sep 28, 1993	Jun CAHN
AP		EQ 250MG BASE/ML	A064045	002	Sep 28, 1993	Jun CAHN

AMINOPHYLLINE

INJECTABLE; INJECTION
AMINOPHYLLINE

@	INTL MEDICATION	25MG/ML	A087209	001	Feb 01, 1982	Jun DISC
@	PHARMA SERVE NY	25MG/ML	A087392	001	Dec 15, 1983	Jun DISC

TABLET; ORAL

	AMINOPHYLLINE					
@	WEST WARD	100MG	A084540	001		Jul DISC
@		200MG	A085003	001		Jul DISC

AMIODARONE HYDROCHLORIDE

INJECTABLE; INJECTION
AMIODARONE HYDROCHLORIDE

@	AGILA SPECLTS	50MG/ML	A076394	001	Apr 25, 2003	Aug CAHN
@	APOTEX INC	50MG/ML	A076394	001	Apr 25, 2003	Apr DISC
AP	+ MYLAN INSTITUTIONAL	50MG/ML	A076217	001	Oct 15, 2002	Apr CAHN
@	TEVA PHARMS USA	50MG/ML	A076163	001	Sep 05, 2003	Apr CAHN

AMLEXANOX

PASTE; DENTAL
APHTHASOL

@	ULURU	5%	N020511	001	Dec 17, 1996	Jun DISC
---	-------	----	---------	-----	--------------	----------

AMLODIPINE BESYLATE

TABLET; ORAL

AMLODIPINE BESYLATE

AB	ACCORD HLTHCARE	EQ 2.5MG BASE	A202553	001	Apr 29, 2013	Apr NEWA
AB		EQ 5MG BASE	A202553	002	Apr 29, 2013	Apr NEWA
AB		EQ 10MG BASE	A202553	003	Apr 29, 2013	Apr NEWA
AB	CIPLA LTD	EQ 2.5MG BASE	A077073	001	Sep 26, 2007	Aug CAHN
AB		EQ 5MG BASE	A077073	002	Sep 26, 2007	Aug CAHN
AB		EQ 10MG BASE	A077073	003	Sep 26, 2007	Aug CAHN
>A> AB	UNICHEM LABS LTD	EQ 2.5MG BASE	A203245	001	Oct 21, 2013	Oct NEWA
>A> AB		EQ 5MG BASE	A203245	002	Oct 21, 2013	Oct NEWA
>A> AB		EQ 10MG BASE	A203245	003	Oct 21, 2013	Oct NEWA

AMLODIPINE BESYLATE; VALSARTAN

TABLET; ORAL

AMLODIPINE BESYLATE AND VALSARTAN

AB	PAR PHARM INC	EQ 5MG BASE; 160MG	A090011	001	Mar 28, 2013	Mar NEWA
AB		EQ 5MG BASE; 320MG	A090144	001	Mar 28, 2013	Mar NEWA
AB		EQ 10MG BASE; 160MG	A090011	002	Mar 28, 2013	Mar NEWA
AB		EQ 10MG BASE; 320MG	A090011	004	Mar 28, 2013	Mar NEWA
	EXFORGE					
AB	NOVARTIS	EQ 5MG BASE; 160MG	N021990	002	Jun 20, 2007	Mar CFTG
AB		EQ 5MG BASE; 320MG	N021990	004	Jun 20, 2007	Mar CFTG
AB	+	EQ 10MG BASE; 160MG	N021990	003	Jun 20, 2007	Mar CFTG
AB	+	EQ 10MG BASE; 320MG	N021990	005	Jun 20, 2007	Mar CFTG

AMMONIA N-13

INJECTABLE; INTRAVENOUS
AMMONIA N 13

AP	CARDINAL HEALTH 414	30MCI-300MCI/8ML (3.75-37.5MCI/ML)	A203700	001	Feb 25, 2013	Feb NEWA
----	---------------------	------------------------------------	---------	-----	--------------	----------

AMMONIA N-13

INJECTABLE; INTRAVENOUS
AMMONIA N 13

AP	+	FEINSTEIN	30MCI-300MCI/8ML (3.75-37.5MCI/ML)	N022119	001	Aug 23, 2007	Feb CFTG
AP		MCPRF	30MCI-300MCI/8ML (3.75-37.5MCI/ML)	A203321	001	Feb 25, 2013	Feb NEWA
AP		UCLA BIOMEDICAL	30MCI-300MCI/8ML (3.75-37.5MCI/ML)	A203812	001	Jun 27, 2013	Jun NEWA

AMOXICILLIN

FOR SUSPENSION; ORAL
AMOXICILLIN

@	RANBAXY	200MG/5ML	A065113	001	Nov 29, 2002	Feb DISC
@		400MG/5ML	A065113	002	Nov 29, 2002	Feb DISC

TABLET; ORAL

@	DAVA PHARMS INC	875MG	A065344	001	Jan 15, 2009	Jun DISC
---	-----------------	-------	---------	-----	--------------	----------

TABLET, CHEWABLE; ORAL

@	DAVA PHARMS INC	125MG	A064139	001	Jan 29, 1996	Mar DISC
@		250MG	A064139	002	Jan 29, 1996	Mar DISC
@	RANBAXY	200MG	A065060	001	Nov 29, 2000	Feb DISC
@		400MG	A065060	002	Nov 29, 2000	Feb DISC

AMOXIL

@	DR REDDYS LABS INC	200MG	N050761	001	Apr 15, 1999	Feb DISC
@		400MG	N050761	002	Apr 15, 1999	Feb DISC

TABLET, FOR SUSPENSION; ORAL

@	AUROBINDO PHARMA LTD	200MG	A065324	001	Jan 17, 2007	Jan DISC
@		400MG	A065324	002	Jan 17, 2007	Jan DISC

AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE

CAPSULE, CAPSULE, DELAYED REL PELLETS, TABLET; ORAL
LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN

AB		TEVA PHARMS USA	500MG, N/A, N/A; N/A, 500MG, N/A; N/A, N/A, 30MG	A200218	001	Aug 30, 2013	Aug NEWA
AB	+	PREVPAC					
AB	+	TAKEDA PHARMS USA	500MG, N/A, N/A; N/A, 500MG, N/A; N/A, N/A, 30MG	N050757	001	Dec 02, 1997	Aug CFTG

AMOXICILLIN; CLAVULANATE POTASSIUM

TABLET; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

	@	APOTEX INC	250MG;EQ	125MG	BASE	A065333	001	Feb 24, 2009	Apr	DISC
	@		500MG;EQ	125MG	BASE	A065333	002	Feb 24, 2009	Apr	DISC
	@		875MG;EQ	125MG	BASE	A065317	003	Oct 20, 2008	Apr	DISC
AB	@	RANBAXY LABS	500MG;EQ	125MG	BASE	A065109	001	Nov 04, 2002	Apr	DISC
		TEVA PHARMS USA	875MG;EQ	125MG	BASE	A065096	001	Oct 29, 2002	Apr	CRLD
		AUGMENTIN '250'								
AB	+	DR REDDYS LABS INC	250MG;EQ	125MG	BASE	N050564	001	Aug 06, 1984	Apr	CRLD
		AUGMENTIN '500'								
AB	+	DR REDDYS LABS INC	500MG;EQ	125MG	BASE	N050564	002	Aug 06, 1984	Apr	CRLD
		AUGMENTIN '875'								
AB	+	DR REDDYS LABS INC	875MG;EQ	125MG	BASE	N050720	001	Feb 13, 1996	Apr	CRLD

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

AMPHETAMINE ASP AMPHETAMINE SULF DEXTROAMPHET SACCHARATE & DEXTR SULF

AB		TEVA	1.25MG; 1.25MG; 1.25MG; 1.25MG	A077488	001	Apr 29, 2013	Apr NEWA
AB			2.5MG; 2.5MG; 2.5MG; 2.5MG	A077488	002	Apr 29, 2013	Apr NEWA
AB			3.75MG; 3.75MG; 3.75MG; 3.75MG	A077488	003	Apr 29, 2013	Apr NEWA
AB			5MG; 5MG; 5MG; 5MG	A077488	004	Apr 29, 2013	Apr NEWA
AB			6.25MG; 6.25MG; 6.25MG; 6.25MG	A077488	005	Apr 29, 2013	Apr NEWA
AB			7.5MG; 7.5MG; 7.5MG; 7.5MG	A077488	006	Apr 29, 2013	Apr NEWA
		DEXTROAMP SACCHARATE, AMP	ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE				
AB		BARR LABS INC	1.25MG; 1.25MG; 1.25MG; 1.25MG	A076536	001	Feb 12, 2013	Jan NEWA
AB			2.5MG; 2.5MG; 2.5MG; 2.5MG	A076536	002	Feb 12, 2013	Jan NEWA
AB			3.75MG; 3.75MG; 3.75MG; 3.75MG	A076536	003	Feb 12, 2013	Jan NEWA
AB			5MG; 5MG; 5MG; 5MG	A076536	004	Feb 12, 2013	Jan NEWA
AB			6.25MG; 6.25MG; 6.25MG; 6.25MG	A076536	005	Feb 12, 2013	Jan NEWA
AB			7.5MG; 7.5MG; 7.5MG; 7.5MG	A076536	006	Feb 12, 2013	Jan NEWA

TABLET; ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

TABLET; ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	MALLINCKRODT INC	1.25MG;1.25MG;1.25MG;1.25MG	A 040440	001	Oct 07, 2003	Sep CMFD
AB		1.875MG;1.875MG;1.875MG;1.875MG	A 040440	002	Oct 07, 2003	Sep CMFD
AB		2.5MG;2.5MG;2.5MG;2.5MG	A 040440	003	Oct 07, 2003	Sep CMFD
AB		3.125MG;3.125MG;3.125MG;3.125MG	A 040440	004	Oct 07, 2003	Sep CMFD
AB		3.75MG;3.75MG;3.75MG;3.75MG	A 040440	005	Oct 07, 2003	Sep CMFD
AB		5MG;5MG;5MG;5MG	A 040440	006	Oct 07, 2003	Sep CMFD
AB		7.5MG;7.5MG;7.5MG;7.5MG	A 040440	007	Oct 07, 2003	Sep CMFD
>D>	@ MUTUAL PHARM	1.25MG;1.25MG;1.25MG;1.25MG	A 040480	001	Sep 09, 2003	Oct CMFD
>A> AB		1.25MG;1.25MG;1.25MG;1.25MG	A 040480	001	Sep 09, 2003	Oct CMFD
>D>	@	1.875MG;1.875MG;1.875MG;1.875MG	A 040480	002	Sep 09, 2003	Oct CMFD
>A> AB		1.875MG;1.875MG;1.875MG;1.875MG	A 040480	002	Sep 09, 2003	Oct CMFD
>D>	@	2.5MG;2.5MG;2.5MG;2.5MG	A 040480	003	Sep 09, 2003	Oct CMFD
>A> AB		2.5MG;2.5MG;2.5MG;2.5MG	A 040480	003	Sep 09, 2003	Oct CMFD
>D>	@	3.125MG;3.125MG;3.125MG;3.125MG	A 040480	004	Sep 09, 2003	Oct CMFD
>A> AB		3.125MG;3.125MG;3.125MG;3.125MG	A 040480	004	Sep 09, 2003	Oct CMFD
>D>	@	3.75MG;3.75MG;3.75MG;3.75MG	A 040480	005	Sep 09, 2003	Oct CMFD
>A> AB		3.75MG;3.75MG;3.75MG;3.75MG	A 040480	005	Sep 09, 2003	Oct CMFD
>D>	@	5MG;5MG;5MG;5MG	A 040480	006	Sep 09, 2003	Oct CMFD
>A> AB		5MG;5MG;5MG;5MG	A 040480	006	Sep 09, 2003	Oct CMFD
>D>	@	7.5MG;7.5MG;7.5MG;7.5MG	A 040480	007	Sep 09, 2003	Oct CMFD
>A> AB		7.5MG;7.5MG;7.5MG;7.5MG	A 040480	007	Sep 09, 2003	Oct CMFD
	@ TEVA PHARMS	1.25MG;1.25MG;1.25MG;1.25MG	A 040472	001	Sep 30, 2003	Jan DISC
	@	2.5MG;2.5MG;2.5MG;2.5MG	A 040472	002	Sep 30, 2003	Jan DISC
	@	5MG;5MG;5MG;5MG	A 040472	003	Sep 30, 2003	Jan DISC
	@	7.5MG;7.5MG;7.5MG;7.5MG	A 040472	004	Sep 30, 2003	Jan DISC

AMPICILLIN SODIUM

INJECTABLE; INJECTION

AMPICILLIN SODIUM

AP	ACS DOBFAR SPA	EQ 1GM BASE/VIAL	A 090884	002	Apr 03, 2013	Mar NEWA
AP		EQ 2GM BASE/VIAL	A 090884	003	Apr 03, 2013	Mar NEWA
AP		EQ 10GM BASE/VIAL	A 090889	001	Apr 03, 2013	Mar NEWA
AP		EQ 500MG BASE/VIAL	A 090884	001	Apr 03, 2013	Mar NEWA
	@ ANTIBIOTICE	EQ 1GM BASE/VIAL	A 090354	003	Dec 28, 2009	Jun DISC
	@	EQ 2GM BASE/VIAL	A 090354	004	Dec 28, 2009	Jun DISC
	@	EQ 250MG BASE/VIAL	A 090354	001	Dec 28, 2009	Jun DISC
	@	EQ 500MG BASE/VIAL	A 090354	002	Dec 28, 2009	Jun DISC

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE; INJECTION

UNASYN

AP	+ PFIZER	EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A 062901	002	Feb 27, 1992	Jul NEWA
AP	+	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A 062901	001	Nov 23, 1988	Jul CRLD

ANAGRELIDE HYDROCHLORIDE

CAPSULE; ORAL

ANAGRELIDE HYDROCHLORIDE

@	WATSON LABS	EQ 0.5MG BASE	A 076417	001	Apr 18, 2005	Sep DISC
@		EQ 1MG BASE	A 076417	002	Apr 18, 2005	Sep DISC

ANASTROZOLE

TABLET; ORAL

ANASTROZOLE

AB	ACCORD HLTHCARE	1MG	A 090568	001	Jun 28, 2010	Apr CAHN
>D> AB	IMPAX LABS INC	1MG	A 091242	001	May 31, 2012	Oct DISC
>A>	@	1MG	A 091242	001	May 31, 2012	Oct DISC
	@ KUDCO IRELAND	1MG	A 091331	001	Jan 05, 2011	Feb DISC

ARIPIPIRAZOLE

FOR SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR

ABILIFY MAINTENA KIT

	OTSUKA PHARM CO LTD	300MG/VIAL	N 202971	001	Feb 28, 2013	Feb NEWA
+		400MG/VIAL	N 202971	002	Feb 28, 2013	Feb NEWA

ARTICAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

ARTICAINE HYDROCHLORIDE WITH EPINEPHRINE

>D>	PIERREL	4%;EQ 0.009MG BASE/1.8ML (EQ 0.005	N 022466	001	Feb 26, 2010	Oct CTNA
-----	---------	------------------------------------	----------	-----	--------------	----------

ARTICAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

ARTICAINE HYDROCHLORIDE WITH EPINEPHRINE

MG BASE/ML)

>D>	+	4%;EQ 0.018MG BASE/1.8ML (EQ 0.01MG BASE/ML)	N022466	002	Feb 26, 2010	Oct CTNA
		ORABLOC				
>A>		PIERREL 4%;EQ 0.009MG BASE/1.8ML (EQ 0.005MG BASE/ML)	N022466	001	Feb 26, 2010	Oct CTNA
>A>	+	4%;EQ 0.018MG BASE/1.8ML (EQ 0.01MG BASE/ML)	N022466	002	Feb 26, 2010	Oct CTNA

ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE

FOR SOLUTION; ORAL

MOVIPREP

@ NOVEL LABS INC	4.7GM;100GM;1.015GM;5.9GM;2.691GM; 7.5GM	A090145	001	Jan 25, 2012	Aug DISC
+ SALIX PHARMS	4.7GM;100GM;1.015GM;5.9GM;2.691GM; 7.5GM	N021881	001	Aug 02, 2006	Aug CTEC

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET; ORAL

ORPHENGESIC

@ PRINSTON INC	385MG;30MG;25MG	A075141	001	May 29, 1998	Apr CAHN
ORPHENGESIC FORTE					
@ PRINSTON INC	770MG;60MG;50MG	A075141	002	May 29, 1998	Apr CAHN

ATENOLOL

TABLET; ORAL

ATENOLOL

@ MYLAN	25MG	A074126	003	Aug 26, 1998	Aug DISC
@	50MG	A074126	001	Mar 23, 1994	Aug DISC
@	100MG	A074126	002	Mar 23, 1994	Aug DISC
@ WATSON LABS	50MG	A073352	001	Dec 27, 1991	Mar DISC
@	100MG	A073353	001	Dec 27, 1991	Mar DISC

ATORVASTATIN CALCIUM

TABLET; ORAL

ATORVASTATIN CALCIUM

AB KUDCO IRELAND	EQ 10MG BASE	A091624	001	Apr 05, 2013	Mar NEWA
AB	EQ 20MG BASE	A091624	002	Apr 05, 2013	Mar NEWA
AB	EQ 40MG BASE	A091624	003	Apr 05, 2013	Mar NEWA
AB	EQ 80MG BASE	A091624	004	Apr 05, 2013	Mar NEWA

ATORVASTATIN CALCIUM; EZETIMIBE

TABLET; ORAL

LIPTRUZET

MERCK SHARP DOHME	EQ 10MG BASE;10MG	N200153	001	May 03, 2013	May NEWA
	EQ 20MG BASE;10MG	N200153	002	May 03, 2013	May NEWA
	EQ 40MG BASE;10MG	N200153	003	May 03, 2013	May NEWA
+	EQ 80MG BASE;10MG	N200153	004	May 03, 2013	May NEWA

AZACITIDINE

INJECTABLE; IV-SC

AZACITIDINE

AP DR REDDYS LABS LTD	100MG/VIAL	A201537	001	Sep 16, 2013	Aug NEWA
VIDAZA					
AP + CELGENE	100MG/VIAL	N050794	001	May 19, 2004	Aug CFTG

AZELAIC ACID

GEL; TOPICAL

FINACEA

+ BAYER HLTHCARE	15%	N021470	001	Dec 24, 2002	Jun CAHN
------------------	-----	---------	-----	--------------	----------

AZILSARTAN KAMEDOXOMIL

TABLET; ORAL

EDARBI

ARBOR PHARMS LLC	EQ 40MG MEDOXOMIL	N200796	001	Feb 25, 2011	Sep CAHN
+	EQ 80MG MEDOXOMIL	N200796	002	Feb 25, 2011	Sep CAHN

AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE

TABLET; ORAL
EDARBYCLOR

ARBOR PHARMS LLC	EQ 40MG MEDOXOMIL;12.5MG	N202331	001	Dec 20, 2011	Sep CAHN
+	EQ 40MG MEDOXOMIL;25MG	N202331	002	Dec 20, 2011	Sep CAHN

AZITHROMYCIN

FOR SUSPENSION, EXTENDED RELEASE; ORAL
ZMAX

+	PF PRISM CV	EQ 2GM BASE/BOT	N050797	001	Jun 10, 2005	Aug CAHN
INJECTABLE; INJECTION						
AZITHROMYCIN						
AP	SUN PHARM INDS LTD	EQ 500MG BASE/VIAL	A090923	001	Apr 02, 2013	Mar NEWA

BACITRACIN

OINTMENT; OPHTHALMIC
BACITRACIN

+	PERRIGO CO TENNESSEE	500 UNITS/GM	A061212	001		Jun CAHN
POWDER; FOR RX COMPOUNDING						
BACI-RX						
@	X GEN PHARMS	5,000,000 UNITS/BOT	A061580	001		Mar DISC

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC
NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC

AT	PERRIGO CO TENNESSEE	400 UNITS/GM; EQ 3.5MG BASE; 10,000 UNITS/GM	A060764	002		Jun CAHN
----	----------------------	--	---------	-----	--	----------

BACITRACIN ZINC; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC
BACITRACIN ZINC AND POLYMYXIN B SULFATE

AT	PERRIGO CO TENNESSEE	500 UNITS/GM; 10,000 UNITS/GM	A065022	001	Feb 27, 2002	Jun CAHN
----	----------------------	-------------------------------	---------	-----	--------------	----------

BACITRACIN; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC
BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE

+	PERRIGO CO TENNESSEE	400 UNITS/GM; 1%; EQ 3.5MG BASE; 10,000 UNITS/GM	A062166	002		Jun CAHN
---	----------------------	--	---------	-----	--	----------

BACLOFEN

INJECTABLE; INTRATHECAL
GABLOFEN

AP	MALLINCKRODT INC	0.05MG/ML	N022462	001	Nov 19, 2010	May CAHN
AP		0.5MG/ML	N022462	002	Nov 19, 2010	May CAHN
		1MG/ML	N022462	004	Jun 22, 2012	May CAHN
AP		2MG/ML	N022462	003	Nov 19, 2010	May CAHN

>A> BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED

>A> TABLET; ORAL
>A> DUAVEE

>A>	+	WYETH PHARMS PFIZER	EQ 20MG BASE; 0.45MG	N022247	001	Oct 03, 2013	Oct NEWA
-----	---	---------------------	----------------------	---------	-----	--------------	----------

BENDAMUSTINE HYDROCHLORIDE

SOLUTION; IV (INFUSION)
TREANDA

>D>	+	CEPHALON	45MG/0.5ML (90MG/ML)	N022249	003	Oct 13, 2013	Oct CMS2
>A>	+		45MG/0.5ML (90MG/ML)	N022249	003	Sep 13, 2013	Oct CMS2
	+		45MG/0.5ML (90MG/ML)	N022249	003	Oct 13, 2013	Sep NEWA
>D>	+		180MG/2ML (90MG/ML)	N022249	004	Oct 13, 2013	Oct CMS2
>A>	+		180MG/2ML (90MG/ML)	N022249	004	Sep 13, 2013	Oct CMS2
	+		180MG/2ML (90MG/ML)	N022249	004	Oct 13, 2013	Sep NEWA

BENZONATATE

CAPSULE; ORAL
BENZONATATE

AA	CARACO	100MG	A040587	001	Mar 19, 2008	May CAHN
AA		200MG	A040587	002	Mar 19, 2008	May CAHN

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL; TOPICAL
ACANYA

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

	GEL;TOPICAL								
	ACANYA								
	+	DOW PHARM	2.5%;1.2%		N050819	001	Oct 23, 2008	Apr	CAHN
		BENZACLIN							
AB		VALEANT BERMUDA	5%;EQ 1% BASE		N050756	001	Dec 21, 2000	Apr	CAHN
BT	+		5%;EQ 1% BASE		N050756	002	Apr 20, 2007	Apr	CAHN

BENZOYL PEROXIDE; ERYTHROMYCIN

	GEL;TOPICAL								
	BENZAMYCIN PAK								
	+	VALEANT LUXEMBOURG	5%;3%		N050769	001	Nov 27, 2000	Jun	CAHN

BENZPHETAMINE HYDROCHLORIDE

	TABLET;ORAL								
	BENZPHETAMINE HYDROCHLORIDE								
	@ COREPHARMA	50MG			A040714	001	Oct 29, 2007	Feb	DISC

BENZTROPINE MESYLATE

	INJECTABLE;INJECTION								
	BENZTROPINE MESYLATE								
AP		NAVINTA LLC	1MG/ML		A091525	001	Feb 05, 2013	Jan	NEWA
	TABLET;ORAL								
	BENZTROPINE MESYLATE								
	@ PROSAM LABS	0.5MG			A040699	001	Feb 14, 2008	Mar	DISC
	@	1MG			A040705	001	Feb 14, 2008	Mar	DISC
	@	2MG			A040706	001	Feb 14, 2008	Mar	DISC

BETAMETHASONE

	SYRUP;ORAL								
	CELESTONE								
	@ MERCK SHARP DOHME	0.6MG/5ML			N014215	002		Apr	CAHN

BETAMETHASONE ACETATE; BETAMETHASONE SODIUM PHOSPHATE

	INJECTABLE;INJECTION								
	CELESTONE SOLUSPAN								
AB	+	MERCK SHARP DOHME	3MG/ML;EQ 3MG BASE/ML		N014602	001		Apr	CAHN

BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE HYDRATE

	SUSPENSION;TOPICAL								
	TACLONEX								
	+	LEO PHARMA AS	0.064%;0.005%		N022185	001	May 09, 2008	Sep	CAHN

BETAMETHASONE VALERATE

	AEROSOL, FOAM;TOPICAL								
	BETAMETHASONE VALERATE								
AB		PERRIGO	0.12%		A078337	001	Nov 26, 2012	Apr	CPOT
		LUXIQ							
AB	+	DELCOR ASSET	0.12%		N020934	001	Feb 28, 1999	Sep	CAHN
AB	+	STIEFEL	0.12%		N020934	001	Feb 28, 1999	Apr	CPOT

BETAXOLOL HYDROCHLORIDE

	SOLUTION/DROPS;OPHTHALMIC								
	BETAXOLOL HYDROCHLORIDE								
	@ APOTEX INC	EQ 0.5% BASE			A075446	001	Sep 28, 2000	Apr	DISC

BETHANECHOL CHLORIDE

	TABLET;ORAL								
	BETHANECHOL CHLORIDE								
AA		CARACO	5MG		A040897	001	Apr 22, 2009	Jun	CAHN
AA			10MG		A040897	002	Apr 22, 2009	Jun	CAHN
AA			25MG		A040897	003	Apr 22, 2009	Jun	CAHN
AA			50MG		A040897	004	Apr 22, 2009	Jun	CAHN
	@ LANNETT HOLDINGS INC	5MG			A040703	001	Mar 27, 2008	Jun	DISC
	@	50MG			A040677	001	Mar 27, 2008	Jun	DISC

BEXAROTENE

	CAPSULE;ORAL								
	TARGETIN								
	+	VALEANT LUXEMBOURG	75MG		N021055	001	Dec 29, 1999	Jun	CAHN

BEXAROTENEGEL;TOPICAL
TARGRETIN+ VALEANT LUXEMBOURG 1%
+ VALEANT PHARMS INC 1%N021056 001 Jun 28, 2000 Jun CAHN
N021056 001 Jun 28, 2000 Feb CAHNBICALUTAMIDETABLET;ORAL
BICALUTAMIDEAB ACCORD HLTHCARE 50MG
@ SYNTHON PHARMS 50MGA078917 001 Jul 06, 2009 Apr CAHN
A077973 001 Jul 06, 2009 Sep DISCBLEOMYCIN SULFATEINJECTABLE;INJECTION
BLEOMYCIN SULFATE

@ PHARMACHEMIE BV EQ 15 UNITS BASE/VIAL

A065201 001 Dec 13, 2007 Feb DISC

BRIMONIDINE TARTRATEGEL;TOPICAL
MIRVASO>D> + GALDERMA LABS LP 0.33%
>A> + EQ 0.33% BASE
+ 0.33%
+ GALDERMA R AND D 0.33%N204708 001 Aug 23, 2013 Oct CPOT
N204708 001 Aug 23, 2013 Oct CPOT
N204708 001 Aug 23, 2013 Sep CAHN
N204708 001 Aug 23, 2013 Aug NEWABRIMONIDINE TARTRATE; BRINZOLAMIDESUSPENSION/DROPS;OPHTHALMIC
SIMBRINZA

+ ALCON RES LTD 0.2%;1%

N204251 001 Apr 19, 2013 Apr NEWA

BRIMONIDINE TARTRATE; TIMOLOL MALEATESOLUTION/DROPS;OPHTHALMIC
COMBIGAN>D> + ALLERGAN 0.2%;0.5%
>A> + 0.2%;EQ 0.5% BASEN021398 001 Oct 30, 2007 Oct CPOT
N021398 001 Oct 30, 2007 Oct CPOTBROMFENAC SODIUMSOLUTION/DROPS;OPHTHALMIC
BROMDAY

+ ISTA PHARMS INC EQ 0.09% ACID

N021664 002 Oct 16, 2010 Apr CPOT

BROMFENAC SODIUM
AT COASTAL PHARMS EQ 0.09% ACID
AT LUITPOLD EQ 0.09% ACID
AT 0.09%A201211 001 May 11, 2011 Apr CPOT
A202030 001 Jan 09, 2013 Apr CPOT
A202030 001 Jan 09, 2013 Feb CAHN

PROLENSA

+ BAUSCH AND LOMB EQ 0.07% ACID
XIBROM
@ ISTA PHARMS INC EQ 0.09% ACIDN203168 001 Apr 05, 2013 Apr NEWA
N021664 001 Mar 24, 2005 Apr CPOTBUDESONIDESUSPENSION;INHALATION
BUDESONIDE@ APOTEX INC 0.25MG/2ML
@ 0.5MG/2ML
AN SANDOZ 0.25MG/2ML
AN 0.5MG/2ML
AN 1MG/2MLA078202 001 Mar 30, 2009 Apr DISC
A078202 002 Mar 30, 2009 Apr DISC
A201966 003 Sep 27, 2013 Sep NEWA
A201966 002 Sep 27, 2013 Sep NEWA
A201966 001 Sep 27, 2013 Sep NEWAPULMICORT RESPULES
AN + ASTRAZENECA 1MG/2ML

N020929 003 Aug 08, 2000 Sep CTEC

TABLET, EXTENDED RELEASE;ORAL
UCERIS

+ SANTARUS 9MG

N203634 001 Jan 14, 2013 Jan NEWA

BUPIVACAINE HYDROCHLORIDE

INJECTABLE;INJECTION

BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE

>A> AP AUROBINDO PHARMA LTD 0.25%
>A> AP 0.5%
>A> AP 0.75%
@ INTL MEDICATED 0.25%
@ 0.5%A203895 001 Nov 05, 2013 Oct NEWA
A203895 002 Nov 05, 2013 Oct NEWA
A203895 003 Nov 05, 2013 Oct NEWA
A076012 001 Jan 09, 2002 Jun DISC
A076012 002 Jan 09, 2002 Jun DISC

BUPIVACAINE HYDROCHLORIDE

INJECTABLE;INJECTION

BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE

@ 0.75%

A076012 003 Jan 09, 2002 Jun DISC

BUPRENORPHINE

FILM, EXTENDED RELEASE;TRANSDERMAL

BUTRANS

PURDUE PHARMA LP 15MCG/HR

N021306 004 Jul 25, 2013 Aug NEWA

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

FILM;SUBLINGUAL

SUBOXONE

RECKITT BENCKISER EQ 8MG BASE;EQ 2MG BASE

N022410 002 Aug 30, 2010 Jul CRLD

+ EQ 12MG BASE;EQ 3MG BASE

N022410 004 Aug 10, 2012 Jul CRLD

TABLET;SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

AB ACTAVIS ELIZABETH EQ 2MG BASE;EQ 0.5MG BASE

A091422 001 Feb 22, 2013 Jul CTNA

AB + EQ 8MG BASE;EQ 2MG BASE

A091422 002 Feb 22, 2013 Jul CTNA

AB AMNEAL PHARMS EQ 8MG BASE;EQ 2MG BASE

A203136 002 Feb 22, 2013 Aug CTNA

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

AB AMNEAL PHARMS EQ 2MG BASE;EQ 0.5MG BASE

A203136 001 Feb 22, 2013 Aug CTNA

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE DIHYDRATE

AB ACTAVIS ELIZABETH EQ 2MG BASE;EQ 0.5MG BASE

A091422 001 Feb 22, 2013 Feb NEWA

AB + EQ 8MG BASE;EQ 2MG BASE

A091422 002 Feb 22, 2013 Apr CRLD

AB EQ 8MG BASE;EQ 2MG BASE

A091422 002 Feb 22, 2013 Feb NEWA

AB AMNEAL PHARMS EQ 2MG BASE;EQ 0.5MG BASE

A203136 001 Feb 22, 2013 Feb NEWA

AB EQ 8MG BASE;EQ 2MG BASE

A203136 002 Feb 22, 2013 Feb NEWA

SUBOXONE

AB @ RECKITT BENCKISER EQ 2MG BASE;EQ 0.5MG BASE

N020733 001 Oct 08, 2002 Mar DISC

EQ 2MG BASE;EQ 0.5MG BASE

N020733 001 Oct 08, 2002 Feb CFTG

AB @ EQ 8MG BASE;EQ 2MG BASE

N020733 002 Oct 08, 2002 Mar DISC

AB + EQ 8MG BASE;EQ 2MG BASE

N020733 002 Oct 08, 2002 Feb CFTG

ZUBSOLV

OREXO AB EQ 1.4MG BASE;EQ 0.36MG BASE

N204242 001 Jul 03, 2013 Jul NEWA

+ EQ 5.7MG BASE;EQ 1.4MG BASE

N204242 002 Jul 03, 2013 Jul NEWA

BUPROPION HYDROBROMIDE

TABLET, EXTENDED RELEASE;ORAL

APLENZIN

VALEANT BERMUDA 174MG

N022108 001 Apr 23, 2008 Apr CAHN

+ 348MG

N022108 002 Apr 23, 2008 Apr CAHN

522MG

N022108 003 Apr 23, 2008 Apr CAHN

BUPROPION HYDROCHLORIDE

TABLET;ORAL

BUPROPION HYDROCHLORIDE

@ TEVA 75MG

A075310 001 Nov 29, 1999 Feb CDFR

@ 100MG

A075310 002 Nov 29, 1999 Feb DISC

TABLET, EXTENDED RELEASE;ORAL

BUPROPION HYDROCHLORIDE

@ IMPAX LABS 300MG

A077415 002 Dec 15, 2006 Apr DISC

AB1 JUBILANT LIFE 100MG

A202774 001 Oct 11, 2013 Sep NEWA

AB1 150MG

A202774 002 Oct 11, 2013 Sep NEWA

AB2 150MG

A202775 001 Oct 11, 2013 Sep NEWA

AB1 200MG

A202774 003 Oct 11, 2013 Sep NEWA

BX WATSON LABS 300MG

A077715 002 Jun 13, 2007 Sep CTEC

AB1 WATSON LABS INC 100MG

A077455 001 Jul 19, 2010 Apr CAHN

AB3 150MG

A077285 001 Nov 26, 2008 Apr CAHN

AB1 150MG

A077455 002 Mar 12, 2008 Apr CAHN

AB1 200MG

A077455 003 Jul 19, 2010 Apr CAHN

AB3 300MG

A077285 002 Aug 15, 2008 Apr CAHN

BUTOCONAZOLE NITRATE

CREAM;VAGINAL

BUTOCONAZOLE NITRATE

+ PERRIGO ISRAEL 2%

A200923 001 May 18, 2012 Mar CRLD

GYNAZOLE-1

@ KV PHARM 2%

N019881 001 Feb 07, 1997 Mar DISC

BUTORPHANOL TARTRATE

INJECTABLE; INJECTION

BUTORPHANOL TARTRATE

@ APOTEX INC	2MG/ML	A075697	001	Oct 23, 2001	Apr	DISC
BUTORPHANOL TARTRATE PRESERVATIVE FREE						
@ APOTEX INC	1MG/ML	A075695	001	Oct 23, 2001	Apr	DISC
@	2MG/ML	A075695	002	Oct 23, 2001	Apr	DISC
STADOL						
@ APOTHECON	2MG/ML	N017857	004		Jun	DISC
STADOL PRESERVATIVE FREE						
@ APOTHECON	1MG/ML	N017857	001		Jun	DISC
@	2MG/ML	N017857	002		Jun	DISC

CABERGOLINE

TABLET; ORAL

CABERGOLINE

AB	APOTEX CORP	0.5MG	A201503	001	Mar 08, 2013	Feb	NEWA
----	-------------	-------	---------	-----	--------------	-----	------

CAFFEINE; ERGOTAMINE TARTRATE

TABLET; ORAL

ERGOTAMINE TARTRATE AND CAFFEINE

AA	MIKART	100MG; 1MG	A040590	001	Sep 16, 2005	Mar	CMFD
	@	100MG; 1MG	A040590	001	Sep 16, 2005	Jan	DISC

CALCIPOTRIENE

OINTMENT; TOPICAL

DOVONEX

@ LEO PHARMA AS	0.005%	N020273	001	Dec 29, 1993	Sep	CAHN
-----------------	--------	---------	-----	--------------	-----	------

CALCITRIOL

CAPSULE; ORAL

CALCITRIOL

AB	BANNER PHARMACAPS	0.25MCG	A091174	001	May 24, 2013	May	NEWA
AB		0.5MCG	A091174	002	May 24, 2013	May	NEWA

CALCIUM ACETATE

CAPSULE; ORAL

CALCIUM ACETATE

AB	INVAGEN PHARMS	EQ 169MG CALCIUM	A203135	001	Feb 07, 2013	Jan	NEWA
----	----------------	------------------	---------	-----	--------------	-----	------

TABLET; ORAL

CALCIUM ACETATE

AB	INVAGEN PHARMS	EQ 169MG CALCIUM	A202420	001	Feb 05, 2013	Jan	NEWA
----	----------------	------------------	---------	-----	--------------	-----	------

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

INJECTABLE; INJECTION

ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER

@ B BRAUN	35MG/100ML; 5GM/100ML; 30MG/100ML; 74 MG/100ML; 640MG/100ML; 500MG/100ML; 7 4MG/100ML	N019867	001	Dec 20, 1993	Mar	DISC
-----------	---	---------	-----	--------------	-----	------

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

INPERSOL-LC/LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

@ FRESENIUS	18.4MG/100ML; 1.5GM/100ML; 5.08MG/10 0ML; 538MG/100ML; 448MG/100ML	N020374	001	Jun 13, 1994	Feb	DISC
-------------	---	---------	-----	--------------	-----	------

INPERSOL-LC/LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

@ FRESENIUS	18.4MG/100ML; 2.5GM/100ML; 5.08MG/10 0ML; 538MG/100ML; 448MG/100ML	N020374	002	Jun 13, 1994	Feb	DISC
-------------	---	---------	-----	--------------	-----	------

INPERSOL-LC/LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

@ FRESENIUS	18.4MG/100ML; 3.5GM/100ML; 5.08MG/10 0ML; 538MG/100ML; 448MG/100ML	N020374	003	Jun 13, 1994	Feb	DISC
-------------	---	---------	-----	--------------	-----	------

INPERSOL-LC/LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

@ FRESENIUS	18.4MG/100ML; 4.25GM/100ML; 5.08MG/1 00ML; 538MG/100ML; 448MG/100ML	N020374	004	Jun 13, 1994	Feb	DISC
-------------	--	---------	-----	--------------	-----	------

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE; INTRATHECAL

ELLIOTTS B SOLUTION

+	LUKARE MEDICAL LLC	0.2MG/ML; 0.8MG/ML; 0.3MG/ML; 0.3MG/M L; 1.9MG/ML; 7.3MG/ML; 0.2MG/ML	N020577	001	Sep 27, 1996	Jun	CAHN
---	--------------------	--	---------	-----	--------------	-----	------

CANAGLIFLOZIN

TABLET; ORAL

INVOKANA

	JANSSSEN PHARMS	100MG	N204042	001	Mar 29, 2013	Apr CAHN
+		300MG	N204042	002	Mar 29, 2013	Apr CAHN
	JANSSSEN RES AND DEV	100MG	N204042	001	Mar 29, 2013	Mar NEWA
+		300MG	N204042	002	Mar 29, 2013	Mar NEWA

CANDESARTAN CILEXETIL

TABLET; ORAL

ATACAND

AB	ASTRAZENECA	4MG	N020838	001	Jun 04, 1998	Apr CFTG
AB		8MG	N020838	002	Jun 04, 1998	Apr CFTG
AB		16MG	N020838	003	Jun 04, 1998	Apr CFTG
AB	+	32MG	N020838	004	Jun 04, 1998	Apr CFTG
	CANDESARTAN CILEXETIL					
AB	SANDOZ	4MG	A078702	001	May 03, 2013	Apr NEWA
AB		8MG	A078702	002	May 03, 2013	Apr NEWA
AB		16MG	A078702	003	May 03, 2013	Apr NEWA
AB		32MG	A078702	004	May 03, 2013	Apr NEWA

CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE

AB	APOTEX INC	32MG; 25MG	A202884	003	Jun 03, 2013	May NEWA
AB	DR REDDYS LABS LTD	16MG; 12.5MG	A202965	001	Jun 03, 2013	May NEWA
AB		32MG; 12.5MG	A202965	002	Jun 03, 2013	May NEWA
AB		32MG; 25MG	A202965	003	Jun 03, 2013	May NEWA

CAPECITABINE

TABLET; ORAL

CAPECITABINE

AB	TEVA PHARMS USA	150MG	A091649	001	Sep 16, 2013	Aug NEWA
AB		500MG	A091649	002	Sep 16, 2013	Aug NEWA
	XELODA					
AB	HOFFMANN LA ROCHE	150MG	N020896	001	Apr 30, 1998	Aug CFTG
AB	+	500MG	N020896	002	Apr 30, 1998	Aug CFTG

CAPSAICIN

PATCH; TOPICAL

QUTENZA

+	ACORDA	8%	N022395	001	Nov 16, 2009	Jul CAHN
---	--------	----	---------	-----	--------------	----------

CAPTOPRIL

TABLET; ORAL

CAPTOPRIL

@ PRINSTON INC

@

@

@

@ TEVA

@

@

@

@

		12.5MG	A074477	001	Feb 13, 1996	Jun DISC
		25MG	A074477	002	Feb 13, 1996	Jun DISC
		50MG	A074477	003	Feb 13, 1996	Jun DISC
		100MG	A074477	004	Feb 13, 1996	Jun DISC
		12.5MG	A074483	001	Feb 13, 1996	Jun DISC
		25MG	A074483	002	Feb 13, 1996	Jun DISC
		50MG	A074483	003	Feb 13, 1996	Jun DISC
		100MG	A074483	004	Feb 13, 1996	Jun DISC

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE; ORAL

CARBAMAZEPINE

AB	TARO	100MG	A201106	001	Jun 21, 2013	Jun NEWA
AB		200MG	A201106	002	Jun 21, 2013	Jun NEWA
AB		300MG	A201106	003	Jun 21, 2013	Jun NEWA

CARBIDOPA; LEVODOPA

TABLET, EXTENDED RELEASE; ORAL

CARBIDOPA AND LEVODOPA

AB	ACCORD HLTHCARE	25MG; 100MG	A202323	001	Feb 08, 2013	Jan NEWA
AB		50MG; 200MG	A202323	002	Feb 08, 2013	Jan NEWA

CARBINOXAMINE MALEATE

SUSPENSION, EXTENDED RELEASE; ORAL

KARBINAL ER

CARBINOXAMINE MALEATE

SUSPENSION, EXTENDED RELEASE; ORAL
KARBINAL ER

+ TRIS PHARMA INC 4MG/5ML N022556 001 Mar 28, 2013 Mar NEWA

CARBOPLATIN

INJECTABLE; INJECTION
CARBOPLATIN

@ PLIVA 50MG/VIAL A076602 001 Nov 16, 2004 Feb DISC
@ 150MG/VIAL A076602 002 Nov 16, 2004 Feb DISC
@ 450MG/VIAL A076602 003 Nov 16, 2004 Feb DISC

INJECTABLE; IV (INFUSION)
CARBOPLATIN

@ FRESenius KABI USA 50MG/5ML (10MG/ML) A077266 001 Feb 15, 2006 Mar DISC
@ 150MG/15ML (10MG/ML) A077266 002 Feb 15, 2006 Mar DISC
@ PHARMACHEMIE BV 50MG/5ML (10MG/ML) A077679 001 Feb 25, 2009 Apr DISC
@ 150MG/15ML (10MG/ML) A077679 002 Feb 25, 2009 Apr DISC
@ 450MG/45ML (10MG/ML) A077679 003 Feb 25, 2009 Apr DISC
>D> @ SAGENT PHARMS 50MG/5ML (10MG/ML) A077096 001 Jun 14, 2005 Oct CMFD
>A> AP 50MG/5ML (10MG/ML) A077096 001 Jun 14, 2005 Oct CMFD
>D> @ 150MG/15ML (10MG/ML) A077096 002 Jun 14, 2005 Oct CMFD
>A> AP 150MG/15ML (10MG/ML) A077096 002 Jun 14, 2005 Oct CMFD
>D> @ 450MG/45ML (10MG/ML) A077096 003 Jun 14, 2005 Oct CMFD
>A> AP 450MG/45ML (10MG/ML) A077096 003 Jun 14, 2005 Oct CMFD
>A> AP 600MG/60ML (10MG/ML) A077096 004 Jun 03, 2013 Oct NEWA

PARAPLATIN

@ CORDENPHARMA 50MG/5ML (10MG/ML) N020452 001 Jul 14, 2003 Mar CAHN
@ 150MG/15ML (10MG/ML) N020452 002 Jul 14, 2003 Mar CAHN
@ 450MG/45ML (10MG/ML) N020452 003 Jul 14, 2003 Mar CAHN
@ 600MG/60ML (10MG/ML) N020452 004 Jan 15, 2004 Mar CAHN

CARISOPRODOL

TABLET; ORAL

CARISOPRODOL

AA ACCEL RX LABS 350MG A040576 001 Jun 07, 2005 May CAHN
@ COREPHARMA 350MG A040397 001 Sep 21, 2000 Feb DISC
@ PROSAM LABS 350MG A040188 001 Mar 07, 1997 Jun DISC

CARMUSTINE

IMPLANT; INTRACRANIAL
GLIADEL

+ ARBOR PHARMS LLC 7.7MG N020637 001 Sep 23, 1996 Mar CAHN

INJECTABLE; INJECTION
BICNU

+ EMCURE PHARMS LTD 100MG/VIAL N017422 001 Jan CAHN

CARTEOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
CARTEOLOL HYDROCHLORIDE

@ APOTEX INC 1% A076097 001 Feb 06, 2002 Apr DISC

CARVEDILOL

TABLET; ORAL

CARVEDILOL

AB CIPLA LTD 3.125MG A077474 001 Sep 05, 2007 Aug CAHN
AB 6.25MG A077474 002 Sep 05, 2007 Aug CAHN
AB 12.5MG A077474 003 Sep 05, 2007 Aug CAHN
AB 25MG A077474 004 Sep 05, 2007 Aug CAHN
@ WOCKHARDT LTD 3.125MG A078786 001 Dec 22, 2009 Feb DISC
@ 6.25MG A078786 002 Dec 22, 2009 Feb DISC
@ 12.5MG A078786 003 Dec 22, 2009 Feb DISC
@ 25MG A078786 004 Dec 22, 2009 Feb DISC

CEFADROXIL/CEFADROXIL HEMIHYDRATE

FOR SUSPENSION; ORAL
CEFADROXIL

AB AUROBINDO EQ 250MG BASE/5ML A065349 001 Apr 25, 2013 Apr NEWA
AB EQ 500MG BASE/5ML A065349 002 Apr 25, 2013 Apr NEWA
@ TEVA PHARMS USA EQ 250MG BASE/5ML A065278 001 Jan 20, 2006 Mar DISC
@ EQ 500MG BASE/5ML A065278 002 Jan 20, 2006 Mar DISC

CEFAZOLIN SODIUM

INJECTABLE; INJECTION							
CEFAZOLIN SODIUM							
	@ AUROBINDO PHARMA	EQ 1GM BASE/VIAL	A065395	002	Aug 08, 2008	Aug	DISC
	@	EQ 500MG BASE/VIAL	A065395	001	Aug 08, 2008	Aug	DISC
AP	+ HOSPIRA INC	EQ 1GM BASE/VIAL	A065226	002	Apr 21, 2005	Feb	CRLD
AP	+	EQ 1GM BASE/VIAL	A065244	001	Aug 12, 2005	Feb	CRLD
AP	+	EQ 10GM BASE/VIAL	A065247	001	Aug 12, 2005	Feb	CRLD
AP	+	EQ 500MG BASE/VIAL	A065226	001	Apr 21, 2005	Feb	CRLD
AP	+ STERI PHARMA	EQ 20GM BASE/VIAL	A063209	002	Apr 30, 1999	Jul	CRLD

CEFEPIME HYDROCHLORIDE

INJECTABLE; INJECTION							
CEFEPIME HYDROCHLORIDE							
	@ SANDOZ	EQ 1GM BASE/VIAL	A090291	002	Dec 21, 2010	Mar	DISC
	@	EQ 2GM BASE/VIAL	A090291	003	Dec 21, 2010	Mar	DISC
	@	EQ 500MG BASE/VIAL	A090291	001	Dec 21, 2010	Mar	DISC

CEFIXIME

FOR SUSPENSION; ORAL							
SUPRAX							
+	LUPIN LTD	500MG/5ML	N202091	001	Feb 20, 2013	Feb	CDFR
	LUPIN PHARMS	100MG/5ML	A065129	001	Feb 23, 2004	Feb	CDFR
		200MG/5ML	A065355	001	Apr 10, 2007	Feb	CDFR

CEFOTAXIME SODIUM

INJECTABLE; INJECTION							
CEFOTAXIME SODIUM							
	@ AUROBINDO PHARMA	EQ 1GM BASE/VIAL	A065517	002	Nov 06, 2009	Aug	DISC
	@	EQ 2GM BASE/VIAL	A065517	003	Nov 06, 2009	Aug	DISC
	@	EQ 500MG BASE/VIAL	A065517	001	Nov 06, 2009	Aug	DISC
	@ AUROBINDO PHARMA LTD	EQ 10GM BASE/VIAL	A065516	001	Nov 06, 2009	Jun	DISC

CEFOXITIN SODIUM

INJECTABLE; INJECTION							
CEFOXITIN							
>D> AP	ACS DOBFAR	EQ 1GM BASE/VIAL	A065414	001	Jun 12, 2009	Oct	CRLD
>A> AP	+	EQ 1GM BASE/VIAL	A065414	001	Jun 12, 2009	Oct	CRLD
>D> AP		EQ 2GM BASE/VIAL	A065414	002	Jun 12, 2009	Oct	CRLD
>A> AP	+	EQ 2GM BASE/VIAL	A065414	002	Jun 12, 2009	Oct	CRLD
>D> AP		EQ 10GM BASE/VIAL	A065415	001	May 19, 2010	Oct	CRLD
>A> AP	+	EQ 10GM BASE/VIAL	A065415	001	May 19, 2010	Oct	CRLD

CEFTAZIDIME

INJECTABLE; INJECTION							
CEFTAZIDIME							
	@ AUROBINDO PHARMA LTD	1GM/VIAL	A065481	002	May 28, 2010	Jun	DISC
	@	2GM/VIAL	A065481	003	May 28, 2010	Jun	DISC
	@	6GM/VIAL	A065482	001	May 28, 2010	Jun	DISC
	@	500MG/VIAL	A065481	001	May 28, 2010	Jun	DISC

CEFTRIAXONE SODIUM

INJECTABLE; IM-IV							
CEFTRIAXONE							
	@ AUROBINDO PHARMA LTD	EQ 1GM BASE/VIAL	A065505	003	Jul 31, 2008	May	DISC
	@	EQ 2GM BASE/VIAL	A065505	004	Jul 31, 2008	May	DISC
	@	EQ 250MG BASE/VIAL	A065505	001	Jul 31, 2008	May	DISC
	@	EQ 500MG BASE/VIAL	A065505	002	Jul 31, 2008	May	DISC
	@ STERI PHARMA	EQ 1GM BASE/VIAL	A065268	001	Feb 28, 2007	Sep	DISC
	@	EQ 2GM BASE/VIAL	A065268	002	Feb 28, 2007	Sep	DISC
	@ TEVA	EQ 1GM BASE/VIAL	A065262	001	Jun 29, 2006	Jul	DISC
	@	EQ 2GM BASE/VIAL	A065262	002	Jun 29, 2006	Jul	DISC
AP	TEVA PHARMS USA	EQ 1GM BASE/VIAL	A065227	003	Mar 15, 2007	May	CAHN
AP		EQ 2GM BASE/VIAL	A065227	004	Mar 15, 2007	May	CAHN
AP		EQ 250MG BASE/VIAL	A065227	001	Mar 15, 2007	May	CAHN
AP		EQ 500MG BASE/VIAL	A065227	002	Mar 15, 2007	May	CAHN
INJECTABLE; INJECTION							
CEFTRIAXONE							
>D> AP	@ AUROBINDO PHARMA LTD	EQ 10GM BASE/VIAL	A065504	001	Jul 31, 2008	May	DISC
>A>	TEVA	EQ 10GM BASE/VIAL	A065274	001	May 01, 2006	Oct	DISC
>A>	@	EQ 10GM BASE/VIAL	A065274	001	May 01, 2006	Oct	DISC

CEFUROXIME SODIUM

INJECTABLE;IM-IV

CEFUROXIME SODIUM

@ TEVA PHARMS EQ 1.5GM BASE/VIAL

A064192 001 Apr 16, 1998 Jul DISC

@ EQ 750MG BASE/VIAL

A064192 002 Apr 16, 1998 Jul DISC

INJECTABLE;INJECTION

CEFUROXIME SODIUM IN PLASTIC CONTAINER

@ SAMSON MEDCL EQ 75GM BASE/VIAL

A065251 001 Dec 30, 2009 Aug DISC

@ EQ 225GM BASE/VIAL

A065251 002 Dec 30, 2009 Aug DISC

ZINACEF IN PLASTIC CONTAINER

@ COVIS PHARMA SARL EQ 15MG BASE/ML

N050643 001 Apr 28, 1989 Jun DISC

CEPHALEXIN

CAPSULE;ORAL

CEPHALEXIN

ALKEM LABS LTD EQ 333MG BASE

A090836 003 Mar 29, 2013 Mar NEWA

AB EQ 750MG BASE

A090836 004 Mar 29, 2013 Mar NEWA

KEFLEX

AB + SHIONOGI INC EQ 750MG BASE

N050405 005 May 12, 2006 Mar CTEC

CETIRIZINE HYDROCHLORIDE

SYRUP;ORAL

CETIRIZINE HYDROCHLORIDE

@ APOTEX INC 5MG/5ML

A078412 001 Jun 18, 2008 Apr DISC

@ AUROBINDO PHARMA LTD 5MG/5ML

A090751 001 Dec 16, 2009 Feb DISC

AA BIO PHARM INC 5MG/5ML

A078870 001 Apr 27, 2009 May CAHN

AA BRECKENRIDGE PHARM 5MG/5ML

A078488 001 Oct 06, 2008 Sep CAHN

AA CARACO 5MG/5ML

A090191 001 Nov 12, 2009 Jun CAHN

CETRORELIX

INJECTABLE;INJECTION

CETROTIDE

@ EMD SERONO INC EQ 3MG BASE/ML

N021197 002 Aug 11, 2000 Jun DISC

CEVIMELINE HYDROCHLORIDE

CAPSULE;ORAL

CEVIMELINE HYDROCHLORIDE

AB ROXANE 30MG

A091591 001 Jul 08, 2013 Jun NEWA

EVOXAC

AB + DAIICHI SANKYO 30MG

N020989 002 Jan 11, 2000 Sep CAHN

CHLORHEXIDINE GLUCONATE

SOLUTION;DENTAL

CHLORHEXIDINE GLUCONATE

@ APOTEX INC 0.12%

A075561 001 Nov 14, 2000 Apr DISC

PAROEX

AT SUNSTAR AMERICAS 0.12%

A076434 001 Nov 29, 2005 Apr CTNA

CHLOROTHIAZIDE

TABLET;ORAL

CHLOROTHIAZIDE

+ MYLAN 250MG

A084388 001 Jul CTEC

500MG

A084217 001 Jul CTEC

@ WEST WARD 250MG

A086028 001 Jul 14, 1982 Jul DISC

@ 500MG

A087736 001 Jul 14, 1982 Jul DISC

DIURIL

@ OAK PHARMS AKORN 250MG

N011145 004 Jan CAHN

@ 500MG

N011145 002 Jan CAHN

CHLOROTHIAZIDE SODIUM

INJECTABLE;INJECTION

CHLOROTHIAZIDE SODIUM

AP LUITPOLD EQ 500MG BASE/VIAL

A202561 001 Apr 22, 2013 Jun CAHN

AP PHARMAFORCE EQ 500MG BASE/VIAL

A202561 001 Apr 22, 2013 Apr NEWA

DIURIL

AP + OAK PHARMS AKORN EQ 500MG BASE/VIAL

N011145 005 Jan CAHN

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE

SOLUTION;ORAL

VITUZ

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE

SOLUTION; ORAL

VITUZ

+	CYPRESS PHARM	4MG/5ML; 5MG/5ML	N204307	001	Feb 20, 2013	Feb NEWA
---	---------------	------------------	---------	-----	--------------	----------

CHLORPROPAMIDE

TABLET; ORAL

CHLORPROPAMIDE

@	WATSON LABS INC	100MG	A088852	001	Sep 26, 1984	Jan DISC
---	-----------------	-------	---------	-----	--------------	----------

@		250MG	A088826	001	Sep 26, 1984	Jan DISC
---	--	-------	---------	-----	--------------	----------

CHLORTHALIDONE

TABLET; ORAL

CHLORTHALIDONE

AB	@	BARR LABS INC	25MG	A088902	001	Sep 19, 1985	Sep DISC
----	---	---------------	------	---------	-----	--------------	----------

			25MG	A088902	001	Sep 19, 1985	Sep CAHN
--	--	--	------	---------	-----	--------------	----------

	@		50MG	A088903	001	Sep 19, 1985	Sep DISC
--	---	--	------	---------	-----	--------------	----------

AB			50MG	A088903	001	Sep 19, 1985	Sep CAHN
----	--	--	------	---------	-----	--------------	----------

		MYLAN	25MG	A086831	002		Sep CTEC
--	--	-------	------	---------	-----	--	----------

+		50MG	A086831	001		Sep CTEC
---	--	------	---------	-----	--	----------

CHOLINE FENOFIBRATE

CAPSULE, DELAYED RELEASE; ORAL

FENOFIBRIC ACID

AB		ANCHEN PHARMS	EQ 45MG FENOFIBRIC ACID	A201573	002	Jul 18, 2013	Jul NEWA
----	--	---------------	-------------------------	---------	-----	--------------	----------

AB			EQ 135MG FENOFIBRIC ACID	A201573	001	Jul 18, 2013	Jul NEWA
----	--	--	--------------------------	---------	-----	--------------	----------

AB		MYLAN PHARMS INC	EQ 45MG FENOFIBRIC ACID	A200913	001	Mar 25, 2013	Mar NEWA
----	--	------------------	-------------------------	---------	-----	--------------	----------

AB			EQ 135MG FENOFIBRIC ACID	A200913	002	Mar 25, 2013	Mar NEWA
----	--	--	--------------------------	---------	-----	--------------	----------

		TRILIPIX					
--	--	----------	--	--	--	--	--

AB		ABBVIE	EQ 45MG FENOFIBRIC ACID	N022224	001	Dec 15, 2008	Mar CFTG
----	--	--------	-------------------------	---------	-----	--------------	----------

AB	+		EQ 135MG FENOFIBRIC ACID	N022224	002	Dec 15, 2008	Mar CFTG
----	---	--	--------------------------	---------	-----	--------------	----------

CICLOPIROX

CREAM; TOPICAL

LOPROX

AB	+	MEDIMETRIKS PHARMS	0.77%	N018748	001	Dec 30, 1982	Sep CAHN
----	---	--------------------	-------	---------	-----	--------------	----------

SOLUTION; TOPICAL

CICLOPIROX

	@	APOTEX INC	8%	A078172	001	Sep 18, 2007	Apr DISC
--	---	------------	----	---------	-----	--------------	----------

AT		CIPLA LTD	8%	A078124	001	Sep 18, 2007	Aug CAHN
----	--	-----------	----	---------	-----	--------------	----------

	@	TEVA PHARMS	8%	A078079	001	Sep 18, 2007	Jan DISC
--	---	-------------	----	---------	-----	--------------	----------

		PENLAC					
--	--	--------	--	--	--	--	--

AT	+	VALEANT BERMUDA	8%	N021022	001	Dec 17, 1999	May CAHN
----	---	-----------------	----	---------	-----	--------------	----------

AT	+	VALEANT INTL	8%	N021022	001	Dec 17, 1999	Feb CAHN
----	---	--------------	----	---------	-----	--------------	----------

SUSPENSION; TOPICAL

LOPROX

>D>	AB	+	MEDICIS	0.77%	N019824	001	Dec 30, 1988	Oct CAHN
-----	----	---	---------	-------	---------	-----	--------------	----------

>A>	AB	+	MEDIMETRIKS PHARMS	0.77%	N019824	001	Dec 30, 1988	Oct CAHN
-----	----	---	--------------------	-------	---------	-----	--------------	----------

CIMETIDINE

TABLET; ORAL

CIMETIDINE

@	WATSON LABS INC	200MG	A074349	001	Aug 30, 1996	May DISC
---	-----------------	-------	---------	-----	--------------	----------

@		300MG	A074349	002	Aug 30, 1996	May DISC
---	--	-------	---------	-----	--------------	----------

@		400MG	A074349	003	Aug 30, 1996	May DISC
---	--	-------	---------	-----	--------------	----------

@		800MG	A074316	001	Feb 28, 1996	Jun DISC
---	--	-------	---------	-----	--------------	----------

CIMETIDINE HYDROCHLORIDE

SOLUTION; ORAL

CIMETIDINE HYDROCHLORIDE

@	APOTEX INC	EQ 300MG BASE/5ML	A075560	001	Mar 15, 2000	Apr DISC
---	------------	-------------------	---------	-----	--------------	----------

CIPROFLOXACIN

INJECTABLE; INJECTION

CIPROFLOXACIN

@	TEVA PHARMS USA	200MG/20ML (10MG/ML)	A077782	001	Aug 28, 2006	Apr CAHN
---	-----------------	----------------------	---------	-----	--------------	----------

@		400MG/40ML (10MG/ML)	A077782	002	Aug 28, 2006	Apr CAHN
---	--	----------------------	---------	-----	--------------	----------

CIPROFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

CIPROFLOXACIN HYDROCHLORIDE

CIPROFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC
CIPROFLOXACIN HYDROCHLORIDE
@ APOTEX INC EQ 0.3% BASE

A075928 001 Jun 09, 2004 Apr DISC

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL
CIPRO XR

@ BAYER HLTHCARE 212.6MG;EQ 287.5MG BASE
@ 425.2MG;EQ 574.9MG BASE

N021473 001 Dec 13, 2002 May DISC
N021473 002 Aug 28, 2003 May DISC

CIPROFLOXACIN EXTENDED RELEASE

AB + @ DR REDDYS LABS LTD 212.6MG;EQ 287.5MG BASE
AB + MYLAN PHARMS INC 212.6MG;EQ 287.5MG BASE
AB + 425.2MG;EQ 574.9MG BASE

A077701 002 Oct 31, 2007 Jun DISC
A078183 001 Mar 22, 2007 May CRLD
A078183 002 Mar 22, 2007 May CRLD

CISPLATIN

INJECTABLE;INJECTION
CISPLATIN

>A> AP HQ SPCLT PHARMA 1MG/ML
@ TEVA PHARMS USA 1MG/ML

N018057 004 Nov 08, 1988 Oct CMFD
A074814 001 May 16, 2000 Sep CAHN

PLATINOL

@ HQ SPCLT PHARMA 10MG/VIAL
@ 50MG/VIAL

N018057 001 Jan CAHN
N018057 002 Jan CAHN

PLATINOL-AQ

>D> @ HQ SPCLT PHARMA 0.5MG/ML
@ 1MG/ML
@ 1MG/ML

N018057 003 Jul 18, 1984 Jan CAHN
N018057 004 Nov 08, 1988 Oct CMFD
N018057 004 Nov 08, 1988 Jan CAHN

CITALOPRAM HYDROBROMIDE

SOLUTION;ORAL
CITALOPRAM HYDROBROMIDE

@ APOTEX INC EQ 10MG BASE/5ML

A077601 001 Nov 15, 2005 Apr DISC

TABLET;ORAL

CITALOPRAM HYDROBROMIDE

AB CIPLA LTD EQ 10MG BASE
AB EQ 20MG BASE
AB EQ 40MG BASE
@ COREPHARMA EQ 10MG BASE
@ EQ 20MG BASE
@ EQ 40MG BASE
@ NATCO PHARMA LTD EQ 20MG BASE
@ EQ 40MG BASE

A077044 001 Nov 05, 2004 Aug CAHN
A077044 002 Nov 05, 2004 Aug CAHN
A077044 003 Nov 05, 2004 Aug CAHN
A077036 001 Oct 28, 2004 Feb DISC
A077036 002 Oct 28, 2004 Feb DISC
A077036 003 Oct 28, 2004 Feb DISC
A077141 002 Apr 10, 2008 Jun DISC
A077141 001 Apr 10, 2008 Jun DISC

CLARITHROMYCIN

TABLET;ORAL
CLARITHROMYCIN

AB ALLIED PHARMA INC 250MG
AB 500MG

A202710 001 Jun 10, 2013 May NEWA
A202710 002 Jun 10, 2013 May NEWA

CLEMASTINE FUMARATE

SYRUP;ORAL
CLEMASTINE FUMARATE

@ APOTEX INC EQ 0.5MG BASE/5ML
@ SILARX EQ 0.5MG BASE/5ML

A075703 001 Nov 27, 2000 Apr DISC
A074884 001 Dec 17, 1997 Mar DISC

CLEVIDIPINE

EMULSION;INTRAVENOUS
CLEVIPREX

+ MEDICINES CO 25MG/50ML (0.5MG/ML)
+ 50MG/100ML (0.5MG/ML)

N022156 001 Aug 01, 2008 Feb CAIN
N022156 002 Aug 01, 2008 Feb CAIN

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION;ORAL
CLINDAMYCIN PALMITATE HYDROCHLORIDE

AA AUROBINDO PHARMA LTD EQ 75MG BASE/5ML

A202409 001 Apr 30, 2013 Apr NEWA

CLINDAMYCIN PHOSPHATE

AEROSOL, FOAM;TOPICAL
EVOCLIN

AT + DELCOR ASSET 1%
GEL;TOPICAL

N050801 001 Oct 22, 2004 Sep CAHN

CLINDAMYCIN PHOSPHATE

GEL; TOPICAL

CLINDAGEL

>D>	BT	+	GALDERMA LABS LP	EQ 1% BASE	N050782	001	Nov 27, 2000	Oct	CAHN
>A>	BT	+	PRECISION DERMAT	EQ 1% BASE	N050782	001	Nov 27, 2000	Oct	CAHN
			INJECTABLE; INJECTION						
			CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER						
AP			AKORN INC	EQ 6MG BASE/ML	A203048	001	Apr 04, 2013	Mar	NEWA
AP				EQ 12MG BASE/ML	A203048	002	Apr 04, 2013	Mar	NEWA
AP				EQ 18MG BASE/ML	A203048	003	Apr 04, 2013	Mar	NEWA
			SOLUTION; TOPICAL						
			CLINDAMYCIN PHOSPHATE						
			@ ACTAVIS MID ATLANTIC	EQ 1% BASE	A062811	001	Sep 01, 1988	May	CAHN
AT			PERRIGO NEW YORK	EQ 1% BASE	A064050	001	Nov 30, 1995	Aug	CMFD
			@	EQ 1% BASE	A064050	001	Nov 30, 1995	Feb	DISC

CLOBAZAM

TABLET; ORAL

ONFI

@ LUNDBECK LLC

5MG

N202067 001 Oct 21, 2011 Jul DISC

CLOBETASOL PROPIONATE

AEROSOL, FOAM; TOPICAL

OLUX E

AB2	+		DELCOR ASSET	0.05%	N022013	001	Jan 12, 2007	Jun	CAHN
			CREAM; TOPICAL						
			CLOBETASOL PROPIONATE						
			@ TEVA PHARMS USA	0.05%	A074087	001	Feb 16, 1994	Jun	DISC
			SOLUTION; TOPICAL						
			EMBELINE						
AT	+		HI TECH PHARMA	0.05%	A074222	001	Dec 06, 1995	Jul	CRLD
			TEMOVATE						
			@ FOUGERA PHARMS	0.05%	N019966	001	Feb 22, 1990	Jul	DISC

CLONAZEPAM

TABLET; ORAL

CLONAZEPAM

AB			ACCORD HLTHCARE	0.5MG	A077147	001	May 02, 2005	Apr	CAHN
AB				1MG	A077147	002	May 02, 2005	Apr	CAHN
AB				2MG	A077147	003	May 02, 2005	Apr	CAHN
			@ APOTEX INC	0.5MG	A075468	001	Oct 06, 2000	Feb	DISC
			@	1MG	A075468	002	Oct 06, 2000	Feb	DISC
			@	2MG	A075468	003	Oct 06, 2000	Feb	DISC

CLONIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

CLONIDINE HYDROCHLORIDE

>A>	AP		EXELA PHARMA SCS LLC	1MG/10ML (0.1MG/ML)	A203167	001	Oct 29, 2013	Oct	NEWA
>A>	AP			5MG/10ML (0.5MG/ML)	A203167	002	Oct 29, 2013	Oct	NEWA
			TABLET; ORAL						
			CLONIDINE HYDROCHLORIDE						
AB			CARLSBAD	0.1MG	A202297	001	Jun 13, 2013	May	NEWA
AB				0.2MG	A202297	002	Jun 13, 2013	May	NEWA
AB				0.3MG	A202297	003	Jun 13, 2013	May	NEWA
			TABLET, EXTENDED RELEASE; ORAL						
			CLONIDINE HYDROCHLORIDE						
AB			ANCHEN PHARMS	0.1MG	A202984	001	Sep 30, 2013	Sep	NEWA
AB				0.2MG	A202984	002	Sep 30, 2013	Sep	NEWA
			JENLOGA						
			@ CONCORDIA PHARMS INC	0.1MG	N022331	001	Sep 30, 2009	May	CAHN
			@	0.2MG	N022331	002	May 25, 2010	May	CAHN
			KAPVAY						
AB	+		CONCORDIA PHARMS INC	0.1MG	N022331	003	Sep 28, 2010	Sep	CFTG
	+			0.1MG	N022331	003	Sep 28, 2010	May	CAHN
AB				0.2MG	N022331	004	Sep 28, 2010	Sep	CFTG
				0.2MG	N022331	004	Sep 28, 2010	May	CAHN

CLOPIDOGREL BISULFATE

TABLET; ORAL

CLOPIDOGREL BISULFATE

CLOPIDOGREL BISULFATE

TABLET; ORAL

CLOPIDOGREL BISULFATE

AB	ACCORD HLTHCARE	EQ 75MG BASE	A202925	001	Mar 27, 2013	Mar NEWA
AB		EQ 300MG BASE	A202925	002	Mar 27, 2013	Mar NEWA
AB	ACTAVIS TOTOWA	EQ 75MG BASE	A090307	001	May 28, 2013	May NEWA
AB	MUTUAL PHARM	EQ 75MG BASE	A078133	001	Jun 10, 2013	May NEWA

CLORAZEPATE DIPOTASSIUM

CAPSULE; ORAL

TRANXENE

@ RECORDATI RARE

3.75MG

N017105 001

May CAHN

@

7.5MG

N017105 002

May CAHN

@

15MG

N017105 003

May CAHN

TABLET; ORAL

TRANXENE

AB RECORDATI RARE

3.75MG

N017105 006

May CAHN

AB

7.5MG

N017105 007

May CAHN

AB +

15MG

N017105 008

May CAHN

TRANXENE SD

@ RECORDATI RARE

11.25MG

N017105 005

May CAHN

@

22.5MG

N017105 004

May CAHN

CLOTTRIMAZOLE

CREAM; TOPICAL

MYCELEX

@ BAYER

1%

N018183 001

Sep CAHN

CLOZAPINE

SUSPENSION; ORAL

VERSACLOZ

+ DOUGLAS PHARMS

50MG/ML

N203479 001

Feb 06, 2013

Feb NEWA

+ JAZZ PHARMS III

50MG/ML

N203479 001

Feb 06, 2013

Mar CAHN

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE

AA AMNEAL PHARMS

10MG/5ML; 6.25MG/5ML

A200894 001

Apr 24, 2013

Apr NEWA

AA CARACO

10MG/5ML; 6.25MG/5ML

A090180 001

Mar 17, 2010

May CAHN

@ PHARM ASSOC

10MG/5ML; 6.25MG/5ML

A089647 001

Dec 22, 1988

Aug DISC

COSYNTROPIN

INJECTABLE; INJECTION

COSYNTROPIN

AP MYLAN LLC

0.25MG/VIAL

A090574 001

Dec 17, 2009

Feb CAHN

CRIZOTINIB

CAPSULE; ORAL

XALKORI

PF PRISM CV

200MG

N202570 001

Aug 26, 2011

Sep CAHN

+

250MG

N202570 002

Aug 26, 2011

Sep CAHN

CROMOLYN SODIUM

CONCENTRATE; ORAL

CROMOLYN SODIUM

AA MICRO LABS LTD INDIA

100MG/5ML

A202745 001

Apr 04, 2013

Mar NEWA

SOLUTION; INHALATION

CROMOLYN SODIUM

@ APOTEX INC

10MG/ML

A075333 001

Apr 30, 2002

Apr DISC

SOLUTION/DROPS; OPHTHALMIC

CROMOLYN SODIUM

@ APOTEX INC

4%

A075615 001

Jan 26, 2001

Apr DISC

CYCLOBENZAPRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

AMRIX

AB IVAX INTL

15MG

N021777 001

Feb 01, 2007

Jan CAHN

AB +

30MG

N021777 002

Feb 01, 2007

Jan CAHN

CYCLOBENZAPRINE HYDROCHLORIDE

AB TWI PHARMS INC

15MG

A091281 001

Jan 31, 2013

Jan NEWA

CYCLOBENZAPRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL					
CYCLOBENZAPRINE HYDROCHLORIDE					
AB	30MG	A091281	002	Jan 31, 2013	Jan NEWA
TABLET;ORAL					
CYCLOBENZAPRINE HYDROCHLORIDE					
AB	MYLAN PHARMS INC 7.5MG	A073144	003	Mar 25, 2013	Mar NEWA
	@ PROSAM LABS 5MG	A077291	001	Feb 03, 2006	Mar DISC
	@ SANDOZ 5MG	A072854	002	Feb 03, 2006	Apr DISC
	@ 10MG	A072854	001	Nov 19, 1991	Apr DISC

CYCLOPENTOLATE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC					
AKPENTOLATE					
	@ AKORN 2%	A040165	001	Jan 13, 1997	Mar DISC
CYCLOGYL					
+	ALCON LABS INC 2%	A084108	001		Mar CTEC

CYCLOPHOSPHAMIDE

CAPSULE;ORAL					
CYCLOPHOSPHAMIDE					
	ROXANE 25MG	N203856	001	Sep 16, 2013	Sep NEWA
+	50MG	N203856	002	Sep 16, 2013	Sep NEWA
INJECTABLE;INJECTION					
CYTOXAN (LYOPHILIZED)					
AP	+ BAXTER HLTHCARE 1GM/VIAL	N012142	004	Aug 30, 1982	Mar CTNA
	@ 1GM/VIAL	N012142	010	Sep 24, 1985	Jan CTNA
AP	+ 2GM/VIAL	N012142	005	Aug 30, 1982	Mar CTNA
	@ 2GM/VIAL	N012142	009	Dec 10, 1985	Jan CTNA
AP	+ 500MG/VIAL	N012142	003		Mar CTNA
	@ 500MG/VIAL	N012142	008	Jan 04, 1984	Jan CTNA

CYCLOSPORINE

SOLUTION;ORAL					
CYCLOSPORINE					
	@ APOTEX INC 100MG/ML	A065167	001	Jan 05, 2005	Apr DISC

CYPROHEPTADINE HYDROCHLORIDE

SYRUP;ORAL					
CYPROHEPTADINE HYDROCHLORIDE					
AA	PHARM ASSOC 2MG/5ML	A091295	001	Mar 28, 2013	Mar NEWA

CYSTEAMINE BITARTRATE

CAPSULE, DELAYED RELEASE;ORAL					
PROCYSBI					
	RAPTOR PHARMS EQ 25MG BASE	N203389	001	Apr 30, 2013	Apr NEWA
+	EQ 75MG BASE	N203389	002	Apr 30, 2013	Apr NEWA

CYTARABINE

INJECTABLE;INJECTION					
CYTOSAR-U					
AP	+ TEVA PHARMS USA 1GM/VIAL	A075206	004	Dec 30, 1998	Jun CAHN
AP	+ 2GM/VIAL	A075206	003	Dec 30, 1998	Jun CAHN
AP	100MG/VIAL	A075206	001	Dec 30, 1998	Jun CAHN
AP	+ 500MG/VIAL	A075206	002	Dec 30, 1998	Jun CAHN

DABRAFENIB MESYLATE

CAPSULE;ORAL					
TAFINLAR					
	GLAXOSMITHKLINE EQ 50MG BASE	N202806	001	May 29, 2013	May NEWA
+	EQ 75MG BASE	N202806	002	May 29, 2013	May NEWA

DACARBAZINE

INJECTABLE;INJECTION					
DACARBAZINE					
AP	TEVA PHARMS USA 200MG/VIAL	A075259	002	Aug 27, 1998	Apr CAHN
AP	+ 500MG/VIAL	A075259	001	Sep 22, 2000	Apr CAHN

DACTINOMYCIN

INJECTABLE;INJECTION
COSMEGEN

DACTINOMYCIN

INJECTABLE; INJECTION						
COSMEGEN						
AP	+ RECORDATI RARE	0.5MG/VIAL	N050682	001		May CAHN
DACTINOMYCIN						
AP	PHARMAFORCE	0.5MG/VIAL	A202562	001	Aug 23, 2013	Aug NEWA

DALTEPARIN SODIUM

INJECTABLE; SUBCUTANEOUS						
FRAGMIN						
	@ EISAI INC	10,000IU/0.4ML (25,000IU/ML)	N020287	002	May 01, 2007	Jun DISC
	@	95,000IU/9.5ML (10,000IU/ML)	N020287	007	Apr 04, 2002	Jun DISC

DANTROLENE SODIUM

CAPSULE; ORAL						
DANTROLENE SODIUM						
AB	MIKAH PHARMA	25MG	A076686	001	Oct 24, 2005	Jul CMFD
AB		50MG	A076686	002	Oct 24, 2005	Jul CMFD
AB		100MG	A076686	003	Oct 24, 2005	Jul CMFD

DAUNORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION						
DAUNORUBICIN HYDROCHLORIDE						
AP	TEVA PHARMS USA	EQ 5MG BASE/ML	A065035	001	Jan 24, 2000	Apr CAHN

DECITABINE

INJECTABLE; INTRAVENOUS						
DACOGEN						
AP	+ EISAI INC	50MG/VIAL	N021790	001	May 02, 2006	Jul CFTG
DECITABINE						
AP	DR REDDYS LABS LTD	50MG/VIAL	A203131	001	Jul 11, 2013	Jul NEWA

DESMOPRESSIN ACETATE

INJECTABLE; INJECTION						
DESMOPRESSIN ACETATE						
AP	SUN PHARM INDS LTD	0.004MG/ML	A091280	001	Jan 25, 2013	Jan NEWA
AP	TEVA PHARMS USA	0.004MG/ML	A074888	001	Oct 15, 1997	Apr CAHN

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-28						
DESOGESTREL AND ETHINYL ESTRADIOL						
AB	FAMY CARE LTD	0.15MG,N/A;0.02MG,0.01MG	A202296	001	Aug 30, 2013	Aug NEWA
AB	NOVAST LABS LTD	0.15MG;0.03MG	A091234	001	Jul 12, 2013	Jul NEWA
ENSKYCE						
AB	LUPIN LTD	0.15MG;0.03MG	A201887	001	Mar 07, 2013	Feb NEWA
PIMTREA						
AB	NOVAST LABS LTD	0.15MG,N/A;0.02MG,0.01MG	A091247	001	Aug 01, 2013	Jul NEWA

DESONIDE

GEL; TOPICAL						
DESONATE						
	+ BAYER HLTHCARE	0.05%	N021844	001	Oct 20, 2006	Jun CAHN

DESOXIMETASONE

OINTMENT; TOPICAL						
DESOXIMETASONE						
AB	GLENMARK GENERICS	0.25%	A202838	001	Sep 20, 2013	Sep NEWA
SPRAY; TOPICAL						
TOPICORT						
	+ TARO	0.25%	N204141	001	Apr 11, 2013	Apr NEWA

DESVENLAFAXINE

TABLET, EXTENDED RELEASE; ORAL						
DESVENLAFAXINE						
BC	+ ALEMBIC PHARMS LTD	50MG	N204150	001	Mar 04, 2013	Jul CTEC
	+	50MG	N204150	001	Mar 04, 2013	Apr CRLD
		50MG	N204150	001	Mar 04, 2013	Mar NEWA
BC	+	100MG	N204150	002	Mar 04, 2013	Jul CTEC
	+	100MG	N204150	002	Mar 04, 2013	Mar NEWA
KHEDEZLA						

DESVENLAFAXINE

TABLET, EXTENDED RELEASE;ORAL
KHEDEZLA

BC	OSMOTICA PHARM CORP	50MG	N204683	001	Jul 10, 2013	Jul NEWA
BC		100MG	N204683	002	Jul 10, 2013	Jul NEWA

DESVENLAFAXINE FUMARATE

TABLET, EXTENDED RELEASE;ORAL
DESVENLAFAXINE FUMARATE

>A>	+	TEVA PHARMS USA	EQ 50MG BASE	N205208	001	Oct 11, 2013	Oct NEWA
>A>	+		EQ 100MG BASE	N205208	002	Oct 11, 2013	Oct NEWA

DEXAMETHASONE

ELIXIR;ORAL
DEXAMETHASONE

AA	WOCKHARDT EU OPERATN	0.5MG/5ML	A088254	001	Jul 27, 1983	May CRLD
----	----------------------	-----------	---------	-----	--------------	----------

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC
NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE

AT	PERRIGO CO TENNESSEE	0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062938	001	Jul 31, 1989	Jun CAHN
----	----------------------	---------------------------------------	---------	-----	--------------	----------

SUSPENSION/DROPS;OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE

@ ALCON PHARMS LTD 0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML

A062721	001	Nov 17, 1986	Jan DISC
---------	-----	--------------	----------

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE;INJECTION
PRECEDEX

+	HOSPIRA	EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)	N021038	002	Mar 13, 2013	Mar NEWA
+		EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)	N021038	003	Mar 13, 2013	Mar NEWA

DEXMETHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL
DEXMETHYLPHENIDATE HYDROCHLORIDE

AB	MYLAN PHARMS INC	30MG	A202580	001	Aug 28, 2013	Aug NEWA
AB	FOCALIN XR					
AB	NOVARTIS	30MG	N021802	005	Oct 23, 2009	Aug CFTG

DEXRAZOXANE HYDROCHLORIDE

INJECTABLE;INJECTION
TOTECT

+ BIOCODEX INC EQ 500MG BASE/VIAL

N022025	001	Sep 06, 2007	May CAHN
---------	-----	--------------	----------

DEXTROAMPHETAMINE SULFATE

SOLUTION;ORAL
DEXTROAMPHETAMINE SULFATE

AA	+	OUTLOOK PHARMS	5MG/5ML	A040776	001	Jan 29, 2008	May CFTG
AA		TRIS PHARMA INC	5MG/5ML	A203644	001	May 29, 2013	May NEWA

TABLET;ORAL

DEXTROAMPHETAMINE SULFATE

AA	AUROLIFE PHARMA LLC	5MG	A202893	001	Jul 31, 2013	Jul NEWA
AA		10MG	A202893	002	Jul 31, 2013	Jul NEWA

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE;INJECTION
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% IN PLASTIC CONTAINER
@ B BRAUN 5GM/100ML;220MG/100ML

N018744	003	Nov 09, 1982	Jan DISC
---------	-----	--------------	----------

DIAZEPAM

INJECTABLE;INJECTION
DIAZEPAM

@ WATSON LABS 5MG/ML

A070296	001	Feb 12, 1986	Jun DISC
---------	-----	--------------	----------

DIAZOXIDE

SUSPENSION;ORAL
PROGLYCEM

+ TEVA BRANDED PHARM 50MG/ML

N017453	001		Apr CAHN
---------	-----	--	----------

<u>DICLOFENAC</u>									
CAPSULE;ORAL									
ZORVOLEX									
>A>		IROKO PHARMS LLC	18MG	N204592	001	Oct 18, 2013	Oct	NEWA	
>A>	+		35MG	N204592	002	Oct 18, 2013	Oct	NEWA	
<u>DICLOFENAC SODIUM</u>									
GEL;TOPICAL									
DICLOFENAC SODIUM									
>A>	AB	TOLMAR	3%	A200936	001	Oct 28, 2013	Oct	NEWA	
SOLARAZE									
>D>	+	FOUGERA PHARMS	3%	N021005	001	Oct 16, 2000	Oct	CFTG	
>A>	AB	+	3%	N021005	001	Oct 16, 2000	Oct	CFTG	
SOLUTION/DROPS;OPHTHALMIC									
DICLOFENAC SODIUM									
		@ APOTEX INC	0.1%	A077600	001	Nov 13, 2008	Apr	DISC	
<u>DICLOFENAC SODIUM; MISOPROSTOL</u>									
TABLET, DELAYED RELEASE;ORAL									
DICLOFENAC SODIUM AND MISOPROSTOL									
AB		SANDOZ	50MG;0.2MG	A200158	001	May 09, 2013	Apr	NEWA	
AB			75MG;0.2MG	A200158	002	May 09, 2013	Apr	NEWA	
<u>DICYCLOMINE HYDROCHLORIDE</u>									
CAPSULE;ORAL									
DICYCLOMINE HYDROCHLORIDE									
		@ WEST WARD	10MG	A040204	001	Feb 28, 1997	Jul	DISC	
<u>DIDANOSINE</u>									
TABLET, FOR SUSPENSION;ORAL									
DIDANOSINE									
		AUROBINDO	100MG	A077275	001	Aug 14, 2012	Apr	CDFR	
			150MG	A077275	002	Aug 14, 2012	Apr	CDFR	
	+		200MG	A077275	003	Aug 14, 2012	Apr	CDFR	
<u>DIFLORASONE DIACETATE</u>									
CREAM;TOPICAL									
DIFLORASONE DIACETATE									
		@ FOUGERA PHARMS	0.05%	A075187	001	Mar 30, 1998	May	DISC	
BX	+	TARO	0.05%	A075508	001	Apr 24, 2000	May	CRLD	
PSORCON									
		@ TARO PHARMS NORTH	0.05%	N020205	001	Nov 20, 1992	Jun	CAHN	
<u>DIGOXIN</u>									
TABLET;ORAL									
DIGOXIN									
		@ CARACO	0.125MG	A076363	001	Jan 31, 2003	Jun	DISC	
		@	0.25MG	A076363	002	Jan 31, 2003	Jun	DISC	
>A>	AB	HIKMA PHARMS	0.125MG	A077002	002	Oct 30, 2007	Oct	CAHN	
>A>	AB		0.25MG	A077002	001	Oct 30, 2007	Oct	CAHN	
>D>	AB	WEST WARD	0.125MG	A077002	002	Oct 30, 2007	Oct	CAHN	
>D>	AB		0.25MG	A077002	001	Oct 30, 2007	Oct	CAHN	
<u>DILTIAZEM HYDROCHLORIDE</u>									
CAPSULE, EXTENDED RELEASE;ORAL									
DILTIAZEM HYDROCHLORIDE									
AB3		PAR PHARM	120MG	A074984	001	Dec 20, 1999	Jan	CAHN	
AB3			180MG	A074984	002	Dec 20, 1999	Jan	CAHN	
AB3			240MG	A074984	003	Dec 20, 1999	Jan	CAHN	
AB3			300MG	A074984	004	Dec 20, 1999	Jan	CAHN	
AB4		SANDOZ	120MG	A091022	001	Sep 28, 2012	Feb	CAHN	
AB4			180MG	A091022	002	Sep 28, 2012	Feb	CAHN	
AB4			240MG	A091022	003	Sep 28, 2012	Feb	CAHN	
AB4			300MG	A091022	004	Sep 28, 2012	Feb	CAHN	
AB4			360MG	A091022	005	Sep 28, 2012	Feb	CAHN	
AB4			420MG	A091022	006	Sep 28, 2012	Feb	CAHN	
INJECTABLE;INJECTION									
DILTIAZEM HYDROCHLORIDE									
AP		AKORN INC	5MG/ML	A075086	001	Apr 09, 1998	Jul	CAHN	
		@ APOTEX INC	5MG/ML	A075375	001	Sep 30, 1999	Apr	DISC	
		@ TEVA PHARMS USA	5MG/ML	A074894	001	Aug 26, 1997	Apr	CAHN	

DILTIAZEM HYDROCHLORIDE

INJECTABLE; INJECTION
DILTIAZEM HYDROCHLORIDE

+		10MG/ML	A074894	002	Apr 19, 2002	Apr CAHN
TABLET; ORAL						
	DILTIAZEM HYDROCHLORIDE					
@	DAVA PHARMS INC	30MG	A074093	001	Nov 05, 1992	Jan DISC
@		60MG	A074093	002	Nov 05, 1992	Jan DISC
@		90MG	A074093	003	Nov 05, 1992	Jan DISC
@		120MG	A074093	004	Nov 05, 1992	Jan DISC

DIMENHYDRINATE

INJECTABLE; INJECTION
DIMENHYDRINATE

+	FRESENIUS KABI USA	50MG/ML	A040519	001	Jun 23, 2004	Apr CRLD
@	WATSON LABS	50MG/ML	A080615	001		Apr DISC

DIMETHYL FUMARATE

CAPSULE, DELAYED RELEASE; ORAL
TECFIDERA

	BIOGEN IDEC INC	120MG	N204063	001	Mar 27, 2013	Mar NEWA
+		240MG	N204063	002	Mar 27, 2013	Mar NEWA

DIPHENHYDRAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
DIPHENHYDRAMINE HYDROCHLORIDE

	@ WATSON LABS INC	10MG/ML	A080873	001		Mar DISC
	@	50MG/ML	A080873	002		Mar DISC
	DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE					
AP	BD RX	50MG/ML	A091526	001	Mar 26, 2013	Mar NEWA
	@ WATSON LABS INC	50MG/ML	A080873	003		Mar DISC

DIPYRIDAMOLE

INJECTABLE; INJECTION
DIPYRIDAMOLE

@	AGILA SPECLTS	5MG/ML	A075769	001	Nov 27, 2002	Aug CAHN
@	APOTEX INC	5MG/ML	A075769	001	Nov 27, 2002	Apr DISC
@	TEVA PHARMS USA	5MG/ML	A074952	001	Nov 26, 1997	May CAHN

TABLET; ORAL

DIPYRIDAMOLE

@	PROSAM LABS	25MG	A040542	001	Apr 21, 2006	Jun DISC
@		50MG	A040542	002	Apr 21, 2006	Jun DISC
@		75MG	A040542	003	Apr 21, 2006	Jun DISC

DISULFIRAM

TABLET; ORAL
DISULFIRAM

AB	ALVOGEN PINE BROOK	250MG	A091681	001	Aug 08, 2013	Jul NEWA
----	--------------------	-------	---------	-----	--------------	----------

DIVALPROEX SODIUM

TABLET, DELAYED RELEASE; ORAL
DIVALPROEX SODIUM

@	MYLAN	EQ 125MG VALPROIC ACID	A077254	001	Jul 29, 2008	Aug DISC
@		EQ 250MG VALPROIC ACID	A077254	002	Jul 29, 2008	Aug DISC
@		EQ 500MG VALPROIC ACID	A077254	003	Jul 29, 2008	Aug DISC

TABLET, EXTENDED RELEASE; ORAL

DIVALPROEX SODIUM

@	TEVA PHARMS USA	EQ 500MG VALPROIC ACID	A078700	001	Aug 03, 2009	Mar DISC
---	-----------------	------------------------	---------	-----	--------------	----------

DOCETAXEL

INJECTABLE; INJECTION
DOCETAXEL

AP	ACCORD HLTHCARE	160MG/8ML (20MG/ML)	N201195	005	Apr 20, 2012	Aug CTEC	
AP	ACTAVIS INC	20MG/ML (20MG/ML)	N203551	001	Apr 12, 2013	Apr NEWA	
AP		80MG/4ML (20MG/ML)	N203551	002	Apr 12, 2013	Apr NEWA	
		140MG/7ML (20MG/ML)	N203551	003	Apr 12, 2013	Apr NEWA	
	@ APOTEX INC	20MG/0.5ML (40MG/ML)	N022312	001	Jan 11, 2012	May DISC	
	@	80MG/2ML (40MG/ML)	N022312	002	Jan 11, 2012	May DISC	
	TAXOTERE						
AP	+	SANOFI AVENTIS US	160MG/8ML (20MG/ML)	N020449	005	Apr 13, 2012	Aug NEWA

DOLUTEGRAVIR SODIUMTABLET;ORAL
TIVICAY

+ VIV HLTHCARE EQ 50MG BASE N204790 001 Aug 12, 2013 Aug NEWA

DONEPEZIL HYDROCHLORIDETABLET;ORAL
ARICEPT

AB	+	EISAI INC	23MG	N022568	001	Jul 23, 2010	Jul CTEC
		DONEPEZIL HYDROCHLORIDE					
		@ ACCORD HLTHCARE	5MG	A201335	001	Aug 29, 2011	Jan DISC
		@	10MG	A201335	002	Aug 29, 2011	Jan DISC
AB		ACTAVIS GRP PTC	5MG	A090551	001	May 31, 2011	Apr CAHN
AB			10MG	A090551	002	May 31, 2011	Apr CAHN
AB		ALEMBIC PHARMS LTD	5MG	A201724	001	Feb 25, 2013	Feb NEWA
AB			10MG	A201724	002	Feb 25, 2013	Feb NEWA
AB		ALVOGEN PINE BROOK	5MG	A202114	001	Jul 05, 2013	Jun NEWA
AB			10MG	A202114	002	Jul 05, 2013	Jun NEWA
AB		CSPC OUYI PHARM CO	5MG	A202114	001	Jul 05, 2013	Sep CAHN
AB			10MG	A202114	002	Jul 05, 2013	Sep CAHN
AB		DR REDDYS LABS LTD	23MG	A202723	001	Jul 24, 2013	Jul NEWA
AB		PAR PHARM	23MG	A202542	001	Jul 24, 2013	Jul NEWA

DORIPENEMINJECTABLE;IV (INFUSION)
DORIBAX

>D>		JANSSEN PHARMS	250MG/VIAL	N022106	002	Oct 05, 2010	Oct CAHN
>D>	+		500MG/VIAL	N022106	001	Oct 12, 2007	Oct CAHN
>A>		SHIONOGI INC	250MG/VIAL	N022106	002	Oct 05, 2010	Oct CAHN
>A>	+		500MG/VIAL	N022106	001	Oct 12, 2007	Oct CAHN

DORZOLAMIDE HYDROCHLORIDESOLUTION/DROPS;OPHTHALMIC
DORZOLAMIDE HYDROCHLORIDE

@ APOTEX INC EQ 2% BASE A078395 001 Oct 28, 2008 Apr DISC

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATESOLUTION/DROPS;OPHTHALMIC
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

@ APOTEX INC EQ 2% BASE;EQ 0.5% BASE A078201 001 Oct 28, 2008 Apr DISC

DOXAPRAM HYDROCHLORIDEINJECTABLE;INJECTION
DOPRAM

AP + HIKMA MAPLE 20MG/ML N014879 001 Jul CAHN

DOXAZOSIN MESYLATETABLET;ORAL
DOXAZOSIN MESYLATE

		@ WATSON LABS INC	EQ 1MG BASE	A075426	001	Oct 18, 2000	Jan DISC
		@	EQ 2MG BASE	A075426	002	Oct 18, 2000	Jan DISC
		@	EQ 4MG BASE	A075426	003	Oct 18, 2000	Jan DISC
		@	EQ 8MG BASE	A075426	004	Oct 18, 2000	Jan DISC

DOXEPIN HYDROCHLORIDECAPSULE;ORAL
DOXEPIN HYDROCHLORIDE

AB		MYLAN PHARMS INC	EQ 10MG BASE	A070791	002	May 13, 1986	Jun CRLD
AB			EQ 10MG BASE	A070791	002	May 13, 1986	May CRLD
AB	+		EQ 25MG BASE	A070791	003	May 13, 1986	Jun CRLD
		@ PAR PHARM	EQ 10MG BASE	A071697	001	Nov 09, 1987	May DISC
		@	EQ 25MG BASE	A071437	001	Nov 09, 1987	May DISC
		@	EQ 50MG BASE	A071595	001	Nov 09, 1987	May DISC
		@	EQ 75MG BASE	A071608	001	Nov 09, 1987	May DISC
		@	EQ 100MG BASE	A071422	001	Nov 09, 1987	May DISC
		@ WATSON LABS	EQ 10MG BASE	A071485	001	Apr 30, 1987	May DISC
		@	EQ 25MG BASE	A071486	001	Apr 30, 1987	May DISC
		@	EQ 50MG BASE	A071238	001	Apr 30, 1987	May DISC
		@	EQ 75MG BASE	A071326	001	Apr 30, 1987	May DISC
		@	EQ 100MG BASE	A071239	001	Apr 30, 1987	May DISC

CONCENTRATE;ORAL

DOXEPIN HYDROCHLORIDE

CONCENTRATE;ORAL

DOXEPIN HYDROCHLORIDE

@ PHARM ASSOC

EQ 10MG BASE/ML

A075924 001 Jan 15, 2004 Mar DISC

TABLET;ORAL

DOXEPIN HYDROCHLORIDE

AB ACTAVIS ELIZABETH

EQ 3MG BASE

A201951 001 Jul 26, 2013 Jul NEWA

AB

EQ 6MG BASE

A201951 002 Jul 26, 2013 Jul NEWA

SILENOR

AB PERNIX THERAPS LLC

EQ 3MG BASE

N022036 001 Mar 17, 2010 Jul CFTG

EQ 3MG BASE

N022036 001 Mar 17, 2010 Apr CAHN

AB +

EQ 6MG BASE

N022036 002 Mar 17, 2010 Jul CFTG

+

EQ 6MG BASE

N022036 002 Mar 17, 2010 Apr CAHN

DOXERCALCIFEROL

INJECTABLE;INJECTION

DOXERCALCIFEROL

>A> AP HIKMA PHARMS LLC

4MCG/2ML (2MCG/ML)

A091101 001 Aug 30, 2013 Oct CAHN

>D> AP INNOPHARMA INC

4MCG/2ML (2MCG/ML)

A091101 001 Aug 30, 2013 Oct CAHN

AP

4MCG/2ML (2MCG/ML)

A091101 001 Aug 30, 2013 Aug NEWA

HECTOROL

AP + GENZYME CORP

4MCG/2ML (2MCG/ML)

N021027 001 Apr 06, 2000 Aug CFTG

DOXORUBICIN HYDROCHLORIDE

INJECTABLE;INJECTION

DOXORUBICIN HYDROCHLORIDE

AP SAGENT PHARMS

2MG/ML

A091495 001 Mar 18, 2013 Mar NEWA

AP TEVA PHARMS USA

2MG/ML

A064140 001 Jul 28, 1995 Jun CAHN

AP 200MG/100ML

A064140 002 Jul 28, 1995 Jun CAHN

INJECTABLE, LIPOSOMAL;INJECTION

DOXIL

AB + JANSSEN RES AND DEV

20MG/10ML (2MG/ML)

N050718 001 Nov 17, 1995 Jan CFTG

AB +

50MG/25ML (2MG/ML)

N050718 002 Jun 13, 2000 Jan CFTG

DOXIL (LIPOSOMAL)

AB JANSSEN RES AND DEV

20MG/10ML (2MG/ML)

N050718 001 Nov 17, 1995 Jun CRLD

AB +

20MG/10ML (2MG/ML)

N050718 001 Nov 17, 1995 Apr CTNA

AB

50MG/25ML (2MG/ML)

N050718 002 Jun 13, 2000 Jun CRLD

AB +

50MG/25ML (2MG/ML)

N050718 002 Jun 13, 2000 Apr CTNA

DOXORUBICIN HYDROCHLORIDE

AB SUN PHARMA GLOBAL

20MG/10ML (2MG/ML)

A203263 001 Feb 04, 2013 Jan NEWA

AB

50MG/25ML (2MG/ML)

A203263 002 Feb 04, 2013 Jan NEWA

DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL)

AB + SUN PHARMA GLOBAL

20MG/10ML (2MG/ML)

A203263 001 Feb 04, 2013 Jun CRLD

AB +

20MG/10ML (2MG/ML)

A203263 001 Feb 04, 2013 Apr CTNA

AB

50MG/25ML (2MG/ML)

A203263 002 Feb 04, 2013 Jun CRLD

AB +

50MG/25ML (2MG/ML)

A203263 002 Feb 04, 2013 Apr CTNA

DOXYCYCLINE

FOR SUSPENSION;ORAL

DOXYCYCLINE

AB CHARTWELL LIFE SCI

EQ 25MG BASE/5ML

A065454 001 Jul 16, 2008 Sep CAHN

AB LUPIN LTD

EQ 25MG BASE/5ML

A201678 001 Mar 18, 2013 Mar NEWA

DOXYCYCLINE HYCLATE

CAPSULE;ORAL

DOXYCYCLINE HYCLATE

AB CHARTWELL LIFE SCI

EQ 50MG BASE

A062500 001 Sep 11, 1984 Sep CAHN

AB

EQ 100MG BASE

A062500 002 Sep 11, 1984 Sep CAHN

AB HIKMA PHARMS

EQ 50MG BASE

A062396 002 Nov 07, 1984 May CAHN

AB EQ 100MG BASE

A062396 001 May 07, 1984 May CAHN

TABLET;ORAL

DOXYCYCLINE HYCLATE

@ BLU CARIBE INC

EQ 50MG BASE

A062269 003 Mar CAHN

@

EQ 100MG BASE

A062269 002 Nov 08, 1982 Mar CAHN

AB CHARTWELL LIFE SCI

EQ 100MG BASE

A062505 001 Sep 11, 1984 Jul CAHN

AB + HIKMA PHARMS

EQ 100MG BASE

A065095 001 Jul 02, 2003 May CAHN

TABLET, DELAYED RELEASE;ORAL

DORYX

MAYNE PHARMA

EQ 80MG BASE

N050795 004 Apr 11, 2013 Apr NEWA

EQ 200MG BASE

N050795 005 Apr 11, 2013 Apr NEWA

DOXYCYCLINE HYCLATE

DOXYCYCLINE HYCLATE

TABLET, DELAYED RELEASE;ORAL
DOXYCYCLINE HYCLATE

AB	HERITAGE PHARMS INC	EQ 75MG BASE	A200856	001	Apr 30, 2013	Apr NEWA
AB		EQ 100MG BASE	A200856	002	Apr 30, 2013	Apr NEWA
AB		EQ 150MG BASE	A200856	003	Apr 30, 2013	Apr NEWA

DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE

TABLET, DELAYED RELEASE;ORAL
DICLEGIS

+	DUCHESNAY	10MG;10MG	N021876	001	Apr 08, 2013	Apr NEWA
---	-----------	-----------	---------	-----	--------------	----------

DUTASTERIDE

CAPSULE;ORAL
DUTASTERIDE

AB	BANNER PHARMACAPS	0.5MG	A200899	001	May 30, 2013	May NEWA
----	-------------------	-------	---------	-----	--------------	----------

ECONAZOLE NITRATE

>A> AEROSOL, FOAM;TOPICAL
>A> ECOZA

>A>	+	AMDERMA PHARMS	1%	N205175	001	Oct 24, 2013	Oct NEWA
		CREAM;TOPICAL					
		ECONAZOLE NITRATE					
AB		IGI LABS INC	1%	A076574	001	Dec 17, 2004	Mar CAHN

EDROPHONIUM CHLORIDE

INJECTABLE;INJECTION
TENSILON

AP	+	VALEANT PHARMS	10MG/ML	N007959	001		Jul CAHN
		TENSILON PRESERVATIVE FREE					
AP	+	VALEANT PHARMS	10MG/ML	N007959	002		Jul CAHN

ENALAPRIL MALEATE

FOR SOLUTION;ORAL
EPANED KIT

+	SILVERGATE PHARMS	1MG/ML	N204308	001	Aug 13, 2013	Aug NEWA
---	-------------------	--------	---------	-----	--------------	----------

TABLET;ORAL
ENALAPRIL MALEATE

@	MYLAN	2.5MG	A075472	001	Aug 22, 2000	Aug DISC
@		5MG	A075472	002	Aug 22, 2000	Aug DISC
@		10MG	A075472	003	Aug 22, 2000	Aug DISC
@		20MG	A075472	004	Aug 22, 2000	Aug DISC

ENALAPRILAT

INJECTABLE;INJECTION
ENALAPRILAT

AP		TEVA PHARMS USA	1.25MG/ML	A075578	001	Aug 22, 2000	May CAHN
----	--	-----------------	-----------	---------	-----	--------------	----------

ENTACAPONE

TABLET;ORAL
ENTACAPONE

AB		MYLAN PHARMS INC	200MG	A202394	001	May 13, 2013	Apr NEWA
----	--	------------------	-------	---------	-----	--------------	----------

EPINEPHRINE

INJECTABLE;IM-SC
EPIPEN

BX	+	MERIDIAN MEDCL TECHN	0.3MG/DELIVERY	N019430	001	Dec 22, 1987	Jul CDFR
BX	+	MYLAN SPECLT	0.3MG/DELIVERY	N019430	001	Dec 22, 1987	Sep CAHN
		EPIPEN JR.					
BX	+	MERIDIAN MEDCL TECHN	0.15MG/DELIVERY	N019430	002	Dec 22, 1987	Jul CDFR
BX	+	MYLAN SPECLT	0.15MG/DELIVERY	N019430	002	Dec 22, 1987	Sep CAHN
		INJECTABLE;INTRAMUSCULAR					
		EPI E Z PEN JR					
	@	MYLAN SPECLT	0.15MG/DELIVERY	N019430	004	Aug 03, 1995	Sep CAHN
		EPIPEN E Z PEN					
	@	MYLAN SPECLT	0.3MG/DELIVERY	N019430	003	Aug 03, 1995	Sep CAHN

EPIRUBICIN HYDROCHLORIDE

INJECTABLE;INJECTION
EPIRUBICIN HYDROCHLORIDE

EPIRUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION							
EPIRUBICIN HYDROCHLORIDE							
	@ MYLAN LLC	50MG/25ML (2MG/ML)	A065371	001	Nov 28, 2007	Feb	DISC
	@	200MG/100ML (2MG/ML)	A065371	002	Nov 28, 2007	Feb	DISC
AP	TEVA PHARMS USA	50MG/25ML (2MG/ML)	A065331	001	Aug 09, 2007	Apr	CAHN
AP		200MG/100ML (2MG/ML)	A065331	002	Aug 09, 2007	Apr	CAHN

EPOPROSTENOL SODIUM

INJECTABLE; INJECTION							
EPOPROSTENOL SODIUM							
AP	TEVA PHARMS USA	EQ 0.5MG BASE/VIAL	A078396	001	Apr 23, 2008	Apr	CAHN
AP		EQ 1.5MG BASE/VIAL	A078396	002	Apr 23, 2008	Apr	CAHN

ERTAPENEM SODIUM

INJECTABLE; INTRAMUSCULAR, IV (INFUSION)							
INVANZ							
+	MERCK SHARP DOHME	EQ 1GM BASE/VIAL	N021337	001	Nov 21, 2001	Jun	CAHN

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS; ORAL							
ERYC							
AB	+	MAYNE PHARMA	250MG	N050536	001		Mar CAHN
	@	WARNER CHILCOTT LLC	250MG	A062338	001		Apr DISC
GEL; TOPICAL							
ERYGEL							
AT	+	DELCOR ASSET CORP	2%	N050617	001	Oct 21, 1987	Jul CAHN
OINTMENT; OPHTHALMIC							
ERYTHROMYCIN							
AT	+	PERRIGO CO TENNESSEE	0.5%	A062447	001	Sep 26, 1983	Jun CAHN
SOLUTION; TOPICAL							
SANSAC							
	@	DOW PHARM	2%	A062522	001	Jan 24, 1985	Apr CAHN

ESCITALOPRAM OXALATE

SOLUTION; ORAL							
ESCITALOPRAM OXALATE							
AA	SILARX PHARMS INC	EQ 5MG BASE/5ML	A090477	001	Jun 12, 2013	May	NEWA

ESOMEPRAZOLE MAGNESIUM; NAPROXEN

TABLET, DELAYED RELEASE; ORAL							
NAPROXEN AND ESOMEPRAZOLE MAGNESIUM							
AB	DR REDDYS LABS LTD	EQ 20MG BASE; 375MG	A202461	001	Sep 27, 2013	Sep	NEWA
AB		EQ 20MG BASE; 500MG	A202461	002	Sep 27, 2013	Sep	NEWA
VIMOVO							
AB	ASTRAZENECA LP	EQ 20MG BASE; 375MG	N022511	002	Apr 30, 2010	Sep	CFTG
AB	+	EQ 20MG BASE; 500MG	N022511	001	Apr 30, 2010	Sep	CFTG

ESOMEPRAZOLE SODIUM

INJECTABLE; INTRAVENOUS							
ESOMEPRAZOLE SODIUM							
AP	SUN PHARMA GLOBAL	EQ 20MG BASE/VIAL	A200882	001	Mar 18, 2013	Mar	NEWA
AP		EQ 40MG BASE/VIAL	A200882	002	Mar 18, 2013	Mar	NEWA
NEXIUM IV							
AP	+	ASTRAZENECA	EQ 20MG BASE/VIAL	N021689	001	Mar 31, 2005	Mar CFTG
AP	+	EQ 40MG BASE/VIAL	N021689	002	Mar 31, 2005	Mar	CFTG

ESOMEPRAZOLE STRONTIUM

CAPSULE, DELAYED RELEASE; ORAL							
ESOMEPRAZOLE STRONTIUM							
	HANMI PHARM CO LTD	EQ 20MG BASE	N202342	001	Aug 06, 2013	Sep	CAHN
+		EQ 40MG BASE	N202342	002	Aug 06, 2013	Sep	CAHN
	HANMI USA	EQ 20MG BASE	N202342	001	Aug 06, 2013	Aug	NEWA
+		EQ 40MG BASE	N202342	002	Aug 06, 2013	Aug	NEWA

ESTRADIOL VALERATE

INJECTABLE; INJECTION							
ESTRADIOL VALERATE							
	@ WATSON LABS	40MG/ML	A083714	001		Jun	DISC
	@ WATSON LABS INC	20MG/ML	A083547	001		Jun	DISC

ESTROGENS, CONJUGATED SYNTHETIC A

CREAM;VAGINAL

SYNTHETIC CONJUGATED ESTROGENS A

@ TEVA WOMENS	0.625MG/GM	N021788	001	Nov 28, 2008	Sep DISC
---------------	------------	---------	-----	--------------	----------

ESTRONE

INJECTABLE;INJECTION

ESTRONE

@ WATSON LABS	5MG/ML	A085239	001		Jun DISC
---------------	--------	---------	-----	--	----------

ESTROPIPATE

TABLET;ORAL

ORTHO-EST

@ CARACO	0.75MG	A089567	001	Feb 27, 1991	Apr DISC
@	1.5MG	A089582	001	Jul 17, 1991	Apr DISC

ESZOPICLONE

TABLET;ORAL

ESZOPICLONE

AB	MYLAN PHARMS INC	1MG	A091151	001	Mar 26, 2013	Mar NEWA
AB		2MG	A091151	002	Mar 26, 2013	Mar NEWA
AB		3MG	A091151	003	Mar 26, 2013	Mar NEWA
AB	SUN PHARMA GLOBAL	1MG	A091103	001	Apr 03, 2013	Mar NEWA
AB		2MG	A091103	002	Apr 03, 2013	Mar NEWA
AB		3MG	A091103	003	Apr 03, 2013	Mar NEWA
	LUNESTA					
AB	SUNOVION PHARMS INC	1MG	N021476	001	Dec 15, 2004	Mar CTEC
AB		2MG	N021476	002	Dec 15, 2004	Mar CTEC
AB	+	3MG	N021476	003	Dec 15, 2004	Mar CTEC

ETHAMBUTOL HYDROCHLORIDE

TABLET;ORAL

ETHAMBUTOL HYDROCHLORIDE

@ WEST WARD	100MG	A075095	001	Nov 30, 1999	Jul DISC	
@	400MG	A075095	002	Nov 30, 1999	Jul DISC	
	MYAMBUTOL					
AB	+	STI PHARMA LLC	400MG	N016320	003	Jul CRLD

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET;ORAL

DAYSEE

AB	LUPIN LTD	0.03MG,0.01MG;0.15MG,N/A	A091467	001	Apr 10, 2013	Mar NEWA
	QUARTETTE					
+	TEVA BRANDED PHARM	0.02MG,0.15MG;0.025MG,0.15MG;0.03MG,0.15MG;0.01MG,N/A	N204061	001	Mar 28, 2013	Mar NEWA

TABLET;ORAL-28

LEVONORGESTREL AND ETHINYL ESTRADIOL

AB1	FAMY CARE LTD	0.02MG;0.1MG	A200245	001	Oct 09, 2013	Sep NEWA
AB1	LUPIN LTD	0.02MG;0.1MG	A091425	001	Jan 18, 2013	Jan NEWA

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET;ORAL-28

NORETHINDRONE AND ETHINYL ESTRADIOL

>D>	AB	FAMY CARE LTD	0.05MG;1MG	A203006	001	Aug 05, 2013	Oct CRLD
>A>	AB	+	0.05MG;1MG	A203006	001	Aug 05, 2013	Oct CRLD
	AB		0.05MG;1MG	A203006	001	Aug 05, 2013	Jul NEWA
>D>		OVCON-50					
>D>	AB	+	WARNER CHILCOTT LLC	0.05MG;1MG	N017576	001	Oct DISC
>A>		@	0.05MG;1MG	N017576	001		Oct DISC
	AB	+	0.05MG;1MG	N017576	001		Jul CFTG
		PIRMELLA 1/35					
	AB	LUPIN LTD	0.035MG;1MG	A201512	001	Apr 24, 2013	Apr NEWA
		PIRMELLA 7/7/7					
	AB	LUPIN LTD	0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG	A201510	001	Apr 24, 2013	Apr NEWA
		VYFEMLA					
	AB	LUPIN LTD	0.035MG;0.4MG	A201886	001	Sep 26, 2013	Sep NEWA
		TABLET, CHEWABLE;ORAL					
		NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE					
	AB	AMNEAL PHARMS	0.035MG;0.4MG	A078892	001	Sep 26, 2011	Sep CAHN

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

CAPSULE;ORAL									
MINASTRIN 24 FE									
	+	WARNER CHILCOTT	0.02MG;1MG	N204426	001	Apr 19, 2013	Apr	NEWA	
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE									
	@	WARNER CHILCOTT	0.02MG;1MG	N204426	001	Apr 19, 2013	May	DISC	
TABLET;ORAL									
FEMHRT									
	@	WARNER CHILCOTT LLC	0.005MG;1MG	N021065	002	Oct 15, 1999	Jan	DISC	
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL									
	+	BARR LABS INC	0.005MG;1MG	A076221	001	Nov 06, 2009	Jan	CRLD	
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE									
AB		AMNEAL PHARMS	0.02MG;1MG	A078267	001	Sep 01, 2009	Sep	CAHN	
TABLET;ORAL-21									
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL									
>A>	AB	FAMY CARE LTD	0.02MG;1MG	A202771	001	Nov 06, 2013	Oct	NEWA	
TABLET;ORAL-28									
LARIN FE 1.5/30									
AB		NOVAST LABS LTD	0.03MG;1.5MG	A091453	001	Aug 23, 2013	Aug	NEWA	
LARIN FE 1/20									
AB		NOVAST LABS LTD	0.02MG;1MG	A091454	001	Aug 26, 2013	Aug	NEWA	
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL									
>A>	AB	FAMY CARE LTD	0.02MG;1MG	A202772	001	Nov 14, 2013	Oct	NEWA	
TABLET, CHEWABLE;ORAL									
MINASTRIN 24 FE									
>A>	+	WARNER CHILCOTT LLC	0.02MG;1MG	N203667	001	May 08, 2013	Oct	CTNA	
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE									
>D>	+	WARNER CHILCOTT LLC	0.02MG;1MG	N203667	001	May 08, 2013	Oct	CTNA	
	+		0.02MG;1MG	N203667	001	May 08, 2003	May	NEWA	
TABLET, CHEWABLE, TABLET;ORAL									
LO MINASTRIN FE									
	+	WARNER CHILCOTT	0.01MG,0.01MG,N/A;1MG,N/A,N/A	N204654	001	Jul 24, 2013	Jul	NEWA	

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET;ORAL-28									
ESTARYLLA									
AB		SANDOZ	0.035MG;0.25MG	A090794	001	Jan 30, 2013	Jan	NEWA	
TRI LO SPRINTC									
	@	BARR LABS INC	0.025MG,0.025MG,0.025MG;0.18MG,0.2	A076784	001	Jun 29, 2009	Apr	DISC	
15MG,0.25MG									
TRI-ESTARYLLA									
AB		SANDOZ	0.035MG,0.035MG,0.035MG;0.18MG,0.2	A090793	001	Jan 30, 2013	Jan	NEWA	
15MG,0.25MG									

ETHOTOIN

TABLET;ORAL									
PEGANONE									
	+	RECORDATI RARE	250MG	N010841	001		May	CAHN	

ETODOLAC

TABLET;ORAL									
ETODOLAC									
	@	PROSAM LABS	400MG	A074819	001	Feb 28, 1997	Mar	DISC	
	@		500MG	A074819	002	Apr 28, 1998	Mar	DISC	

ETOPOSIDE

INJECTABLE;INJECTION									
ETOPOSIDE									
AP		ACCORD HLTHCARE	20MG/ML	A074513	001	Mar 14, 1996	Apr	CAHN	
	@	PHARMACHEMIE	20MG/ML	A074227	001	Feb 22, 1996	Apr	DISC	
AP		TEVA PHARMS USA	20MG/ML	A074284	001	Feb 10, 1994	May	CAHN	
AP			20MG/ML	A074529	001	Jul 24, 1996	Apr	CAHN	

FAMCICLOVIR

TABLET;ORAL									
FAMCICLOVIR									
AB		CIPLA LTD	125MG	A078278	001	Mar 21, 2011	Jul	CAHN	
AB			250MG	A078278	002	Mar 21, 2011	Jul	CAHN	
AB			500MG	A078278	003	Mar 21, 2011	Jul	CAHN	

FAMOTIDINE

INJECTABLE; INJECTION

FAMOTIDINE

		@ APOTEX INC	10MG/ML	A075942	001	Aug 02, 2002	Apr DISC
>D>	AP	+ HIKMA MAPLE	10MG/ML	A075799	001	Apr 30, 2002	Oct DISC
>A>		@	10MG/ML	A075799	001	Apr 30, 2002	Oct DISC
		FAMOTIDINE PRESERVATIVE FREE					
	AP	AKORN INC	10MG/ML	A076324	001	Nov 27, 2002	Mar CAHN
		@ APOTEX INC	10MG/ML	A076324	001	Nov 27, 2002	Apr DISC
>D>	AP	+ HIKMA MAPLE	10MG/ML	A075789	001	Apr 30, 2002	Oct DISC
>A>		@	10MG/ML	A075789	001	Apr 30, 2002	Oct DISC
		FAMOTIDINE PRESERVATIVE FREE (PHARMACY BULK)					
	AP	AKORN INC	10MG/ML	A076322	001	Nov 27, 2002	Mar CAHN
		@ APOTEX INC	10MG/ML	A076322	001	Nov 27, 2002	Apr DISC
		PEPCID PRESERVATIVE FREE IN PLASTIC CONTAINER					
		@ MERCK SHARP DOHME	0.4MG/ML	N020249	001	Feb 18, 1994	Apr CAHN
		TABLET; ORAL					
		FAMOTIDINE					
		@ WATSON LABS	20MG	A075062	002	Apr 16, 2001	Sep DISC
		@	40MG	A075062	001	Apr 16, 2001	Sep DISC

FELODIPINE

TABLET, EXTENDED RELEASE; ORAL

FELODIPINE

>A>	AB	HERITAGE PHARMS INC	2.5MG	A201964	001	Nov 08, 2013	Oct NEWA
>A>	AB		5MG	A201964	002	Nov 08, 2013	Oct NEWA
>A>	AB		10MG	A201964	003	Nov 08, 2013	Oct NEWA

FENOFIBRATE

CAPSULE; ORAL

ANTARA (MICRONIZED)

>A>		LUPIN ATLANTIS	30MG	N021695	004	Oct 18, 2013	Oct NEWA
>A>			90MG	N021695	005	Oct 18, 2013	Oct NEWA
		FENOFIBRATE (MICRONIZED)					
	AB	APOTEX INC	43MG	A202252	001	Jul 26, 2013	Jul NEWA
	AB		130MG	A202252	002	Jul 26, 2013	Jul NEWA

FENOFIBRIC ACID

TABLET; ORAL

FIBRICOR

MUTUAL PHARM CO INC 35MG
+ 105MG

N022418 001 Aug 14, 2009 Feb CAHN
N022418 002 Aug 14, 2009 Feb CAHN

FENOPROFEN CALCIUM

TABLET; ORAL

FENOPROFEN CALCIUM

@ IVAX SUB TEVA PHARMS EQ 600MG BASE
+ MYLAN PHARMS INC EQ 600MG BASE

A072557 001 Aug 29, 1988 Mar DISC
A072267 001 Aug 17, 1988 Mar CTEC

FENTANYL

SPRAY; SUBLINGUAL

SUBSYS

INSYS THERAP 1.2MG
1.6MG

N202788 006 Aug 30, 2012 Aug NEWA
N202788 007 Aug 30, 2012 Aug NEWA

FENTANYL CITRATE

FILM; BUCCAL

ONSOLIS

@ MEDA PHARMS EQ 0.2MG BASE
@ EQ 0.4MG BASE
@ EQ 0.6MG BASE
@ EQ 0.8MG BASE
@ EQ 1.2MG BASE

N022266 001 Jul 16, 2009 May DISC
N022266 002 Jul 16, 2009 May DISC
N022266 003 Jul 16, 2009 May DISC
N022266 004 Jul 16, 2009 May DISC
N022266 005 Jul 16, 2009 May DISC

INJECTABLE; INJECTION

FENTANYL CITRATE PRESERVATIVE FREE

AP + HIKMA MAPLE EQ 0.05MG BASE/ML

N019101 001 Jul 11, 1984 Jul CAHN

SPRAY, METERED; NASAL

LAZANDA

DEPOMED INC EQ 0.1MG BASE
+ EQ 0.4MG BASE

N022569 001 Jun 30, 2011 Sep CAHN
N022569 002 Jun 30, 2011 Sep CAHN

TABLET; BUCCAL, SUBLINGUAL

FENTANYL CITRATETABLET;BUCCAL, SUBLINGUAL
FENTORA

AB	CEPHALON	EQ 0.1MG BASE	N021947	001	Sep 25, 2006	Feb CDFR
AB		EQ 0.2MG BASE	N021947	002	Sep 25, 2006	Feb CDFR
	@	EQ 0.3MG BASE	N021947	006	Mar 02, 2007	Feb CDFR
AB	+	EQ 0.4MG BASE	N021947	003	Sep 25, 2006	Feb CDFR
AB		EQ 0.6MG BASE	N021947	004	Sep 25, 2006	Feb CDFR
AB		EQ 0.8MG BASE	N021947	005	Sep 25, 2006	Feb CDFR

TABLET;SUBLINGUAL
ABSTRAL

GALENA BIOPHARMA

		EQ 0.1MG BASE	N022510	001	Jan 07, 2011	May CAHN
		EQ 0.2MG BASE	N022510	002	Jan 07, 2011	May CAHN
		EQ 0.3MG BASE	N022510	003	Jan 07, 2011	May CAHN
	+	EQ 0.4MG BASE	N022510	004	Jan 07, 2011	May CAHN
		EQ 0.6MG BASE	N022510	005	Jan 07, 2011	May CAHN
		EQ 0.8MG BASE	N022510	006	Jan 07, 2011	May CAHN

FERRIC CARBOXYMALTOS

INJECTABLE;IV

INJECTAFER

+	LUITPOLD	750MG IRON/15ML (50MG IRON/ML)	N203565	001	Jul 25, 2013	Jul NEWA
---	----------	--------------------------------	---------	-----	--------------	----------

FERUMOXIL

SUSPENSION;ORAL

GASTROMARK

@	AMAG PHARMS INC	EQ 0.175MG IRON/ML	N020410	001	Dec 06, 1996	Feb DISC
---	-----------------	--------------------	---------	-----	--------------	----------

FINASTERIDE

TABLET;ORAL

FINASTERIDE

AB	ACCORD HLTHCARE	5MG	A090121	001	Feb 23, 2010	Apr CAHN	
>A>	AB	ACCORD HLTHCARE INC	1MG	A091643	001	Nov 05, 2013	Oct NEWA
>A>	AB	ACTAVIS TOTOWA	1MG	A078371	001	Nov 05, 2013	Oct NEWA
>A>	AB	AUROBINDO PHARMA LTD	1MG	A203687	001	Nov 05, 2013	Oct NEWA
AB		HETERO LABS LTD III	1MG	A090060	001	Jul 01, 2013	Jun NEWA
AB		5MG	A090061	001	Jun 07, 2010	Apr CAHN	
>A>	AB	MYLAN PHARMS INC	1MG	A078161	001	Nov 05, 2013	Oct NEWA
AB		SUN PHARMA GLOBAL	1MG	A090508	001	Jul 01, 2013	Jun NEWA
>A>	AB	TEVA	1MG	A076905	001	Nov 05, 2013	Oct NEWA

FLECAINIDE ACETATE

TABLET;ORAL

FLECAINIDE ACETATE

	@	APOTEX INC	50MG	A079164	001	Jul 09, 2009	Apr DISC
	@		100MG	A079164	002	Jul 09, 2009	Apr DISC
	@		150MG	A079164	003	Jul 09, 2009	Apr DISC
AB	+	ROXANE	150MG	A076278	003	Jan 14, 2003	May CRLD
	@	MEDICIS	50MG	N018830	004	Aug 23, 1988	May DISC
	@		100MG	N018830	001	Oct 31, 1985	May DISC
	@		150MG	N018830	003	Jun 03, 1988	May DISC

FLUCONAZOLE

FOR SUSPENSION;ORAL

FLUCONAZOLE

@	TARO PHARM INDS	50MG/5ML	A076918	001	Dec 18, 2006	Mar DISC
@		200MG/5ML	A076918	002	Dec 18, 2006	Mar DISC

INJECTABLE;INJECTION

FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER

@	AGILA SPECLTS	200MG/100ML (2MG/ML)	A076888	001	Mar 25, 2005	Aug CAHN
@		400MG/200ML (2MG/ML)	A076888	002	Mar 25, 2005	Aug CAHN
@	APOTEX INC	200MG/100ML (2MG/ML)	A076888	001	Mar 25, 2005	Apr DISC
@		400MG/200ML (2MG/ML)	A076888	002	Mar 25, 2005	Apr DISC

FLUCONAZOLE IN SODIUM CHLORIDE 0.9%

AP	TEVA PHARMS USA	200MG/100ML (2MG/ML)	A076653	001	Jul 29, 2004	May CAHN
AP		400MG/200ML (2MG/ML)	A076653	002	Jul 29, 2004	May CAHN

FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

@	AGILA SPECLTS	200MG/100ML (2MG/ML)	A076889	001	Mar 25, 2005	Aug CAHN
@		400MG/200ML (2MG/ML)	A076889	002	Mar 25, 2005	Aug CAHN
@	APOTEX INC	200MG/100ML (2MG/ML)	A076889	001	Mar 25, 2005	Apr DISC

FLUCONAZOLE

INJECTABLE;INJECTION

FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

@ 400MG/200ML (2MG/ML)

A076889 002 Mar 25, 2005 Apr DISC

TABLET;ORAL

FLUCONAZOLE

@ HARRIS PHARM

50MG

A078423 001 Mar 07, 2011 Sep DISC

@

100MG

A078423 002 Mar 07, 2011 Sep DISC

@

150MG

A078423 003 Mar 07, 2011 Sep DISC

@

200MG

A078423 004 Mar 07, 2011 Sep DISC

FLUDARABINE PHOSPHATE

INJECTABLE;INJECTION

FLUDARABINE PHOSPHATE

AP + FRESENIUS KABI USA 50MG/2ML (25MG/ML)

A078393 001 Oct 15, 2007 Jan CRLD

AP TEVA PARENTERAL 50MG/2ML (25MG/ML)

A076661 001 Apr 28, 2004 Jan CRLD

AP TEVA PHARMS USA 50MG/VIAL

A076349 001 Aug 28, 2003 Apr CAHN

AP 50MG/2ML (25MG/ML)

A076661 001 Apr 28, 2004 Apr CAHN

FLUDEOXYGLUCOSE F-18

INJECTABLE;INTRAVENOUS

FLUDEOXYGLUCOSE F18

+ HOUSTON CYCLOTRON 20-500mCi/ML

A203665 001 Feb 14, 2013 Jun CRLD

+ 20-500mCi/ML

A203665 001 Feb 14, 2013 Jan NEWA

MCPRF 20-240mCi/ML

A203612 001 Aug 05, 2013 Jul NEWA

+ UCLA BIOMEDICAL 4-40mCi/ML

A203811 001 Jun 27, 2013 Jun NEWA

FLUMAZENIL

INJECTABLE;INJECTION

FLUMAZENIL

@ APOTEX INC

0.5MG/5ML (0.1MG/ML)

A076755 002 Oct 12, 2004 Apr DISC

@

1MG/10ML (0.1MG/ML)

A076755 001 Oct 12, 2004 Apr DISC

>D> AP PFIZER 1MG/10ML (0.1MG/ML)

A078595 002 May 13, 2008 Oct CRLD

>A> AP + 1MG/10ML (0.1MG/ML)

A078595 002 May 13, 2008 Oct CRLD

@ TEVA PHARMS USA 0.5MG/5ML (0.1MG/ML)

A076589 002 Oct 12, 2004 Apr CAHN

@

1MG/10ML (0.1MG/ML)

A076589 001 Oct 12, 2004 Apr CAHN

ROMAZICON

@ HOFFMANN LA ROCHE

1MG/10ML (0.1MG/ML)

N020073 001 Dec 20, 1991 Sep DISC

@

0.5MG/5ML (0.1MG/ML)

N020073 002 Dec 20, 1991 Sep DISC

FLUNISOLIDE

AEROSOL, METERED;INHALATION

AEROBID

@ ROCHE PALO

0.25MG/INH

N018340 001 Aug 17, 1984 Sep DISC

FLUOCINOLONE ACETONIDE

OIL;TOPICAL

FLUOCINOLONE ACETONIDE

AT PERRIGO ISRAEL 0.01%

A202847 001 Aug 09, 2013 Jul NEWA

AT 0.01%

A202848 001 Aug 09, 2013 Jul NEWA

FLUOCINONIDE

CREAM;TOPICAL

LIDEX

@ CNTY LINE PHARMS

0.05%

N016908 002 Jan CAHN

LIDEX-E

@ CNTY LINE PHARMS

0.05%

N016908 003 Jan CAHN

GEL;TOPICAL

FLUOCINONIDE

AB + TARO 0.05%

A074935 001 Jul 29, 1997 Jan CRLD

LIDEX

@ CNTY LINE PHARMS

0.05%

N017373 001 Jan CAHN

OINTMENT;TOPICAL

FLUOCINONIDE

AB + TARO 0.05%

A075008 001 Jun 30, 1999 Jan CRLD

LIDEX

@ CNTY LINE PHARMS

0.05%

N016909 002 Jan CAHN

SOLUTION;TOPICAL

FLUOCINONIDE

AT ACTAVIS MID ATLANTIC 0.05%

A071535 001 Dec 02, 1988 May CAHN

FLUOCINONIDESOLUTION; TOPICAL
FLUOCINONIDE

AT	+	TARO	0.05%	A074799	001	Dec 31, 1996	Jan CRLD
		LIDEX					
		@ CNTY LINE PHARMS	0.05%	N018849	001	Apr 06, 1984	May CAHN
		@ MEDICIS	0.05%	N018849	001	Apr 06, 1984	Jan DISC

FLUORESCEIN SODIUMINJECTABLE; INTRAVENOUS
AK-FLUOR 25%

>D>		AKORN	EQ 500MG BASE/2ML (EQ 250MG BASE/ML)	N022186	002	Aug 08, 2008	Oct CRLD
>A>	+		EQ 500MG BASE/2ML (EQ 250MG BASE/ML)	N022186	002	Aug 08, 2008	Oct CRLD

FLUOROURACILINJECTABLE; INJECTION
FLUOROURACIL

AP	+	MYLAN LLC	1GM/20ML (50MG/ML)	A040743	001	Apr 26, 2007	Feb CAHN
AP	+		500MG/10ML (50MG/ML)	A040743	002	Apr 26, 2007	Feb CAHN
AP	+	TEVA PHARMS USA	2.5GM/50ML (50MG/ML)	A040334	001	Feb 25, 2000	May CAHN
AP	+		5GM/100ML (50MG/ML)	A040334	002	Feb 25, 2000	May CAHN
AP	+		500MG/10ML (50MG/ML)	A040333	001	Jan 27, 2000	May CAHN

FLUOXETINE HYDROCHLORIDECAPSULE; ORAL
FLUOXETINE HYDROCHLORIDE

		@ CARLSBAD	EQ 10MG BASE	A076022	001	Jan 30, 2002	Mar DISC
		@	EQ 20MG BASE	A076022	002	Jan 30, 2002	Mar DISC
		@ CR DOUBLE CRANE	EQ 10MG BASE	A076165	001	Feb 01, 2002	Apr DISC
AB1			EQ 10MG BASE	A076165	001	Feb 01, 2002	Mar CAHN
		@	EQ 20MG BASE	A076165	002	Feb 01, 2002	Apr DISC
AB1			EQ 20MG BASE	A076165	002	Feb 01, 2002	Mar CAHN
AB1		DR REDDYS LABS LTD	EQ 10MG BASE	A075465	001	Jan 29, 2002	Sep CAHN
AB1			EQ 20MG BASE	A075465	002	Jan 29, 2002	Sep CAHN
AB			EQ 40MG BASE	A075465	003	Aug 02, 2001	Sep CAHN
AB1		TEVA PHARMS USA	EQ 10MG BASE	A076001	001	Jan 29, 2002	Jul CAHN
AB1			EQ 20MG BASE	A076001	002	Jan 29, 2002	Jul CAHN
		@ WOCKHARDT LTD	EQ 10MG BASE	A078143	001	Jan 16, 2008	Feb DISC
		@	EQ 20MG BASE	A078143	002	Jan 16, 2008	Feb DISC
		@	EQ 40MG BASE	A078143	003	Jan 16, 2008	Feb DISC

SOLUTION; ORAL
FLUOXETINE HYDROCHLORIDE

		@ APOTEX INC	EQ 20MG BASE/5ML	A075292	001	Feb 07, 2002	Apr DISC
--	--	--------------	------------------	---------	-----	--------------	----------

FLUOXETINE HYDROCHLORIDE; OLANZAPINECAPSULE; ORAL
OLANZAPINE AND FLUOXETINE HYDROCHLORIDE

AB		TEVA PHARMS	EQ 25MG BASE; EQ 3MG BASE	A202074	001	Mar 25, 2013	Mar NEWA
----	--	-------------	---------------------------	---------	-----	--------------	----------

FLUPHENAZINE DECANOATEINJECTABLE; INJECTION
FLUPHENAZINE DECANOATE

		@ AGILA SPECLTS	25MG/ML	A075918	001	Aug 17, 2001	Aug CAHN
		@ APOTEX INC	25MG/ML	A075918	001	Aug 17, 2001	Apr DISC

FLURAZEPAM HYDROCHLORIDECAPSULE; ORAL
FLURAZEPAM HYDROCHLORIDE

		@ WEST WARD	15MG	A071107	001	Dec 08, 1986	Jul DISC
		@	30MG	A071108	001	Dec 08, 1986	Jul DISC

>A> FLUTEMETAMOL F-18

>A> INJECTABLE; INTRAVENOUS

>A> VIZAMYL

>A>	+	GE HEALTHCARE	40.5mCi/10ML (4.05mCi/ML)	N203137	001	Oct 25, 2013	Oct NEWA
>A>	+		121.5mCi/30ML (4.05mCi/ML)	N203137	002	Oct 25, 2013	Oct NEWA

FLUTICASONE FUROATE; VILANTEROL TRIFENATATE

POWDER; INHALATION

FLUTICASONE FUROATE; VILANTEROL TRIFENATATEPOWDER; INHALATION
BREQ ELLIPTA

+	GLAXO GRP LTD	0.1MG/INH;EQ 0.025MG BASE/INH	N204275	001	May 10, 2013	May NEWA
---	---------------	-------------------------------	---------	-----	--------------	----------

FLUTICASONE PROPIONATECREAM; TOPICAL
CUTIVATE

@	FOUGERA PHARMS	0.05%	N019958	001	Dec 18, 1990	Aug DISC
---	----------------	-------	---------	-----	--------------	----------

LOTION; TOPICAL

FLUTICASONE PROPIONATE

AB	PERRIGO ISRAEL	0.05%	A091553	001	Jul 30, 2013	Jul NEWA
----	----------------	-------	---------	-----	--------------	----------

POWDER; INHALATION

FLOVENT DISKUS 100

+	GLAXO GRP LTD	0.1MG/INH	N020833	002	Sep 29, 2000	May CAHN
---	---------------	-----------	---------	-----	--------------	----------

FLOVENT DISKUS 250

+	GLAXO GRP LTD	0.25MG/INH	N020833	003	Sep 29, 2000	May CAHN
---	---------------	------------	---------	-----	--------------	----------

FLOVENT DISKUS 50

+	GLAXO GRP LTD	0.05MG/INH	N020833	001	Sep 29, 2000	May CAHN
---	---------------	------------	---------	-----	--------------	----------

FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE

AEROSOL, METERED; INHALATION

ADV AIR HFA

+	GLAXO GRP LTD	0.045MG/INH;EQ 0.021MG BASE/INH	N021254	001	Jun 08, 2006	May CAHN
---	---------------	---------------------------------	---------	-----	--------------	----------

+		0.115MG/INH;EQ 0.021MG BASE/INH	N021254	002	Jun 08, 2006	May CAHN
---	--	---------------------------------	---------	-----	--------------	----------

+		0.23MG/INH;EQ 0.021MG BASE/INH	N021254	003	Jun 08, 2006	May CAHN
---	--	--------------------------------	---------	-----	--------------	----------

POWDER; INHALATION

ADV AIR DISKUS 100/50

+	GLAXO GRP LTD	0.1MG/INH;EQ 0.05MG BASE/INH	N021077	001	Aug 24, 2000	May CAHN
---	---------------	------------------------------	---------	-----	--------------	----------

ADV AIR DISKUS 250/50

+	GLAXO GRP LTD	0.25MG/INH;EQ 0.05MG BASE/INH	N021077	002	Aug 24, 2000	May CAHN
---	---------------	-------------------------------	---------	-----	--------------	----------

ADV AIR DISKUS 500/50

+	GLAXO GRP LTD	0.5MG/INH;EQ 0.05MG BASE/INH	N021077	003	Aug 24, 2000	May CAHN
---	---------------	------------------------------	---------	-----	--------------	----------

FLUVOXAMINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL

FLUVOXAMINE MALEATE

AB	ACTAVIS ELIZABETH	100MG	A091482	001	Apr 23, 2013	Apr NEWA
----	-------------------	-------	---------	-----	--------------	----------

AB	ANCHEN PHARMS	100MG	A091476	001	Mar 13, 2013	Mar NEWA
----	---------------	-------	---------	-----	--------------	----------

AB		150MG	A091476	002	Mar 13, 2013	Mar NEWA
----	--	-------	---------	-----	--------------	----------

LUVOX CR

AB	JAZZ PHARMS	100MG	N022033	001	Feb 28, 2008	Mar CFTG
----	-------------	-------	---------	-----	--------------	----------

AB	+	150MG	N022033	002	Feb 28, 2008	Mar CFTG
----	---	-------	---------	-----	--------------	----------

TABLET; ORAL

FLUVOXAMINE MALEATE

@	CARACO	25MG	A075900	001	Feb 23, 2006	Jun DISC
---	--------	------	---------	-----	--------------	----------

@		50MG	A075900	002	Feb 23, 2006	Jun DISC
---	--	------	---------	-----	--------------	----------

@		100MG	A075900	003	Feb 23, 2006	Jun DISC
---	--	-------	---------	-----	--------------	----------

FOLIC ACID

TABLET; ORAL

FOLIC ACID

AA	BICON PHARM	1MG	A091145	001	Jul 12, 2013	Jul NEWA
----	-------------	-----	---------	-----	--------------	----------

FOSAPREPITANT DIMEGLUMINE

POWDER; INTRAVENOUS

EMEND

@	MERCK AND CO INC	EQ 115MG BASE/VIAL	N022023	001	Jan 25, 2008	Sep DISC
---	------------------	--------------------	---------	-----	--------------	----------

FOSINOPRIL SODIUM

TABLET; ORAL

FOSINOPRIL SODIUM

@	WATSON LABS	10MG	A076987	001	Dec 23, 2004	Mar DISC
---	-------------	------	---------	-----	--------------	----------

@		20MG	A076987	002	Dec 23, 2004	Mar DISC
---	--	------	---------	-----	--------------	----------

@		40MG	A076987	003	Dec 23, 2004	Mar DISC
---	--	------	---------	-----	--------------	----------

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

TABLET; ORAL

FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

@	MYLAN	10MG;12.5MG	A077705	001	Aug 14, 2006	Aug DISC
---	-------	-------------	---------	-----	--------------	----------

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

TABLET; ORAL

FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

@	20MG; 12.5MG	A077705	002	Aug 14, 2006	Aug DISC
---	--------------	---------	-----	--------------	----------

FOSPHENYTOIN SODIUM

INJECTABLE; INJECTION

FOSPHENYTOIN SODIUM

AP	AMNEAL PHARMS	EQ 50MG PHENYTOIN NA/ML	A078476	001	Mar 18, 2008	May CAHN
	@ APOTEX INC	EQ 50MG PHENYTOIN NA/ML	A078126	001	Aug 06, 2007	Apr DISC
	@ TEVA PHARMS USA	EQ 50MG PHENYTOIN NA/ML	A076886	001	Aug 06, 2007	May CAHN

FUROSEMIDE

INJECTABLE; INJECTION

FUROSEMIDE

@	INTL MEDICATION	10MG/ML	N018025	001		Jan DISC
---	-----------------	---------	---------	-----	--	----------

TABLET; ORAL

FUROSEMIDE

@	DAVA PHARMS INC	20MG	N018415	001	Jul 27, 1982	Feb DISC
@		40MG	N018415	002	Jul 27, 1982	Feb DISC
@		80MG	N018415	003	Nov 26, 1984	Feb DISC

GABAPENTIN

CAPSULE; ORAL

GABAPENTIN

AB	TARO	100MG	A077261	001	Aug 02, 2013	Jul NEWA
AB		300MG	A077261	002	Aug 02, 2013	Jul NEWA
AB		400MG	A077261	003	Aug 02, 2013	Jul NEWA

SOLUTION; ORAL

GABAPENTIN

AA	TARO	250MG/5ML	A076672	001	Jul 03, 2013	Jun NEWA
----	------	-----------	---------	-----	--------------	----------

TABLET; ORAL

GABAPENTIN

AB	ALLIED PHARMA INC	600MG	A203244	002	Jul 12, 2013	Jul NEWA
AB		800MG	A203244	001	Jul 12, 2013	Jul NEWA

GABAPENTIN ENACARBIL

TABLET, EXTENDED RELEASE; ORAL

HORIZANT

	XENOPORT INC	300MG	N022399	002	Dec 13, 2011	May CAHN
+		600MG	N022399	001	Apr 06, 2011	May CAHN

GADOTERATE MEGLUMINE

SOLUTION; INTRAVENOUS

DOTAREM

+	GUERBET	3.769GM/10ML (376.9MG/ML)	N204781	002	Mar 20, 2013	Mar NEWA
+		5.6535GM/15ML (376.9MG/ML)	N204781	003	Mar 20, 2013	Mar NEWA
+		7.538GM/20ML (376.9MG/ML)	N204781	004	Mar 20, 2013	Mar NEWA
+		37.69GM/100ML (376.9MG/ML)	N204781	001	Mar 20, 2013	Mar NEWA

GADOXETATE DISODIUM

SOLUTION; INTRAVENOUS

EOVIST

	BAYER HLTHCARE	2.72145GM/15ML (181.43MG/ML)	N022090	002	Feb 04, 2013	Feb NEWA
--	----------------	------------------------------	---------	-----	--------------	----------

GALLIUM NITRATE

INJECTABLE; INJECTION

GANITE

@	CHAPTER 7 TRUSTEE	25MG/ML	N019961	002	Jan 17, 1991	Jul CAHN
@	GENTA	25MG/ML	N019961	002	Jan 17, 1991	Jul DISC

GANCICLOVIR

IMPLANT; IMPLANTATION

VITRASERT

@	BAUSCH AND LOMB	4.5MG	N020569	001	Mar 04, 1996	May DISC
---	-----------------	-------	---------	-----	--------------	----------

GANCICLOVIR SODIUM

INJECTABLE; INJECTION

GANCICLOVIR

>A> AP	LUITPOLD	EQ 500MG BASE/VIAL	A202624	001	Sep 18, 2013	Oct CAHN
--------	----------	--------------------	---------	-----	--------------	----------

GANCICLOVIR SODIUMINJECTABLE; INJECTION
GANCICLOVIR

>D>	AP	PHARMAFORCE	EQ 500MG BASE/VIAL	A202624	001	Sep 18, 2013	Oct CAHN
	AP		EQ 500MG BASE/VIAL	A202624	001	Sep 18, 2013	Aug NEWA

GANIRELIX ACETATEINJECTABLE; INJECTION
GANIRELIX ACETATE

	+	ORGANON USA INC	EQ 250MCG BASE/0.5ML	N021057	001	Jul 29, 1999	Aug CTNA
--	---	-----------------	----------------------	---------	-----	--------------	----------

GATIFLOXACINSOLUTION/DROPS; OPHTHALMIC
GATIFLOXACIN

		@ APOTEX INC	0.3%	A079084	001	Aug 19, 2011	Apr DISC
AT		LUPIN LTD	0.5%	A202653	001	Aug 28, 2013	Aug NEWA
		ZYMAXID					
AT	+	ALLERGAN	0.5%	N022548	001	May 18, 2010	Aug CFTG

GEMCITABINE HYDROCHLORIDEINJECTABLE; INJECTION
GEMCITABINE HYDROCHLORIDE

AP		CIPLA LTD	EQ 1GM BASE/VIAL	A078759	002	Jul 25, 2011	Jul CAHN
AP			EQ 200MG BASE/VIAL	A078759	001	Jul 25, 2011	Jul CAHN
AP		DR REDDYS LABS LTD	EQ 2GM BASE/VIAL	A202997	001	May 07, 2013	Apr NEWA
AP		JIANGSU HANSON PHARM	EQ 1GM BASE/VIAL	A202485	002	May 07, 2013	Apr NEWA
AP			EQ 200MG BASE/VIAL	A202485	001	May 07, 2013	Apr NEWA
AP		LUITPOLD	EQ 1GM BASE/VIAL	A202031	002	May 07, 2013	Aug CAHN
AP			EQ 200MG BASE/VIAL	A202031	001	May 07, 2013	Aug CAHN
AP		PHARMAFORCE	EQ 1GM BASE/VIAL	A202031	002	May 07, 2013	Apr NEWA
AP			EQ 200MG BASE/VIAL	A202031	001	May 07, 2013	Apr NEWA
AP		SAGENT PHARMS	EQ 1GM BASE/VIAL	A091597	002	May 07, 2013	Apr NEWA
AP			EQ 200MG BASE/VIAL	A091597	001	May 07, 2013	Apr NEWA

GEMFIBROZILTABLET; ORAL
GEMFIBROZIL

AB		CARACO	600MG	A079239	001	Dec 29, 2008	Jun CAHN
----	--	--------	-------	---------	-----	--------------	----------

GENTAMICIN SULFATEINJECTABLE; INJECTION
GENTAMICIN SULFATE

		@ FRESENIUS KABI USA	EQ 10MG BASE/ML	A062356	001	Mar 04, 1982	Aug DISC
AP			EQ 10MG BASE/ML	A062366	002	Feb 06, 1986	Aug NEWA
		@	EQ 40MG BASE/ML	A062356	002	Mar 04, 1982	Aug DISC
AP	+		EQ 40MG BASE/ML	A062366	001	Aug 04, 1983	Aug CRLD

OINTMENT; OPHTHALMIC
GENTAMICIN SULFATE

AT		PERRIGO CO TENNESSEE	EQ 0.3% BASE	A065024	001	Jul 30, 2004	Jun CAHN
		SOLUTION/DROPS; OPHTHALMIC					
		GENTAMICIN SULFATE					
AT		PERRIGO CO TENNESSEE	EQ 0.3% BASE	A065121	001	Jan 30, 2004	Jun CAHN

GLATIRAMER ACETATEFOR SOLUTION; SUBCUTANEOUS
COPAXONE

		@ TEVA PHARMS USA	20MG/VIAL	N020622	001	Dec 20, 1996	Apr CAHN
--	--	-------------------	-----------	---------	-----	--------------	----------

INJECTABLE; SUBCUTANEOUS
COPAXONE

	+	TEVA PHARMS USA	20MG/ML	N020622	002	Feb 12, 2002	Apr CAHN
--	---	-----------------	---------	---------	-----	--------------	----------

GLIMEPIRIDE

TABLET; ORAL

GLIMEPIRIDE

		@ COREPHARMA	1MG	A077274	001	Oct 06, 2005	Feb DISC
		@	2MG	A077274	002	Oct 06, 2005	Feb DISC
		@	4MG	A077274	003	Oct 06, 2005	Feb DISC
AB		HIKMA PHARMS	1MG	A078952	001	Aug 01, 2013	Jul NEWA
AB			2MG	A078952	002	Aug 01, 2013	Jul NEWA
AB			4MG	A078952	003	Aug 01, 2013	Jul NEWA
AB		INDOCO REMEDIES	1MG	A202112	001	Apr 17, 2013	Apr NEWA

GLIMEPIRIDE

TABLET;ORAL

GLIMEPIRIDE

AB		2MG	A202112	002	Apr 17, 2013	Apr NEWA
AB		4MG	A202112	003	Apr 17, 2013	Apr NEWA
AB	MICRO LABS LTD INDIA	1MG	A091220	001	Jun 29, 2012	Jul CAHN
AB		2MG	A091220	002	Jun 29, 2012	Jul CAHN
		3MG	A091220	003	Jun 29, 2012	Jul CAHN
AB		4MG	A091220	004	Jun 29, 2012	Jul CAHN
		6MG	A091220	005	Jun 29, 2012	Jul CAHN
AB		8MG	A091220	006	Jun 29, 2012	Jul CAHN
	@ MYLAN	1MG	A077486	001	Feb 10, 2006	Aug DISC
	@	2MG	A077486	002	Feb 10, 2006	Aug DISC
	@	4MG	A077486	003	Feb 10, 2006	Aug DISC

GLIPIZIDE

TABLET;ORAL

GLIPIZIDE

AB	ACCORD HLTHCARE	5MG	A074550	001	Sep 11, 1997	Apr CAHN
AB		10MG	A074550	002	Sep 11, 1997	Apr CAHN
	@ BARR LABS INC	5MG	A074619	001	Apr 04, 1997	May CAHN
	@	10MG	A074619	002	Apr 04, 1997	May CAHN
	TABLET, EXTENDED RELEASE;ORAL					
	GLIPIZIDE					
AB	PAR PHARM	5MG	A076159	002	Sep 20, 2013	Sep NEWA
AB		10MG	A076159	001	Sep 20, 2013	Sep NEWA

GLYCEROL PHENYLBUTYRATE

LIQUID;ORAL

RAVICTI

+	HYPERION THERAP INC	1.1GM/ML	N203284	001	Feb 01, 2013	Feb NEWA
---	---------------------	----------	---------	-----	--------------	----------

GLYCOPYRROLATE

INJECTABLE;INJECTION

ROBINUL

AP	+	HIKMA MAPLE	0.2MG/ML	N017558	001	Apr CAHN
----	---	-------------	----------	---------	-----	----------

TABLET;ORAL

GLYCOPYRROLATE

AA	AUROLIFE PHARMA LLC	1MG	A202675	001	Apr 15, 2013	Apr NEWA
	@ COREPHARMA	1MG	A040568	001	Dec 22, 2004	Mar DISC
	@	2MG	A040568	002	Dec 22, 2004	Mar DISC
	@ WEST WARD	1MG	A040836	001	Mar 05, 2009	Jul DISC
	@	2MG	A040836	002	Mar 05, 2009	Jul DISC

GRANISETRON HYDROCHLORIDE

INJECTABLE;INJECTION

GRANISETRON HYDROCHLORIDE

	@ APOTEX INC	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078197	001	Dec 31, 2007	Apr DISC	
	@	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078198	001	Jun 30, 2008	Apr DISC	
	@	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078198	002	Jun 30, 2008	Apr DISC	
	@ EBEWE PHARMA	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078808	001	Apr 29, 2008	Feb DISC	
AP	+	TEVA PHARMS USA	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078392	001	Dec 31, 2007	May CAHN
AP	+		EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A077963	001	Jan 03, 2008	May CAHN
AP	+		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A077297	001	Jun 30, 2008	May CAHN
	GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE						
	@ TEVA PHARMS USA	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A077165	001	Dec 31, 2007	May CAHN	

GRISEOFULVIN, MICROSIZE

SUSPENSION;ORAL

GRIFULVIN V

AB	+	VALEANT LUXEMBOURG	125MG/5ML	A062483	001	Jan 26, 1984	Apr CAHN
----	---	--------------------	-----------	---------	-----	--------------	----------

TABLET;ORAL

GRISEOFULVIN

	SANDOZ	250MG	A091592	001	Aug 07, 2013	Jul NEWA
AB		500MG	A091592	002	Aug 07, 2013	Jul NEWA

GUANFACINE HYDROCHLORIDE

TABLET;ORAL

GUANFACINE HYDROCHLORIDE

GUANFACINE HYDROCHLORIDE

TABLET; ORAL

GUANFACINE HYDROCHLORIDE

@ EPIC PHARMA LLC EQ 1MG BASE
 @ EQ 2MG BASE

A074673 001 Feb 28, 1997 Jun DISC
 A074673 002 Feb 28, 1997 Jun DISC

HALOBETASOL PROPIONATE

OINTMENT; TOPICAL

HALOBETASOL PROPIONATE

@ FOUGERA PHARMS 0.05%
 @ G AND W LABS INC 0.05%
 @ TARO 0.05%

A076903 001 Dec 16, 2004 Apr DISC
 A077109 001 Jun 14, 2005 Jun CAHN
 A076994 001 Dec 16, 2004 Mar DISC

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION

HALOPERIDOL DECANOATE

@ AGILA SPECLTS EQ 50MG BASE/ML
 @ EQ 100MG BASE/ML
 @ EQ 100MG BASE/ML
 @ APOTEX INC EQ 50MG BASE/ML
 @ EQ 100MG BASE/ML
 AO TEVA PHARMS USA EQ 50MG BASE/ML
 AO EQ 100MG BASE/ML

A075440 001 Feb 28, 2000 Aug CAHN
 A075440 002 Feb 28, 2000 Aug CAHN
 A075440 002 Feb 28, 2000 Aug CAHN
 A075440 001 Feb 28, 2000 Apr DISC
 A075440 002 Feb 28, 2000 Apr DISC
 A075393 001 May 11, 1999 Jun CAHN
 A075393 002 May 11, 1999 Jun CAHN

HALOPERIDOL LACTATE

INJECTABLE; INJECTION

HALOPERIDOL

@ APOTEX INC EQ 5MG BASE/ML
 @ EQ 5MG BASE/ML
 AP TEVA PHARMS USA EQ 5MG BASE/ML

A076791 001 Aug 25, 2004 Apr DISC
 A076828 001 Aug 25, 2004 Apr DISC
 A076035 001 Aug 29, 2001 Jun CAHN

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM

AP + HIKMA MAPLE 1,000 UNITS/ML
 AP + 5,000 UNITS/ML
 @ 5,000 UNITS/0.5ML
 AP + 10,000 UNITS/ML

N017037 001 Aug CAHN
 N017037 002 Aug CAHN
 N017037 013 Apr 07, 1986 Aug CAHN
 N017037 003 Aug CAHN

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

TABLET; ORAL

HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE

AA NOVEL LABS INC 1.5MG; 5MG
 TUSSIGON
 AA + KING PHARMS 1.5MG; 5MG

A091528 001 Apr 20, 2011 Sep CTEC
 A088508 001 Jul 30, 1985 Sep CTEC

HYALURONIDASE

INJECTABLE; INJECTION

VITRASE

+ BAUSCH AND LOMB 200 UNITS/VIAL
 @ 6,200 UNITS/VIAL

N021640 002 Dec 02, 2004 May CAHN
 N021640 001 May 05, 2004 May CAHN

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDRALAZINE HYDROCHLORIDE

AP NAVINTA LLC 20MG/ML

A202938 001 Mar 28, 2013 Mar NEWA

TABLET; ORAL

HYDRALAZINE HYDROCHLORIDE

AA ACTAVIS GRP PTC 10MG
 AA 25MG
 AA 50MG
 AA 100MG
 AA ACTAVIS PHARMA 10MG
 AA 25MG
 AA 50MG
 AA 100MG
 AA ALKEM LABS LTD 10MG
 AA 25MG
 AA 50MG
 AA 100MG
 AA HETERO LABS LTD III 10MG

A091679 001 Mar 04, 2013 Apr CAHN
 A091679 002 Mar 04, 2013 Apr CAHN
 A091679 003 Mar 04, 2013 Apr CAHN
 A091679 004 Mar 04, 2013 Apr CAHN
 A091679 001 Mar 04, 2013 Feb NEWA
 A091679 002 Mar 04, 2013 Feb NEWA
 A091679 003 Mar 04, 2013 Feb NEWA
 A091679 004 Mar 04, 2013 Feb NEWA
 A200737 001 Dec 07, 2012 Apr CTEC
 A200737 002 Dec 07, 2012 Apr CTEC
 A200737 003 Dec 07, 2012 Apr CTEC
 A200737 004 Dec 07, 2012 Apr CTEC
 A040901 001 Sep 12, 2008 Apr CAHN

HYDRALAZINE HYDROCHLORIDE

TABLET; ORAL

HYDRALAZINE HYDROCHLORIDE

AA		25MG	A040901	002	Sep 12, 2008	Apr	CAHN
AA		50MG	A040901	003	Sep 12, 2008	Apr	CAHN
AA		100MG	A040901	004	Sep 12, 2008	Apr	CAHN
AA	STRIDES ARCOLAB LTD	25MG	A200770	001	May 03, 2013	Apr	NEWA
AA		50MG	A200770	002	May 03, 2013	Apr	NEWA
AA		100MG	A200770	003	May 03, 2013	Apr	NEWA
	@ ZYDUS PHARMS USA	10MG	A040858	001	Feb 26, 2010	Jun	DISC
	@	25MG	A040858	002	Feb 26, 2010	Jun	DISC
	@	50MG	A040858	003	Feb 26, 2010	Jun	DISC
	@	100MG	A040858	004	Feb 26, 2010	Jun	DISC

HYDROCHLOROTHIAZIDE

TABLET; ORAL

HYDROCHLOROTHIAZIDE

@	WATSON LABS	25MG	A081189	001	Jan 24, 1992	Mar	DISC
---	-------------	------	---------	-----	--------------	-----	------

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL

IRBESARTAN AND HYDROCHLOROTHIAZIDE

AB	AUROBINDO PHARMA LTD	12.5MG;150MG	A203630	001	Feb 22, 2013	Feb	NEWA
AB		12.5MG;300MG	A203630	002	Feb 22, 2013	Feb	NEWA
AB	LUPIN LTD	12.5MG;150MG	A201524	001	Feb 27, 2013	Feb	NEWA
AB		12.5MG;300MG	A201524	002	Feb 27, 2013	Feb	NEWA

HYDROCHLOROTHIAZIDE; LISINOPRIL

TABLET; ORAL

LISINOPRIL AND HYDROCHLOROTHIAZIDE

>A>	AB	HIKMA PHARMS LLC	12.5MG;10MG	A076265	001	Jul 08, 2002	Oct	CAHN
>A>	AB		12.5MG;20MG	A076265	002	Jul 08, 2002	Oct	CAHN
>A>	AB		25MG;20MG	A076265	003	Jul 08, 2002	Oct	CAHN
>D>	AB	WEST WARD	12.5MG;10MG	A076265	001	Jul 08, 2002	Oct	CAHN
>D>	AB		12.5MG;20MG	A076265	002	Jul 08, 2002	Oct	CAHN
>D>	AB		25MG;20MG	A076265	003	Jul 08, 2002	Oct	CAHN

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET; ORAL

HYZAAR

>D>	AB	MERCK	12.5MG;50MG	N020387	001	Apr 28, 1995	Oct	CAHN
>D>	AB		12.5MG;100MG	N020387	003	Oct 20, 2005	Oct	CAHN
>D>	AB	+	25MG;100MG	N020387	002	Nov 10, 1998	Oct	CAHN
>A>	AB	MERCK SHARP DOHME	12.5MG;50MG	N020387	001	Apr 28, 1995	Oct	CAHN
>A>	AB		12.5MG;100MG	N020387	003	Oct 20, 2005	Oct	CAHN
>A>	AB	+	25MG;100MG	N020387	002	Nov 10, 1998	Oct	CAHN
		LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE						
	AB	IPCA LABS LTD	12.5MG;50MG	A201682	001	Mar 01, 2013	Feb	NEWA
	AB		12.5MG;100MG	A201682	002	Mar 01, 2013	Feb	NEWA
	AB		25MG;100MG	A201682	003	Mar 01, 2013	Feb	NEWA

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

TABLET; ORAL

METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE

>A>	AB	ALEMBIC PHARMS LTD	25MG;50MG	A202870	001	Nov 06, 2013	Oct	NEWA
>A>	AB		25MG;100MG	A202870	002	Nov 06, 2013	Oct	NEWA
>A>	AB		50MG;100MG	A202870	003	Nov 06, 2013	Oct	NEWA

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

INDERIDE-40/25

AB	+	WYETH PHARMS INC	25MG;40MG	N018031	001		Jul	CAHN
		INDERIDE-80/25						
	@	WYETH PHARMS INC	25MG;80MG	N018031	002		Jul	CAHN
		PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE						
	@	WATSON LABS	25MG;40MG	A070301	001	Apr 18, 1986	Sep	DISC
	@		25MG;80MG	A070305	001	Apr 18, 1986	Sep	DISC

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB	APOTEX CORP	12.5MG;EQ 10MG BASE	A091524	001	Mar 12, 2013	Mar	NEWA
AB		12.5MG;EQ 20MG BASE	A091524	002	Mar 12, 2013	Mar	NEWA
AB		25MG;EQ 20MG BASE	A091524	003	Mar 12, 2013	Mar	NEWA

HYDROCHLOROTHIAZIDE; TRIAMTERENE

TABLET; ORAL

MAXZIDE

AB	+ MYLAN PHARMS INC	50MG;75MG	N019129	001	Oct 22, 1984	May	CAHN
	MAXZIDE-25						
AB	MYLAN PHARMS INC	25MG;37.5MG	N019129	003	May 13, 1988	May	CAHN
	TRIAMTERENE AND HYDROCHLOROTHIAZIDE						
	@ WATSON LABS	50MG;75MG	A071969	001	Apr 17, 1988	Jan	DISC

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL

VALSARTAN AND HYDROCHLOROTHIAZIDE

AB	ALEMBIC LTD	12.5MG;80MG	A201662	001	Mar 21, 2013	Mar	NEWA
AB		12.5MG;160MG	A201662	002	Mar 21, 2013	Mar	NEWA
AB		12.5MG;320MG	A201662	003	Mar 21, 2013	Mar	NEWA
AB		25MG;160MG	A201662	004	Mar 21, 2013	Mar	NEWA
AB		25MG;320MG	A201662	005	Mar 21, 2013	Mar	NEWA
AB	APOTEX INC	12.5MG;80MG	A203026	001	Mar 21, 2013	Mar	NEWA
AB		12.5MG;160MG	A203026	002	Mar 21, 2013	Mar	NEWA
AB		12.5MG;320MG	A203026	003	Mar 21, 2013	Mar	NEWA
AB		25MG;160MG	A203026	004	Mar 21, 2013	Mar	NEWA
AB		25MG;320MG	A203026	005	Mar 21, 2013	Mar	NEWA
AB	AUROBINDO PHARMA LTD	12.5MG;80MG	A202519	001	Mar 21, 2013	Mar	NEWA
AB		12.5MG;160MG	A202519	002	Mar 21, 2013	Mar	NEWA
AB		12.5MG;320MG	A202519	003	Mar 21, 2013	Mar	NEWA
AB		25MG;160MG	A202519	004	Mar 21, 2013	Mar	NEWA
AB		25MG;320MG	A202519	005	Mar 21, 2013	Mar	NEWA
AB	LUPIN LTD	12.5MG;80MG	A078946	003	Mar 21, 2013	Mar	NEWA
AB		12.5MG;160MG	A078946	004	Mar 21, 2013	Mar	NEWA
AB		12.5MG;320MG	A078946	001	Mar 21, 2013	Mar	NEWA
AB		25MG;160MG	A078946	005	Mar 21, 2013	Mar	NEWA
AB		25MG;320MG	A078946	002	Mar 21, 2013	Mar	NEWA
AB	MACLEODS PHARMS LTD	12.5MG;80MG	A203145	001	Apr 19, 2013	Apr	NEWA
AB		12.5MG;160MG	A203145	002	Apr 19, 2013	Apr	NEWA
AB		12.5MG;320MG	A203145	003	Apr 19, 2013	Apr	NEWA
AB		25MG;160MG	A203145	004	Apr 19, 2013	Apr	NEWA
AB		25MG;320MG	A203145	005	Apr 19, 2013	Apr	NEWA
AB	WATSON LABS INC	12.5MG;80MG	A091519	001	Mar 21, 2013	Mar	NEWA
AB		12.5MG;160MG	A091519	002	Mar 21, 2013	Mar	NEWA
AB		12.5MG;320MG	A091519	003	Mar 21, 2013	Mar	NEWA
AB		25MG;160MG	A091519	004	Mar 21, 2013	Mar	NEWA
AB		25MG;320MG	A091519	005	Mar 21, 2013	Mar	NEWA

>A> HYDROCODONE BITARTRATE

>A> CAPSULE, EXTENDED RELEASE; ORAL

>A> ZOXYDRO ER

>A>	+ ZOGENIX INC	10MG	N202880	001	Oct 25, 2013	Oct	NEWA
>A>		15MG	N202880	002	Oct 25, 2013	Oct	NEWA
>A>		20MG	N202880	003	Oct 25, 2013	Oct	NEWA
>A>		30MG	N202880	004	Oct 25, 2013	Oct	NEWA
>A>		40MG	N202880	005	Oct 25, 2013	Oct	NEWA
>A>		50MG	N202880	006	Oct 25, 2013	Oct	NEWA

HYDROCODONE BITARTRATE; IBUPROFEN

TABLET; ORAL

HYDROCODONE BITARTRATE AND IBUPROFEN

AB	SUN PHARM INDS INC	2.5MG;200MG	A091633	001	May 28, 2013	May	NEWA
AB		5MG;200MG	A091633	002	May 28, 2013	May	NEWA
AB		7.5MG;200MG	A091633	003	May 28, 2013	May	NEWA
AB		10MG;200MG	A091633	004	May 28, 2013	May	NEWA
	REPREXAIN						
AB	AMNEAL PHARMS NY	2.5MG;200MG	A076642	003	Oct 19, 2007	May	CFTG
AB		10MG;200MG	A076642	004	Oct 19, 2007	May	CFTG

HYDROCORTISONE

LOTION; TOPICAL
STIE-CORT

@ PERRIGO CO 1% A089066 001 Nov 25, 1985 Feb DISC

OINTMENT; TOPICAL
HYDROCORTISONE

@ TARO 2.5% A040310 001 Dec 29, 2000 Mar DISC

HYDROCORTISONE ACETATE

PASTE; TOPICAL
ORABASE HCA

@ COLGATE 0.5% A083205 001 Mar DISC

HYDROCORTISONE ACETATE; UREA

CREAM; TOPICAL
CARMOL HC

@ FOUGERA PHARMS 1%; 10% A080505 001 Aug DISC

U-CORT

TARO 1%; 10% A089472 001 Jun 13, 1988 Aug CTEC

HYDROCORTISONE BUTYRATE

CREAM; TOPICAL

HYDROCORTISONE BUTYRATE

AB GLENMARK GENERICS 0.1% A202145 001 Sep 27, 2013 Sep NEWA

LOCOID LIPOCREAM

AB + PRECISION DERMAT 0.1% N020769 001 Sep 08, 1997 Sep CTEC

HYDROCORTISONE VALERATE

OINTMENT; TOPICAL

HYDROCORTISONE VALERATE

@ FOUGERA PHARMS 0.2% A075085 001 Jul 31, 2001 Feb DISC

+ TARO 0.2%

A075043 001 Aug 25, 1998 Feb CRLD

WESTCORT

@ RANBAXY 0.2% N018726 001 Aug 08, 1983 Feb DISC

HYDROMORPHONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

EXALGO

MALLINCKRODT INC 16MG N021217 003 Mar 01, 2010 Jan CRLD

+ 32MG N021217 004 Aug 24, 2012 Jan CRLD

HYDROXYUREA

CAPSULE; ORAL

HYDROXYUREA

@ BARR LABS INC 250MG A075020 002 Jun 26, 2000 Jun CAHN

@ 500MG A075020 001 Jul 30, 1998 Jun CAHN

HYDROXYZINE HYDROCHLORIDE

SYRUP; ORAL

HYDROXYZINE HYDROCHLORIDE

AA SILARX PHARMS INC 10MG/5ML A201674 001 Aug 21, 2013 Jul NEWA

TABLET; ORAL

HYDROXYZINE HYDROCHLORIDE

AB CARACO 10MG A040899 001 Jun 10, 2008 Jun CAHN

AB 25MG A040899 002 Jun 10, 2008 Jun CAHN

AB 50MG A040899 003 Jun 10, 2008 Jun CAHN

AB HETERO LABS LTD III 10MG A040805 001 May 29, 2008 Apr CAHN

AB 25MG A040805 002 May 29, 2008 Apr CAHN

AB 50MG A040805 003 May 29, 2008 Apr CAHN

HYDROXYZINE PAMOATE

CAPSULE; ORAL

HYDROXYZINE PAMOATE

AB EMCURE PHARMS USA 25MG A201507 001 Jun 03, 2013 May NEWA

AB 50MG A201507 002 Jun 03, 2013 May NEWA

IBUPROFEN

SOLUTION; INTRAVENOUS

CALDOLOR

@ CUMBERLAND PHARMS 400MG/4ML (100MG/ML) N022348 001 Jun 11, 2009 May DISC

IBUPROFEN LYSINEINJECTABLE; INTRAVENOUS
NEOPROFEN

+ RECORDATI RARE EQ 20MG BASE/2ML (EQ 10MG BASE/ML) N021903 001 Apr 13, 2006 May CAHN

ICOSAPENT ETHYLCAPSULE; ORAL
VASCEPA

+ AMARIN PHARMS 1GM N202057 001 Jul 26, 2012 Jun NEWA

IDARUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

IDARUBICIN HYDROCHLORIDE PFS

AP TEVA PHARMS USA 1MG/ML A065036 001 May 01, 2002 Apr CAHN

IFOSFAMIDE

INJECTABLE; INJECTION

IFOSFAMIDE

AP + TEVA PHARMS USA 1GM/20ML (50MG/ML) A076657 001 Apr 04, 2007 May CAHN

AP + 3GM/60ML (50MG/ML) A076657 002 Apr 04, 2007 May CAHN

IFOSFAMIDE; MESNA

INJECTABLE; INTRAVENOUS

IFOSFAMIDE/MESNA KIT

+ TEVA PHARMS USA 1GM/20ML; 1GM/10ML (50MG/ML; 100MG/ML) A075874 001 Feb 26, 2002 May CAHN

+ 3GM/60ML; 1GM/10ML (50MG/ML; 100MG/ML) A075874 002 Feb 26, 2002 May CAHN

IMIPRAMINE HYDROCHLORIDE

TABLET; ORAL

IMIPRAMINE HYDROCHLORIDE

@ PROSAM LABS 10MG A040753 001 Feb 28, 2008 Mar DISC

@ 25MG A040752 001 Feb 28, 2008 Mar DISC

@ 50MG A040751 001 Feb 28, 2008 Mar DISC

IMIPRAMINE PAMOATE

CAPSULE; ORAL

IMIPRAMINE PAMOATE

AB MYLAN PHARMS INC EQ 75MG HCL A202338 001 Jun 28, 2013 Jun NEWA

AB EQ 100MG HCL A202338 002 Jun 28, 2013 Jun NEWA

AB EQ 125MG HCL A202338 003 Jun 28, 2013 Jun NEWA

AB EQ 150MG HCL A202338 004 Jun 28, 2013 Jun NEWA

INDINAVIR SULFATE

CAPSULE; ORAL

CRIXIVAN

@ MERCK SHARP DOHME EQ 100MG BASE N020685 006 Apr 19, 2000 Jun DISC

INDOMETHACIN

CAPSULE; ORAL

INDOCIN

@ ICEUTICA OPERATIONS 25MG N016059 001 Mar CAHN

@ 50MG N016059 002 Mar CAHN

INDOMETHACIN

AB CARACO 25MG A091401 001 Mar 28, 2013 Jun CAHN

AB 50MG A091401 002 Mar 28, 2013 Jun CAHN

AB HETERO LABS LTD III 25MG A091240 001 Apr 12, 2011 Apr CAHN

AB 50MG A091240 002 Apr 12, 2011 Apr CAHN

AB SUN PHARM INDS INC 25MG A091401 001 Mar 28, 2013 Mar NEWA

AB 50MG A091401 002 Mar 28, 2013 Mar NEWA

INDOMETHACIN SODIUM

INJECTABLE; INJECTION

INDOCIN

AP + RECORDATI RARE EQ 1MG BASE/VIAL N018878 001 Jan 30, 1985 May CAHN

INSULIN GLARGINE RECOMBINANT

INJECTABLE; INJECTION

LANTUS SOLOSTAR

+ SANOFI AVENTIS US 300 UNITS/3ML (100 UNITS/ML) N021081 002 Apr 27, 2007 Aug NEWA

IPRATROPIUM BROMIDESOLUTION; INHALATION
IPRATROPIUM BROMIDE@ APOTEX INC 0.02%
@ TEVA PHARMS USA 0.02%A075441 001 Mar 28, 2001 Apr DISC
A075313 001 Feb 07, 2000 Mar DISCSPRAY, METERED; NASAL
IPRATROPIUM BROMIDE@ APOTEX INC 0.021MG/SPRAY
@ 0.042MG/SPRAYA076156 001 Apr 18, 2003 Apr DISC
A076155 001 Apr 18, 2003 Apr DISCIRINOTECAN HYDROCHLORIDEINJECTABLE; INJECTION
IRINOTECAN HYDROCHLORIDEAP TEVA PHARMS USA 40MG/2ML (20MG/ML)
AP 100MG/5ML (20MG/ML)
AP 500MG/25ML (20MG/ML)A090101 002 Feb 27, 2008 Sep CAHN
A090101 003 Feb 27, 2008 Sep CAHN
A090101 001 Nov 26, 2008 Sep CAHNIRON SUCROSEINJECTABLE; INTRAVENOUS
VENOFER@ LUITPOLD EQ 65MG BASE/3.25ML (EQ 20MG
BASE/ML)
EQ 65MG BASE/3.25ML (EQ 20MG
BASE/ML)N021135 005 Mar 29, 2013 Sep DISC
N021135 005 Mar 29, 2013 Mar NEWAISONIAZIDTABLET; ORAL
ISONIAZID@ MIKART 100MG
@ 300MG
@ WATSON LABS 300MGA040090 001 Jun 26, 1997 Aug DISC
A040090 002 Jun 26, 1997 Aug DISC
A080521 001 Jun DISCISONIAZID; RIFAMPINCAPSULE; ORAL
RIFAMATE+ SANOFI AVENTIS US 150MG; 300MG
RIFAMPIN AND ISONIAZID
@ WEST WARD PHARM CORP 150MG; 300MGA061884 001 Apr CTEC
A065221 001 Jul 29, 2005 Apr DISCISOPROTERENOL HYDROCHLORIDEINJECTABLE; INJECTION
ISOPROTERENOL HYDROCHLORIDE@ INTL MEDICATION 0.2MG/ML
ISUPREL

A083724 001 Mar DISC

+ HOSPIRA 0.2MG/ML

N010515 001 Mar CTEC

ISOSORBIDE DINITRATECAPSULE, EXTENDED RELEASE; ORAL
DILATRATE-SR

+ ACTIENT PHARMS 40MG

N019790 001 Sep 02, 1988 May CAHN

TABLET; ORAL
ISORDILAB VALEANT BERMUDA 5MG
AB 10MG
AB 20MG
AB + 30MG
+ 40MG
AB VALEANT PHARM NORTH 5MG
AB 10MG
AB 20MG
AB + 30MG
+ 40MGN012093 007 Jul 29, 1988 Apr CAHN
N012093 002 Jul 29, 1988 Apr CAHN
N012093 006 Jul 29, 1988 Apr CAHN
N012093 005 Jul 29, 1988 Apr CAHN
N012093 001 Jul 29, 1988 Apr CAHN
N012093 007 Jul 29, 1988 Mar CAHN
N012093 002 Jul 29, 1988 Mar CAHN
N012093 006 Jul 29, 1988 Mar CAHN
N012093 005 Jul 29, 1988 Mar CAHN
N012093 001 Jul 29, 1988 Mar CAHN

ISOSORBIDE DINITRATE

AB PAR PHARM 5MG
@ 5MG
@ WATSON LABS 5MG
@ 10MGA086923 001 Mar 12, 1987 Apr CMFD
A086923 001 Mar 12, 1987 Feb DISC
A086034 001 Jan 06, 1988 Apr DISC
A086032 001 Jan 07, 1988 Apr DISCTABLET; SUBLINGUAL
ISOSORBIDE DINITRATE@ WATSON LABS 2.5MG
@ 5MGA086033 001 Feb 26, 1988 Jun DISC
A086031 001 Sep 29, 1987 Jun DISC

ISOSORBIDE DINITRATE

TABLET;SUBLINGUAL

ISOSORBIDE DINITRATE

	@ WEST WARD	2.5MG	A086054	001	Oct 29, 1987	Aug	DISC
	@ WEST WARD PHARM CORP	5MG	A086055	001	Nov 02, 1987	Aug	DISC
AB	+	5MG	A086055	001	Nov 02, 1987	Jun	CRLD

ISOSORBIDE MONONITRATE

TABLET, EXTENDED RELEASE;ORAL

ISOSORBIDE MONONITRATE

>A>	AB	HIKMA PHARMS	30MG	A076813	002	Mar 30, 2006	Oct	CAHN
>A>	AB		60MG	A076813	001	Jan 07, 2005	Oct	CAHN
>D>	AB	WEST WARD	30MG	A076813	002	Mar 30, 2006	Oct	CAHN
>D>	AB		60MG	A076813	001	Jan 07, 2005	Oct	CAHN

ISOTRETINOIN

CAPSULE;ORAL

ABSORICA

BX		RANBAXY	10MG	N021951	001	May 25, 2012	Feb	CAHN
BX			20MG	N021951	002	May 25, 2012	Feb	CAHN
BX			30MG	N021951	003	May 25, 2012	Feb	CAHN
BX	+		40MG	N021951	004	May 25, 2012	Aug	CRLD
BX			40MG	N021951	004	May 25, 2012	Feb	CAHN
		AMNESTEEM						
AB		MYLAN PHARMS INC	20MG	A075945	002	Nov 08, 2002	Apr	CRLD
		CLARAVIS						
AB		TEVA PHARMS USA	10MG	A076356	001	Apr 11, 2003	May	CAHN
AB			30MG	A076135	003	May 11, 2006	Apr	CRLD
AB	+		40MG	A076135	001	Apr 11, 2003	Apr	CRLD
		ZENATANE						
AB		DR REDDYS LABS LTD	10MG	A202099	001	Mar 25, 2013	Mar	NEWA
AB			20MG	A202099	002	Mar 25, 2013	Mar	NEWA
AB			40MG	A202099	003	Mar 25, 2013	Mar	NEWA

ISRADIPINE

TABLET, EXTENDED RELEASE;ORAL

DYNACIRC CR

@	GLAXOSMITHKLINE LLC	5MG
@		10MG

N020336	001	Jun 01, 1994	Jun	DISC
N020336	002	Jun 01, 1994	Jun	DISC

KETOROLAC TROMETHAMINE

INJECTABLE;INJECTION

KETOROLAC TROMETHAMINE

@	APOTEX INC	15MG/ML
@		30MG/ML
@		30MG/ML
@		30MG/ML
@	LUITPOLD	15MG/ML
@		30MG/ML

A075631	002	Jun 29, 2001	Apr	DISC
A075626	001	Jul 24, 2001	Apr	DISC
A075631	001	Jun 29, 2001	Apr	DISC
A077201	001	Oct 14, 2005	Apr	DISC
A078145	001	Jan 14, 2008	Jun	DISC
A078145	002	Jan 14, 2008	Jun	DISC

SOLUTION/DROPS;OPHTHALMIC

ACULAR PRESERVATIVE FREE

@	ALLERGAN	0.5%
---	----------	------

N020811	001	Nov 03, 1997	May	DISC
---------	-----	--------------	-----	------

LABETALOL HYDROCHLORIDE

INJECTABLE;INJECTION

LABETALOL HYDROCHLORIDE

AP		AKORN INC	5MG/ML
AP			5MG/ML
	@	APOTEX INC	5MG/ML

A075431	001	Nov 29, 1999	Jul	CAHN
A075524	001	Nov 29, 1999	Jul	CAHN
A076051	001	Jul 05, 2002	Apr	DISC

TABLET;ORAL

LABETALOL HYDROCHLORIDE

AB	+	SANDOZ	200MG
		TRANDATE	
	@	PROMETHEUS LABS	100MG
	@		200MG

A075113	002	Aug 04, 1998	Jan	CRLD
N018716	001	May 24, 1985	Jan	DISC
N018716	002	Aug 01, 1984	Jan	DISC

LACTULOSE

SOLUTION;ORAL

LACTULOSE

@	APOTEX INC	10GM/15ML
---	------------	-----------

A075911	001	Feb 21, 2002	Apr	DISC
---------	-----	--------------	-----	------

SOLUTION;ORAL, RECTAL

LACTULOSESOLUTION;ORAL, RECTAL
LACTULOSE

@ APOTEX INC

10GM/15ML

A076645 001 Jul 28, 2003 Apr DISC

LAMOTRIGINE

TABLET;ORAL

LAMICTAL

AB + GLAXOSMITHKLINE LLC

25MG

N020241 005 Dec 27, 1994 Mar CAHN

@

50MG

N020241 006 Dec 27, 1994 Mar CAHN

AB 100MG

N020241 001 Dec 27, 1994 Mar CAHN

AB 150MG

N020241 002 Dec 27, 1994 Mar CAHN

AB 200MG

N020241 003 Dec 27, 1994 Mar CAHN

@

250MG

N020241 004 Dec 27, 1994 Mar CAHN

LAMOTRIGINE

AB ALKEM LABS LTD

25MG

A200694 001 Jun 14, 2013 Jun NEWA

AB 100MG

A200694 002 Jun 14, 2013 Jun NEWA

AB 150MG

A200694 003 Jun 14, 2013 Jun NEWA

AB 200MG

A200694 004 Jun 14, 2013 Jun NEWA

AB CIPLA LTD

25MG

A077783 001 Nov 01, 2010 Aug CAHN

AB 100MG

A077783 002 Nov 01, 2010 Aug CAHN

AB 150MG

A077783 003 Nov 01, 2010 Aug CAHN

AB 200MG

A077783 004 Nov 01, 2010 Aug CAHN

TABLET, CHEWABLE;ORAL

LAMICTAL CD

AB GLAXOSMITHKLINE LLC

2MG

N020764 004 Sep 08, 2000 Mar CAHN

AB 5MG

N020764 001 Aug 24, 1998 Mar CAHN

AB + 25MG

N020764 002 Aug 24, 1998 Mar CAHN

@

100MG

N020764 003 Aug 24, 1998 Mar CAHN

TABLET, EXTENDED RELEASE;ORAL

LAMICTAL XR

AB GLAXOSMITHKLINE LLC

25MG

N022115 001 May 29, 2009 Mar CAHN

AB + 50MG

N022115 002 May 29, 2009 Mar CAHN

AB 100MG

N022115 003 May 29, 2009 Mar CAHN

AB 200MG

N022115 004 May 29, 2009 Mar CAHN

AB 250MG

N022115 006 Jun 21, 2011 Mar CAHN

AB 300MG

N022115 005 Apr 14, 2010 Mar CAHN

LAMOTRIGINE

AB ACTAVIS ELIZABETH

100MG

A200672 003 Oct 17, 2013 Sep NEWA

AB 200MG

A200672 004 Oct 17, 2013 Sep NEWA

AB 25MG

A200672 001 Oct 17, 2013 Sep NEWA

AB 50MG

A200672 002 Oct 17, 2013 Sep NEWA

>A> AB 250MG

A203733 001 Nov 13, 2013 Oct NEWA

AB 300MG

A200672 005 Oct 17, 2013 Sep NEWA

AB DR REDDYS LABS LTD

25MG

A202383 001 Jun 19, 2013 Jun NEWA

AB 50MG

A202383 002 Jun 19, 2013 Jun NEWA

AB 100MG

A202383 003 Jun 19, 2013 Jun NEWA

AB 200MG

A202383 004 Jun 19, 2013 Jun NEWA

AB 300MG

A202383 005 Jun 19, 2013 Jun NEWA

AB PAR PHARM

25MG

A201791 001 Jan 18, 2013 Jan NEWA

AB 50MG

A201791 002 Jan 18, 2013 Jan NEWA

AB 100MG

A201791 003 Jan 18, 2013 Jan NEWA

AB 200MG

A201791 004 Jan 18, 2013 Jan NEWA

AB 250MG

A201791 005 Jan 18, 2013 Jan NEWA

AB 300MG

A201791 006 Jan 18, 2013 Jan NEWA

AB WILSHIRE PHARMS INC

25MG

A202887 001 Jun 17, 2013 Jun NEWA

AB 50MG

A202887 002 Jun 17, 2013 Jun NEWA

AB 100MG

A202887 003 Jun 17, 2013 Jun NEWA

AB 200MG

A202887 004 Jun 17, 2013 Jun NEWA

TABLET, ORALLY DISINTEGRATING;ORAL

LAMICTAL ODT

AB GLAXOSMITHKLINE LLC

25MG

N022251 001 May 08, 2009 Jul CFTG

25MG

N022251 001 May 08, 2009 Mar CAHN

AB + 50MG

N022251 002 May 08, 2009 Jul CFTG

+ 50MG

N022251 002 May 08, 2009 Mar CAHN

AB 100MG

N022251 003 May 08, 2009 Jul CFTG

AB 100MG

N022251 003 May 08, 2009 Mar CAHN

AB 200MG

N022251 004 May 08, 2009 Jul CFTG

200MG

N022251 004 May 08, 2009 Mar CAHN

LAMOTRIGINE

AB WATSON LABS INC

25MG

A200828 001 Jul 15, 2013 Jul NEWA

AB 50MG

A200828 002 Jul 15, 2013 Jul NEWA

LAMOTRIGINE

TABLET, ORALLY DISINTEGRATING;ORAL
LAMOTRIGINE

AB		100MG	A200828	003	Jul 15, 2013	Jul NEWA
AB		200MG	A200828	004	Jul 15, 2013	Jul NEWA

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL
LANSOPRAZOLE

AB	SUN PHARMA GLOBAL	15MG	A202637	001	Sep 13, 2013	Aug NEWA
AB		30MG	A091509	001	Sep 13, 2013	Aug NEWA
AB	ZYDUS HLTHCARE	15MG	A202366	001	Aug 19, 2013	Jul NEWA
AB		30MG	A202366	002	Aug 19, 2013	Jul NEWA
	LANSOPRAZOLE					
AB	KRKA TOVARNA ZDRAVIL	15MG	A091212	001	Sep 16, 2013	Aug NEWA
AB		30MG	A091212	002	Sep 16, 2013	Aug NEWA

LATANOPROST

SOLUTION/DROPS;OPHTHALMIC
LATANOPROST

	@ APOTEX INC	0.005%	A077697	001	Mar 22, 2011	Apr DISC
AT	DR REDDYS LABS LTD	0.005%	A202077	001	Feb 11, 2013	Jan NEWA

LENALIDOMIDE

CAPSULE;ORAL
REVLIMID

	CELGENE	20MG	N021880	006	Jun 05, 2013	Jun NEWA
--	---------	------	---------	-----	--------------	----------

LEPIRUDIN RECOMBINANT

INJECTABLE;INJECTION
REFLUDAN

	@ BAYER HLTHCARE	50MG/VIAL	N020807	001	Mar 06, 1998	Jun DISC
--	------------------	-----------	---------	-----	--------------	----------

LETROZOLE

TABLET;ORAL
LETROZOLE

AB	JIANGSU HENGRUI MED	2.5MG	A202716	001	May 16, 2013	Apr NEWA
----	---------------------	-------	---------	-----	--------------	----------

LEUCOVORIN CALCIUM

INJECTABLE;INJECTION
LEUCOVORIN CALCIUM

AP	TEVA PHARMS USA	EQ 100MG BASE/VIAL	A081277	001	Sep 28, 1993	Mar CAHN
AP		EQ 350MG BASE/VIAL	A040174	001	Jun 12, 1997	Mar CAHN
	LEUCOVORIN CALCIUM PRESERVATIVE FREE					
	@ LUITPOLD	EQ 50MG BASE/VIAL	A040338	001	Jan 31, 2001	Jun DISC

LEUPROLIDE ACETATE

INJECTABLE;INJECTION
LEUPROLIDE ACETATE

AP	TEVA PHARMS USA	1MG/0.2ML	A075471	001	Oct 25, 2000	Mar CAHN
	LUPRON					
	@ ABBVIE ENDOCRINE INC	1MG/0.2ML	N019010	001	Apr 09, 1985	Jul CAHN
	LUPRON DEPOT					
+	ABBVIE ENDOCRINE INC	3.75MG/VIAL	N020011	001	Oct 22, 1990	Apr CAHN
+		7.5MG/VIAL	N019732	001	Jan 26, 1989	Jul CAHN
+		11.25MG/VIAL	N020708	001	Mar 07, 1997	Jul CAHN
+		22.5MG/VIAL	N020517	001	Dec 22, 1995	Jul CAHN
+		30MG/VIAL	N020517	002	May 30, 1997	Jul CAHN
		45MG/VIAL	N020517	003	Jun 17, 2011	Jul CAHN
	LUPRON DEPOT-PED					
	@ ABBVIE ENDOCRINE INC	3.75MG/VIAL, 7.5MG/VIAL	N020263	003	Apr 16, 1993	Jul CAHN
	@	7.5MG/VIAL, 7.5MG/VIAL	N020263	004	Apr 16, 1993	Jul CAHN
+		7.5MG/VIAL	N020263	002	Apr 16, 1993	Jul CAHN
+		11.25MG/VIAL	N020263	005	Jan 21, 1994	Jul CAHN
+		11.25MG/VIAL	N020263	007	Aug 15, 2011	Jul CAHN
+		15MG/VIAL	N020263	006	Jan 21, 1994	Jul CAHN
+		30MG/VIAL	N020263	008	Aug 15, 2011	Jul CAHN

LEVALBUTEROL HYDROCHLORIDE

SOLUTION;INHALATION
LEVALBUTEROL HYDROCHLORIDE

LEVALBUTEROL HYDROCHLORIDE

SOLUTION; INHALATION

LEVALBUTEROL HYDROCHLORIDE

AN	DEY	EQ 0.0103% BASE	A077800	001	Mar 15, 2013	Mar NEWA
AN		EQ 0.021% BASE	A077800	002	Mar 15, 2013	Mar NEWA
AN		EQ 0.042% BASE	A077800	003	Mar 15, 2013	Mar NEWA
AN	TEVA PHARMS USA	EQ 0.0103% BASE	A090297	001	Apr 26, 2013	Apr NEWA
AN		EQ 0.021% BASE	A090297	002	Apr 26, 2013	Apr NEWA
AN		EQ 0.042% BASE	A090297	003	Apr 26, 2013	Apr NEWA

LEVETIRACETAM

INJECTABLE; IV (INFUSION)

LEVETIRACETAM

AP	SAGENT PHARMS	500MG/5ML (100MG/ML)	A091627	001	Jun 26, 2013	Jun NEWA
----	---------------	----------------------	---------	-----	--------------	----------

SOLUTION; ORAL

LEVETIRACETAM

	@ APOTEX INC	100MG/ML	A090187	001	Aug 05, 2011	Apr DISC
AA	BRECKENRIDGE PHARM	100MG/ML	A079120	001	Jan 16, 2009	Sep CAHN
AA	HETERO DRUGS LTD	100MG/ML	A203052	001	Feb 28, 2013	Feb NEWA
AA	HETERO LABS LTD III	100MG/ML	A203052	001	Feb 28, 2013	Apr CAHN
AA	ORIT LABS LLC	100MG/ML	A203067	001	May 09, 2013	Apr NEWA

TABLET; ORAL

LEVETIRACETAM

AB	HETERO LABS LTD III	1GM	A090515	004	Oct 08, 2010	Apr CAHN
AB		250MG	A090515	001	Oct 08, 2010	Apr CAHN
AB		500MG	A090515	002	Oct 08, 2010	Apr CAHN
AB		750MG	A090515	003	Oct 08, 2010	Apr CAHN
AB	PRINSTON INC	1GM	A078106	004	Feb 10, 2009	Apr CAHN
AB		250MG	A078106	001	Feb 10, 2009	Apr CAHN
AB		500MG	A078106	002	Feb 10, 2009	Apr CAHN
AB		750MG	A078106	003	Feb 10, 2009	Apr CAHN

TABLET, EXTENDED RELEASE; ORAL

LEVETIRACETAM

	@ SANDOZ	500MG	A091668	001	Nov 01, 2012	Mar DISC
	@	750MG	A091668	002	Nov 01, 2012	Mar DISC
AB	SUN PHARMA GLOBAL	500MG	A203059	001	Sep 09, 2013	Aug NEWA
AB		750MG	A203059	002	Sep 09, 2013	Aug NEWA
AB	VINTAGE PHARMS LLC	500MG	A202533	001	Jul 20, 2012	Jan NEWA
AB		750MG	A202533	002	Jul 20, 2012	Jan NEWA

LEVOBUNOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

LEVOBUNOLOL HYDROCHLORIDE

	@ APOTEX INC	0.25%	A075473	001	Aug 03, 2000	Apr DISC
	@	0.5%	A075475	001	Aug 03, 2000	Apr DISC

LEVOCARNITINE

INJECTABLE; INJECTION

LEVOCARNITINE

AP	TEVA PHARMS USA	200MG/ML	A075881	001	Mar 29, 2001	May CAHN
----	-----------------	----------	---------	-----	--------------	----------

LEVOCETIRIZINE DIHYDROCHLORIDE

SOLUTION; ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

AA	TARO PHARM INDS	2.5MG/5ML	A202673	001	Jul 26, 2013	Jul NEWA
----	-----------------	-----------	---------	-----	--------------	----------

TABLET; ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

AB	MICRO LABS LTD INDIA	5MG	A202046	001	Sep 17, 2013	Aug NEWA
AB	SANDOZ	5MG	A090486	001	Mar 26, 2013	Mar NEWA
AB	SUN PHARMA GLOBAL	5MG	A090362	001	Jan 31, 2013	Jan NEWA

LEVOFLOXACIN

INJECTABLE; INJECTION

LEVOFLOXACIN

AP	AUROBINDO PHARMA LTD	EQ 500MG/20ML (EQ 25MG/ML)	A202328	001	Jan 24, 2013	Jan NEWA
AP		EQ 750MG/30ML (EQ 25MG/ML)	A202328	002	Jan 24, 2013	Jan NEWA
AP	CLARIS LIFESCIENCES	EQ 500MG/20ML (EQ 25MG/ML)	A091436	001	Jun 05, 2013	May NEWA
AP	EMCURE PHARMS LTD	EQ 500MG/20ML (EQ 25MG/ML)	A202590	001	Jan 24, 2013	Jan NEWA
AP		EQ 750MG/30ML (EQ 25MG/ML)	A202590	002	Jan 24, 2013	Jan NEWA
	LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER					
AP	CLARIS LIFESCIENCES	EQ 250MG/50ML (EQ 5MG/ML)	A091397	001	Aug 08, 2013	Jul NEWA

LEVOFLOXACIN

INJECTABLE;INJECTION

LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

AP		EQ 500MG/100ML (EQ 5MG/ML)	A091397	002	Aug 08, 2013	Jul NEWA
AP		EQ 750MG/150ML (EQ 5MG/ML)	A091397	003	Aug 08, 2013	Jul NEWA
AP	FRESENIUS KABI USA	EQ 250MG/50ML (EQ 5MG/ML)	A200674	001	Jun 19, 2013	Jun NEWA
AP		EQ 500MG/100ML (EQ 5MG/ML)	A200674	002	Jun 19, 2013	Jun NEWA
AP		EQ 750MG/150ML (EQ 5MG/ML)	A200674	003	Jun 19, 2013	Jun NEWA

SOLUTION/DROPS;OPHTHALMIC

LEVOFLOXACIN

@ APOTEX INC

0.5%

A078282 001 Dec 20, 2010 Apr DISC

LEVOMILNACIPRAN HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

FETZIMA

FOREST LABS INC

EQ 20MG BASE

N204168 001 Jul 25, 2013 Jul NEWA

EQ 40MG BASE

N204168 002 Jul 25, 2013 Jul NEWA

EQ 80MG BASE

N204168 003 Jul 25, 2013 Jul NEWA

+

EQ 120MG BASE

N204168 004 Jul 25, 2013 Jul NEWA

LEVONORDEFIN; MEPIVACAINE HYDROCHLORIDE

INJECTABLE;INJECTION

ISOCAINE HYDROCHLORIDE W/ LEVONORDEFIN

@ NOVOCOL

0.05MG/ML;2%

A084697 001 Jun DISC

SCANDONEST L

+ DEPROCO

0.05MG/ML;2%

A088388 001 Oct 10, 1984 Jun CRLD

LEVONORGESTREL

INTRAUTERINE DEVICE;INTRAUTERINE

SKYLA

+ BAYER HLTHCARE

13.5MG

N203159 001 Jan 09, 2013 Jan NEWA

TABLET;ORAL

LEVONORGESTREL

AB LUPIN LTD 0.75MG

A091328 001 Jan 23, 2013 Jan NEWA

AB NOVEL LABS INC 1.5MG

A202508 001 Feb 22, 2013 Feb NEWA

LEVOTHYROXINE SODIUM **

**See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET;ORAL

LEVOTHYROXINE SODIUM

@ MERCK KGAA

0.025MG

A076752 001 Jun 16, 2005 Jul DISC

@

0.05MG

A076752 002 Jun 16, 2005 Jul DISC

@

0.075MG

A076752 003 Jun 16, 2005 Jul DISC

@

0.088MG

A076752 004 Jun 16, 2005 Jul DISC

@

0.1MG

A076752 005 Jun 16, 2005 Jul DISC

@

0.112MG

A076752 006 Jun 16, 2005 Jul DISC

@

0.125MG

A076752 007 Jun 16, 2005 Jul DISC

@

0.15MG

A076752 008 Jun 16, 2005 Jul DISC

@

0.175MG

A076752 009 Jun 16, 2005 Jul DISC

@

0.2MG

A076752 010 Jun 16, 2005 Jul DISC

@

0.3MG

A076752 011 Jun 16, 2005 Jul DISC

LEVOXYL

AB1, KING PHARMS R AND D 0.025MG

N021301 001 May 25, 2001 Mar CAHN

AB3

AB1, 0.05MG

N021301 002 May 25, 2001 Mar CAHN

AB3

AB1, 0.075MG

N021301 003 May 25, 2001 Mar CAHN

AB3

AB1, 0.088MG

N021301 004 May 25, 2001 Mar CAHN

AB3

AB1, 0.1MG

N021301 005 May 25, 2001 Mar CAHN

AB3

AB1, 0.112MG

N021301 006 May 25, 2001 Mar CAHN

AB3

AB1, 0.125MG

N021301 007 May 25, 2001 Mar CAHN

AB3

AB1, 0.137MG

N021301 008 May 25, 2001 Mar CAHN

AB3

AB1, 0.15MG

N021301 009 May 25, 2001 Mar CAHN

AB3

AB1, 0.175MG

N021301 010 May 25, 2001 Mar CAHN

AB3

AB1, + 0.2MG

N021301 011 May 25, 2001 Mar CAHN

AB3

LEVOTHYROXINE SODIUM **

**See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET;ORAL

LEVOXYL

@	0.3MG	N021301	012	May 25, 2001	Mar CAHN
---	-------	---------	-----	--------------	----------

LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION

LIDOCAINE HYDROCHLORIDE

AP	INTL MEDICATION	1%	A083173	001	Sep CMFD
----	-----------------	----	---------	-----	----------

AP		2%	A083173	002	Sep CMFD
----	--	----	---------	-----	----------

@ LUITPOLD	2%	A083198	001	Mar DISC
------------	----	---------	-----	----------

LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE

AP	AUROBINDO PHARMA LTD	1%	A203040	001	Mar 14, 2013	Mar NEWA
----	----------------------	----	---------	-----	--------------	----------

AP		1%	A203082	001	Mar 14, 2013	Mar NEWA
----	--	----	---------	-----	--------------	----------

AP		2%	A203040	002	Mar 14, 2013	Mar NEWA
----	--	----	---------	-----	--------------	----------

AP		2%	A203082	002	Mar 14, 2013	Mar NEWA
----	--	----	---------	-----	--------------	----------

JELLY;TOPICAL

ANESTACON

@ POLYMEDICA	2%	A080429	001	May DISC
--------------	----	---------	-----	----------

LIDOCAINE HYDROCHLORIDE

@ TEVA PHARMS USA	2%	A081318	001	Apr 29, 1993	Jun DISC
-------------------	----	---------	-----	--------------	----------

LIDOCAINE; TETRACAINE

PATCH;TOPICAL

SYNERA

+	GALEN SPECIALTY	70MG;70MG	N021623	001	Jun 23, 2005	Aug CAHN
---	-----------------	-----------	---------	-----	--------------	----------

LIOTHYRONINE SODIUM

TABLET;ORAL

CYTOMEL

AB	KING PHARMS R AND D	EQ 0.005MG BASE	N010379	001	Mar CAHN
----	---------------------	-----------------	---------	-----	----------

AB		EQ 0.025MG BASE	N010379	002	Mar CAHN
----	--	-----------------	---------	-----	----------

AB	+	EQ 0.05MG BASE	N010379	003	Mar CAHN
----	---	----------------	---------	-----	----------

LISINOPRIL

TABLET;ORAL

LISINOPRIL

AB	ACCORD HLTHCARE	2.5MG	A202554	001	Jul 30, 2013	Jul NEWA
----	-----------------	-------	---------	-----	--------------	----------

AB		5MG	A202554	002	Jul 30, 2013	Jul NEWA
----	--	-----	---------	-----	--------------	----------

AB		10MG	A202554	003	Jul 30, 2013	Jul NEWA
----	--	------	---------	-----	--------------	----------

AB		20MG	A202554	004	Jul 30, 2013	Jul NEWA
----	--	------	---------	-----	--------------	----------

AB		30MG	A202554	005	Jul 30, 2013	Jul NEWA
----	--	------	---------	-----	--------------	----------

AB		40MG	A202554	006	Jul 30, 2013	Jul NEWA
----	--	------	---------	-----	--------------	----------

>A> AB	HIKMA PHARMS	2.5MG	A076063	001	Jul 01, 2002	Oct CAHN
--------	--------------	-------	---------	-----	--------------	----------

>A> AB		5MG	A076063	002	Jul 01, 2002	Oct CAHN
--------	--	-----	---------	-----	--------------	----------

>A> AB		10MG	A076063	003	Jul 01, 2002	Oct CAHN
--------	--	------	---------	-----	--------------	----------

>A> AB		20MG	A076063	004	Jul 01, 2002	Oct CAHN
--------	--	------	---------	-----	--------------	----------

>A> AB		30MG	A076063	006	Jun 27, 2003	Oct CAHN
--------	--	------	---------	-----	--------------	----------

>A> AB		40MG	A076063	005	Jul 01, 2002	Oct CAHN
--------	--	------	---------	-----	--------------	----------

>A> AB	INVAGEN PHARMS	2.5MG	A203508	001	Oct 29, 2013	Oct NEWA
--------	----------------	-------	---------	-----	--------------	----------

>A> AB		5MG	A203508	002	Oct 29, 2013	Oct NEWA
--------	--	-----	---------	-----	--------------	----------

>A> AB		10MG	A203508	003	Oct 29, 2013	Oct NEWA
--------	--	------	---------	-----	--------------	----------

>A> AB		20MG	A203508	004	Oct 29, 2013	Oct NEWA
--------	--	------	---------	-----	--------------	----------

>A> AB		30MG	A203508	005	Oct 29, 2013	Oct NEWA
--------	--	------	---------	-----	--------------	----------

>A> AB		40MG	A203508	006	Oct 29, 2013	Oct NEWA
--------	--	------	---------	-----	--------------	----------

@ SANDOZ	2.5MG	A075903	001	Jul 01, 2002	Aug DISC
----------	-------	---------	-----	--------------	----------

@	2.5MG	A075999	001	Jul 01, 2002	Jan CAHN
---	-------	---------	-----	--------------	----------

@	5MG	A075903	002	Jul 01, 2002	Aug DISC
---	-----	---------	-----	--------------	----------

@	5MG	A075999	002	Jul 01, 2002	Jan CAHN
---	-----	---------	-----	--------------	----------

@	10MG	A075903	003	Jul 01, 2002	Aug DISC
---	------	---------	-----	--------------	----------

@	10MG	A075999	003	Jul 01, 2002	Jan CAHN
---	------	---------	-----	--------------	----------

@	20MG	A075903	004	Jul 01, 2002	Aug DISC
---	------	---------	-----	--------------	----------

@	20MG	A075999	004	Jul 01, 2002	Jan CAHN
---	------	---------	-----	--------------	----------

@	30MG	A075903	005	Jul 01, 2002	Aug DISC
---	------	---------	-----	--------------	----------

@	30MG	A075999	005	Jul 01, 2002	Jan CAHN
---	------	---------	-----	--------------	----------

@	40MG	A075903	006	Jul 01, 2002	Aug DISC
---	------	---------	-----	--------------	----------

@	40MG	A075999	006	Jul 01, 2002	Jan CAHN
---	------	---------	-----	--------------	----------

>D> AB	WEST WARD	2.5MG	A076063	001	Jul 01, 2002	Oct CAHN
--------	-----------	-------	---------	-----	--------------	----------

>D> AB		5MG	A076063	002	Jul 01, 2002	Oct CAHN
--------	--	-----	---------	-----	--------------	----------

>D> AB		10MG	A076063	003	Jul 01, 2002	Oct CAHN
--------	--	------	---------	-----	--------------	----------

>D> AB		20MG	A076063	004	Jul 01, 2002	Oct CAHN
--------	--	------	---------	-----	--------------	----------

LISINOPRILTABLET; ORAL
LISINOPRIL

>D>	AB	30MG	A076063	006	Jun 27, 2003	Oct	CAHN
>D>	AB	40MG	A076063	005	Jul 01, 2002	Oct	CAHN

LITHIUM CARBONATE

CAPSULE; ORAL

LITHIUM CARBONATE

	@ APOTEX INC	300MG	A076795	001	Nov 22, 2004	Feb	DISC
AB	HETERO LABS LTD III	150MG	A090702	001	Sep 25, 2009	Apr	CAHN
AB		300MG	A090702	002	Sep 25, 2009	Apr	CAHN
AB		600MG	A090702	003	Sep 25, 2009	Apr	CAHN

TABLET; ORAL

LITHIUM CARBONATE

	@ WEST WARD	300MG	A078715	001	Dec 28, 2010	Aug	DISC
--	-------------	-------	---------	-----	--------------	-----	------

LOMUSTINE

CAPSULE; ORAL

CEENU

	CORDEN PHARMA	10MG	N017588	001		Apr	CAHN
		40MG	N017588	002		Apr	CAHN
+		100MG	N017588	003		Apr	CAHN

LORAZEPAM

CONCENTRATE; ORAL

LORAZEPAM

AA	LUPIN LTD	2MG/ML	A091407	001	Feb 19, 2013	Feb	NEWA
----	-----------	--------	---------	-----	--------------	-----	------

INJECTABLE; INJECTION

LORAZEPAM

AP	AKORN	2MG/ML	A075025	001	Jul 23, 1998	Jul	CAHN
	@ WATSON LABS	2MG/ML	A074276	001	Apr 15, 1994	Sep	DISC
	@	4MG/ML	A074276	002	Apr 15, 1994	Sep	DISC

TABLET; ORAL

LORAZEPAM

	@ SANDOZ	0.5MG	A071193	001	Apr 15, 1988	Apr	DISC
	@	1MG	A071194	001	Apr 15, 1988	Apr	DISC
	@	2MG	A071195	001	Apr 15, 1988	Apr	DISC

LOSARTAN POTASSIUM

TABLET; ORAL

COZAAR

>D>	AB	MERCK	25MG	N020386	001	Apr 14, 1995	Oct	CAHN
>D>	AB		50MG	N020386	002	Apr 14, 1995	Oct	CAHN
>D>	AB	+	100MG	N020386	003	Oct 13, 1998	Oct	CAHN
>A>	AB	MERCK SHARP DOHME	25MG	N020386	001	Apr 14, 1995	Oct	CAHN
>A>	AB		50MG	N020386	002	Apr 14, 1995	Oct	CAHN
>A>	AB	+	100MG	N020386	003	Oct 13, 1998	Oct	CAHN

LOSARTAN POTASSIUM

AB	ACTAVIS GRP PTC	25MG	A090382	001	Oct 06, 2010	Mar	CAHN
AB		50MG	A090382	002	Oct 06, 2010	Mar	CAHN
AB		100MG	A090382	003	Oct 06, 2010	Mar	CAHN
AB	IPCA LABS LTD	25MG	A200290	001	Aug 30, 2013	Aug	NEWA
AB		50MG	A200290	002	Aug 30, 2013	Aug	NEWA
AB		100MG	A200290	003	Aug 30, 2013	Aug	NEWA

LOVASTATIN

TABLET; ORAL

LOVASTATIN

AB	+	CARLSBAD	40MG	A075991	003	Jun 05, 2002	Feb	CRLD
		MEVACOR						
		@ MERCK	20MG	N019643	003	Aug 31, 1987	Feb	DISC
		@	40MG	N019643	004	Dec 14, 1988	Feb	DISC

LOXAPINE

POWDER; INHALATION

ADASUVE

+	TEVA PHARMS USA INC	10MG	N022549	001	Dec 21, 2012	Jul	CAHN
---	---------------------	------	---------	-----	--------------	-----	------

LOXAPINE SUCCINATE

CAPSULE; ORAL

LOXAPINE SUCCINATE

CAPSULE;ORAL

LOXAPINE SUCCINATE

AB	MIKAH PHARMA	EQ 5MG BASE	A076868	001	Aug 04, 2005	May CMFD
AB		EQ 10MG BASE	A076868	002	Aug 04, 2005	May CMFD
AB		EQ 25MG BASE	A076868	003	Aug 04, 2005	May CMFD
AB		EQ 50MG BASE	A076868	004	Aug 04, 2005	May CMFD

LURASIDONE HYDROCHLORIDE

TABLET;ORAL

LATUDA

	SUNOVION PHARMS INC	60MG	N200603	005	Jul 12, 2013	Jul NEWA
--	---------------------	------	---------	-----	--------------	----------

>A> MACITENTAN

>A> TABLET;ORAL

>A> OPSUMIT

>A>	+ ACTELION PHARMS LTD	10MG	N204410	001	Oct 18, 2013	Oct NEWA
-----	-----------------------	------	---------	-----	--------------	----------

MAFENIDE ACETATE

CREAM;TOPICAL

SULFAMYLON

	+ MYLAN INSTITUTIONAL	EQ 85MG BASE/GM	N016763	001		May CAHN
--	-----------------------	-----------------	---------	-----	--	----------

FOR SOLUTION;TOPICAL

MAFENIDE ACETATE

AB	PAR FORM	5%	A201511	001	Feb 12, 2013	Jan NEWA
----	----------	----	---------	-----	--------------	----------

SULFAMYLON

AB	+ MYLAN INSTITUTIONAL	5%	N019832	003	Jun 05, 1998	May CAHN
----	-----------------------	----	---------	-----	--------------	----------

AB	+ MYLAN LLC	5%	N019832	003	Jun 05, 1998	Jan CFTG
----	-------------	----	---------	-----	--------------	----------

MAGNESIUM SULFATE; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; POTASSIUM SULFATE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE

SOLUTION;ORAL

SUCLEAR

	+ BRAINTREE LABS	1.6GM/BOT,3.13GM/BOT,17.5GM/BOT,N/A,N/A,N/A,N/A;N/A,N/A,N/A,210GM,0.74GM,2.86GM,5.6GM	N203595	001	Jan 18, 2013	Jan NEWA
--	------------------	---	---------	-----	--------------	----------

MANNITOL

INJECTABLE;INJECTION

MANNITOL 20%

	@ B BRAUN	20GM/100ML	N014738	001		Jan DISC
--	-----------	------------	---------	-----	--	----------

MECAMYLAMINE HYDROCHLORIDE

TABLET;ORAL

MECAMYLAMINE HYDROCHLORIDE

	NEXGEN PHARMA	2.5MG	A204054	001	Mar 19, 2013	Mar NEWA
--	---------------	-------	---------	-----	--------------	----------

MECHLORETHAMINE HYDROCHLORIDE

GEL;TOPICAL

VALCHLOR

	+ ACTELION PHARMS LTD	0.02%	N202317	001	Aug 23, 2013	Sep CAHN
--	-----------------------	-------	---------	-----	--------------	----------

	+ CEPTARIS THERAP	0.02%	N202317	001	Aug 23, 2013	Aug NEWA
--	-------------------	-------	---------	-----	--------------	----------

INJECTABLE;INJECTION

MUSTARGEN

	+ RECORDATI RARE	10MG/VIAL	N006695	001		May CAHN
--	------------------	-----------	---------	-----	--	----------

MECLOFENAMATE SODIUM

CAPSULE;ORAL

MECLOFENAMATE SODIUM

MYLAN

		EQ 50MG BASE	A071081	002	Sep 03, 1986	Sep CTEC
--	--	--------------	---------	-----	--------------	----------

	+ @ WATSON LABS	EQ 100MG BASE	A071081	001	Sep 03, 1986	Sep CTEC
--	-----------------	---------------	---------	-----	--------------	----------

	@	EQ 50MG BASE	A071468	001	Apr 15, 1987	Sep DISC
--	---	--------------	---------	-----	--------------	----------

	@	EQ 100MG BASE	A071469	001	Apr 15, 1987	Sep DISC
--	---	---------------	---------	-----	--------------	----------

MEDROXYPROGESTERONE ACETATE

INJECTABLE;INJECTION

MEDROXYPROGESTERONE ACETATE

	@ TEVA PHARMS USA	150MG/ML	A076552	001	Oct 27, 2004	May CAHN
--	-------------------	----------	---------	-----	--------------	----------

AB		150MG/ML	A076553	001	Jul 28, 2004	May CAHN
----	--	----------	---------	-----	--------------	----------

MEFENAMIC ACID

CAPSULE;ORAL

MEFENAMIC ACID

AB	BRECKENRIDGE PHARM	250MG	A090359	001	Feb 05, 2013	Sep CAHN
AB	CYPRESS PHARM	250MG	A090359	001	Feb 05, 2013	Jan NEWA

MEFLOQUINE HYDROCHLORIDE

TABLET;ORAL

MEFLOQUINE HYDROCHLORIDE

@ WEST WARD PHARM CORP 250MG

A077699 001 Apr 21, 2010 Jun DISC

MEGESTROL ACETATE

SUSPENSION;ORAL

MEGESTROL ACETATE

@ APOTEX INC 40MG/ML

A077404 001 Feb 16, 2006 Apr DISC

MELOXICAM

TABLET;ORAL

MELOXICAM

AB	CIPLA LTD	7.5MG	A077929	001	Jul 19, 2006	Aug CAHN
AB		15MG	A077929	002	Jul 19, 2006	Aug CAHN
	@ COREPHARMA	7.5MG	A077930	001	Jul 19, 2006	Feb DISC
	@	15MG	A077930	002	Jul 19, 2006	Feb DISC
	@ CR DOUBLE CRANE	7.5MG	A078039	001	Dec 14, 2006	Apr DISC
AB		7.5MG	A078039	001	Dec 14, 2006	Mar CAHN
	@	15MG	A078039	002	Dec 14, 2006	Apr DISC
AB		15MG	A078039	002	Dec 14, 2006	Mar CAHN
	@ MYLAN	7.5MG	A077934	001	Jul 20, 2006	Aug DISC
	@	15MG	A077934	002	Jul 20, 2006	Aug DISC

MEPROBAMATE

TABLET;ORAL

MEPROBAMATE

@ TARO 200MG

A200998 001 May 23, 2011 Jan DISC

@ 400MG

A200998 002 May 23, 2011 Jan DISC

MESALAMINE

CAPSULE, DELAYED RELEASE;ORAL

DELZICOL

+ WARNER CHILCOTT LLC 400MG

N204412 001 Feb 01, 2013 Feb NEWA

SUPPOSITORY;RECTAL

CANASA

+ APTALIS PHARMA US 1GM

N021252 002 Nov 05, 2004 Feb CRLD

MESNA

INJECTABLE;INTRAVENOUS

MESNA

AP	TEVA PHARMS USA	100MG/ML	A075764	001	Apr 27, 2001	May CAHN
----	-----------------	----------	---------	-----	--------------	----------

METAPROTERENOL SULFATE

SOLUTION;INHALATION

METAPROTERENOL SULFATE

@ APOTEX INC 0.4%

A075402 001 Feb 28, 2001 Apr DISC

@ 0.6%

A075403 001 Feb 28, 2001 Apr DISC

SYRUP;ORAL

METAPROTERENOL SULFATE

@ APOTEX INC 10MG/5ML

A075235 001 Jan 27, 2000 Apr DISC

@ NOVEX 10MG/5ML

A075235 001 Jan 27, 2000 Feb DISC

+ SILARX 10MG/5ML

A073632 001 Jul 22, 1992 Feb CTEC

TABLET;ORAL

METAPROTERENOL SULFATE

PAR PHARM 10MG

A072024 001 Jun 28, 1988 Mar CTEC

+ 20MG

A072025 001 Jun 28, 1988 Mar CTEC

@ WATSON LABS 10MG

A073013 001 Jan 31, 1991 Mar DISC

@ 20MG

A072795 001 Jan 31, 1991 Mar DISC

METAXALONE

TABLET;ORAL

METAXALONE

AB	AMNEAL PHARMS	800MG	A203399	001	Jun 21, 2013	Jun NEWA
----	---------------	-------	---------	-----	--------------	----------

METFORMIN HYDROCHLORIDE

TABLET; ORAL

METFORMIN HYDROCHLORIDE

AB	CHARTWELL LIFE SCI	1GM	A075972	003	Jan 24, 2002	Aug CAHN
AB		500MG	A075972	001	Jan 24, 2002	Aug CAHN
		625MG	A075972	005	Jan 24, 2002	Aug CAHN
		750MG	A075972	004	Jan 24, 2002	Aug CAHN
AB		850MG	A075972	002	Jan 24, 2002	Aug CAHN
AB	SANDOZ	1GM	A075965	003	Jan 25, 2002	May CMFD
	@	1GM	A075965	003	Jan 25, 2002	Mar DISC
AB		500MG	A075965	001	Jan 25, 2002	May CMFD
	@	500MG	A075965	001	Jan 25, 2002	Mar DISC
AB		850MG	A075965	002	Jan 25, 2002	May CMFD
	@	850MG	A075965	002	Jan 25, 2002	Mar DISC
AB	SCIEGEN PHARMS INC	500MG	A203769	001	Sep 11, 2013	Aug NEWA
AB		850MG	A203769	002	Sep 11, 2013	Aug NEWA
AB		1GM	A203769	003	Sep 11, 2013	Aug NEWA

TABLET, EXTENDED RELEASE; ORAL

FORTAMET

AB2	+ ANDRX LABS LLC	1GM	N021574	002	Apr 27, 2004	Jul CTEC
	GLUMETZA					
AB3	+ SANTARUS	1GM	N021748	002	Jun 03, 2005	Jul CTEC
AB3		500MG	N021748	001	Jun 03, 2005	Jul CTEC
	METFORMIN HYDROCHLORIDE					
AB1	CSPC OUYI PHARM CO	500MG	A078321	001	Apr 17, 2008	Sep CAHN
AB		750MG	A078321	002	Apr 17, 2008	Sep CAHN
AB2	LUPIN LTD	1GM	A090692	002	Jun 29, 2011	Jul CTEC
AB3		1GM	A091664	002	Jul 19, 2013	Jul NEWA
AB3		500MG	A091664	001	Jul 19, 2013	Jul NEWA
AB2	MYLAN PHARMS INC	1GM	A200690	002	Aug 01, 2012	Jul CTEC
	@ TORRENT PHARMS LTD	750MG	A079226	001	Feb 18, 2010	Jun DISC
	@ WATSON LABS INC	500MG	A076818	001	Dec 14, 2004	Mar DISC

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE

AB	AUROBINDO PHARMA LTD	500MG;EQ 15MG BASE	A200823	001	Feb 13, 2013	Jan NEWA
AB		850MG;EQ 15MG BASE	A200823	002	Feb 13, 2013	Jan NEWA
AB	SANDOZ	500MG;EQ 15MG BASE	A091273	001	Apr 16, 2013	Apr NEWA
AB		850MG;EQ 15MG BASE	A091273	002	Apr 16, 2013	Apr NEWA
AB	TORRENT PHARMS LTD	500MG;EQ 15MG BASE	A202001	001	Feb 13, 2013	Jan NEWA
AB		850MG;EQ 15MG BASE	A202001	002	Feb 13, 2013	Jan NEWA

METHADONE HYDROCHLORIDE

TABLET, FOR SUSPENSION; ORAL

METHADONE HYDROCHLORIDE

AA	MALLINCKRODT INC	40MG	A077142	001	Jul 12, 2005	Mar CDFR
AA	+ ROXANE	40MG	N017058	001		Mar CDFR
AA	SANDOZ	40MG	A075082	001	Mar 25, 1998	Mar CDFR
	METHADOSE					
AA	MALLINCKRODT	40MG	A074184	001	Apr 29, 1993	Mar CDFR

METHAMPHETAMINE HYDROCHLORIDE

TABLET; ORAL

DESOXYN

AA	+ RECORDATI RARE	5MG	N005378	002		May CAHN
----	------------------	-----	---------	-----	--	----------

METHOCARBAMOL

INJECTABLE; INJECTION

METHOCARBAMOL

	@ WATSON LABS	100MG/ML	A086459	001		Jul DISC
	ROBAXIN					
	+ BAXTER HLTHCARE CORP	100MG/ML	N011790	001		Jul CTEC
	+ HIKMA MAPLE	100MG/ML	N011790	001		Sep CAHN

TABLET; ORAL

METHOCARBAMOL

AA	AUSTARPHARMA LLC	500MG	A200958	001	Oct 21, 2011	May CMFD
	@	500MG	A200958	001	Oct 21, 2011	Jan DISC
AA		750MG	A200958	002	Oct 21, 2011	May CMFD
AA	HETERO LABS LTD III	500MG	A090200	001	Nov 06, 2009	Apr CAHN
AA		750MG	A090200	002	Nov 06, 2009	Apr CAHN

METHOCARBAMOL

TABLET; ORAL

METHOCARBAMOL

>A>	AA	HIKMA PHARMS	750MG	A085123	001		Oct	CAHN
	AA	PRINSTON INC	500MG	A086989	001		Feb	CMFD
	AA		750MG	A086988	001		Feb	CAHN
		@ SOLCO HLTHCARE	500MG	A086989	001		Jan	DISC
>D>	AA	WEST WARD	750MG	A085123	001		Oct	CAHN

>A> METHOTREXATE

>A> SOLUTION; SUBCUTANEOUS

>A> OTREXUP

>A>		ANTARES PHARMA INC	10MG/0.4ML	N204824	001	Oct 11, 2013	Oct	NEWA
>A>			15MG/0.4ML	N204824	002	Oct 11, 2013	Oct	NEWA
>A>			20MG/0.4ML	N204824	003	Oct 11, 2013	Oct	NEWA
>A>	+		25MG/0.4ML	N204824	004	Oct 11, 2013	Oct	NEWA

METHOXSALEN

CAPSULE; ORAL

OXSORALEN-ULTRA

+	DOW PHARM	10MG	N019600	001	Oct 30, 1986	Apr	CAHN
---	-----------	------	---------	-----	--------------	-----	------

METHYCLOTHIAZIDE

TABLET; ORAL

METHYCLOTHIAZIDE

+	MYLAN PHARMS INC	5MG	A087672	001	Aug 17, 1982	Jan	CTEC
	@ WATSON LABS	5MG	A088724	001	Sep 06, 1984	Jan	DISC

METHYL AMINOLEVULINATE HYDROCHLORIDE

CREAM; TOPICAL

METVIXIA

@	GALDERMA LABS LP	EQ 16.8% BASE	N021415	001	Jul 27, 2004	Jun	DISC
---	------------------	---------------	---------	-----	--------------	-----	------

METHYLDOPA

TABLET; ORAL

METHYLDOPA

	@	ACCORD HLTHCARE	125MG	A070070	003	Oct 15, 1985	Apr	CAHN
AB			250MG	A070084	001	Oct 15, 1985	Apr	CAHN
AB			500MG	A070085	001	Oct 15, 1985	Apr	CAHN

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

METADATE CD

AB2		UCB INC	10MG	N021259	003	May 27, 2003	Sep	CTEC
AB2			50MG	N021259	005	Feb 19, 2006	Sep	CTEC
AB2	+		60MG	N021259	006	Feb 19, 2006	Sep	CTEC

METHYLPHENIDATE HYDROCHLORIDE

AB2		TEVA PHARMS	10MG	A077707	001	Jul 19, 2012	Sep	CTEC
AB2			50MG	A078873	002	Jul 19, 2012	Sep	CTEC
AB2			60MG	A078873	003	Jul 19, 2012	Sep	CTEC
AB1		WATSON LABS INC	20MG	A078458	001	Dec 01, 2011	Apr	CAHN
AB1			30MG	A078458	002	Dec 01, 2011	Apr	CAHN
AB1			40MG	A078458	003	Dec 01, 2011	Apr	CAHN

SOLUTION; ORAL

METHYLPHENIDATE HYDROCHLORIDE

>A>	AA	CARACO	5MG/5ML	A201466	001	Nov 12, 2013	Oct	NEWA
>A>	AA		10MG/5ML	A201466	002	Nov 12, 2013	Oct	NEWA

TABLET; ORAL

METHYLPHENIDATE HYDROCHLORIDE

AB		CARACO	5MG	A090710	001	Mar 15, 2012	May	CAHN
AB			10MG	A090710	002	Mar 15, 2012	May	CAHN
AB			20MG	A090710	003	Mar 15, 2012	May	CAHN

TABLET, EXTENDED RELEASE; ORAL

CONCERTA

AB		JANSSEN PHARMS	18MG	N021121	001	Aug 01, 2000	Jun	CTEC
		METHYLIN ER						
		MALLINCKRODT INC	10MG	A075629	001	May 09, 2000	Feb	CTEC
		METHYLPHENIDATE HYDROCHLORIDE						
AB		KUDCO IRELAND	18MG	A091695	001	Jul 09, 2013	Jun	NEWA
AB			27MG	A091695	002	Jul 09, 2013	Jun	NEWA
AB			36MG	A091695	003	Sep 23, 2013	Sep	NEWA

METHYLPHENIDATE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL
METHYLPHENIDATE HYDROCHLORIDE

AB	54MG	A091695	004	Sep 23, 2013	Sep NEWA
----	------	---------	-----	--------------	----------

METHYLPREDNISOLONE

TABLET;ORAL
MEDROL

>D>	@ PHARMACIA AND UPJOHN	2MG	N011153	002		Oct CMFD
>A>	AB	2MG	N011153	002		Oct CMFD

METHYLPREDNISOLONE ACETATE

INJECTABLE;INJECTION
METHYLPREDNISOLONE ACETATE

AB	TEVA PHARMS USA	40MG/ML	A040557	001	Feb 23, 2005	May CAHN
AB		40MG/ML	A040620	001	Oct 27, 2006	May CAHN
AB		80MG/ML	A040557	002	Feb 23, 2005	May CAHN
AB		80MG/ML	A040620	002	Oct 27, 2006	May CAHN

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE;INJECTION
METOCLOPRAMIDE HYDROCHLORIDE

AP	BD RX	EQ 5MG BASE/ML	A091392	001	Apr 19, 2013	Apr NEWA
	@ TEVA PARENTERAL	EQ 5MG BASE/ML	A073135	001	Nov 27, 1991	Feb DISC
	@ TEVA PHARMS USA	EQ 5MG BASE/ML	A073135	001	Nov 27, 1991	May CAHN

TABLET, ORALLY DISINTEGRATING;ORAL
METOZOLV ODT

+	SALIX PHARMS	EQ 5MG BASE	N022246	001	Sep 04, 2009	Jul CRLD
@		EQ 10MG BASE	N022246	002	Sep 04, 2009	Jul DISC

METOLAZONE

TABLET;ORAL
METOLAZONE

@	TEVA	2.5MG	A076600	001	Jan 06, 2004	Mar DISC
@		5MG	A076833	001	Mar 01, 2004	Jun DISC
@		10MG	A075543	003	Dec 24, 2003	May DISC

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE;ORAL
METOPROLOL SUCCINATE

@	NESHER PHARMS	EQ 25MG TARTRATE	A077779	001	Mar 20, 2008	Feb DISC
@		EQ 50MG TARTRATE	A077176	001	May 14, 2008	May DISC

METOPROLOL TARTRATE

INJECTABLE;INJECTION
METOPROLOL TARTRATE

AP	CLARIS LIFESCIENCES	1MG/ML	A078950	001	Apr 29, 2013	Apr NEWA
	@ WATSON LABS	1MG/ML	A074032	001	Dec 21, 1993	Mar DISC

TABLET;ORAL

METOPROLOL TARTRATE

AB	ALEMBIC PHARMS LTD	25MG	A202871	001	May 28, 2013	May NEWA
AB		50MG	A202871	002	May 28, 2013	May NEWA
AB		100MG	A202871	003	May 28, 2013	May NEWA
	@ PRINSTON INC	50MG	A074453	001	Apr 27, 1995	Mar CAHN
	@	100MG	A074453	002	Apr 27, 1995	Mar CAHN

METRONIDAZOLE

TABLET;ORAL
METRONIDAZOLE

AB	TEVA PHARMS USA	250MG	A070027	001	Nov 06, 1984	Mar CAHN
----	-----------------	-------	---------	-----	--------------	----------

METYROSINE

CAPSULE;ORAL
DEMSEER

+	ATON PHARMA VPNA	250MG	N017871	001		Jun CAHN
---	------------------	-------	---------	-----	--	----------

MEXILETINE HYDROCHLORIDE

CAPSULE;ORAL
MEXILETINE HYDROCHLORIDE

TEVA	150MG	A074377	001	May 16, 1995	Sep CTEC
	200MG	A074377	002	May 16, 1995	Sep CTEC

MEXILETINE HYDROCHLORIDE

CAPSULE; ORAL

MEXILETINE HYDROCHLORIDE

+		250MG	A074377	003	May 16, 1995	Sep CTEC
@	WATSON LABS	150MG	A074711	001	Feb 26, 1997	Sep DISC
@		150MG	A074865	001	Apr 13, 1998	Sep DISC
@		200MG	A074711	002	Feb 26, 1997	Sep DISC
@		200MG	A074865	002	Apr 13, 1998	Sep DISC
@		250MG	A074711	003	Feb 26, 1997	Sep DISC
@		250MG	A074865	003	Apr 13, 1998	Sep DISC

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION

MIDAZOLAM HYDROCHLORIDE

AP	AKORN INC	EQ 1MG BASE/ML	A075494	001	Jun 30, 2000	Jul CAHN
AP		EQ 5MG BASE/ML	A075481	001	Jun 30, 2000	Jul CAHN
AP		EQ 5MG BASE/ML	A075494	002	Jun 30, 2000	Jul CAHN
@	APOTEX INC	EQ 1MG BASE/ML	A075637	001	Oct 31, 2000	Apr DISC
@		EQ 5MG BASE/ML	A075637	002	Oct 31, 2000	Apr DISC
@	CLARIS LIFESCIENCES	EQ 1MG BASE/ML	A075637	001	Oct 31, 2000	Jan DISC
@		EQ 5MG BASE/ML	A075637	002	Oct 31, 2000	Jan DISC
@	INTL MEDICATED	EQ 1MG BASE/ML	A076144	001	Jan 26, 2005	Jun DISC
@		EQ 5MG BASE/ML	A076144	002	Jan 26, 2005	Jun DISC
@	INTL MEDICATION	EQ 1MG BASE/ML	A076020	001	Jul 16, 2004	May DISC
@		EQ 5MG BASE/ML	A076020	002	Jul 16, 2004	May DISC

SYRUP; ORAL

MIDAZOLAM HYDROCHLORIDE

@	APOTEX INC	EQ 2MG BASE/ML	A077115	001	Sep 09, 2005	Apr DISC
---	------------	----------------	---------	-----	--------------	----------

MILRINONE LACTATE

INJECTABLE; INJECTION

MILRINONE LACTATE

@	APOTEX INC	EQ 1MG BASE/ML	A076427	001	Sep 21, 2004	Apr DISC
	MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER					
@	APOTEX INC	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A077151	001	Jul 20, 2005	Apr DISC

MINOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL

MINOCYCLINE HYDROCHLORIDE

AB	CARACO	EQ 50MG BASE	A090867	001	May 13, 2013	Apr NEWA
AB		EQ 75MG BASE	A090867	002	May 13, 2013	Apr NEWA
AB		EQ 100MG BASE	A090867	003	May 13, 2013	Apr NEWA

CAPSULE, EXTENDED RELEASE; ORAL

XIMINO

@	RANBAXY LABS LTD	EQ 45MG BASE	N201922	001	Jul 11, 2012	May DISC
@		EQ 67.5MG BASE	N201922	002	Jul 11, 2012	May DISC
@		EQ 90MG BASE	N201922	003	Jul 11, 2012	May DISC
@		EQ 112.5MG BASE	N201922	004	Jul 11, 2012	May DISC
@		EQ 135MG BASE	N201922	005	Jul 11, 2012	May DISC

TABLET, EXTENDED RELEASE; ORAL

SOLODYN

@	MEDICIS	EQ 45MG BASE	N050808	001	May 08, 2006	Apr DISC
+		EQ 55MG BASE	N050808	008	Aug 27, 2010	Apr CRLD
+		EQ 80MG BASE	N050808	007	Aug 27, 2010	Apr CRLD
@		EQ 135MG BASE	N050808	003	May 08, 2006	Apr DISC

MIPOMERSEN SODIUM

SOLUTION; SUBCUTANEOUS

KYNAMRO

+	GENZYME CORP	200MG/ML (200MG/ML)	N203568	001	Jan 29, 2013	Jan NEWA
---	--------------	---------------------	---------	-----	--------------	----------

MIRTAZAPINE

TABLET, ORALLY DISINTEGRATING; ORAL

MIRTAZAPINE

@	ACTAVIS ELIZABETH	15MG	A077959	001	Feb 14, 2011	Jun DISC
@		30MG	A077959	002	Feb 14, 2011	Jun DISC
@		45MG	A077959	003	Feb 14, 2011	Jun DISC

MITOXANTRONE HYDROCHLORIDE

INJECTABLE; INJECTION

MITOXANTRONE HYDROCHLORIDE

INJECTABLE; INJECTION

MITOXANTRONE HYDROCHLORIDE

AP	ONCO THERAPIES LTD	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	A201014	001	Dec 11, 2012	Mar	CAIN
AP	TEVA PHARMS USA	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	A077356	001	Apr 11, 2006	May	CAHN
AP		EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)	A077356	002	Apr 11, 2006	May	CAHN
AP		EQ 30MG BASE/15ML (EQ 2MG BASE/ML)	A077356	003	Apr 11, 2006	May	CAHN

MOMETASONE FUROATE

CREAM; TOPICAL

ELOCON

AB	MERCK SHARP DOHME	0.1%	N019625	002	Apr 19, 2013	Apr	NEWA
	OINTMENT; TOPICAL						
	MOMETASONE FUROATE						
	@ TARO	0.1%	A076624	001	Dec 03, 2004	May	DISC

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

KADIAN

AB1	+	WATSON LABS INC	10MG	N020616	008	Apr 20, 2007	May	CTEC
	+		10MG	N020616	008	Apr 20, 2007	Apr	CAHN
AB1			20MG	N020616	001	Jul 03, 1996	Apr	CAHN
AB1			30MG	N020616	004	Mar 09, 2001	Apr	CAHN
			40MG	N020616	009	Jul 09, 2012	Apr	CAHN
AB1			50MG	N020616	002	Jul 03, 1996	Apr	CAHN
AB1			60MG	N020616	005	Mar 09, 2001	Apr	CAHN
			70MG	N020616	010	Jul 09, 2012	Apr	CAHN
AB1			80MG	N020616	006	Oct 27, 2006	Apr	CAHN
AB1	+		100MG	N020616	003	Jul 03, 1996	Apr	CAHN
			130MG	N020616	011	Jul 09, 2012	Apr	CAHN
			150MG	N020616	012	Jul 09, 2012	Apr	CAHN
AB1	+		200MG	N020616	007	Feb 27, 2007	May	CTEC
	+		200MG	N020616	007	Feb 27, 2007	Apr	CAHN

MORPHINE SULFATE

AB1		PAR PHARM INC	20MG	A200812	001	Nov 10, 2011	Apr	CTEC
AB1			30MG	A200812	002	Nov 10, 2011	Apr	CTEC
AB1			50MG	A200812	003	Nov 10, 2011	Apr	CTEC
AB1			60MG	A200812	004	Nov 10, 2011	Apr	CTEC
AB1			80MG	A200812	005	Nov 10, 2011	Apr	CTEC
AB1			100MG	A200812	006	Nov 10, 2011	Apr	CTEC
AB1		UPSHER SMITH	10MG	A202104	001	Jun 03, 2013	May	NEWA
AB1			20MG	A202104	002	Jun 03, 2013	May	NEWA
AB1			30MG	A202104	003	Jun 03, 2013	May	NEWA
AB1			50MG	A202104	004	Jun 03, 2013	May	NEWA
AB1			60MG	A202104	005	Jun 03, 2013	May	NEWA
AB1			80MG	A202104	006	Jun 03, 2013	May	NEWA
AB1			100MG	A202104	007	Jun 03, 2013	May	NEWA

>A> SOLUTION; IM-IV

>A> MORPHINE SULFATE

>A>	+	BD RX	2MG/ML (2MG/ML)	N204223	001	Oct 30, 2013	Oct	NEWA
>A>	+		4MG/ML (4MG/ML)	N204223	002	Oct 30, 2013	Oct	NEWA
>A>	+		5MG/ML (5MG/ML)	N204223	003	Oct 30, 2013	Oct	NEWA
>A>	+		8MG/ML (8MG/ML)	N204223	004	Oct 30, 2013	Oct	NEWA
>A>	+		10MG/ML (10MG/ML)	N204223	005	Oct 30, 2013	Oct	NEWA

SOLUTION; ORAL

MORPHINE SULFATE

LANNETT HOLDINGS INC 100MG/5ML

N201517 001 Jun 23, 2011 Jul CPOT

MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

EMBEDA

+	ALPHARMA KING	60MG; 2.4MG	N022321	004	Aug 13, 2009	Jul	CRLD
		100MG; 4MG	N022321	006	Aug 13, 2009	Jul	CRLD

MUPIROCIN CALCIUM

CREAM; TOPICAL

BACTROBAN

AB	+	GLAXOSMITHKLINE	EQ 2% BASE	N050746	001	Dec 11, 1997	Jan	CFTG
		MUPIROCIN						
AB		GLENMARK GENERICS	EQ 2% BASE	A201587	001	Jan 24, 2013	Jan	NEWA

MYCOPHENOLATE MOFETIL

CAPSULE; ORAL

MYCOPHENOLATE MOFETIL

AB	ACCORD HLTHCARE	250MG	A090253	001	May 04, 2009	Apr CAHN
AB	ALKEM LABS LTD	250MG	A200197	001	Jun 13, 2013	Jun NEWA

NABUMETONE

TABLET; ORAL

NABUMETONE

@ DR REDDYS LABS LTD

500MG

A078420 001 Sep 24, 2008 Apr DISC

@

750MG

A078420 002 Sep 24, 2008 Apr DISC

@ PROSAM LABS

500MG

A079093 001 Feb 27, 2009 Mar DISC

@

750MG

A079093 002 Feb 27, 2009 Mar DISC

NAFTIFINE HYDROCHLORIDE

GEL; TOPICAL

NAFTIN

+ MERZ PHARMS 2%

N204286 001 Jun 27, 2013 Jun NEWA

NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL

NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE

AB GAVIS PHARMS

EQ 0.5MG BASE; EQ 50MG BASE

A075735 001 Jul 11, 2001 Aug CTNA

AB RANBAXY

EQ 0.5MG BASE; EQ 50MG BASE

A075523 001 Mar 17, 2000 Aug CTNA

AB + WATSON LABS

EQ 0.5MG BASE; EQ 50MG BASE

A074736 001 Jan 21, 1997 Aug CTNA

NALTREXONE HYDROCHLORIDE

TABLET; ORAL

NALTREXONE HYDROCHLORIDE

@ SANDOZ

50MG

A075434 001 Mar 08, 2000 Apr DISC

REVIA

AB + TEVA WOMENS

50MG

N018932 001 Nov 20, 1984 Jul CAHN

NAPHAZOLINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

NAPHAZOLINE HYDROCHLORIDE

AT AKORN INC

0.1%

A083590 001 Jul CAHN

NAPROXEN

TABLET; ORAL

NAPROXEN

AB WEST WARD PHARM CORP

250MG

A076494 001 Jan 14, 2004 Apr CAHN

AB

375MG

A076494 002 Jan 14, 2004 Apr CAHN

AB

500MG

A076494 003 Jan 14, 2004 Apr CAHN

NARATRIPTAN HYDROCHLORIDE

TABLET; ORAL

AMERGE

AB GLAXOSMITHKLINE LLC

EQ 1MG BASE

N020763 002 Feb 10, 1998 Mar CAHN

AB +

EQ 2.5MG BASE

N020763 001 Feb 10, 1998 Mar CAHN

NELFINAVIR MESYLATE

POWDER; ORAL

VIRACEPT

@ AGOURON

EQ 50MG BASE/SCOOPFUL

N020778 001 Mar 14, 1997 Jun DISC

NEOMYCIN SULFATE

POWDER; FOR RX COMPOUNDING

NEO-RX

@ X GEN PHARMS

100%

A061579 001 Mar DISC

NEOMYCIN SULFATE; POLYMYXIN B SULFATE; PREDNISOLONE ACETATE

SUSPENSION/DROPS; OPHTHALMIC

POLY-PRED

@ ALLERGAN

EQ 0.35% BASE; 10,000 UNITS/ML; 0.5%

N050081 002 May DISC

NEOSTIGMINE METHYLSULFATE

SOLUTION; INTRAVENOUS

BLOXIVERZ

+ ECLAT PHARMS LLC

5MG/10ML (0.5MG/ML)

N204078 001 May 31, 2013 May NEWA

+

10MG/10ML (1MG/ML)

N204078 002 May 31, 2013 May NEWA

NEPAFENACSUSPENSION/DROPS;OPHTHALMIC
ILEVRO

+ ALCON RES LTD 0.3% N203491 001 Oct 16, 2012 Aug CTNA

NIACINTABLET, EXTENDED RELEASE;ORAL
NIACIN

AB	BARR	1GM	A076250	001	Apr 14, 2005	Aug	CMFD
AB		500MG	A076378	001	Apr 26, 2005	Aug	CMFD
AB		750MG	A076378	002	Apr 26, 2005	Aug	CMFD

NIASSPAN

>D>	+	ABBVIE	1GM	N020381	004	Jul 28, 1997	Oct	CTEC
>A>	AB	+	1GM	N020381	004	Jul 28, 1997	Oct	CTEC
>D>			500MG	N020381	002	Jul 28, 1997	Oct	CTEC
>A>	AB		500MG	N020381	002	Jul 28, 1997	Oct	CTEC
>D>	+		750MG	N020381	003	Jul 28, 1997	Oct	CTEC
>A>	AB	+	750MG	N020381	003	Jul 28, 1997	Oct	CTEC

NIFEDIPINECAPSULE;ORAL
NIFEDIPINE

AB	ACTAVIS ELIZABETH	20MG	A072556	001	Sep 20, 1990	Apr	CTEC
	@ CATALENT	10MG	A073250	001	Oct 08, 1991	Apr	DISC
AB	EMCURE PHARMS USA	10MG	A202644	001	Apr 25, 2013	Apr	NEWA
AB		20MG	A202644	002	Apr 25, 2013	Apr	NEWA

NILUTAMIDETABLET;ORAL
NILANDRON

	@ COVIS PHARMA SARL	50MG	N020169	001	Sep 19, 1996	Apr	CAHN
	+	150MG	N020169	002	Apr 30, 1999	Apr	CAHN

NIMODIPINECAPSULE;ORAL
NIMODIPINE

AB	+	BANNER PHARMACAPS	30MG	A076740	001	Jan 17, 2008	Jul	CRLD
AB		SUN PHARM INDS INC	30MG	A077067	001	Apr 17, 2007	Jul	CRLD

SOLUTION;ORAL
NYMALIZE

	+	ARBOR PHARMS INC	60MG/20ML	N203340	001	May 10, 2013	May	NEWA
--	---	------------------	-----------	---------	-----	--------------	-----	------

NISOLDIPINETABLET, EXTENDED RELEASE;ORAL
NISOLDIPINE

	MYLAN	20MG	A079051	001	Jul 25, 2008	Jul	CRLD	
>D>	AB	25.5MG	A091001	003	Jan 26, 2011	Oct	CTEC	
>A>		25.5MG	A091001	003	Jan 26, 2011	Oct	CTEC	
>D>		SULAR						
>D>	AB	SHIONOGI INC	25.5MG	N020356	006	Jan 02, 2008	Oct	DISC
>A>	@	25.5MG	N020356	006	Jan 02, 2008	Oct	DISC	

NITISINONECAPSULE;ORAL
ORFADIN

	SWEDISH ORPHAN	2MG	N021232	001	Jan 18, 2002	May	CAHN
		5MG	N021232	002	Jan 18, 2002	May	CAHN
	+	10MG	N021232	003	Jan 18, 2002	May	CAHN

NITROFURANTOINSUSPENSION;ORAL
NITROFURANTOIN

AB	CARACO	25MG/5ML	A201355	001	Aug 14, 2013	Jul	NEWA
----	--------	----------	---------	-----	--------------	-----	------

NITROFURANTOIN, MACROCRYSTALLINECAPSULE;ORAL
MACRODANTIN

	ALVOGEN INC	25MG	N016620	003		Mar	CTEC
AB		25MG	N016620	003		Feb	CAHN
AB		50MG	N016620	001		Feb	CAHN
AB	+	100MG	N016620	002		Feb	CAHN

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL

NITROFURANTOIN

@ WATSON LABS

25MG

A073696 001 Dec 31, 1992 Mar DISC

@

50MG

A073696 002 Dec 31, 1992 Mar DISC

@

100MG

A073696 003 Dec 31, 1992 Mar DISC

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL

MACROBID

AB + ALVOGEN INC

75MG;25MG

N020064 001 Dec 24, 1991 Mar CAHN

NITROGLYCERIN

FILM, EXTENDED RELEASE;TRANSDERMAL

NITRO-DUR

AB1 + MERCK SHARP DOHME

0.1MG/HR

N020145 001 Apr 04, 1995 Mar CAHN

AB1 +

0.2MG/HR

N020145 002 Apr 04, 1995 Mar CAHN

+

0.3MG/HR

N020145 003 Apr 04, 1995 Mar CAHN

AB1 +

0.4MG/HR

N020145 004 Apr 04, 1995 Mar CAHN

AB1 +

0.6MG/HR

N020145 005 Apr 04, 1995 Mar CAHN

+

0.8MG/HR

N020145 006 Apr 04, 1995 Mar CAHN

INJECTABLE;INJECTION

NITROGLYCERIN

@ HOSPIRA

5MG/ML

N018531 001

Jul DISC

+ LUITPOLD

5MG/ML

A072034 001 May 24, 1988

Jul CTEC

SPRAY, METERED;SUBLINGUAL

NITROGLYCERIN

AB PERRIGO ISRAEL

0.4MG/SPRAY

A091496 001 Sep 20, 2013 Sep NEWA

NITROLINGUAL PUMPSPRAY

AB + POHL BOSKAMP

0.4MG/SPRAY

N018705 002 Jan 10, 1997 Sep CFTG

NIZATIDINE

CAPSULE;ORAL

NIZATIDINE

@ APOTEX INC

150MG

A076383 001 Jan 23, 2003 Feb DISC

@

300MG

A076383 002 Jan 23, 2003 Feb DISC

NOREPINEPHRINE BITARTRATE

INJECTABLE;INJECTION

NOREPINEPHRINE BITARTRATE

AP TEVA PHARMS USA

EQ 1MG BASE/ML

A040455 001 Mar 03, 2003 May CAHN

NORETHINDRONE

TABLET;ORAL

NORETHINDRONE

AB1 HAUPT PHARMA

0.35MG

A202260 001 Aug 01, 2013 Jul NEWA

TABLET;ORAL-28

JENCYCLA

AB2 LUPIN LTD

0.35MG

A091323 001 Mar 28, 2013 Apr CTEC

AB

0.35MG

A091323 001 Mar 28, 2013 Mar NEWA

NORETHINDRONE

AB2 FAMY CARE LTD

0.35MG

A200980 001 Jun 12, 2013 May NEWA

AB1

0.35MG

A201483 001 Jun 24, 2013 Jun NEWA

AB1 HAUPT PHARMA

0.35MG

A202260 001 Aug 01, 2013 Aug CDFR

AB2 NOVAST LABS

0.35MG

A200961 001 Sep 13, 2013 Aug NEWA

AB1 NOVAST LABS LTD

0.35MG

A202014 001 Sep 13, 2013 Aug NEWA

NORETHINDRONE ACETATE

TABLET;ORAL

NORETHINDRONE ACETATE

AB AMNEAL PHARMS

5MG

A200275 001 Jul 30, 2012 Sep CTNA

NYSTATIN

SUSPENSION;ORAL

NILSTAT

@ GLENMARK GENERICS

100,000 UNITS/ML

N050299 001

Feb DISC

OCTREOTIDE ACETATE

INJECTABLE;INJECTION

OCTREOTIDE ACETATE

OCTREOTIDE ACETATEINJECTABLE;INJECTION
OCTREOTIDE ACETATE

>A>	AP	SAGENT PHARMS	EQ 0.2MG BASE/ML	A091041	001	Nov 12, 2013	Oct NEWA
>A>	AP		EQ 1MG BASE/ML	A091041	002	Nov 12, 2013	Oct NEWA
	AP	TEVA PHARMS USA	EQ 0.05MG BASE/ML	A075957	001	Oct 03, 2005	May CAHN
	AP		EQ 0.1MG BASE/ML	A075957	002	Oct 03, 2005	May CAHN
	AP		EQ 0.2MG BASE/ML	A075959	001	Nov 21, 2005	May CAHN
	AP		EQ 0.5MG BASE/ML	A075957	003	Oct 03, 2005	May CAHN
	AP		EQ 1MG BASE/ML	A075959	002	Nov 21, 2005	May CAHN
		OCTREOTIDE ACETATE (PRESERVATIVE FREE)					
>A>	AP	SAGENT PHARMS	EQ 0.05MG BASE/ML	A090834	001	Nov 12, 2013	Oct NEWA
>A>	AP		EQ 0.1MG BASE/ML	A090834	002	Nov 12, 2013	Oct NEWA
>A>	AP		EQ 0.5MG BASE/ML	A090834	003	Nov 12, 2013	Oct NEWA

OFLOXACINSOLUTION/DROPS;OPHTHALMIC
OFLOXACIN

AT		ALTAIRE PHARMS INC	0.3%	A202692	001	Apr 29, 2013	Apr NEWA
		@ APOTEX INC	0.3%	A076513	001	May 14, 2004	Apr DISC

>A> OLIVE OIL; SOYBEAN OIL>A> INJECTABLE;INJECTION
>A> CLINOLIPID 20%

>A>	+	BAXTER HLTHCARE	16% (160GM/1000ML) ; 4% (40GM/1000ML)	N204508	001	Oct 03, 2013	Oct NEWA
-----	---	-----------------	---------------------------------------	---------	-----	--------------	----------

OMEPRAZOLE; SODIUM BICARBONATE

FOR SUSPENSION;ORAL

OMEPRAZOLE AND SODIUM BICARBONATE

AB		PAR PHARM	20MG/PACKET;1.68GM/PACKET	A079182	001	Apr 19, 2013	Apr NEWA
AB			40MG/PACKET;1.68GM/PACKET	A079182	002	Apr 19, 2013	Apr NEWA
		ZEGERID					
AB		SANTARUS	20MG/PACKET;1.68GM/PACKET	N021636	001	Jun 15, 2004	Apr CFTG
AB	+		40MG/PACKET;1.68GM/PACKET	N021636	002	Dec 21, 2004	Apr CFTG

ONDANSETRON HYDROCHLORIDE

INJECTABLE;INJECTION

ONDANSETRON HYDROCHLORIDE

		@ APOTEX INC	EQ 2MG BASE/ML	A077368	001	Dec 26, 2006	Apr DISC
AP		CLARIS LIFESCIENCES	EQ 2MG BASE/ML	A078288	001	Feb 22, 2013	Jul CPOT
AP			2MG/ML	A078288	001	Feb 22, 2013	Feb NEWA
		@ LUITPOLD	EQ 2MG BASE/ML	A077582	001	Dec 26, 2006	Mar DISC
		@ PLIVA HRVATSKA DOO	EQ 2MG BASE/ML	A077544	001	Dec 26, 2006	Feb DISC
		ONDANSETRON HYDROCHLORIDE AND DEXTROSE IN PLASTIC CONTAINER					
		@ CLARIS LIFESCIENCES	EQ 0.64MG BASE/ML	A078308	001	Mar 17, 2008	Jan DISC
		@ HOSPIRA	EQ 0.64MG BASE/ML	A077348	001	Feb 01, 2007	Jan DISC
		ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE					
		@ APOTEX INC	EQ 2MG BASE/ML	A077343	001	Dec 26, 2006	Apr DISC
AP		BD RX	EQ 2MG BASE/ML	A202253	001	Jul 19, 2013	Jul NEWA
AP		CLARIS LIFESCIENCES	EQ 2MG BASE/ML	A078287	001	Feb 22, 2013	Jul CPOT
AP			2MG/ML	A078287	001	Feb 22, 2013	Feb NEWA
		@ LUITPOLD	EQ 2MG BASE/ML	A077387	001	Dec 26, 2006	Mar DISC

TABLET;ORAL

ONDANSETRON HYDROCHLORIDE

		@ TARO	EQ 4MG BASE	A077729	001	Mar 28, 2011	Sep DISC
		@	EQ 8MG BASE	A077729	002	Mar 28, 2011	Sep DISC
		@	EQ 24MG BASE	A077729	003	Mar 28, 2011	Sep DISC

ORPHENADRINE CITRATE

TABLET, EXTENDED RELEASE;ORAL

ORPHENADRINE CITRATE

>D>	AB	CNTY LINE PHARMS	100MG	A040249	001	Jan 29, 1999	Oct CAHN
>A>	AB	TEDOR PHARMA INC	100MG	A040249	001	Jan 29, 1999	Oct CAHN

OSPENIFENE

TABLET;ORAL

OSPENIFENE

	+	SHIONOGI INC	60MG	N203505	001	Feb 26, 2013	Feb NEWA
--	---	--------------	------	---------	-----	--------------	----------

OXACILLIN SODIUM

INJECTABLE; INJECTION
OXACILLIN SODIUM

AP	AUROBINDO PHARMA LTD	EQ 1GM BASE/VIAL	A201539	001	Jan 18, 2013	Jan NEWA
AP		EQ 2GM BASE/VIAL	A201539	002	Jan 18, 2013	Jan NEWA
AP		EQ 10GM BASE/VIAL	A201538	001	Jan 18, 2013	Jan NEWA

OXAPROZIN

TABLET; ORAL
OXAPROZIN
@ CARACO

600MG

A075844 001 Jan 03, 2002 Jan DISC

OXAZEPAM

CAPSULE; ORAL
OXAZEPAM

AB	+ ACTAVIS ELIZABETH	30MG	A072253	001	Apr 14, 1988	Jul CRLD
AB	IVAX SUB TEVA PHARMS	30MG	A070945	001	Aug 03, 1987	Jul CRLD

OXCARBAZEPINE

TABLET; ORAL
OXCARBAZEPINE

@ TEVA PHARMS USA 150MG
@ 300MG
@ 600MG

A078005 001 Dec 11, 2007 Mar DISC
A078005 002 Dec 11, 2007 Mar DISC
A078005 003 Dec 11, 2007 Mar DISC

OXYBUTYNIN

GEL, METERED; TRANSDERMAL
GELNIQUE 3%

+ WATSON LABS INC 3%

N202513 001 Dec 07, 2011 Jun CTNA

OXYBUTYNIN CHLORIDE

SYRUP; ORAL
OXYBUTYNIN CHLORIDE

@ APOTEX INC 5MG/5ML
@ MIKART 5MG/5ML

A074997 001 Oct 15, 1997 Apr DISC
A075039 001 Jan 29, 1999 Jun DISC

TABLET; ORAL
OXYBUTYNIN CHLORIDE

AB	TEVA PHARMS USA	5MG	A071655	001	Nov 14, 1988	Mar CAHN
----	-----------------	-----	---------	-----	--------------	----------

OXYCODONE HYDROCHLORIDE

SOLUTION; ORAL
OXYCODONE HYDROCHLORIDE

AA	ROXANE	5MG/5ML	A204037	001	Jul 15, 2013	Jul NEWA
AA		100MG/5ML	A203208	001	Jul 12, 2013	Jul NEWA
AA	+ VISTAPHARM	5MG/5ML	N201194	001	Jan 12, 2012	Jul CTEC

TABLET; ORAL
OXYCODONE HYDROCHLORIDE

AB	NESHER PHARMS	5MG	A077290	001	Dec 08, 2005	Jun CMFD
	@	5MG	A077290	001	Dec 08, 2005	Mar DISC
AB		10MG	A077290	002	Dec 08, 2005	Jun CMFD
	@	10MG	A077290	002	Dec 08, 2005	Mar DISC
AB		15MG	A077290	003	Dec 08, 2005	Jun CMFD
	@	15MG	A077290	003	Dec 08, 2005	Mar DISC
AB		20MG	A077290	004	Dec 08, 2005	Jun CMFD
	@	20MG	A077290	004	Dec 08, 2005	Mar DISC
AB		30MG	A077290	005	Dec 08, 2005	Jun CMFD
	@	30MG	A077290	005	Dec 08, 2005	Mar DISC

OXYMORPHONE HYDROCHLORIDE

TABLET; ORAL
OXYMORPHONE HYDROCHLORIDE

AB	AVANTHI INC	5MG	A203601	001	Jan 30, 2013	Jan NEWA
AB		10MG	A203601	002	Jan 30, 2013	Jan NEWA
AB	MALLINCKRODT INC	5MG	A202321	001	Apr 25, 2013	Apr NEWA
AB		10MG	A202321	002	Apr 25, 2013	Apr NEWA

TABLET, EXTENDED RELEASE; ORAL
OXYMORPHONE HYDROCHLORIDE

AB	ACTAVIS ELIZABETH	5MG	A079046	003	Jul 11, 2013	Jul NEWA
AB		7.5MG	A079046	001	Dec 13, 2010	Apr CAHN
AB		10MG	A079046	004	Jul 11, 2013	Jul NEWA
AB		15MG	A079046	002	Dec 13, 2010	Apr CAHN

OXYMORPHONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL
OXYMORPHONE HYDROCHLORIDE

AB		20MG	A079046	005	Jul 11, 2013	Jul NEWA
AB		30MG	A079046	006	Jul 11, 2013	Jul NEWA
AB		40MG	A079046	007	Jul 11, 2013	Jul NEWA
AB	IMPAX LABS	5MG	A079087	001	Jun 14, 2010	Jul CTEC
AB		10MG	A079087	003	Jun 14, 2010	Jul CTEC
AB		20MG	A079087	005	Jun 14, 2010	Jul CTEC
AB		30MG	A079087	006	Jul 22, 2010	Jul CTEC
AB		40MG	A079087	007	Jun 14, 2010	Jul CTEC
AB	ROXANE	5MG	A200822	002	Jul 15, 2013	Jul NEWA
AB		7.5MG	A200822	003	Jul 15, 2013	Jul NEWA
AB		10MG	A200822	004	Jul 15, 2013	Jul NEWA
AB		15MG	A200822	005	Jul 15, 2013	Jul NEWA
AB		20MG	A200822	006	Jul 15, 2013	Jul NEWA
AB		30MG	A200822	007	Jul 15, 2013	Jul NEWA
AB		40MG	A200822	001	Jul 15, 2013	Jul NEWA

OXYTOCIN

INJECTABLE;INJECTION
OXYTOCIN

AP	HIKMA FARMACEUTICA	10USP UNITS/ML (10USP UNITS/ML)	A200219	001	Feb 13, 2013	Jan NEWA
	@ TEVA PHARMS USA	10USP UNITS/ML (10USP UNITS/ML)	A077453	001	Jan 24, 2008	May CAHN
	@	100USP UNITS/10ML (10USP UNITS/ML)	A077453	002	Jan 24, 2008	May CAHN

PACLITAXEL

INJECTABLE;INJECTION
PACLITAXEL

	@ ACCORD HLTHCARE	6MG/ML	A075436	001	Nov 12, 2004	Apr DISC
	@ TEVA PHARMS USA	6MG/ML	A075297	001	Jan 25, 2002	May CAHN
	TAXOL					
AP	HQ SPCLT PHARMA	6MG/ML	N020262	001	Dec 29, 1992	Apr CMFD
	@	6MG/ML	N020262	001	Dec 29, 1992	Jan CAHN

PAMIDRONATE DISODIUM

INJECTABLE;INJECTION
PAMIDRONATE DISODIUM

AP	TEVA PHARMS USA	30MG/10ML (3MG/ML)	A076153	001	Mar 27, 2002	Mar CAHN
AP		90MG/10ML (9MG/ML)	A076153	002	Mar 27, 2002	Mar CAHN

PANCRELIPASE (AMYLASE;LIPASE;PROTEASE)

CAPSULE, DELAYED RELEASE;ORAL
CREON

	ABBVIE	180,000USP UNITS;36,000USP UNITS;114,000USP UNITS	N020725	005	Mar 14, 2013	Mar NEWA
--	--------	---	---------	-----	--------------	----------

PANCURONIUM BROMIDE

INJECTABLE;INJECTION
PANCURONIUM BROMIDE

AP	+ TEVA PHARMS USA	1MG/ML	A072759	001	Jul 31, 1990	May CAHN
AP	+	2MG/ML	A072760	001	Jul 31, 1990	Mar CAHN

PARICALCITOL

CAPSULE;ORAL
PARICALCITOL

AB	TEVA PHARMS USA	1MCG	A090829	001	Sep 27, 2013	Sep NEWA
AB		2MCG	A090829	002	Sep 27, 2013	Sep NEWA
AB		4MCG	A090829	003	Sep 27, 2013	Sep NEWA
	ZEMPLAR					
AB	ABBVIE	1MCG	N021606	001	May 26, 2005	Sep CFTG
AB		2MCG	N021606	002	May 26, 2005	Sep CFTG
AB	+	4MCG	N021606	003	May 26, 2005	Sep CFTG

PAROXETINE HYDROCHLORIDE

SUSPENSION;ORAL
PAROXETINE HYDROCHLORIDE

	@ APOTEX INC	EQ 10MG BASE/5ML	A077395	001	Dec 05, 2006	Apr DISC
--	--------------	------------------	---------	-----	--------------	----------

PAROXETINE MESYLATE

CAPSULE;ORAL

PAROXETINE MESYLATECAPSULE; ORAL
BRISDELLE

+	NOVEN THERAP	EQ 7.5MG BASE	N204516	001	Jun 28, 2013	Jun NEWA
---	--------------	---------------	---------	-----	--------------	----------

PEGINESATIDE ACETATESOLUTION; INTRAVENOUS, SUBCUTANEOUS
OMONTYS

@	TAKEDA PHARMS USA	EQ 10MG BASE/ML (EQ 10MG BASE/ML)	N202799	007	Mar 27, 2012	May DISC
+		EQ 10MG BASE/ML (EQ 10MG BASE/ML)	N202799	007	Mar 27, 2012	Apr CAHN
@		EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	N202799	008	Mar 27, 2012	May DISC
+		EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	N202799	008	Mar 27, 2012	Apr CAHN
OMONTYS PRESERVATIVE FREE						
@	TAKEDA PHARMS USA	EQ 1MG BASE/0.5ML (EQ 1MG BASE/0.5ML)	N202799	001	Mar 27, 2012	May DISC
+		EQ 1MG BASE/0.5ML (EQ 1MG BASE/0.5ML)	N202799	001	Mar 27, 2012	Apr CAHN
@		EQ 2MG BASE/0.5ML (EQ 2MG BASE/0.5ML)	N202799	002	Mar 27, 2012	May DISC
+		EQ 2MG BASE/0.5ML (EQ 2MG BASE/0.5ML)	N202799	002	Mar 27, 2012	Apr CAHN
@		EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML)	N202799	003	Mar 27, 2012	May DISC
+		EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML)	N202799	003	Mar 27, 2012	Apr CAHN
@		EQ 4MG BASE/0.5ML (EQ 4MG BASE/0.5ML)	N202799	004	Mar 27, 2012	May DISC
+		EQ 4MG BASE/0.5ML (EQ 4MG BASE/0.5ML)	N202799	004	Mar 27, 2012	Apr CAHN
@		EQ 5MG BASE/0.5ML (EQ 5MG BASE/0.5ML)	N202799	005	Mar 27, 2012	May DISC
+		EQ 5MG BASE/0.5ML (EQ 5MG BASE/0.5ML)	N202799	005	Mar 27, 2012	Apr CAHN
@		EQ 6MG BASE/0.5ML (EQ 6MG BASE/0.5ML)	N202799	006	Mar 27, 2012	May DISC
+		EQ 6MG BASE/0.5ML (EQ 6MG BASE/0.5ML)	N202799	006	Mar 27, 2012	Apr CAHN

PENICILLIN V POTASSIUMTABLET; ORAL
PENICILLIN V POTASSIUM

AB	HIKMA PHARMS	EQ 250MG BASE	A090549	001	Oct 11, 2013	Sep NEWA
AB		EQ 500MG BASE	A090549	002	Oct 11, 2013	Sep NEWA

PHENYLEPHRINE HYDROCHLORIDESOLUTION/DROPS; OPHTHALMIC
PHENYLEPHRINE HYDROCHLORIDE

	PARAGON BIOTECK	2.5%	N203510	001	Mar 21, 2013	Mar NEWA
+		10%	N203510	002	Mar 21, 2013	Mar NEWA

PHENYTOIN SODIUMINJECTABLE; INJECTION
PHENYTOIN SODIUM

@	HOSPIRA	50MG/ML	A089744	001	Dec 18, 1987	Mar DISC
---	---------	---------	---------	-----	--------------	----------

PHYTONADIONETABLET; ORAL
MEPHYTON

+	VALEANT PHARMS	5MG	N010104	003		Jun CAHN
---	----------------	-----	---------	-----	--	----------

PINDOLOLTABLET; ORAL
PINDOLOL

	MYLAN PHARMS INC	5MG	A074019	001	Sep 03, 1992	Jun CTEC
+		10MG	A074019	002	Sep 03, 1992	Jun CTEC
@	WATSON LABS	5MG	A074437	001	Feb 27, 1995	Jun DISC
@		10MG	A074437	002	Feb 27, 1995	Jun DISC

PIOGLITAZONE HYDROCHLORIDETABLET; ORAL
PIOGLITAZONE HYDROCHLORIDE

AB	ACCORD HLTHCARE	EQ 15MG BASE	A200044	001	Feb 13, 2013	Jan NEWA
AB		EQ 30MG BASE	A200044	002	Feb 13, 2013	Jan NEWA
AB		EQ 45MG BASE	A200044	003	Feb 13, 2013	Jan NEWA

PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

PIOGLITAZONE HYDROCHLORIDE

AB	AUROBINDO PHARMA LTD	EQ 15MG BASE	A200268	001	Feb 13, 2013	Jan NEWA
AB		EQ 30MG BASE	A200268	002	Feb 13, 2013	Jan NEWA
AB		EQ 45MG BASE	A200268	003	Feb 13, 2013	Jan NEWA
AB	DR REDDYS LABS LTD	EQ 15MG BASE	A078383	001	Mar 12, 2013	Mar NEWA
AB		EQ 30MG BASE	A078383	002	Mar 12, 2013	Mar NEWA
AB		EQ 45MG BASE	A078383	003	Mar 12, 2013	Mar NEWA
AB	MACLEODS PHARMS LTD	EQ 15MG BASE	A202467	001	Feb 06, 2013	Jan NEWA
AB		EQ 30MG BASE	A202467	002	Feb 06, 2013	Jan NEWA
AB		EQ 45MG BASE	A202467	003	Feb 06, 2013	Jan NEWA
AB	SANDOZ	EQ 15MG BASE	A078670	001	Feb 13, 2013	Jan NEWA
AB		EQ 30MG BASE	A078670	002	Feb 13, 2013	Jan NEWA
AB		EQ 45MG BASE	A078670	003	Feb 13, 2013	Jan NEWA
AB	SYNTHON PHARMS	EQ 15MG BASE	A078472	001	Feb 13, 2013	Jan NEWA
AB		EQ 30MG BASE	A078472	002	Feb 13, 2013	Jan NEWA
AB		EQ 45MG BASE	A078472	003	Feb 13, 2013	Jan NEWA
AB	TORRENT PHARMS LTD	EQ 15MG BASE	A091298	001	Feb 13, 2013	Jan NEWA
AB		EQ 30MG BASE	A091298	002	Feb 13, 2013	Jan NEWA
AB		EQ 45MG BASE	A091298	003	Feb 13, 2013	Jan NEWA
AB	ZYDUS PHARMS USA INC	EQ 15MG BASE	A202456	001	Feb 13, 2013	Jan NEWA
AB		EQ 30MG BASE	A202456	002	Feb 13, 2013	Jan NEWA
AB		EQ 45MG BASE	A202456	003	Feb 13, 2013	Jan NEWA

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

FOR SOLUTION; ORAL

COLYTE

	MEDA PHARMS	227.1GM/BOT; 2.82GM/BOT; 6.36GM/BOT; 5.53GM/BOT; 21.5GM/BOT	N018983	010	Jan 31, 1989	Jul CTEC
@		240GM/BOT; 2.98GM/BOT; 6.72GM/BOT; 5.84GM/BOT; 22.72GM/BOT	N018983	007	Jun 12, 1987	Jul DISC
	COLYTE WITH FLAVOR PACKS					
	MEDA PHARMS	240GM/BOT; 2.98GM/BOT; 6.72GM/BOT; 5.84GM/BOT; 22.72GM/BOT	N018983	012	Oct 08, 1998	Jul CTEC
	COLYTE-FLAVORED					
@	MEDA PHARMS	227.1GM/BOT; 2.82GM/BOT; 6.36GM/BOT; 5.53GM/BOT; 21.5GM/BOT	N018983	008	Nov 14, 1991	Jul DISC
@		240GM/BOT; 2.98GM/BOT; 6.72GM/BOT; 5.84GM/BOT; 22.72GM/BOT	N018983	009	Nov 14, 1991	Jul DISC

POLYMYXIN B SULFATE

POWDER; FOR RX COMPOUNDING

POLY-RX

@	X GEN PHARMS	100,000,000 UNITS/BOT	A061578	001		Mar DISC
---	--------------	-----------------------	---------	-----	--	----------

POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE

SOLUTION/DROPS; OPHTHALMIC

TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE

AT	AKORN INC	10,000 UNITS/ML; EQ 1MG BASE/ML	A065006	001	Dec 17, 1998	Jul CAHN
----	-----------	---------------------------------	---------	-----	--------------	----------

POMALIDOMIDE

CAPSULE; ORAL

POMALYST

	CELGENE	1MG	N204026	001	Feb 08, 2013	Feb NEWA
		2MG	N204026	002	Feb 08, 2013	Feb NEWA
		3MG	N204026	003	Feb 08, 2013	Feb NEWA
+		4MG	N204026	004	Feb 08, 2013	Feb NEWA

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

POTASSIUM CHLORIDE

AB	AMNEAL PHARMS	10MEQ	A202128	001	Feb 22, 2013	Feb NEWA
----	---------------	-------	---------	-----	--------------	----------

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET; ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

AB	ACTAVIS GRP PTC	0.125MG	A091254	001	Nov 30, 2010	Mar CAHN
AB		0.25MG	A091254	002	Nov 30, 2010	Mar CAHN
AB		0.5MG	A091254	003	Nov 30, 2010	Mar CAHN
AB		0.75MG	A091254	004	Nov 30, 2010	Mar CAHN
AB		1MG	A091254	005	Nov 30, 2010	Mar CAHN

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET; ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

AB		1.5MG	A091254	006	Nov 30, 2010	Mar CAHN
AB	SUN PHARM INDS INC	0.125MG	A091683	001	Mar 27, 2013	Mar NEWA
AB		0.25MG	A091683	002	Mar 27, 2013	Mar NEWA
AB		0.5MG	A091683	003	Mar 27, 2013	Mar NEWA
AB		0.75MG	A091683	004	Mar 27, 2013	Mar NEWA
AB		1MG	A091683	005	Mar 27, 2013	Mar NEWA
AB		1.5MG	A091683	006	Mar 27, 2013	Mar NEWA

PRAMLINTIDE ACETATE

INJECTABLE; SUBCUTANEOUS

SYMLIN

	AMYLIN PHARMS	EQ 1.5MG BASE/1.5ML (EQ 1MG BASE/ML)	N021332	002	Sep 25, 2007	Jan CAHN
		EQ 2.7MG BASE/2.7ML (EQ 1MG BASE/ML)	N021332	003	Sep 25, 2007	Jan CAHN
+		EQ 3MG BASE/5ML (EQ 600MCG BASE/ML)	N021332	001	Mar 16, 2005	Jan CAHN
+	AMYLIN PHARMS LLC	EQ 2.7MG BASE/2.7ML (EQ 1MG BASE/ML)	N021332	003	Sep 25, 2007	Jun CRLD
@		EQ 3MG BASE/5ML (EQ 600MCG BASE/ML)	N021332	001	Mar 16, 2005	Jun DISC

PRAVASTATIN SODIUM

TABLET; ORAL

PRAVASTATIN SODIUM

AB	CIPLA LTD	10MG	A077904	001	Oct 23, 2006	Aug CAHN
AB		20MG	A077904	002	Oct 23, 2006	Aug CAHN
AB		40MG	A077904	003	Oct 23, 2006	Aug CAHN

PRAZIOUANTEL

TABLET; ORAL

BILTRICIDE

+	BAYER HLTHCARE	600MG	N018714	001	Dec 29, 1982	Jun CAHN
---	----------------	-------	---------	-----	--------------	----------

PREDNISOLONE

SYRUP; ORAL

PREDNISOLONE

@	APOTEX INC	5MG/5ML	A040570	001	Aug 25, 2005	Apr DISC
@		15MG/5ML	A040571	001	Aug 25, 2005	Apr DISC

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION; ORAL

ORAPRED

AA	+	CONCORDIA PHARMS INC	EQ 15MG BASE/5ML	A075117	001	Dec 14, 2000	May CAHN
		PREDNISOLONE SODIUM PHOSPHATE					
	@	NESHER PHARMS	EQ 15MG BASE/5ML	A076988	001	May 24, 2005	May DISC
	@	PHARM ASSOC	EQ 5MG BASE/5ML	A076123	001	Dec 23, 2002	Mar DISC
	@	WE PHARMS	EQ 15MG BASE/5ML	A075250	001	Jul 12, 2002	Mar DISC

TABLET, ORALLY DISINTEGRATING; ORAL

ORAPRED ODT

AB		CONCORDIA PHARMS INC	EQ 10MG BASE	N021959	001	Jun 01, 2006	May CAHN
AB			EQ 15MG BASE	N021959	002	Jun 01, 2006	May CAHN
AB	+		EQ 30MG BASE	N021959	003	Jun 01, 2006	May CAHN
AB		SHIONOGI INC	EQ 10MG BASE	N021959	001	Jun 01, 2006	Mar CFTG
AB			EQ 15MG BASE	N021959	002	Jun 01, 2006	Mar CFTG
AB	+		EQ 30MG BASE	N021959	003	Jun 01, 2006	Mar CFTG
		PREDNISOLONE SODIUM PHOSPHATE					
AB		MYLAN PHARMS INC	EQ 10MG BASE	A202179	001	Apr 10, 2013	Mar NEWA
AB			EQ 15MG BASE	A202179	002	Apr 10, 2013	Mar NEWA
AB			EQ 30MG BASE	A202179	003	Apr 10, 2013	Mar NEWA

PREDNISONE

TABLET; ORAL

PREDNISONE

AB	HIKMA PHARMS	1MG	A040890	001	Nov 01, 2010	May CAHN
AB		2.5MG	A040538	001	Jan 08, 2004	May CAHN
AB		5MG	A080292	001		May CAHN
AB		10MG	A088832	001	Dec 04, 1985	May CAHN
AB		20MG	A083677	001		May CAHN

PREDNISONETABLET;ORAL
PREDNISONE

AB		50MG	A088465	001	Jun 01, 1984	May CAHN
----	--	------	---------	-----	--------------	----------

PRIMIDONETABLET;ORAL
PRIMIDONE

@ DR REDDYS LABS LTD	50MG
@	250MG
@ WEST WARD	50MG

A040862	001	Oct 03, 2008	Apr DISC
A040862	002	Oct 03, 2008	Apr DISC
A040667	001	Jul 27, 2006	Jul DISC

PROBENECIDTABLET;ORAL
PROBENECID

@ IVAX SUB TEVA PHARMS	500MG
------------------------	-------

A083740	001	May 09, 1984	May DISC
---------	-----	--------------	----------

PROCHLORPERAZINE EDISYLATEINJECTABLE;INJECTION
PROCHLORPERAZINE EDISYLATE

AP	EMCURE PHARMS LTD	EQ 5MG BASE/ML
----	-------------------	----------------

A204147	001	Oct 15, 2013	Sep NEWA
---------	-----	--------------	----------

PROGESTERONECAPSULE;ORAL
PROGESTERONE

AB	BANNER PHARMACAPS	100MG
AB		200MG

A200900	001	Aug 16, 2013	Jul NEWA
A200900	002	Aug 16, 2013	Jul NEWA

PROMETRIUM

AB	ABBVIE INC	100MG
AB	+	200MG
	@	300MG

N019781	001	May 14, 1998	May CAHN
N019781	002	Oct 15, 1999	May CAHN
N019781	003	Oct 15, 1999	May CAHN

PROMETHAZINE HYDROCHLORIDEINJECTABLE;INJECTION
PROMETHAZINE HYDROCHLORIDE

AP	+	TEVA PHARMS USA	25MG/ML
AP	+		50MG/ML

A040454	001	Aug 22, 2002	Mar CAHN
A040454	002	Aug 22, 2002	Mar CAHN

SYRUP;ORAL

PROMETHAZINE HYDROCHLORIDE

AA	CARACO	6.25MG/5ML
----	--------	------------

A040891	001	Mar 13, 2009	May CAHN
---------	-----	--------------	----------

TABLET;ORAL

PROMETHAZINE HYDROCHLORIDE

AB	CARACO	12.5MG
AB		25MG
AB		50MG

A040863	001	Dec 30, 2008	May CAHN
A040863	002	Dec 30, 2008	May CAHN
A040863	003	Dec 30, 2008	May CAHN

PROPARACAINE HYDROCHLORIDESOLUTION/DROPS;OPHTHALMIC
PROPARACAINE HYDROCHLORIDE

AT	AKORN INC	0.5%
----	-----------	------

A040277	001	Mar 16, 2000	Jul CAHN
---------	-----	--------------	----------

PROPOFOLINJECTABLE;INJECTION
PROPOFOL

AB	TEVA PHARMS USA	10MG/ML
----	-----------------	---------

A075102	001	Jan 04, 1999	Mar CAHN
---------	-----	--------------	----------

PROPRANOLOL HYDROCHLORIDECAPSULE, EXTENDED RELEASE;ORAL
PROPRANOLOL HYDROCHLORIDE

AB	GLATT AIR	60MG
AB		80MG
AB		120MG
AB		160MG

A078065	001	Jan 26, 2007	Feb CAHN
A078065	002	Jan 26, 2007	Feb CAHN
A078065	003	Jan 26, 2007	Feb CAHN
A078065	004	Jan 26, 2007	Feb CAHN

TABLET;ORAL

INDERAL

	@ WYETH PHARMS INC	10MG
	@	20MG
AB		40MG
AB		60MG
AB	+	80MG
	@	90MG

N016418	001		Jul CAHN
N016418	003		Jul CAHN
N016418	002		Jul CAHN
N016418	009	Oct 18, 1982	Jul CAHN
N016418	004		Jul CAHN
N016418	010	Oct 18, 1982	Jul CAHN

PROTRIPTYLINE HYDROCHLORIDE

TABLET;ORAL

VIVACTIL

@ TEVA WOMENS

5MG

N016012 001

Mar CAHN

@

10MG

N016012 002

Mar CAHN

PYRIMETHAMINE

TABLET;ORAL

DARAPRIM

+ AMEDRA PHARMS

25MG

N008578 001

Apr CAHN

QUAZEPAM

TABLET;ORAL

DORAL

@ SCIECURE PHARMA INC

7.5MG

N018708 003 Feb 26, 1987

Jun CAHN

+

15MG

N018708 001 Dec 27, 1985

Jun CAHN

QUETIAPINE FUMARATE

TABLET;ORAL

QUETIAPINE FUMARATE

AB ACCORD HLTHCARE

EQ 25MG BASE

A202152 001 Mar 27, 2012 Apr CAHN

AB EQ 50MG BASE

A202152 002 Mar 27, 2012 Apr CAHN

AB EQ 100MG BASE

A202152 003 Mar 27, 2012 Apr CAHN

AB EQ 200MG BASE

A202152 004 Mar 27, 2012 Apr CAHN

AB EQ 300MG BASE

A202152 005 Mar 27, 2012 Apr CAHN

AB EQ 400MG BASE

A202152 006 Mar 27, 2012 Apr CAHN

AB ACTAVIS GRP PTC

EQ 25MG BASE

A201762 001 Feb 27, 2013 May CAHN

AB EQ 50MG BASE

A201762 002 Feb 27, 2013 May CAHN

AB EQ 100MG BASE

A201762 003 Feb 27, 2013 May CAHN

AB EQ 150MG BASE

A201762 004 Feb 27, 2013 May CAHN

AB EQ 200MG BASE

A201762 005 Feb 27, 2013 May CAHN

AB EQ 300MG BASE

A201762 006 Feb 27, 2013 May CAHN

AB EQ 400MG BASE

A201762 007 Feb 27, 2013 May CAHN

AB ACTAVIS PHARMA

EQ 25MG BASE

A201762 001 Feb 27, 2013 Feb NEWA

AB EQ 50MG BASE

A201762 002 Feb 27, 2013 Feb NEWA

AB EQ 100MG BASE

A201762 003 Feb 27, 2013 Feb NEWA

AB EQ 150MG BASE

A201762 004 Feb 27, 2013 Feb NEWA

AB EQ 200MG BASE

A201762 005 Feb 27, 2013 Feb NEWA

AB EQ 300MG BASE

A201762 006 Feb 27, 2013 Feb NEWA

AB EQ 400MG BASE

A201762 007 Feb 27, 2013 Feb NEWA

AB ALKEM LABS LTD

EQ 25MG BASE

A201504 001 Feb 12, 2013 Jan NEWA

AB EQ 50MG BASE

A201504 002 Feb 12, 2013 Jan NEWA

AB EQ 100MG BASE

A201504 003 Feb 12, 2013 Jan NEWA

AB EQ 150MG BASE

A201504 004 Feb 12, 2013 Jan NEWA

AB EQ 200MG BASE

A201504 005 Feb 12, 2013 Jan NEWA

AB EQ 300MG BASE

A201504 006 Feb 12, 2013 Jan NEWA

AB EQ 400MG BASE

A201504 007 Feb 12, 2013 Jan NEWA

QUINAPRIL HYDROCHLORIDE

TABLET;ORAL

QUINAPRIL HYDROCHLORIDE

@ APOTEX INC

EQ 5MG BASE

A076240 001 Jan 26, 2006 Mar DISC

@ EQ 10MG BASE

A076240 002 Jan 26, 2006 Mar DISC

@ EQ 20MG BASE

A076240 003 Jan 26, 2006 Mar DISC

@ EQ 40MG BASE

A076240 004 Jan 26, 2006 Mar DISC

AB AUROBINDO PHARMA LTD

EQ 5MG BASE

A202725 001 Apr 29, 2013 Apr NEWA

AB EQ 10MG BASE

A202725 002 Apr 29, 2013 Apr NEWA

AB EQ 20MG BASE

A202725 003 Apr 29, 2013 Apr NEWA

AB EQ 40MG BASE

A202725 004 Apr 29, 2013 Apr NEWA

@ MYLAN

EQ 5MG BASE

A076036 001 Jan 28, 2005 Aug DISC

@ EQ 10MG BASE

A076036 002 Jan 28, 2005 Aug DISC

@ EQ 20MG BASE

A076036 003 Jan 28, 2005 Aug DISC

@ EQ 40MG BASE

A076036 004 Jan 28, 2005 Aug DISC

RABEPRAZOLE SODIUM

CAPSULE, DELAYED RELEASE;ORAL

ACIPHEX SPRINKLE

EISAI INC

5MG

N204736 001 Mar 26, 2013 Mar NEWA

+

10MG

N204736 002 Mar 26, 2013 Mar NEWA

TABLET, DELAYED RELEASE;ORAL

ACIPHEX

>D>

+ EISAI INC

20MG

N020973 002 Aug 19, 1999 Oct CFTG

RABEPRAZOLE SODIUMTABLET, DELAYED RELEASE;ORAL
ACIPHEX

>A>	AB	+		20MG	N020973	002	Aug 19, 1999	Oct	CFTG
>A>			RABEPRAZOLE SODIUM						
>A>	AB		DR REDDYS LABS LTD	20MG	A076824	001	Nov 08, 2013	Oct	NEWA
>A>	AB		KREMERS URBAN DEV	20MG	A090678	001	Nov 08, 2013	Oct	NEWA
>A>	AB		LUPIN LTD	20MG	A078964	001	Nov 08, 2013	Oct	NEWA
>A>	AB		MYLAN PHARMS INC	20MG	A076885	001	Nov 08, 2013	Oct	NEWA
>A>	AB		TEVA PHARMS USA	20MG	A076822	001	Nov 08, 2013	Oct	NEWA
>A>	AB		TORRENT PHARMS LTD	20MG	A202376	001	Nov 08, 2013	Oct	NEWA

RADIUM RA-223 DICHLORIDESOLUTION;INTRAVENOUS
XOFIGO

+	BAYER HLTHCARE	162MCI/6ML (27MCI/ML)	N203971	001	May 15, 2013	May	NEWA
---	----------------	-----------------------	---------	-----	--------------	-----	------

RAMELTEONTABLET;ORAL
RAMELTEON

AB			TEVA PHARMS USA	8MG	A091693	001	Jul 26, 2013	Jul	NEWA
			ROZEREM						
AB	+		TAKEDA PHARMS USA	8MG	N021782	001	Jul 22, 2005	Jul	CFTG

RAMIPRILCAPSULE;ORAL
RAMIPRIL

@	CIPLA	1.25MG	A077004	001	Aug 07, 2008	Jul	DISC
@		2.5MG	A077004	002	Aug 07, 2008	Jul	DISC
@		5MG	A077004	003	Aug 07, 2008	Jul	DISC
@		10MG	A077004	004	Aug 07, 2008	Jul	DISC

RANITIDINE HYDROCHLORIDEGRANULE, EFFERVESCENT;ORAL
ZANTAC 150

@	GLAXO GRP LTD	EQ 150MG BASE/PACKET	N020251	002	Mar 31, 1994	Jun	CAHN
---	---------------	----------------------	---------	-----	--------------	-----	------

INJECTABLE;INJECTION

RANITIDINE HYDROCHLORIDE

AP			ZYDUS PHARMS USA INC	25MG/ML	A091534	001	Feb 22, 2013	Feb	NEWA
			ZANTAC IN PLASTIC CONTAINER						
	@	COVIS PHARMA SARL	EQ 1MG BASE/ML		N019593	002	Sep 27, 1991	Jun	DISC

SYRUP;ORAL

RANITIDINE HYDROCHLORIDE

@	APOTEX INC	EQ 15MG BASE/ML	A077602	001	Sep 17, 2007	Apr	DISC
AA	BIO PHARM INC	EQ 15MG BASE/ML	A090102	001	May 26, 2009	Apr	CAHN
AA	BRECKENRIDGE PHARM	EQ 15MG BASE/ML	A078684	001	Aug 27, 2009	Sep	CAHN
AA	CARACO	EQ 15MG BASE/ML	A091091	001	Sep 20, 2011	Apr	CAHN

ZANTAC

AA	+	GLAXO GRP LTD	EQ 15MG BASE/ML		N019675	001	Dec 30, 1988	Jun	CAHN
----	---	---------------	-----------------	--	---------	-----	--------------	-----	------

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

@	WATSON LABS	EQ 150MG BASE	A074864	001	Oct 20, 1997	Jan	DISC
@		EQ 300MG BASE	A074864	002	Oct 20, 1997	Jan	DISC
@	WATSON LABS INC	EQ 150MG BASE	A077426	001	Dec 19, 2005	Mar	DISC
@		EQ 300MG BASE	A077426	002	Dec 19, 2005	Mar	DISC

ZANTAC 150

AB			GLAXO GRP LTD	EQ 150MG BASE	N018703	001	Jun 09, 1983	Jun	CAHN
----	--	--	---------------	---------------	---------	-----	--------------	-----	------

ZANTAC 300

AB	+	GLAXO GRP LTD	EQ 300MG BASE		N018703	002	Dec 09, 1985	Jun	CAHN
----	---	---------------	---------------	--	---------	-----	--------------	-----	------

TABLET, EFFERVESCENT;ORAL

ZANTAC 150

@	GLAXO GRP LTD	EQ 150MG BASE	N020251	001	Mar 31, 1994	Jun	CAHN
---	---------------	---------------	---------	-----	--------------	-----	------

ZANTAC 25

+	GLAXO GRP LTD	EQ 25MG BASE	N020251	003	Apr 01, 2004	Jun	CAHN
---	---------------	--------------	---------	-----	--------------	-----	------

RANOLAZINETABLET, EXTENDED RELEASE;ORAL
RANEXA

AB	+	GILEAD	1GM	N021526	001	Feb 12, 2007	Jul	CFTG
AB			500MG	N021526	002	Jan 27, 2006	Jul	CFTG

RANOLAZINE

TABLET, EXTENDED RELEASE;ORAL
RANOLAZINE

AB	LUPIN LTD	500MG	A201046	001	Jul 29, 2013	Jul NEWA
AB		1GM	A201046	002	Jul 29, 2013	Jul NEWA

RASAGILINE MESYLATE

TABLET;ORAL
AZILECT

AB	TEVA	EQ 0.5MG BASE	N021641	001	May 16, 2006	Jun CFTG
AB	+	EQ 1MG BASE	N021641	002	May 16, 2006	Jun CFTG

RASAGILINE MESYLATE

AB	APOTEX INC	EQ 0.5MG BASE	A201950	001	Sep 12, 2013	Aug NEWA
AB		EQ 1MG BASE	A201950	002	Sep 12, 2013	Aug NEWA
AB	WATSON LABS INC	EQ 0.5MG BASE	A201823	001	Jul 01, 2013	Jun NEWA
AB		EQ 1MG BASE	A201823	002	Jul 01, 2013	Jun NEWA

REPAGLINIDE

TABLET;ORAL
PRANDIN

AB	NOVO NORDISK INC	0.5MG	N020741	001	Dec 22, 1997	Jul CTEC
AB		1MG	N020741	002	Dec 22, 1997	Jul CFTG
AB	+	2MG	N020741	003	Dec 22, 1997	Jul CFTG

REPAGLINIDE

AB	CARACO	1MG	A077571	002	Jul 11, 2013	Jul NEWA
AB		2MG	A077571	003	Jul 11, 2013	Jul NEWA
AB	MYLAN PHARMS INC	0.5MG	A090252	001	Aug 23, 2013	Aug NEWA
AB	PADDOCK LLC	0.5MG	A201189	001	Jul 17, 2013	Jul NEWA

RESERPINE

TABLET;ORAL
SERPALAN

@	LANNETT	0.1MG	N010124	001		May DISC
@		0.25MG	N010124	002		May DISC

RIFAMPIN

CAPSULE;ORAL
RIFAMPIN

AB	LUPIN PHARMS	150MG	A090034	001	Aug 21, 2013	Jul NEWA
AB		300MG	A090034	002	Aug 21, 2013	Jul NEWA

RILUZOLE

TABLET;ORAL
RILUTEK

AB	+	COVIS PHARMA SARL	50MG	N020599	001	Dec 12, 1995	Apr CAHN
AB		RILUZOLE					
AB	APOTEX CORP	50MG	A091300	001	Jun 18, 2013	Jun NEWA	
AB	GLENMARK GENERICS	50MG	A091394	001	Jun 18, 2013	Jun NEWA	
AB	MYLAN PHARMS INC	50MG	A203042	001	Jul 01, 2013	Jun NEWA	
AB	SUN PHARM INDS LTD	50MG	A091417	001	Jun 18, 2013	Jun NEWA	

RIMANTADINE HYDROCHLORIDE

TABLET;ORAL
RIMANTADINE HYDROCHLORIDE

@	COREPHARMA	100MG	A075916	001	Nov 02, 2001	Feb DISC
---	------------	-------	---------	-----	--------------	----------

>A> RIOCIGUAT

>A> TABLET;ORAL
>A> ADEMPAS

>A>	BAYER HLTHCARE	0.5MG	N204819	001	Oct 08, 2013	Oct NEWA
>A>		1MG	N204819	002	Oct 08, 2013	Oct NEWA
>A>		1.5MG	N204819	003	Oct 08, 2013	Oct NEWA
>A>		2MG	N204819	004	Oct 08, 2013	Oct NEWA
>A>	+	2.5MG	N204819	005	Oct 08, 2013	Oct NEWA

RISPERIDONE

SOLUTION;ORAL
RISPERIDONE

AA	BIO PHARM INC	1MG/ML	A078909	001	Jul 29, 2009	May CAHN
	TABLET, ORALLY DISINTEGRATING;ORAL					
	RISPERIDONE					

RISPERIDONE

TABLET, ORALLY DISINTEGRATING;ORAL
RISPERIDONE

AB	MYLAN PHARMS INC	0.25MG	A091537	006	Feb 12, 2013	Feb NEWA
AB	PAR PHARM	0.25MG	A077494	001	Apr 30, 2009	Feb CTEC
AB	SUN PHARM INDS LTD	0.5MG	A078464	001	Apr 08, 2013	Mar NEWA
AB		1MG	A078464	002	Apr 08, 2013	Mar NEWA
AB		2MG	A078464	003	Apr 08, 2013	Mar NEWA
AB		3MG	A078464	004	Apr 08, 2013	Mar NEWA
AB		4MG	A078464	005	Apr 08, 2013	Mar NEWA

RIVASTIGMINE TARTRATE

CAPSULE;ORAL
RIVASTIGMINE TARTRATE

AB	APOTEX INC	EQ 1.5MG BASE	A091072	001	May 16, 2013	Apr NEWA
AB		EQ 3MG BASE	A091072	002	May 16, 2013	Apr NEWA
AB		EQ 4.5MG BASE	A091072	003	May 16, 2013	Apr NEWA
AB		EQ 6MG BASE	A091072	004	May 16, 2013	Apr NEWA

RIZATRIPTAN BENZOATE

TABLET;ORAL
RIZATRIPTAN BENZOATE

AB	CIPLA LTD	EQ 5MG BASE	A077526	001	Mar 26, 2013	Mar NEWA
AB		EQ 10MG BASE	A077526	002	Mar 26, 2013	Mar NEWA
AB	INVAGEN PHARMS	EQ 5MG BASE	A204339	001	Jul 01, 2013	Jun NEWA
AB		EQ 10MG BASE	A204339	002	Jul 01, 2013	Jun NEWA

TABLET, ORALLY DISINTEGRATING;ORAL
RIZATRIPTAN BENZOATE

AB	APOTEX INC	EQ 5MG BASE	A202477	001	Jul 01, 2013	Jun NEWA
AB		EQ 10MG BASE	A202477	002	Jul 01, 2013	Jun NEWA
AB	AUROBINDO PHARMA LTD	EQ 5MG BASE	A203062	001	Jul 01, 2013	Jun NEWA
AB		EQ 10MG BASE	A203062	002	Jul 01, 2013	Jun NEWA
AB	GLENMARK GENERICS	EQ 5MG BASE	A201914	001	Jul 01, 2013	Jun NEWA
AB		EQ 10MG BASE	A201914	002	Jul 01, 2013	Jun NEWA
AB	NATCO PHARMA LTD	EQ 5MG BASE	A203478	001	Jul 01, 2013	Jun NEWA
AB		EQ 10MG BASE	A203478	002	Jul 01, 2013	Jun NEWA
AB	SANDOZ	EQ 5MG BASE	A078739	001	Jul 01, 2013	Jun NEWA
AB		EQ 10MG BASE	A078739	002	Jul 01, 2013	Jun NEWA

ROCURONIUM BROMIDE

INJECTABLE;INJECTION
ZEMURON

AP	+ ORGANON USA INC	50MG/5ML (10MG/ML)	N020214	001	Mar 17, 1994	Jan CAHN
	@	10MG/ML (10MG/ML)	N020214	002	Mar 17, 1994	Jan CAHN
AP	+	100MG/10ML (10MG/ML)	N020214	003	Mar 17, 1994	Jan CAHN

ROPINIROLE HYDROCHLORIDE

TABLET;ORAL
REQUIP

AB	+ GLAXOSMITHKLINE LLC	EQ 0.25MG BASE	N020658	001	Sep 19, 1997	Mar CAHN
AB		EQ 0.5MG BASE	N020658	002	Sep 19, 1997	Mar CAHN
AB		EQ 1MG BASE	N020658	003	Sep 19, 1997	Mar CAHN
AB		EQ 2MG BASE	N020658	004	Sep 19, 1997	Mar CAHN
AB		EQ 3MG BASE	N020658	006	Jan 27, 1999	Mar CAHN
AB		EQ 4MG BASE	N020658	007	Jan 27, 1999	Mar CAHN
AB		EQ 5MG BASE	N020658	005	Sep 19, 1997	Mar CAHN

ROPINIROLE HYDROCHLORIDE

@	COREPHARMA	EQ 0.25MG BASE	A078230	001	May 20, 2008	Jul DISC
@		EQ 0.5MG BASE	A078230	002	May 20, 2008	Jul DISC
@		EQ 1MG BASE	A078230	003	May 20, 2008	Jul DISC
@		EQ 2MG BASE	A078230	004	May 20, 2008	Jul DISC
@		EQ 3MG BASE	A078230	005	May 20, 2008	Jul DISC
@		EQ 4MG BASE	A078230	006	May 20, 2008	Jul DISC
@		EQ 5MG BASE	A078230	007	May 20, 2008	Jul DISC

TABLET, EXTENDED RELEASE;ORAL
REQUIP XL

AB	+ GLAXOSMITHKLINE LLC	EQ 2MG BASE	N022008	001	Jun 13, 2008	Mar CAHN
	@	EQ 3MG BASE	N022008	002	Jun 13, 2008	Mar CAHN
AB		EQ 4MG BASE	N022008	003	Jun 13, 2008	Mar CAHN
AB		EQ 6MG BASE	N022008	006	Apr 10, 2009	Mar CAHN
AB		EQ 8MG BASE	N022008	004	Jun 13, 2008	Mar CAHN
AB		EQ 12MG BASE	N022008	005	Oct 31, 2008	Mar CAHN

ROPINIROLE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL
ROPINIROLE HYDROCHLORIDE

AB	ACTAVIS ELIZABETH	EQ 2MG BASE	A090869	001	May 17, 2012	Apr CAHN
AB		EQ 4MG BASE	A090869	002	May 17, 2012	Apr CAHN
AB		EQ 6MG BASE	A090869	003	May 17, 2012	Apr CAHN
AB		EQ 8MG BASE	A090869	004	May 17, 2012	Apr CAHN
AB		EQ 12MG BASE	A090869	005	May 17, 2012	Apr CAHN
AB	ALEMBIC LTD	EQ 2MG BASE	A202786	001	Apr 22, 2013	Apr NEWA
AB		EQ 4MG BASE	A202786	002	Apr 22, 2013	Apr NEWA
AB		EQ 6MG BASE	A202786	003	Apr 22, 2013	Apr NEWA
AB		EQ 8MG BASE	A202786	004	Apr 22, 2013	Apr NEWA
AB		EQ 12MG BASE	A202786	005	Apr 22, 2013	Apr NEWA

ROSIGLITAZONE MALEATE

TABLET;ORAL
AVANDIA

AB	SB PHARMCO	EQ 2MG BASE	N021071	002	May 25, 1999	Jan CFTG
AB		EQ 4MG BASE	N021071	003	May 25, 1999	Jan CFTG
AB	+	EQ 8MG BASE	N021071	004	May 25, 1999	Jan CFTG
	ROSIGLITAZONE MALEATE					
AB	TEVA	EQ 2MG BASE	A076747	001	Jan 25, 2013	Jan NEWA
AB		EQ 4MG BASE	A076747	002	Jan 25, 2013	Jan NEWA
AB		EQ 8MG BASE	A076747	003	Jan 25, 2013	Jan NEWA

ROTIGOTINE

FILM, EXTENDED RELEASE;TRANSDERMAL
NEUPRO

+	UCB INC	2MG/24HR	N021829	001	May 09, 2007	May CRLD
		8MG/24HR	N021829	006	Apr 02, 2012	May CRLD

SAQUINAVIR MESYLATE

TABLET;ORAL
INVIRASE

+	HOFFMAN LA ROCHE	EQ 500MG BASE	N021785	001	Dec 17, 2004	Feb CAHN
---	------------------	---------------	---------	-----	--------------	----------

SELEGILINE HYDROCHLORIDE

TABLET;ORAL

SELEGILINE HYDROCHLORIDE
@ DAVA PHARMS INC

5MG	A074641	001	Aug 02, 1996	Jan DISC
-----	---------	-----	--------------	----------

SERTACONAZOLE NITRATE

CREAM;TOPICAL
ERTACZO

+	VALEANT LUXEMBOURG	2%	N021385	001	Dec 10, 2003	Jun CAHN
---	--------------------	----	---------	-----	--------------	----------

SERTRALINE HYDROCHLORIDE

TABLET;ORAL

SERTRALINE HYDROCHLORIDE

@	CIPLA LTD	EQ 25MG BASE	A077162	001	Feb 06, 2007	Aug CAHN
@		EQ 50MG BASE	A077162	002	Feb 06, 2007	Aug CAHN
@		EQ 100MG BASE	A077162	003	Feb 06, 2007	Aug CAHN
@	DR REDDYS LABS LTD	EQ 25MG BASE	A076442	001	Apr 30, 2007	Apr DISC
@		EQ 50MG BASE	A076442	002	Apr 30, 2007	Apr DISC
@		EQ 100MG BASE	A076442	003	Apr 30, 2007	Apr DISC

SILDENAFIL CITRATE

TABLET;ORAL

SILDENAFIL CITRATE

AB	ACTAVIS GRP PTC	EQ 20MG BASE	A200149	001	Feb 25, 2013	Apr CAHN
AB	ACTAVIS PHARMA	EQ 20MG BASE	A200149	001	Feb 25, 2013	Feb NEWA
AB	AMNEAL PHARMS	EQ 20MG BASE	A202025	001	Feb 28, 2013	Feb NEWA

SIMVASTATIN; SITAGLIPTIN PHOSPHATE

TABLET;ORAL

JUVISYNC

@	MERCK SHARP DOHME	10MG;EQ 50MG BASE	N202343	004	Sep 18, 2012	Sep DISC
@		10MG;EQ 100MG BASE	N202343	001	Oct 07, 2011	Sep DISC
@		20MG;EQ 50MG BASE	N202343	005	Sep 18, 2012	Sep DISC
@		20MG;EQ 100MG BASE	N202343	002	Oct 07, 2011	Sep DISC
@		40MG;EQ 50MG BASE	N202343	006	Sep 18, 2012	Sep DISC

SIMVASTATIN; SITAGLIPTIN PHOSPHATETABLET; ORAL
JUVISYNC

@	40MG;EQ 100MG BASE	N202343	003	Oct 07, 2011	Sep DISC
---	--------------------	---------	-----	--------------	----------

SIROLIMUSSOLUTION; ORAL
RAPAMUNE

+ PF PRISM CV	1MG/ML	N021083	001	Sep 15, 1999	Sep CAHN
---------------	--------	---------	-----	--------------	----------

TABLET; ORAL
RAPAMUNE

PF PRISM CV	0.5MG	N021110	004	Jan 25, 2010	Sep CAHN
	1MG	N021110	001	Aug 25, 2000	Sep CAHN
+	2MG	N021110	002	Aug 22, 2002	Sep CAHN
@	5MG	N021110	003	Feb 23, 2004	Sep CAHN

SODIUM CHLORIDEINJECTABLE; INJECTION
SODIUM CHLORIDE 0.9%

MEDEFIL INC	18MG/2ML (9MG/ML)	N202832	002	Jan 06, 2012	Mar NEWA
	22.5MG/2.5ML (9MG/ML)	N202832	003	Jan 06, 2012	Mar NEWA
	27MG/3ML (9MG/ML)	N202832	004	Jan 06, 2012	Mar NEWA
	45MG/5ML (9MG/ML)	N202832	005	Jan 06, 2012	Mar NEWA
	90MG/10ML (9MG/ML)	N202832	006	Jan 06, 2012	Mar NEWA

SODIUM CHLORIDE 0.9%

HIKMA MAPLE	9MG/ML	A201833	001	Sep 24, 2013	Sep NEWA
-------------	--------	---------	-----	--------------	----------

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

MEDEFIL INC	9MG/ML (9MG/ML)	N202832	001	Jan 06, 2012	Mar CPOT
-------------	-----------------	---------	-----	--------------	----------

SOLUTION; IRRIGATION

SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

@ BAXTER HLTHCARE	450MG/100ML	N017864	001		Jan DISC
-------------------	-------------	---------	-----	--	----------

SODIUM FLUORIDE F-18INJECTABLE; INTRAVENOUS
SODIUM FLUORIDE F-18

+ MCPRF	10-91.5MCI/ML	A203605	001	Jun 28, 2013	Jun NEWA
---------	---------------	---------	-----	--------------	----------

SODIUM IODIDE I-123

CAPSULE; ORAL

SODIUM IODIDE I 123

@ CARDINAL HLTH 414	400uCi	N018671	003	May 27, 1982	Sep DISC
---------------------	--------	---------	-----	--------------	----------

SODIUM PHENYLBUTYRATEPOWDER; ORAL
BUPHENYL

AB + MEDICIS	3GM/TEASPOONFUL	N020573	001	Apr 30, 1996	Mar CFTG
--------------	-----------------	---------	-----	--------------	----------

SODIUM PHENYLBUTYRATE

AB SIGMAPHARM LABS LLC	3GM/TEASPOONFUL	A202819	001	Mar 22, 2013	Mar NEWA
------------------------	-----------------	---------	-----	--------------	----------

SODIUM PHOSPHATE, DIBASIC ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATETABLET; ORAL
VISICOL

@ SALIX PHARMS	0.398GM;1.102GM	N021097	001	Sep 21, 2000	Jul DISC
----------------	-----------------	---------	-----	--------------	----------

SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE

TABLET; ORAL

MONOBASIC SODIUM PHOSPHATE AND DIBASIC SODIUM PHOSPHATE

@ NOVEL LABS INC	0.398GM;1.102GM	A079247	001	Dec 30, 2011	Aug DISC
------------------	-----------------	---------	-----	--------------	----------

OSMOPREP

+ SALIX PHARMS	0.398GM;1.102GM	N021892	001	Mar 16, 2006	Aug CTEC
----------------	-----------------	---------	-----	--------------	----------

SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS

INJECTABLE; INJECTION

SODIUM PHOSPHATES IN PLASTIC CONTAINER

+ HOSPIRA	142MG/ML;276MG/ML	N018892	001	May 10, 1983	Jun CRLD
-----------	-------------------	---------	-----	--------------	----------

SODIUM POLYSTYRENE SULFONATEPOWDER; ORAL, RECTAL
KAYEXALATE

AA + COVIS PHARMA SARL	453.6GM/BOT	N011287	001		Apr CAHN
------------------------	-------------	---------	-----	--	----------

SODIUM POLYSTYRENE SULFONATE

SUSPENSION;ORAL, RECTAL

SODIUM POLYSTYRENE SULFONATE

>D>	@ ROXANE	15GM/60ML	A089049	001	Nov 17, 1986	Oct	CMFD
>A> AA		15GM/60ML	A089049	001	Nov 17, 1986	Oct	CMFD
	@	15GM/60ML	A089049	001	Nov 17, 1986	Mar	DISC

STAVUDINE

CAPSULE;ORAL

STAVUDINE

AB	HETERO LABS LTD III	15MG	A078957	001	Dec 29, 2008	Apr	CAHN
AB		20MG	A078957	002	Dec 29, 2008	Apr	CAHN
AB		30MG	A078957	003	Dec 29, 2008	Apr	CAHN
AB		40MG	A078957	004	Dec 29, 2008	Apr	CAHN

STREPTOZOCIN

INJECTABLE;INJECTION

ZANOSAR

+	TEVA PHARMS USA	1GM/VIAL	N050577	001	May 07, 1982	Apr	CAHN
---	-----------------	----------	---------	-----	--------------	-----	------

SUCCIMER

CAPSULE;ORAL

CHEMET

+	RECORDATI RARE	100MG	N019998	002	Jan 30, 1991	May	CAHN
---	----------------	-------	---------	-----	--------------	-----	------

SULFACETAMIDE SODIUM

LOTION;TOPICAL

KLARON

AB	+	VALEANT BERMUDA	10%	N019931	001	Dec 23, 1996	Feb	CAHN
----	---	-----------------	-----	---------	-----	--------------	-----	------

OINTMENT;OPHTHALMIC

SULFACETAMIDE SODIUM

AT		PERRIGO CO TENNESSEE	10%	A080029	001		Jun	CAHN
----	--	----------------------	-----	---------	-----	--	-----	------

SULFAMETHOXAZOLE; TRIMETHOPRIM

INJECTABLE;INJECTION

SULFAMETHOXAZOLE AND TRIMETHOPRIM

+	TEVA PHARMS USA	80MG/ML;16MG/ML	A073303	001	Oct 31, 1991	Mar	CAHN
---	-----------------	-----------------	---------	-----	--------------	-----	------

TABLET;ORAL

SULFAMETHOPRIM

@	NOVEL LABS INC	400MG;80MG	A070022	001	Feb 15, 1985	Mar	DISC
---	----------------	------------	---------	-----	--------------	-----	------

SULFAMETHOPRIM-DS

@	NOVEL LABS INC	800MG;160MG	A070032	001	Feb 15, 1985	Mar	DISC
---	----------------	-------------	---------	-----	--------------	-----	------

SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH

@	SANDOZ	800MG;160MG	N018598	004	May 19, 1982	Jun	DISC
---	--------	-------------	---------	-----	--------------	-----	------

SULINDAC

TABLET;ORAL

SULINDAC

AB		HERITAGE PHARMS INC	150MG	A073262	002	Sep 06, 1991	Apr	CMFD
AB			200MG	A073262	001	Sep 06, 1991	Apr	CMFD

SUMATRIPTAN SUCCINATE

INJECTABLE;SUBCUTANEOUS

SUMATRIPTAN SUCCINATE

AP	AUROBINDO PHARMA LTD	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A202758	001	Apr 23, 2013	Apr	NEWA
AP	HIKMA FARMACEUTICA	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A200183	001	Sep 16, 2013	Aug	NEWA
AP	SAGENT AGILA	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A090641	001	Jul 28, 2010	Feb	CAHN
AP	TEVA PHARMS USA	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A077907	001	Feb 06, 2009	Mar	CAHN

SYSTEM;IONTOPHORESIS

ZECUITY

+	NUPATHE	EQ 6.5MG BASE/4HR	N202278	001	Jan 17, 2013	Jan	NEWA
---	---------	-------------------	---------	-----	--------------	-----	------

TABLET;ORAL

SUMATRIPTAN SUCCINATE

AB	HIKMA PHARMS	EQ 25MG BASE	A078298	001	May 21, 2013	May	NEWA
AB		EQ 50MG BASE	A078298	002	May 21, 2013	May	NEWA
AB		EQ 100MG BASE	A078298	003	May 21, 2013	May	NEWA
	@ MYLAN	EQ 25MG BASE	A077163	001	Nov 02, 2009	Aug	DISC

SUMATRIPTAN SUCCINATE

TABLET;ORAL

SUMATRIPTAN SUCCINATE

@ EQ 50MG BASE
 @ EQ 100MG BASE

A077163 002 Nov 02, 2009 Aug DISC
 A077163 003 Nov 02, 2009 Aug DISC

TACROLIMUS

CAPSULE, EXTENDED RELEASE;ORAL

ASTAGRAF XL

ASTELLAS EQ 0.5MG BASE
 EQ 1MG BASE
 + EQ 5MG BASE

N204096 001 Jul 19, 2013 Jul NEWA
 N204096 002 Jul 19, 2013 Jul NEWA
 N204096 003 Jul 19, 2013 Jul NEWA

OINTMENT;TOPICAL

PROTOPIC

+ ASTELLAS 0.03%

N050777 001 Dec 08, 2000 Jun CRLD

TAMSULOSIN HYDROCHLORIDE

CAPSULE;ORAL

TAMSULOSIN HYDROCHLORIDE

AB AUROBINDO PHARMA LTD 0.4MG

A202433 001 Apr 30, 2013 Apr NEWA

TECHNETIUM TC-99M TILMANOCEPT

INJECTABLE;INJECTION

LYMPHOSEEK KIT

+ NAVIDEA BIOPHARMS N/A

N202207 001 Mar 13, 2013 Mar NEWA

TENIPOSIDE

INJECTABLE;INJECTION

VUMON

+ CORDEN PHARMA 10MG/ML
 + HQ SPECILT PHARMA 10MG/ML

N020119 001 Jul 14, 1992 Apr CAHN
 N020119 001 Jul 14, 1992 Jul CAHN

TERBINAFINE HYDROCHLORIDE

TABLET;ORAL

TERBINAFINE HYDROCHLORIDE

AB CIPLA LTD EQ 250MG BASE
 @ MYLAN EQ 250MG BASE

A077137 001 Jul 02, 2007 Jul CAHN
 A077136 001 Jul 02, 2007 Aug DISC

TERBUTALINE SULFATE

INJECTABLE;INJECTION

TERBUTALINE SULFATE

>A> AP @ TEVA PHARMS USA 1MG/ML
 UNITED BIOMEDCL 1MG/ML

A076853 001 Jul 20, 2004 Mar CAHN
 A200122 001 Nov 08, 2013 Oct NEWA

TESTOSTERONE

GEL;TRANSDERMAL

TESTOSTERONE

PERRIGO ISRAEL 25MG/2.5GM PACKET
 50MG/5GM PACKET

N203098 002 Jan 31, 2013 Jan NEWA
 N203098 003 Jan 31, 2013 Jan NEWA

GEL, METERED;TRANSDERMAL

TESTOSTERONE

PERRIGO ISRAEL 12.5MG/1.25GM ACTUATION

N203098 001 Jan 31, 2013 Jan NEWA

TESTOSTERONE CYPIONATE

INJECTABLE;INJECTION

TESTOSTERONE CYPIONATE

AO SUN PHARM INDS LTD 100MG/ML
 AO 200MG/ML

A201720 001 Jun 03, 2013 May NEWA
 A201720 002 Jun 03, 2013 May NEWA

TESTOSTERONE ENANTHATE

INJECTABLE;INJECTION

DELATESTRYL

AO @ ENDO PHARMS 200MG/ML
 + 200MG/ML

N009165 001 Jan CAHN
 N009165 003 Jan CAHN

THALLOUS CHLORIDE TL-201

INJECTABLE;INTRAVENOUS

THALLOUS CHLORIDE TL 201

@ MALLINCKRODT 2mCi/ML

A077698 001 Nov 09, 2006 Aug DISC

THEOPHYLLINE

TABLET, EXTENDED RELEASE;ORAL						
THEOPHYLLINE						
AB	+ TEVA PHARMS	450MG	A081236	001	Nov 09, 1992	Mar CAHN

THIABENDAZOLE

SUSPENSION;ORAL

MINTEZOL

@ MERCK SHARP DOHME

500MG/5ML

N016097 001

May CAHN

TABLET, CHEWABLE;ORAL

MINTEZOL

@ MERCK SHARP DOHME

500MG

N016096 001

May CAHN

THIOGUANINE

TABLET;ORAL

THIOGUANINE

+ ASPEN GLOBAL INC

40MG

N012429 001

Mar CAHN

TICLOPIDINE HYDROCHLORIDE

TABLET;ORAL

TICLOPIDINE HYDROCHLORIDE

@ MYLAN

250MG

A075161 001 Sep 13, 1999 Aug DISC

TIGECYCLINE

INJECTABLE;IV (INFUSION)

TYGACIL

+ PF PRISM CV

50MG/VIAL

N021821 001 Jun 15, 2005 Aug CAHN

TILUDRONATE DISODIUM

TABLET;ORAL

SKELID

@ SANOFI AVENTIS US

EQ 200MG BASE

N020707 001 Mar 07, 1997 Jun DISC

TIMOLOL MALEATE

SOLUTION, GEL FORMING/DROPS;OPHTHALMIC

TIMOPTIC-XE

AB + VALEANT PHARMS LLC

EQ 0.25% BASE

N020330 001 Nov 04, 1993 Jan CAHN

AB +

EQ 0.5% BASE

N020330 002 Nov 04, 1993 Jan CAHN

SOLUTION/DROPS;OPHTHALMIC

ISTALOL

BT + BAUSCH AND LOMB

EQ 0.5% BASE

N021516 001 Jun 04, 2004 May CAHN

TIMOLOL MALEATE

@ AKORN

EQ 0.25% BASE

A074515 001 Mar 25, 1997 Jun DISC

@ APOTEX INC

EQ 0.25% BASE

A075411 001 Sep 08, 2000 Apr DISC

@

EQ 0.5% BASE

A075412 001 Sep 08, 2000 Apr DISC

TINIDAZOLE

TABLET;ORAL

TINIDAZOLE

AB UNIQUE PHARM LABS

250MG

A202489 001 Oct 09, 2013 Sep NEWA

AB

500MG

A202489 002 Oct 09, 2013 Sep NEWA

TIOPRONIN

TABLET;ORAL

THIOLA

+ MISSION PHARMA

100MG

N019569 001 Aug 11, 1988 Aug CTNA

TIZANIDINE HYDROCHLORIDE

CAPSULE;ORAL

TIZANIDINE HYDROCHLORIDE

AB MYLAN PHARMS INC

EQ 2MG BASE

A091502 001 Nov 09, 2012 May CAHN

AB

EQ 4MG BASE

A091502 002 Nov 09, 2012 May CAHN

AB

EQ 6MG BASE

A091502 003 Nov 09, 2012 May CAHN

TABLET;ORAL

TIZANIDINE HYDROCHLORIDE

@ MYLAN PHARMS INC

EQ 2MG BASE

A076282 001 Dec 16, 2003 Feb DISC

@

EQ 4MG BASE

A076282 002 Dec 16, 2003 Feb DISC

TOBRAMYCIN

POWDER;INHALATION

TOBRAMYCIN

		POWDER; INHALATION							
		TOBI PODHALER							
	+	NOVARTIS	28MG	N201688	001	Mar 22, 2013	Mar	NEWA	
		SOLUTION; INHALATION							
		TOBI							
AN	+	NOVARTIS PHARMS	300MG/5ML	N050753	001	Dec 22, 1997	Sep	CFTG	
		TOBRAMYCIN							
AN		TEVA PHARMS USA	300MG/5ML	A091589	001	Oct 10, 2013	Sep	NEWA	
		SOLUTION/DROPS; OPHTHALMIC							
		TOBRAMYCIN							
	@	APOTEX INC	0.3%	A065087	001	Feb 25, 2002	Apr	DISC	

TOBRAMYCIN SULFATE

		INJECTABLE; INJECTION							
		TOBRAMYCIN SULFATE							
AP		TEVA PHARMS USA	EQ 40MG BASE/ML	A063100	001	Jan 30, 1992	Sep	CAHN	

TOFACITINIB CITRATE

		TABLET; ORAL							
		XELJANZ							
	+	PF PRISM CV	EQ 5MG BASE	N203214	001	Nov 06, 2012	Sep	CAHN	

TOLAZAMIDE

		TABLET; ORAL							
		TOLAZAMIDE							
		MYLAN PHARMS INC	250MG	A070259	001	Jan 02, 1986	Mar	CTEC	
	+		500MG	A070259	003	Mar 17, 1986	Mar	CTEC	
	@	WATSON LABS	250MG	A070514	001	Jan 09, 1986	Mar	DISC	
	@		500MG	A070515	001	Jan 09, 1986	Mar	DISC	

TOLTERODINE TARTRATE

		CAPSULE, EXTENDED RELEASE; ORAL							
		DETROL LA							
>D>		PHARMACIA AND UPJOHN	2MG	N021228	001	Dec 22, 2000	Oct	CFTG	
>A>	AB		2MG	N021228	001	Dec 22, 2000	Oct	CFTG	
>D>	+		4MG	N021228	002	Dec 22, 2000	Oct	CFTG	
>A>	AB	+	4MG	N021228	002	Dec 22, 2000	Oct	CFTG	
>A>		TOLTERODINE TARTRATE							
>A>	AB	MYLAN PHARMS INC	2MG	A201486	001	Oct 31, 2013	Oct	NEWA	
>A>	AB		4MG	A201486	002	Oct 31, 2013	Oct	NEWA	

TOPIRAMATE

		CAPSULE, EXTENDED RELEASE; ORAL							
		TROKENDI XR							
		SUPERNUS PHARMS	25MG	N201635	001	Aug 16, 2013	Aug	NEWA	
			50MG	N201635	002	Aug 16, 2013	Aug	NEWA	
			100MG	N201635	003	Aug 16, 2013	Aug	NEWA	
	+		200MG	N201635	004	Aug 16, 2013	Aug	NEWA	
		TABLET; ORAL							
		TOPAMAX							
AB		JANSSEN PHARMS	25MG	N020505	004	Dec 24, 1996	Apr	CRLD	
AB	+		100MG	N020505	001	Dec 24, 1996	Apr	CRLD	
		TOPIRAMATE							
AB		ACTIVIS TOTOWA LLC	25MG	A078637	001	Feb 27, 2013	Feb	NEWA	
AB			50MG	A078637	002	Feb 27, 2013	Feb	NEWA	
AB			100MG	A078637	003	Feb 27, 2013	Feb	NEWA	
AB			200MG	A078637	004	Feb 27, 2013	Feb	NEWA	
AB		LUPIN	25MG	A078410	001	Sep 11, 2013	Aug	NEWA	
AB			50MG	A078410	002	Sep 11, 2013	Aug	NEWA	
AB			100MG	A078410	003	Sep 11, 2013	Aug	NEWA	
AB			200MG	A078410	004	Sep 11, 2013	Aug	NEWA	
AB		UNICHEM LABS LTD	200MG	A090162	004	Feb 19, 2013	Feb	NEWA	
	@	UPSHER SMITH	25MG	A078499	001	Jan 07, 2010	Jun	DISC	
	@		50MG	A078499	002	Jan 07, 2010	Jun	DISC	
	@		100MG	A078499	003	Jan 07, 2010	Jun	DISC	
	@		200MG	A078499	004	Jan 07, 2010	Jun	DISC	

TOPOTECAN HYDROCHLORIDE

CAPSULE; ORAL
HYCAMTIN

TOPOTECAN HYDROCHLORIDECAPSULE; ORAL
HYCANTINGLAXO WELLCOME EQ 0.25MG BASE
+ EQ 1MG BASEN020981 001 Oct 11, 2007 Sep CAHN
N020981 002 Oct 11, 2007 Sep CAHN

INJECTABLE; INJECTION

TOPOTECAN HYDROCHLORIDE

AP ACCORD HLTHCARE EQ 4MG BASE/VIAL
AP SUN PHARM INDS LTD EQ 4MG BASE/VIALA202351 001 Jun 26, 2013 Jun NEWA
A202203 001 Aug 29, 2013 Aug NEWATOREMIFENE CITRATETABLET; ORAL
FARESTON

+ PROSTRAKAN INC EQ 60MG BASE

N020497 001 May 29, 1997 May CAHN

TORSEMIDETABLET; ORAL
TORSEMIDEAB HETERO LABS LTD III 5MG
AB 10MG
AB 20MG
AB 100MGA079234 001 Jan 27, 2009 Apr CAHN
A079234 002 Jan 27, 2009 Apr CAHN
A079234 003 Jan 27, 2009 Apr CAHN
A079234 004 Jan 27, 2009 Apr CAHNTRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HYDROCHLORIDE

AB ACCORD HLTHCARE INC 50MG
AB CSPC OUYI PHARM CO 50MGA202390 001 May 16, 2013 Apr NEWA
A091498 001 Mar 29, 2013 Mar NEWATABLET, EXTENDED RELEASE; ORAL
RYZOLT@ PURDUE PHARMA 100MG
@ 200MG
@ 300MGN021745 001 Dec 30, 2008 Jan DISC
N021745 002 Dec 30, 2008 Jan DISC
N021745 003 Dec 30, 2008 Jan DISC

TRAMADOL HYDROCHLORIDE

AB2 ACTAVIS ELIZABETH 100MG
AB2 200MG
AB2 300MG
AB1 PAR PHARM INC 100MG
AB2 + SUN PHARMA GLOBAL 100MGA091609 001 Jun 27, 2012 Apr CAHN
A091609 002 Jun 27, 2012 Apr CAHN
A091609 003 Jun 27, 2012 Apr CAHN
A078783 001 Nov 13, 2009 Feb CRLD
A091607 001 Dec 30, 2011 Feb CRLDTABLET, ORALLY DISINTEGRATING; ORAL
RYBIX ODT

@ SHIONOGI INC 50MG

N021693 001 May 05, 2005 Aug DISC

TRAMETINIB DIMETHYL SULFOXIDETABLET; ORAL
MEKINISTGLAXOSMITHKLINE LLC EQ 0.5MG NON-SOLVATED PARENT
EQ 1MG NON-SOLVATED PARENT
+ EQ 2MG NON-SOLVATED PARENTN204114 001 May 29, 2013 May NEWA
N204114 002 May 29, 2013 May NEWA
N204114 003 May 29, 2013 May NEWATRANDOLAPRIL

TABLET; ORAL

TRANDOLAPRIL

@ CIPLA 1MG
@ 2MG
@ 4MG
@ DR REDDYS LABS LTD 1MG
@ 2MG
@ 4MGA077307 002 Jun 12, 2007 Jul DISC
A077307 001 Jun 12, 2007 Jul DISC
A077307 003 Jun 12, 2007 Jul DISC
A078493 001 Aug 25, 2008 Apr DISC
A078493 002 Aug 25, 2008 Apr DISC
A078493 003 Aug 25, 2008 Apr DISCTRANEXAMIC ACIDINJECTABLE; INJECTION
TRANEXAMIC ACID>D> AP CUSTOPHARM INC 100MG/ML
AP 100MG/ML
>A> AP X-GEN PHARMS INC 100MG/MLA201580 001 Jun 14, 2013 Oct CAHN
A201580 001 Jun 14, 2013 Jun NEWA
A201580 001 Jun 14, 2013 Oct CAHNTRAVOPROSTSOLUTION/DROPS; OPHTHALMIC
TRAVOPROST

PAR PHARM 0.004%

A091340 001 Mar 01, 2013 Feb NEWA

TRAZODONE HYDROCHLORIDE

TABLET; ORAL						
TRAZODONE HYDROCHLORIDE						
AB	TEVA PHARMS USA	50MG	A071523	001	Dec 11, 1987	Mar CAHN
AB		100MG	A071524	001	Dec 11, 1987	Mar CAHN
TABLET, EXTENDED RELEASE; ORAL						
OLEPTRO						
	@ ANGELINI LLC	150MG	N022411	001	Feb 02, 2010	May DISC
	@	300MG	N022411	002	Feb 02, 2010	May DISC
+	ANGELINI PHARMA	150MG	N022411	001	Feb 02, 2010	Jun CMFD
		300MG	N022411	002	Feb 02, 2010	Jun CMFD

TREPROSTINIL

INJECTABLE; IV (INFUSION) -SC						
REMODULIN						
	UNITED THERAP	1MG/ML	N021272	001	May 21, 2002	May CAIN
		2.5MG/ML	N021272	002	May 21, 2002	May CAIN
		5MG/ML	N021272	003	May 21, 2002	May CAIN
+		10MG/ML	N021272	004	May 21, 2002	Jun CAIN
SOLUTION; INHALATION						
TYVASO						
+	UNITED THERAP	EQ 0.6MG BASE/ML	N022387	001	Jul 30, 2009	May CAIN

TRETINOIN

CREAM; TOPICAL						
RETIN-A						
AB	+ VALEANT BERMUDA	0.025%	N019049	001	Sep 16, 1988	Jun CAHN
AB1	+	0.05%	N017522	001		Jun CAHN
AB	+	0.1%	N017340	001		Jun CAHN
GEL; TOPICAL						
ATRALIN						
	+ DOW PHARM	0.05%	N022070	001	Jul 26, 2007	Apr CAHN
RETIN-A MICRO						
AB	+ VALEANT INTL	0.04%	N020475	002	May 10, 2002	Jul CTEC
AB	+	0.1%	N020475	001	Feb 07, 1997	Jul CTEC
TRETINOIN						
AB	SPEAR PHARMS INC	0.04%	A202567	001	Jul 17, 2013	Jul NEWA
AB		0.1%	A202026	001	Jul 17, 2013	Jul NEWA

TRIAMCINOLONE ACETONIDE

	CREAM;TOPICAL							
	KENALOG							
	@	APOTHECON	0.025%	N011601	003		Apr	DISC
	@		0.1%	N011601	006		Apr	DISC
	TRIACET							
	@	TEVA	0.025%	A084908	001		Apr	DISC
	@		0.5%	A084908	003		Apr	DISC
	TRIAMCINOLONE ACETONIDE							
AT	+	FOUGERA PHARMS	0.025%	A085692	001		Apr	CRLD
AT	+		0.1%	A085692	003		Apr	CRLD
	@	G AND W LABS	0.025%	A089797	001	May 31, 1991	May	DISC
	@	TARO	0.025%	A086277	001		Apr	DISC
	@		0.1%	A086276	001		Apr	DISC
	@		0.5%	A086275	001		Apr	DISC
	INJECTABLE;INTRA-ARTICULAR, INTRAMUSCULAR, INTRAVITREAL							
	TRIVARIS							
	@	ALLERGAN	8MG/0.1ML (8MG/0.1ML)	N022220	001	Jun 16, 2008	May	DISC
	LOTION;TOPICAL							
	TRIAMCINOLONE ACETONIDE							
AT		VERSAPHARM INC	0.025%	A202374	001	May 08, 2013	Apr	NEWA
AT			0.1%	A202374	002	May 08, 2013	Apr	NEWA
AT	+	WOCKHARDT EU OPERATN	0.025%	A088450	001	Apr 01, 1985	Apr	CAHN
	OINTMENT;TOPICAL							
	KENALOG							
	@	APOTHECON	0.025%	N011600	003		Apr	DISC
	@		0.1%	N011600	001		Apr	DISC
	TRIAMCINOLONE ACETONIDE							
	@	TARO	0.025%	A040040	001	Sep 30, 1994	May	DISC
	@		0.025%	A040374	001	Jun 05, 2001	May	DISC
	@		0.1%	A087902	001	Dec 27, 1982	May	DISC
	@		0.5%	A040386	001	Jun 05, 2001	May	DISC

AB	VALEANT BERMUDA	EQ 37.5MG BASE	A090071	001	Apr 15, 2011	Jul CAHN
AB		EQ 75MG BASE	A090071	002	Apr 15, 2011	Jul CAHN
AB		EQ 150MG BASE	A090071	003	Apr 15, 2011	Jul CAHN

VERAPAMIL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL							
VERELAN PM							
AB	ALKERMES GAINESVILLE	100MG	N020943	001	Nov 25, 1998	Sep	CAHN
AB		200MG	N020943	002	Nov 25, 1998	Sep	CAHN
AB	+	300MG	N020943	003	Nov 25, 1998	Sep	CAHN
INJECTABLE;INJECTION							
VERAPAMIL HYDROCHLORIDE							
	@ INTL MEDICATION	2.5MG/ML	A070451	001	Dec 16, 1985	Mar	DISC
TABLET;ORAL							
VERAPAMIL HYDROCHLORIDE							
AB	HERITAGE PHARMS INC	80MG	A071880	001	Apr 05, 1988	Aug	CMFD
AB		120MG	A071881	001	Apr 05, 1988	Aug	CMFD
TABLET, EXTENDED RELEASE;ORAL							
VERAPAMIL HYDROCHLORIDE							
AB	CARACO	120MG	A090529	001	Dec 30, 2011	May	CAHN
AB		180MG	A090529	002	Dec 30, 2011	May	CAHN
AB		240MG	A090529	003	Dec 30, 2011	May	CAHN

VERTEPORFIN

INJECTABLE;INJECTION							
VISUDYNE							
	+ VALEANT PHARMS INC	15MG/VIAL	N021119	001	Apr 12, 2000	Jan	CAHN

VINCRISTINE SULFATE

INJECTABLE;INJECTION							
VINCRISTINE SULFATE PFS							
AP	TEVA PHARMS USA	1MG/ML	A075493	001	Sep 01, 1999	Apr	CAHN

VINORELBINE TARTRATE

INJECTABLE;INJECTION							
VINORELBINE TARTRATE							
AP	DR REDDYS LABS LTD	EQ 10MG BASE/ML	A202017	001	Sep 12, 2013	Aug	NEWA
AP	TEVA PHARMS USA	EQ 10MG BASE/ML	A076028	001	Feb 03, 2003	Apr	CAHN

VORICONAZOLE

FOR SUSPENSION;ORAL							
VFEND							
AB	+ PFIZER	200MG/5ML	N021630	001	Dec 19, 2003	May	CFTG
VORICONAZOLE							
AB	MYLAN PHARMS INC	200MG/5ML	A202361	001	May 28, 2013	May	NEWA

VORTIOXETINE HYDROBROMIDE

TABLET;ORAL							
BRINTELLIX							
	TAKEDA PHARMS USA	EQ 5MG BASE	N204447	001	Sep 30, 2013	Sep	NEWA
		EQ 10MG BASE	N204447	002	Sep 30, 2013	Sep	NEWA
		EQ 15MG BASE	N204447	003	Sep 30, 2013	Sep	NEWA
	+	EQ 20MG BASE	N204447	004	Sep 30, 2013	Sep	NEWA

WARFARIN SODIUM

TABLET;ORAL							
WARFARIN SODIUM							
AB	AMNEAL PHARMS	1MG	A202202	001	Mar 04, 2013	Feb	NEWA
AB		2MG	A202202	002	Mar 04, 2013	Feb	NEWA
AB		2.5MG	A202202	003	Mar 04, 2013	Feb	NEWA
AB		3MG	A202202	004	Mar 04, 2013	Feb	NEWA
AB		4MG	A202202	005	Mar 04, 2013	Feb	NEWA
AB		5MG	A202202	006	Mar 04, 2013	Feb	NEWA
AB		6MG	A202202	007	Mar 04, 2013	Feb	NEWA
AB		7.5MG	A202202	008	Mar 04, 2013	Feb	NEWA
AB		10MG	A202202	009	Mar 04, 2013	Feb	NEWA
AB	IPCA LABS LTD	1MG	A200104	001	Jun 27, 2013	Jun	NEWA
AB		2MG	A200104	002	Jun 27, 2013	Jun	NEWA
AB		2.5MG	A200104	003	Jun 27, 2013	Jun	NEWA
AB		3MG	A200104	004	Jun 27, 2013	Jun	NEWA
AB		4MG	A200104	005	Jun 27, 2013	Jun	NEWA
AB		5MG	A200104	006	Jun 27, 2013	Jun	NEWA
AB		6MG	A200104	007	Jun 27, 2013	Jun	NEWA
AB		7.5MG	A200104	008	Jun 27, 2013	Jun	NEWA
AB		10MG	A200104	009	Jun 27, 2013	Jun	NEWA

ZALEPLONCAPSULE;ORAL
SONATA

AB		PFIZER	5MG	N020859	001	Aug 13, 1999	Apr CAHN
AB	+		10MG	N020859	002	Aug 13, 1999	Apr CAHN

ZIDOVUDINETABLET;ORAL
RETROVIR

		@ VIIV HLTHCARE	300MG	N020518	002	Oct 04, 1996	Apr DISC
		ZIDOVUDINE					
>D>	AB	HEC PHARM USA INC	300MG	A202058	001	Oct 07, 2011	Oct CAHN
	AB		300MG	A202058	001	Oct 07, 2011	Feb CMFD
		@	300MG	A202058	001	Oct 07, 2011	Jan DISC
	AB	+ HETERO LABS LTD III	300MG	A090092	001	Apr 25, 2008	Apr CRLD
>A>	AB	SUNSHINE LAKE	300MG	A202058	001	Oct 07, 2011	Oct CAHN

ZIPRASIDONE HYDROCHLORIDECAPSULE;ORAL
ZIPRASIDONE HYDROCHLORIDE

AB		MYLAN PHARMS INC	EQ 20MG BASE	A202395	001	Oct 10, 2013	Sep NEWA
AB			EQ 40MG BASE	A202395	002	Oct 10, 2013	Sep NEWA
AB			EQ 60MG BASE	A202395	003	Oct 10, 2013	Sep NEWA
AB			EQ 80MG BASE	A202395	004	Oct 10, 2013	Sep NEWA

ZOLEDRONIC ACIDINJECTABLE;INJECTION
ZOLEDRONIC ACID

AP		DR REDDYS LABS LTD	EQ 5MG BASE/100ML	A091363	001	Mar 29, 2013	Mar NEWA
AP		EMCURE PHARMS LTD	EQ 5MG BASE/100ML	A201801	001	Mar 29, 2013	Mar NEWA

INJECTABLE;IV (INFUSION)
RECLAST

AP	+	NOVARTIS	EQ 5MG BASE/100ML	N021817	001	Apr 16, 2007	Mar CTEC
		ZOLEDRONIC ACID					
AP		ACS DOBFAR INFO SA	EQ 4MG BASE/100ML	N203231	001	Aug 02, 2013	Aug NEWA
AP			EQ 5MG BASE/100ML	A202828	001	Sep 23, 2013	Sep NEWA
AP		ACTAVIS INC	EQ 4MG BASE/5ML	A202472	001	Mar 04, 2013	Feb NEWA
AP		AGILA SPECLTS	EQ 4MG BASE/5ML	A202650	001	Mar 04, 2013	Feb NEWA
AP		DR REDDYS LABS LTD	EQ 4MG BASE/5ML	A091186	001	Mar 04, 2013	Feb NEWA
AP			EQ 5MG BASE/100ML	A091363	001	Mar 29, 2013	Jul CDFR
AP		EMCURE PHARMS LTD	EQ 4MG BASE/5ML	A201783	001	Mar 12, 2013	Mar NEWA
AP			EQ 5MG BASE/100ML	A201801	001	Mar 29, 2013	Jul CDFR
AP		GLAND PHARMA LTD	EQ 4MG BASE/5ML	A202930	001	Aug 05, 2013	Jul NEWA
AP		HIKMA FARMACEUTICA	EQ 4MG BASE/5ML	A202182	001	Jun 03, 2013	May NEWA
AP		HOSPIRA INC	EQ 5MG BASE/100ML	A202837	001	Apr 05, 2013	Mar NEWA
AP		PHARMACEUTICS	EQ 4MG BASE/5ML	A091170	001	Mar 04, 2013	Feb NEWA
AP			EQ 5MG BASE/100ML	A202163	001	Aug 05, 2013	Jul NEWA
AP		PHARMS	EQ 4MG BASE/5ML	A202571	001	May 07, 2013	Apr NEWA
	+	SUN PHARMA GLOBAL	EQ 4MG BASE/VIAL	A090018	001	Mar 04, 2013	Feb NEWA
AP			EQ 4MG BASE/5ML	A202746	001	Mar 04, 2013	Feb NEWA
		ZOMETA					
AP	+	NOVARTIS	EQ 4MG BASE/5ML	N021223	002	Mar 07, 2003	Feb CFTG
AP	+		EQ 4MG BASE/100ML	N021223	003	Jun 17, 2011	Aug CTEC

ZOLMITRIPTANSPRAY;NASAL
ZOMIG

ASTRAZENECA 2.5MG/SPRAY

N021450 003 Sep 16, 2013 Sep NEWA

TABLET;ORAL
ZOLMITRIPTAN

AB		APOTEX INC	2.5MG	A202078	001	May 14, 2013	Apr NEWA
AB			5MG	A202078	002	May 14, 2013	Apr NEWA
AB		GLENMARK GENERICS	2.5MG	A201779	001	May 14, 2013	Apr NEWA
AB			5MG	A201779	002	May 14, 2013	Apr NEWA
AB		MYLAN PHARMS INC	2.5MG	A203186	001	May 14, 2013	Apr NEWA
AB			5MG	A203186	002	May 14, 2013	Apr NEWA
		ZOMIG					
AB		IPR	2.5MG	N020768	001	Nov 25, 1997	Apr CFTG
AB	+		5MG	N020768	002	Nov 25, 1997	Apr CFTG

TABLET, ORALLY DISINTEGRATING;ORAL
ZOLMITRIPTAN

ZOLMITRIPTAN

TABLET, ORALLY DISINTEGRATING;ORAL
ZOLMITRIPTAN

AB	APOTEX INC	2.5MG	A202476	001	May 14, 2013	Apr	NEWA
AB		5MG	A202476	002	May 14, 2013	Apr	NEWA
AB	GLENMARK GENERICS	2.5MG	A202560	001	May 14, 2013	Apr	NEWA
AB		5MG	A202560	002	May 14, 2013	Apr	NEWA
AB	ZYDUS PHARMS USA INC	2.5MG	A202890	001	May 15, 2013	Apr	NEWA
AB		5MG	A202890	002	May 15, 2013	Apr	NEWA
	ZOMIG-ZMT						
AB	ASTRAZENECA	2.5MG	N021231	001	Feb 13, 2001	Apr	CFTG
AB	+	5MG	N021231	002	Sep 17, 2001	Apr	CFTG

ZOLPIDEM TARTRATE

TABLET;ORAL
ZOLPIDEM TARTRATE

	@ DR REDDYS LABS LTD	5MG	A077985	001	Apr 23, 2007	Apr	DISC
	@	10MG	A077985	002	Apr 23, 2007	Apr	DISC
	TABLET, EXTENDED RELEASE;ORAL ZOLPIDEM TARTRATE						
AB	ACTAVIS ELIZABETH	6.25MG	A078179	002	Oct 13, 2010	Apr	CAHN
AB		12.5MG	A078179	001	Jun 06, 2011	Apr	CAHN
AB	APOTEX INC	6.25MG	A200266	001	Sep 10, 2013	Aug	NEWA
AB		12.5MG	A200266	002	Sep 10, 2013	Aug	NEWA
AB	LUPIN LTD	6.25MG	A078970	001	Sep 11, 2013	Aug	NEWA
AB		12.5MG	A078970	002	Sep 11, 2013	Aug	NEWA
AB	WATSON LABS INC FL	6.25MG	A090153	001	Mar 25, 2013	Mar	NEWA
AB		12.5MG	A090153	002	Mar 25, 2013	Mar	NEWA

ZONISAMIDE

CAPSULE;ORAL
ZONISAMIDE

@	COREPHARMA	25MG	A077876	001	Feb 21, 2007	Feb	DISC
@		50MG	A077876	002	Feb 21, 2007	Feb	DISC
@		100MG	A077876	003	Feb 21, 2007	Feb	DISC
@	DR REDDYS LABS LTD	25MG	A077645	002	Sep 29, 2006	Mar	DISC
@		50MG	A077645	003	Sep 29, 2006	Mar	DISC
@		100MG	A077645	001	Dec 22, 2005	Mar	DISC

ACETAMINOPHEN

TABLET, EXTENDED RELEASE;ORAL
TYLENOL

+	MCNEIL CONS	650MG	N019872	001	Jun 08, 1994	Jul CTNA
+		650MG	N019872	002	Jan 11, 2001	Jul CTNA

ASPIRIN

CAPSULE;ORAL
ASPIRIN

+	PLX PHARMA	325MG	N203697	001	Jan 14, 2013	Jan NEWA
---	------------	-------	---------	-----	--------------	----------

CETIRIZINE HYDROCHLORIDE

SYRUP;ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

@	APOTEX INC	5MG/5ML	A090188	002	Apr 22, 2008	Apr DISC
	BIO PHARM INC	5MG/5ML	A090474	002	Mar 30, 2009	May CAHN
	CARACO	5MG/5ML	A091327	001	Oct 17, 2011	May CAHN
	PERRIGO R AND D	5MG/5ML	A204226	001	Sep 09, 2013	Aug NEWA

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

@	APOTEX INC	5MG/5ML	A090188	001	Apr 22, 2008	Apr DISC
	BIO PHARM INC	5MG/5ML	A090474	001	Mar 30, 2009	May CAHN
	CARACO	5MG/5ML	A091327	002	Oct 17, 2011	May CAHN

TABLET;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

	CIPLA LTD	5MG	A077318	001	Jul 25, 2013	Jul NEWA
		10MG	A077318	002	Jul 25, 2013	Jul NEWA
>D>	CONTRACT PHARMA	5MG	A076047	001	Dec 27, 2007	Oct CAHN
>D>		10MG	A076047	002	Dec 27, 2007	Oct CAHN
>A>	CONTRACT PHARMACAL	5MG	A076047	001	Dec 27, 2007	Oct CAHN
>A>		10MG	A076047	002	Dec 27, 2007	Oct CAHN

TABLET, CHEWABLE;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

+	SANDOZ	10MG	A078692	002	Feb 14, 2008	Apr CRLD
---	--------	------	---------	-----	--------------	----------

CHILDREN'S ZYRTEC ALLERGY

@	MCNEIL CONS	5MG	N021621	003	Nov 16, 2007	Apr DISC
+		5MG	N021621	003	Nov 16, 2007	Feb CRLD
@		10MG	N021621	004	Nov 16, 2007	Feb DISC

CHILDREN'S ZYRTEC HIVES RELIEF

@	MCNEIL CONS	5MG	N021621	005	Nov 16, 2007	Apr DISC
+		5MG	N021621	005	Nov 16, 2007	Feb CRLD
@		10MG	N021621	006	Nov 16, 2007	Feb DISC

CHLORHEXIDINE GLUCONATE

SOLUTION;TOPICAL
DYNA-HEX

	BAJAJ MEDICAL LLC	0.75%	N020111	001	Sep 11, 1997	Apr CAHN
--	-------------------	-------	---------	-----	--------------	----------

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SWAB;TOPICAL

PREVANTICS MAXI SWABSTICK

+	PROF DSPLS	3.15%;70% (5.1ML)	N021524	003	Jun 03, 2005	Mar CTNA
---	------------	-------------------	---------	-----	--------------	----------

PREVANTICS SWAB

+	PROF DSPLS	3.15%;70% (1ML)	N021524	001	Jun 03, 2005	Mar CTNA
---	------------	-----------------	---------	-----	--------------	----------

PREVANTICS SWABSTICK

+	PROF DSPLS	3.15%;70% (1.6ML)	N021524	002	Jun 03, 2005	Mar CTNA
---	------------	-------------------	---------	-----	--------------	----------

CIMETIDINE

TABLET;ORAL

TAGAMET HB

@	MEDTECH PRODS	100MG	N020238	001	Jun 19, 1995	Aug CAHN
+		200MG	N020238	002	Aug 21, 1996	Aug CAHN

CLOTTRIMAZOLE

CREAM;VAGINAL

MYCELEX-7

	BAYER	1%	N018230	002	Dec 26, 1991	Sep CAHN
--	-------	----	---------	-----	--------------	----------

CREAM, TABLET;TOPICAL, VAGINAL

MYCELEX-7 COMBINATION PACK

	BAYER	1%,100MG	N020389	002	Jun 23, 1994	Sep CAHN
--	-------	----------	---------	-----	--------------	----------

CLOTRIMAZOLETABLET;VAGINAL
MYCELEX-7

BAYER

100MG

N018182 002 Dec 26, 1991 Sep CAHN

DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATETABLET, EXTENDED RELEASE;ORAL
DEXBROMPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE SULFATE

AVANTHI INC

6MG;120MG

A078648 001 Feb 27, 2013 Feb NEWA

FAMOTIDINETABLET;ORAL
PEPCID AC

MCNEIL CONS

10MG

N020902 001 Aug 05, 1999 Jul CTNA

FEXOFENADINE HYDROCHLORIDETABLET, ORALLY DISINTEGRATING;ORAL
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

DR REDDYS LABS LTD 30MG

A202978 001 Jan 18, 2013 Jan NEWA

CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES

DR REDDYS LABS LTD 30MG

A202978 002 Jan 18, 2013 Jan NEWA

KETOTIFEN FUMARATESOLUTION/DROPS;OPHTHALMIC
KETOTIFEN FUMARATE

@ APOTEX INC

EQ 0.025% BASE

A077354 001 May 09, 2006 Apr DISC

LEVONORGESTRELTABLET;ORAL
LEVONORGESTREL

LUPIN LTD 0.75MG

A091328 001 Jan 23, 2013 Jan NEWA

NOVEL LABS INC 1.5MG

A202508 001 Feb 22, 2013 Feb NEWA

LORATADINESYRUP;ORAL
LORATADINE

@ APOTEX INC

1MG/ML

A075565 001 Oct 05, 2004 Apr DISC

LORATADINE; PSEUDOEPHEDRINE SULFATETABLET, EXTENDED RELEASE;ORAL
LORATADINE AND PSEUDOEPHEDRINE SULFATE

@ WATSON LABS INC FL 5MG;120MG

A076208 001 Jan 28, 2004 Feb DISC

MICONAZOLE NITRATECREAM;VAGINAL
MICONAZOLE NITRATE

APHENA PHARMA MD 2%

A074366 001 Feb 22, 1996 Jan CAHN

G AND W LABS INC 2%

A074366 001 Feb 22, 1996 Sep CAHN

MINOXIDILSOLUTION;TOPICAL
MINOXIDIL (FOR MEN)

@ APOTEX INC 2%

A074924 001 Apr 29, 1998 Apr DISC

MINOXIDIL (FOR WOMEN)

@ APOTEX INC 2%

A074924 002 Apr 29, 1998 Apr DISC

MINOXIDIL EXTRA STRENGTH (FOR MEN)

@ APOTEX INC 5%

A075839 001 Oct 01, 2001 Apr DISC

NAPHAZOLINE HYDROCHLORIDE; PHENIRAMINE MALEATESOLUTION/DROPS;OPHTHALMIC
NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE

AKORN INC 0.025%;0.3%

A202795 001 Jan 24, 2013 Jan NEWA

OMEPRazole; SODIUM BICARBONATEFOR SUSPENSION;ORAL
ZEGERID OTC

+ MSD CONSUMER 20MG/PACKET;1.68GM/PACKET

N022283 001 Jun 17, 2013 Jun NEWA

OXYBUTYNIN

FILM, EXTENDED RELEASE;TRANSDERMAL

OXYBUTYNINFILM, EXTENDED RELEASE;TRANSDERMAL
OXYTROL FOR WOMEN

+ MSD CONSUMER 3.9MG/24HR N202211 001 Jan 25, 2013 Jan NEWA

PIPERONYL BUTOXIDE; PYRETHRINSAEROSOL;TOPICAL
RID MOUSSE

+ BAYER 4%;EQ 0.33% BASE N021043 001 Mar 07, 2000 Sep CAHN

POLYETHYLENE GLYCOL 3350FOR SOLUTION;ORAL
POLYETHYLENE GLYCOL 3350
PAR PHARM

17GM/SCOOPFUL

A079214 001 Jan 31, 2013 Jan NEWA

RANITIDINE HYDROCHLORIDETABLET;ORAL
RANITIDINE HYDROCHLORIDE
@ WATSON LABS

EQ 75MG BASE

A075212 001 Jan 14, 2000 Mar DISC

>A> TRIAMCINOLONE ACETONIDE>A> SPRAY, METERED;NASAL
>A> NASACORT ALLERGY 24 HOUR

>A> SANOFI AVENTIS US 0.055MG/SPRAY

N020468 002 Oct 11, 2013 Oct NEWA

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 10 OCTOBER 2013

NO OCTOBER 2013 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:

<http://www.fda.gov/orphan/designat/list.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO OCTOBER 2013 ADDITIONS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ACETYLCYSTEINE - ACETADOTE</u>						
N 021539 001	8399445	Aug 24, 2025	U-1373			
<u>ACYCLOVIR - SITAVIG</u>						
N 203791 001					NP	Apr 12, 2016
<u>ADAPALENE - DIFFERIN</u>						
N 022502 001	8435502	Sep 15, 2026	DP U-1078			
<u>ADAPALENE; BENZOYL PEROXIDE - EPIDUO</u>						
N 022320 001	8445543	Jul 12, 2027	U-1078		NPP	Feb 01, 2016
<u>ADEFOVIR DIPIVOXIL - ADEFOVIR DIPIVOXIL</u>						
A 202051 001					PC	Mar 02, 2014
<u>AFATINIB DIMALEATE - GILOTTRIF</u>						
N 201292 001	6251912	Jul 29, 2018	DS DP U-1067		NCE	Jul 12, 2018
	8426586	Oct 10, 2029	DS DP		ODE	Jul 12, 2020
	>A> 8545884	Dec 19, 2029	DP			
	RE43431	Jan 22, 2022	DS DP			
<u>AFATINIB DIMALEATE - GILOTTRIF</u>						
N 201292 002	6251912	Jul 29, 2018	DS DP U-1067		NCE	Jul 12, 2018
	8426586	Oct 10, 2029	DS DP		ODE	Jul 12, 2020
	>A> 8545884	Dec 19, 2029	DP			
	RE43431	Jan 22, 2022	DS DP			
<u>AFATINIB DIMALEATE - GILOTTRIF</u>						
N 201292 003	6251912	Jul 29, 2018	DS DP U-1067		NCE	Jul 12, 2018
	8426586	Oct 10, 2029	DS DP		ODE	Jul 12, 2020
	>A> 8545884	Dec 19, 2029	DP			
	RE43431	Jan 22, 2022	DS DP			
<u>ALCAFTADINE - LASTACFT</u>						
N 022134 001	5468743	Apr 20, 2016	DS DP			
<u>ALISKIREN HEMIFUMARATE; VALSARTAN - VALTURNA</u>						
N 022217 001	8168616	Jul 03, 2026	DP			
<u>ALISKIREN HEMIFUMARATE; VALSARTAN - VALTURNA</u>						
N 022217 002	8168616	Jul 03, 2026	DP			
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 001	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6211205	Jun 19, 2016	U-1331			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 002	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6211205	Jun 19, 2016	U-1331			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 003	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6211205	Jun 19, 2016	U-1331			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
<u>ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO</u>						
N 203414 001	5965584	Jun 19, 2016	U-1339		NC	Jan 25, 2016
	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
<u>ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO</u>						
N 203414 002	5965584	Jun 19, 2016	U-1339		NC	Jan 25, 2016
	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 001	5965584	Jun 19, 2016	DP U-1339		NC	Jan 25, 2016
	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6271243	Jun 19, 2016	U-1344			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 002	5965584	Jun 19, 2016	DP U-1339		NC	Jan 25, 2016
	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6271243	Jun 19, 2016	U-1344			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 003	5965584	Jun 19, 2016	DP U-1339		NC	Jan 25, 2016
	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6271243	Jun 19, 2016	U-1344			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 004	5965584	Jun 19, 2016	DP U-1339		NC	Jan 25, 2016
	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6271243	Jun 19, 2016	U-1344			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 005	5965584	Jun 19, 2016	DP U-1339		NC	Jan 25, 2016
	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6271243	Jun 19, 2016	U-1344			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 006	5965584	Jun 19, 2016	DP U-1339		NC	Jan 25, 2016
	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6271243	Jun 19, 2016	U-1344			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
<u>ALVIMOPAN - ENTEREG</u>						
N 021775 001 >A>	8112290	Jul 31, 2030	DP U-1443		>A> M-128	Oct 18, 2016
<u>AMBRISANTAN - LETAIRIS</u>						
N 022081 001	8349843	Oct 07, 2015	DS DP			
<u>AMBRISANTAN - LETAIRIS</u>						
N 022081 002	8349843	Oct 07, 2015	DS DP			
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N 022314 001	8475839	May 16, 2023	DP			
	8475839*PED	Nov 16, 2023				
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N 022314 002	8475839	May 16, 2023	DP			
	8475839*PED	Nov 16, 2023				
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N 022314 003	8475839	May 16, 2023	DP			
	8475839*PED	Nov 16, 2023				
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N 022314 004	8475839	May 16, 2023	DP			
	8475839*PED	Nov 16, 2023				
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N 022314 005	8475839	May 16, 2023	DP			
	8475839*PED	Nov 16, 2023				
<u>AMOXICILLIN - MOXATAG</u>						
N 050813 001	8357394	Dec 08, 2026	DP			
<u>APIXABAN - ELIQUIS</u>						
N 202155 001	6413980	Dec 22, 2019	DS DP U-1200			
	6967208	Feb 03, 2023	DS DP U-1200			
	6967208	Feb 03, 2023	DS DP U-1323			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>APIXABAN - ELIQUIS</u>						
N 202155 002	6413980	Dec 22, 2019	DS DP U-1200			
	6967208	Feb 03, 2023	DS DP U-1200			
	6967208	Feb 03, 2023	DS DP U-1323			
<u>ARFORMOTEROL TARTRATE - BROVANA</u>						
N 021912 001	6589508	Apr 03, 2014	U-793			
	7348362	Jun 22, 2021	DP U-793			
	7462645	Jun 22, 2021	U-793			
	7465756	Jun 22, 2021	DP			
	7473710	Jun 22, 2021	U-793			
	7541385	Jun 22, 2021	U-793			
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 001	5006528	Apr 20, 2015	DS DP U-543		NDF	Feb 28, 2016
	7807680	Oct 19, 2024	DP			
	8030313	Oct 19, 2024	U-543			
	8338427	Mar 15, 2025	DP U-543			
	8338428	Aug 06, 2023	DP U-543			
	8399469	Dec 29, 2023	DS			
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 002	5006528	Apr 20, 2015	DS DP U-543		NDF	Feb 28, 2016
	7807680	Oct 19, 2024	DP			
	8030313	Oct 19, 2024	U-543			
	8338427	Mar 15, 2025	DP U-543			
	8338428	Aug 06, 2023	DP U-543			
	8399469	Dec 29, 2023	DS			
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 001	5763476	Jun 09, 2020	DP U-326			
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 002	5763476	Jun 09, 2020	DP U-326			
<u>ATORVASTATIN CALCIUM; EZETIMIBE - LIPTRUZET</u>						
N 200153 001	5846966	Sep 21, 2013	DP U-1400		NC	May 03, 2016
	5846966*PED	Mar 21, 2014				
	RE42461	Oct 25, 2016	DS DP U-1400			
	RE42461*PED	Apr 25, 2017				
<u>ATORVASTATIN CALCIUM; EZETIMIBE - LIPTRUZET</u>						
N 200153 002	5846966	Sep 21, 2013	DP U-1400		NC	May 03, 2016
	5846966*PED	Mar 21, 2014				
	RE42461	Oct 25, 2016	DS DP U-1400			
	RE42461*PED	Apr 25, 2017				
<u>ATORVASTATIN CALCIUM; EZETIMIBE - LIPTRUZET</u>						
N 200153 003	5846966	Sep 21, 2013	DP U-1400		NC	May 03, 2016
	5846966*PED	Mar 21, 2014				
	RE42461	Oct 25, 2016	DS DP U-1400			
	RE42461*PED	Apr 25, 2017				
<u>ATORVASTATIN CALCIUM; EZETIMIBE - LIPTRUZET</u>						
N 200153 004	5846966	Sep 21, 2013	DP U-1400		NC	May 03, 2016
	5846966*PED	Mar 21, 2014				
	RE42461	Oct 25, 2016	DS DP U-1400			
	RE42461*PED	Apr 25, 2017				
<u>AZELASTINE HYDROCHLORIDE - ASTEPRO</u>						
N 022203 001	8518919	Nov 22, 2025	U-1430		M-129 NPP	Aug 30, 2016 Aug 30, 2016
<u>AZELASTINE HYDROCHLORIDE - ASTEPRO</u>						
N 022371 001	8518919	Nov 22, 2025	U-1430			
<u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR</u>						
N 202331 002					NC NCE	Dec 20, 2014 Feb 25, 2016
<u>AZTREONAM - CAYSTON</u>						
N 050814 001	8399496	Dec 20, 2021	DP U-1377			
<u>BALSALAZIDE DISODIUM - GIAZO</u>						
N 022205 001	8497256	Jun 23, 2031	U-1229			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED - DUAVEE</u>						
N 022247 001	>A> 5998402	Apr 04, 2017	DS DP U-594			
	>A> 6479535	May 06, 2019	DP U-594			
	>A> 6479535	May 06, 2019	DP U-904			
	>A> 7138392	Apr 04, 2017	DS DP U-594			
	>A> 7683051	Mar 10, 2027	DS DP U-594			
	>A> 7683051	Mar 10, 2027	DS DP U-904			
<u>BEDAQUILINE FUMARATE - SIRTURO</u>						
N 204384 001	7498343	Oct 02, 2024	DS DP U-1321		ODE	Dec 28, 2019
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249 001	8436190	Oct 26, 2030	DP			
	8436190*PED	Apr 26, 2031				
	8445524	Mar 26, 2029	DS DP U-1402			
	8445524*PED	Sep 26, 2029				
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249 002	8436190	Oct 26, 2030	DP			
	8436190*PED	Apr 26, 2031				
	8445524	Mar 26, 2029	DS DP U-1402			
	8445524*PED	Sep 26, 2029				
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249 003	8344006	Sep 23, 2029	DP U-1402		ODE	Mar 20, 2015
	8344006*PED	Mar 23, 2030			PED	Sep 20, 2015
	8445524	Mar 26, 2029	DS			
	8445524*PED	Sep 26, 2029				
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249 004	8344006	Sep 23, 2029	DP U-1402		ODE	Mar 20, 2015
	8344006*PED	Mar 23, 2030			PED	Sep 20, 2015
	8445524	Mar 26, 2029	DS			
	8445524*PED	Sep 26, 2029				
<u>BEPOTASTINE BESILATE - BEPREVE</u>						
N 022288 001	6780877	Sep 19, 2019	DS DP			
<u>BESIFLOXACIN HYDROCHLORIDE - BESIVANCE</u>						
N 022308 001	8415342	Nov 07, 2030	U-80			
	8481526	Jan 09, 2031	DS			
<u>BIMATOPROST - LUMIGAN</u>						
N 022184 001	8524777	Mar 16, 2025	U-1235			
<u>BIMATOPROST - LATISSE</u>						
N 022369 001	>A> 8541466	Jan 21, 2022	U-1217			
<u>BOCEPREVIR - VICTRELIS</u>						
N 202258 001					M-126 NPP	Feb 27, 2016 Feb 13, 2016
<u>BRIMONIDINE TARTRATE - MIRVASO</u>						
N 204708 001	7439241	Aug 25, 2025	U-1428		NDF	Aug 23, 2016
	8053427	Jun 13, 2031	DP U-1428			
	8163725	Jun 13, 2031	DP			
	8231885	May 24, 2025	DP			
	8410102	May 24, 2025	U-1428			
	8426410	May 24, 2025	U-1428			
	8513247	Mar 25, 2031	DP U-1428			
	8513249	Mar 25, 2031	DP U-1428			
<u>BRIMONIDINE TARTRATE; BRINZOLAMIDE - SIMBRINZA</u>						
N 204251 001	6316441	Dec 07, 2019	U-778		NC	Apr 19, 2016
<u>BRIMONIDINE TARTRATE; TIMOLOL MALEATE - COMBIGAN</u>						
N 021398 001	7323463	Jan 19, 2023	DP	Y		
	8354409	Apr 19, 2022	DP U-1371			
<u>BROMFENAC SODIUM - PROLENSA</u>						
N 203168 001	8129431	Sep 11, 2025	DS DP		NP	Apr 05, 2016

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BROMOCRIPTINE MESYLATE - CYCLOSET</u>						
N 020866 001	7888310	Jul 25, 2023	U-1433			
	8137992	Jul 25, 2023	U-1433			
	8137993	Jul 25, 2023	U-1433			
	8137994	Jul 25, 2023	U-1433			
	8431155	Apr 30, 2032	DP U-976			
<u>BUDESONIDE - UCERIS</u>						
N 203634 001	7410651	Jun 09, 2020	DP U-1325		NDF	Jan 14, 2016
	7431943	Jun 09, 2020	DP			
	8293273	Jun 09, 2020	DP			
	RE43799	Jun 09, 2020	DP U-1325			
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929 001	8387615	Nov 10, 2024	DP			
	8528545	Oct 16, 2028	DP			
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929 002	8387615	Nov 10, 2024	DP			
	8461211	Sep 09, 2018	U-1118			
	8528545	Oct 16, 2028	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 001	8475832	Mar 26, 2030	DP U-1411			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 002	8475832	Mar 26, 2030	DP U-1411			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 003	8475832	Mar 26, 2030	DP U-1411			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 004	8475832	Mar 26, 2030	DP U-1411			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 001	8454996	Sep 24, 2019	U-1421			
	8470361	Oct 14, 2029	DP U-1425			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 002	8454996	Sep 24, 2019	U-1421			
	8470361	Oct 14, 2029	DP U-1425			
<u>CABOZANTINIB S-MALATE - COMETRIO</u>						
N 203756 001					ODE	Nov 29, 2019
<u>CABOZANTINIB S-MALATE - COMETRIO</u>						
N 203756 002					ODE	Nov 29, 2019
<u>CALCITONIN SALMON RECOMBINANT - FORTICAL</u>						
N 021406 001	RE43580	Feb 02, 2021	DP U-227			
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042 001	7943582	Feb 26, 2029	DS DP U-493		NCE	Mar 29, 2018
	7943788	Jul 14, 2027	DS DP			
	8222219	Jul 30, 2024	U-493			
	8513202	Dec 03, 2027	DS DP U-493			
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042 002	7943582	Feb 26, 2029	DS DP U-493		NCE	Mar 29, 2018
	7943788	Jul 14, 2027	DS DP			
	8222219	Jul 30, 2024	U-493			
	8513202	Dec 03, 2027	DS DP U-493			
<u>CANDESARTAN CILEXETIL - CANDESARTAN CILEXETIL</u>						
A 078702 001					PC	Jul 09, 2013
<u>CANDESARTAN CILEXETIL - CANDESARTAN CILEXETIL</u>						
A 078702 002					PC	Jul 09, 2013
<u>CANDESARTAN CILEXETIL - CANDESARTAN CILEXETIL</u>						
A 078702 003					PC	Jul 09, 2013
<u>CANDESARTAN CILEXETIL - CANDESARTAN CILEXETIL</u>						
A 078702 004					PC	Jul 09, 2013
<u>CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE - CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE</u>						
A 090704 003					PC	Jun 02, 2013

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CAPECITABINE - XELODA</u>						
N 020896 001	5472949	Dec 14, 2013	U-271			
	5472949*PED	Jun 14, 2014				
<u>CAPECITABINE - XELODA</u>						
N 020896 002	5472949	Dec 14, 2013	U-271			
	5472949*PED	Jun 14, 2014				
<u>CARBINOXAMINE MALEATE - KARBINAL ER</u>						
N 022556 001	8062667	Mar 29, 2029	DP			
<u>CELECOXIB - CELEBREX</u>						
N 020998 001	RE44048	Jun 02, 2015	U-247			
	RE44048	Jun 02, 2015	U-1348			
	RE44048	Jun 02, 2015	U-1349			
	RE44048	Jun 02, 2015	U-1350			
	RE44048	Jun 02, 2015	U-1351			
	RE44048	Jun 02, 2015	U-1352			
	RE44048*PED	Dec 02, 2015				
<u>CELECOXIB - CELEBREX</u>						
N 020998 002	RE44048	Jun 02, 2015	U-247			
	RE44048	Jun 02, 2015	U-1348			
	RE44048	Jun 02, 2015	U-1349			
	RE44048	Jun 02, 2015	U-1350			
	RE44048	Jun 02, 2015	U-1351			
	RE44048	Jun 02, 2015	U-1352			
	RE44048*PED	Dec 02, 2015				
<u>CELECOXIB - CELEBREX</u>						
N 020998 003	RE44048	Jun 02, 2015	U-247			
	RE44048	Jun 02, 2015	U-1348			
	RE44048	Jun 02, 2015	U-1349			
	RE44048	Jun 02, 2015	U-1350			
	RE44048	Jun 02, 2015	U-1351			
	RE44048	Jun 02, 2015	U-1352			
	RE44048*PED	Dec 02, 2015				
<u>CELECOXIB - CELEBREX</u>						
N 020998 004	RE44048	Jun 02, 2015	U-247			
	RE44048	Jun 02, 2015	U-1348			
	RE44048	Jun 02, 2015	U-1349			
	RE44048	Jun 02, 2015	U-1350			
	RE44048	Jun 02, 2015	U-1351			
	RE44048	Jun 02, 2015	U-1352			
	RE44048*PED	Dec 02, 2015				
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP WITH TINT</u>						
N 020832 002	7422388	Apr 25, 2027	DP U-1397			
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP WITH TINT</u>						
N 020832 005	7422388	Apr 25, 2027	DP U-1397			
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP WITH TINT</u>						
N 020832 007	7422388	Apr 25, 2027	DP U-1397			
<u>CICLESONIDE - ALVESCO</u>						
N 021658 002	8371292	Aug 25, 2027	U-1355		M-125	Dec 17, 2015
<u>CICLESONIDE - ALVESCO</u>						
N 021658 003	8371292	Aug 25, 2027	U-1355		M-125	Dec 17, 2015
<u>CICLESONIDE - OMNARIS</u>						
N 022004 001	8371292	Aug 25, 2027	U-1356			
	8383611	Oct 20, 2020	DP			
<u>CICLESONIDE - ZETONNA</u>						
N 202129 001	8371292	Aug 25, 2027	U-1357			
<u>CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE - CIPRO XR</u>						
N 021473 001	8187632	Jun 23, 2021	DP			
	8187632*PED	Dec 23, 2021				
<u>CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE - CIPRO XR</u>						
N 021473 002	8187632	Jun 23, 2021	DP			
	8187632*PED	Dec 23, 2021				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE - PREPOPIK</u>						
N 202535 001	8450338	Oct 10, 2028	DP			
	8481083	Oct 10, 2028	DP			
<u>CLOBAZAM - ONFI</u>						
N 203993 001					ODE	Oct 21, 2018
<u>CLOBETASOL PROPIONATE - CLOBETASOL PROPIONATE</u>						
A 201402 001					PC	Jul 31, 2013
<u>CLOBETASOL PROPIONATE - OLUX E</u>						
N 022013 001	8460641	Nov 05, 2028	DP U-1410			
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - STRIBILD</u>						
N 203100 001	7635704	Oct 26, 2026	DS DP U-257			
<u>COLCHICINE - COLCRYS</u>						
N 022352 001	8415395	Oct 06, 2028	U-1007			
	8415396	Oct 06, 2028	U-1007			
	8440721	Feb 17, 2029	U-1007			
	8440722	Feb 17, 2029	U-1020			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 001	8026284	Sep 22, 2027	U-1399		NDF	Apr 30, 2016
	8129433	Jan 26, 2027	DP			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 002	8026284	Sep 22, 2027	U-1399		NDF	Apr 30, 2016
	8129433	Jan 26, 2027	DP			
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 001	7994185	Jan 20, 2030	DS DP U-1406		NCE	May 29, 2018
	8415345	Jan 20, 2030	DS DP U-1406		ODE	May 29, 2020
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 002	7994185	Jan 20, 2030	DS DP U-1406		NCE	May 29, 2018
	8415345	Jan 20, 2030	DS DP U-1406		ODE	May 29, 2020
<u>DALFAMPRIDINE - AMPYRA</u>						
N 022250 001	5540938	Jul 30, 2018	U-1030			
	8354437	Dec 22, 2026	U-1030			
	8440703	Apr 08, 2025	U-1030			
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 001	8518987	Feb 16, 2024	DS DP		D-135	Feb 01, 2016
	8518987*PED	Aug 16, 2024			PED	Aug 01, 2016
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 002	8518987	Feb 16, 2024	DS DP		D-135	Feb 01, 2016
	8518987*PED	Aug 16, 2024			PED	Aug 01, 2016
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 003	8518987	Feb 16, 2024	DS DP		D-135	Feb 01, 2016
	8518987*PED	Aug 16, 2024			PED	Aug 01, 2016
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 004	8518987	Feb 16, 2024	DS DP		D-135	Feb 01, 2016
	8518987*PED	Aug 16, 2024			PED	Aug 01, 2016
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 005	8518987	Feb 16, 2024	DS DP		D-135	Feb 01, 2016
	8518987*PED	Aug 16, 2024			PED	Aug 01, 2016
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 006	8518987	Feb 16, 2024	DS DP		D-135	Feb 01, 2016
	8518987*PED	Aug 16, 2024			PED	Aug 01, 2016
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 202895 001	8518987	Feb 16, 2024	DS DP		D-135	Feb 01, 2016
	8518987*PED	Aug 16, 2024			PED	Aug 01, 2016
<u>DEFERASIROX - EXJADE</u>						
N 021882 001					I-665	Jan 23, 2016
<u>DEFERASIROX - EXJADE</u>						
N 021882 002					I-665	Jan 23, 2016
<u>DEFERASIROX - EXJADE</u>						
N 021882 003					I-665	Jan 23, 2016

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DESONIDE - VERDESO</u>						
N 021978 001	8460641	Nov 05, 2028	DP U-1412			
<u>DESOXIMETASONE - TOPICORT</u>						
N 204141 001	5990100	Mar 24, 2018	DP U-1408		NDF	Apr 11, 2016
	8277780	Apr 23, 2028	DP U-1408			
<u>DESVENLAFAXINE SUCCINATE - PRISTIQ</u>						
N 021992 001	6673838	Feb 11, 2022	DS DP U-860		I-675	Feb 14, 2016
	6673838	Feb 11, 2022	DS DP U-1364			
<u>DESVENLAFAXINE SUCCINATE - PRISTIQ</u>						
N 021992 002	6673838	Feb 11, 2022	DS DP U-860		I-675	Feb 14, 2016
	6673838	Feb 11, 2022	DS DP U-1364			
<u>DEXAMETHASONE - OZURDEX</u>						
N 022315 001	8506987	Jan 09, 2023	U-1204			
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N 022287 001	8461187	Jan 17, 2026	DP			
	8461187*PED	Jul 17, 2026				
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N 022287 002	8461187	Jan 17, 2026	DP			
	8461187*PED	Jul 17, 2026				
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 001	4910214	Jul 15, 2013	DS DP U-421			
	4910214*PED	Jan 15, 2014				
	6716867	Mar 31, 2019	U-572			
	6716867*PED	Oct 01, 2019				
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 002	4910214	Jul 15, 2013	DS DP U-421			
	4910214*PED	Jan 15, 2014				
	6716867	Mar 31, 2019	U-572			
	6716867*PED	Oct 01, 2019				
	8242158	Jan 04, 2032	DP			
	8242158*PED	Jul 04, 2032				
	8338470	Jan 04, 2032	DP			
	8338470*PED	Jul 04, 2032				
	8455527	Jan 04, 2032	U-421			
	8455527*PED	Jul 04, 2032				
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 003	4910214	Jul 15, 2013	DS DP U-421			
	4910214*PED	Jan 15, 2014				
	6716867	Mar 31, 2019	U-572			
	6716867*PED	Oct 01, 2019				
	8242158	Jan 04, 2032	DP			
	8242158*PED	Jul 04, 2032				
	8338470	Jan 04, 2032	DP			
	8338470*PED	Jul 04, 2032				
	8455527	Jan 04, 2032	U-421			
	8455527*PED	Jul 04, 2032				
<u>DICLOFENAC - ZORVOLEX</u>						
N 204592 001					>A> NP	Oct 18, 2016
<u>DICLOFENAC - ZORVOLEX</u>						
N 204592 002					>A> NP	Oct 18, 2016
<u>DICLOFENAC SODIUM - PENNSAID</u>						
N 020947 001	8546450	Aug 09, 2030	U-1435			
	8546450	Aug 09, 2030	U-1436			
<u>DIFLUPREDNATE - DUREZOL</u>						
N 022212 001	6114319	May 18, 2019	DP		I-653	Jun 13, 2015
	6114319*PED	Nov 18, 2019			M-127	Mar 22, 2016
					ODE	Jun 13, 2019
					PED	Dec 13, 2015
					PED	Dec 13, 2019
					PED	Sep 22, 2016

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DIMETHYL FUMARATE - TECFIDERA</u>						
N 204063 001	6509376	Oct 29, 2019	DP		NCE	Mar 27, 2018
	7320999	May 18, 2020	U-1384			
	7619001	Apr 01, 2018	U-1384			
	7803840	Apr 01, 2018	U-1385			
	8399514	Feb 07, 2028	U-1384			
	8524773	Apr 01, 2018	U-1384			
<u>DIMETHYL FUMARATE - TECFIDERA</u>						
N 204063 002	6509376	Oct 29, 2019	DP		NCE	Mar 27, 2018
	7320999	May 18, 2020	U-1384			
	7619001	Apr 01, 2018	U-1384			
	7803840	Apr 01, 2018	U-1385			
	8399514	Feb 07, 2028	U-1384			
	8524773	Apr 01, 2018	U-1384			
<u>DOLUTEGRAVIR SODIUM - TIVICAY</u>						
N 204790 001	8129385	Oct 05, 2027	DS DP		NCE	Aug 12, 2018
<u>DONEPEZIL HYDROCHLORIDE - DONEPEZIL HYDROCHLORIDE</u>						
A 202542 001					PC	Jan 22, 2014
<u>DONEPEZIL HYDROCHLORIDE - DONEPEZIL HYDROCHLORIDE</u>						
A 202723 001					PC	Jan 22, 2014
<u>DONEPEZIL HYDROCHLORIDE - ARICEPT</u>						
N 022568 001	8481565	Oct 04, 2026	DP			
<u>DOXEPIH HYDROCHLORIDE - SILENOR</u>						
N 022036 001	8513299	Apr 14, 2030	U-620			
<u>DOXEPIH HYDROCHLORIDE - SILENOR</u>						
N 022036 002	8513299	Apr 14, 2030	U-620			
<u>DOXYCYCLINE - ORACEA</u>						
N 050805 001	8394405	Apr 07, 2024	DP U-925			
	8394406	Apr 07, 2024	DP U-925			
	8470364	Apr 07, 2024	DP U-925			
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N 050795 004	6958161	Dec 15, 2022	DP U-918			
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N 050795 005	6958161	Dec 15, 2022	DP U-918		D-136 NS	Apr 11, 2016 Apr 11, 2016
<u>DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE - DICLEGIS</u>						
N 021876 001	6340695	Jun 21, 2021	DP U-1382		NP	Apr 08, 2016
	7560122	Jan 25, 2019	DP			
<u>DRONEDARONE HYDROCHLORIDE - MULTAQ</u>						
N 022425 001	5223510	Jul 26, 2016	DS DP U-992			
	5223510	Jul 26, 2016	DS DP U-1261			
	8410167	Apr 16, 2029	U-1387			
	8410167	Apr 16, 2029	U-1388			
<u>DROSPIRENONE; ETHINYL ESTRADIOL - YAZ</u>						
N 021676 001	RE43916	Jun 30, 2014	U-1326			
<u>DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM - BEYAZ</u>						
N 022532 001	RE43916	Jun 30, 2014	U-1326			
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N 021427 001					M-61 PED	Oct 18, 2015 Apr 18, 2016
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N 021427 002					M-61 PED	Oct 18, 2015 Apr 18, 2016
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N 021427 004					M-61 PED	Oct 18, 2015 Apr 18, 2016
<u>ECONAZOLE NITRATE - ECOZA</u>						
N 205175 001					>A> NDF	Oct 24, 2016

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EFAVIRENZ - SUSTIVA</u>						
N 020972 001	5519021	May 21, 2013	DS DP		NPP	May 02, 2016
	5519021*PED	Nov 21, 2013			PED	Nov 02, 2016
	5663169	Sep 02, 2014	U-257			
	5663169*PED	Mar 02, 2015				
	6238695	Apr 06, 2019	DP			
	6238695*PED	Oct 06, 2019				
	6555133	Apr 06, 2019	U-248			
	6555133*PED	Oct 06, 2019				
	6639071	Feb 14, 2018	DS			
	6639071*PED	Aug 14, 2018				
	6939964	Jan 20, 2018	DS			
	6939964*PED	Jul 20, 2018				
<u>EFAVIRENZ - SUSTIVA</u>						
N 020972 002	5519021	May 21, 2013	DS DP			
	5519021*PED	Nov 21, 2013				
	5663169	Sep 02, 2014	U-257			
	5663169*PED	Mar 02, 2015				
	6238695	Apr 06, 2019	DP			
	6238695*PED	Oct 06, 2019				
	6555133	Apr 06, 2019	U-248			
	6555133*PED	Oct 06, 2019				
	6639071	Feb 14, 2018	DS			
	6639071*PED	Aug 14, 2018				
	6939964	Jan 20, 2018	DS			
	6939964*PED	Jul 20, 2018				
<u>EFAVIRENZ - SUSTIVA</u>						
N 020972 003	5519021	May 21, 2013	DS DP		NPP	May 02, 2016
	5519021*PED	Nov 21, 2013			PED	Nov 02, 2016
	5663169	Sep 02, 2014	U-257			
	5663169*PED	Mar 02, 2015				
	6238695	Apr 06, 2019	DP			
	6238695*PED	Oct 06, 2019				
	6555133	Apr 06, 2019	U-248			
	6555133*PED	Oct 06, 2019				
	6639071	Feb 14, 2018	DS			
	6639071*PED	Aug 14, 2018				
	6939964	Jan 20, 2018	DS			
	6939964*PED	Jul 20, 2018				
<u>EFAVIRENZ - SUSTIVA</u>						
N 021360 001	5519021	May 21, 2013				
	5519021*PED	Nov 21, 2013				
	5663169	Sep 02, 2014				
	5663169*PED	Mar 02, 2015				
	6639071	Feb 14, 2018	DS			
	6639071*PED	Aug 14, 2018				
	6939964	Jan 20, 2018	DS			
	6939964*PED	Jul 20, 2018				
<u>EFAVIRENZ - SUSTIVA</u>						
N 021360 002	5519021	May 21, 2013	DS DP		NPP	May 02, 2016
	5519021*PED	Nov 21, 2013			PED	Nov 02, 2016
	5663169	Sep 02, 2014	U-248			
	5663169*PED	Mar 02, 2015				
	6639071	Feb 14, 2018	DS			
	6639071*PED	Aug 14, 2018				
	6939964	Jan 20, 2018	DS			
	6939964*PED	Jul 20, 2018				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - ATRIPLA</u>						
N 021937 001	5519021	May 21, 2013	DS DP			
	5519021*PED	Nov 21, 2013				
	5663169	Sep 02, 2014	U-750			
	5663169	Sep 02, 2014	U-1170			
	5663169*PED	Mar 02, 2015				
	6639071	Feb 14, 2018	DS			
	6639071*PED	Aug 14, 2018				
	6939964	Jan 20, 2018	DS			
	6939964*PED	Jul 20, 2018				
<u>ENALAPRIL MALEATE - EPANED KIT</u>						
N 204308 001 >A>	8568747	Nov 06, 2032	DP			
<u>EPINEPHRINE - AUVI-O</u>						
N 201739 001	7731686	Jun 01, 2026	DP			
	7731690	Jan 15, 2025	DP			
	7749194	Oct 30, 2028	DP			
	7918823	Nov 23, 2024	DP			
	7947017	Mar 12, 2028	DP			
	8016788	Mar 21, 2025	DP			
	8021344	Nov 02, 2029	DP			
	8206360	Feb 27, 2027	DP			
	8361029	Nov 23, 2024	DP			
	8425462	Nov 23, 2024	DP			
<u>EPINEPHRINE - AUVI-O</u>						
N 201739 002	7731686	Jun 01, 2026	DP			
	7731690	Jan 15, 2025	DP			
	7749194	Oct 30, 2028	DP			
	7918823	Nov 23, 2024	DP			
	7947017	Mar 12, 2028	DP			
	8016788	Mar 21, 2025	DP			
	8021344	Nov 02, 2029	DP			
	8206360	Feb 27, 2027	DP			
	8361029	Nov 23, 2024	DP			
	8425462	Nov 23, 2024	DP			
<u>EPOPROSTENOL SODIUM - VELETRI</u>						
N 022260 001	8318802	Mar 15, 2027	DP			
<u>EPOPROSTENOL SODIUM - VELETRI</u>						
N 022260 002	8318802	Mar 15, 2027	DP			
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743 001	6900221	Nov 09, 2020	DS DP U-659		I-671	May 14, 2016
	6900221	Nov 09, 2020	DS DP U-875			
	6900221	Nov 09, 2020	DS DP U-1046			
	6900221	Nov 09, 2020	DS DP U-1403			
	7087613	Nov 09, 2020	U-659			
	7087613	Nov 09, 2020	U-1045			
	7087613	Nov 09, 2020	U-1403			
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743 002	6900221	Nov 09, 2020	DS DP U-659		I-671	May 14, 2016
	6900221	Nov 09, 2020	DS DP U-875			
	6900221	Nov 09, 2020	DS DP U-1046			
	6900221	Nov 09, 2020	DS DP U-1403			
	7087613	Nov 09, 2020	U-659			
	7087613	Nov 09, 2020	U-1045			
	7087613	Nov 09, 2020	U-1403			
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743 003	6900221	Nov 09, 2020	DS DP U-659		I-671	May 14, 2016
	6900221	Nov 09, 2020	DS DP U-875			
	6900221	Nov 09, 2020	DS DP U-1046			
	6900221	Nov 09, 2020	DS DP U-1403			
	7087613	Nov 09, 2020	U-659			
	7087613	Nov 09, 2020	U-1045			
	7087613	Nov 09, 2020	U-1403			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N 021153 001	8466175	May 25, 2018	U-1417			
	8466175*PED	Nov 25, 2018				
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N 021153 002	8466175	May 25, 2018	U-1417			
	8466175*PED	Nov 25, 2018				
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N 021957 001	8466175	May 25, 2018	U-1417			
	8466175*PED	Nov 25, 2018				
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N 021957 002	8466175	May 25, 2018	U-1417			
	8466175*PED	Nov 25, 2018				
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N 022511 001 >A>	8557285	May 31, 2022	DP			
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N 022511 002 >A>	8557285	May 31, 2022	DP			
<u>ESTRADIOL - MINIVELLE</u>						
N 203752 001	5656286	Aug 12, 2014	DS DP			
	6024976	Jan 07, 2014	DS DP			
	8231906	Jul 04, 2030	DS DP			
<u>ESTRADIOL - MINIVELLE</u>						
N 203752 002	5656286	Aug 12, 2014	DS DP			
	6024976	Jan 07, 2014	DS DP			
	8231906	Jul 04, 2030	DS DP			
<u>ESTRADIOL - MINIVELLE</u>						
N 203752 003	5656286	Aug 12, 2014	DS DP			
	6024976	Jan 07, 2014	DS DP			
	8231906	Jul 04, 2030	DS DP			
<u>ESTRADIOL - MINIVELLE</u>						
N 203752 004	5656286	Aug 12, 2014	DS DP			
	6024976	Jan 07, 2014	DS DP			
	8231906	Jul 04, 2030	DS DP			
<u>ESZOPICLONE - LUNESTA</u>						
N 021476 001					M-61 PED	Oct 10, 2015 Apr 10, 2016
<u>ESZOPICLONE - LUNESTA</u>						
N 021476 002					M-61 PED	Oct 10, 2015 Apr 10, 2016
<u>ESZOPICLONE - LUNESTA</u>						
N 021476 003					M-61 PED	Oct 10, 2015 Apr 10, 2016
<u>ETHINYL ESTRADIOL; LEVONORGESTREL - QUARTETTE</u>						
N 204061 001	8415332	Mar 11, 2029	DP		NP	Mar 28, 2016
	8450299	Oct 07, 2025	U-1			
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - MINASTRIN 24 FE</u>						
N 203667 001	5552394	Jul 22, 2014	U-1		NDF	May 08, 2016
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE</u>						
N 204426 001	5552394	Jul 22, 2014	U-1			
	6652880	Mar 29, 2020	DP			
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - LO MINASTRIN FE</u>						
N 204654 001	5552394	Jul 22, 2014	U-1			
	6667050	Apr 06, 2019	DP U-1			
	7704984	Feb 02, 2029	U-1			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EVEROLIMUS - ZORTRESS</u>						
N 021560 001	5665772	Sep 09, 2019	DS DP U-1049		I-668	Feb 15, 2016
	5665772	Sep 09, 2019	DS DP U-1365			
	5665772*PED	Mar 09, 2020				
	6004973	Jul 12, 2016	DP U-1049			
	6004973	Jul 12, 2016	DP U-1365			
	6004973*PED	Jan 12, 2017				
	6440990	Sep 24, 2013	DP U-1049			
	6440990	Sep 24, 2013	DP U-1365			
	6440990*PED	Mar 24, 2014				
	6455518	Jul 29, 2017	U-1049			
	6455518	Jul 29, 2017	U-1365			
	6455518*PED	Jan 29, 2018				
<u>EVEROLIMUS - ZORTRESS</u>						
N 021560 002	5665772	Sep 09, 2019	DS DP U-1049		I-668	Feb 15, 2016
	5665772	Sep 09, 2019	DS DP U-1365			
	5665772*PED	Mar 09, 2020				
	6004973	Jul 12, 2016	DP U-1049			
	6004973	Jul 12, 2016	DP U-1365			
	6004973*PED	Jan 12, 2017				
	6440990	Sep 24, 2013	DP U-1049			
	6440990	Sep 24, 2013	DP U-1365			
	6440990*PED	Mar 24, 2014				
	6455518	Jul 29, 2017	U-1049			
	6455518	Jul 29, 2017	U-1365			
	6455518*PED	Jan 29, 2018				
<u>EVEROLIMUS - ZORTRESS</u>						
N 021560 003	5665772	Sep 09, 2019	DS DP U-1049		I-668	Feb 15, 2016
	5665772	Sep 09, 2019	DS DP U-1365			
	5665772*PED	Mar 09, 2020				
	6004973	Jul 12, 2016	DP U-1049			
	6004973	Jul 12, 2016	DP U-1365			
	6004973*PED	Jan 12, 2017				
	6440990	Sep 24, 2013	DP U-1049			
	6440990	Sep 24, 2013	DP U-1365			
	6440990*PED	Mar 24, 2014				
	6455518	Jul 29, 2017	U-1049			
	6455518	Jul 29, 2017	U-1365			
	6455518*PED	Jan 29, 2018				
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 001	8410131	May 22, 2025	DS DP U-1368			
	8410131*PED	Nov 22, 2025				
	8436010	Feb 22, 2022	DS DP U-1396			
	8436010*PED	Aug 22, 2022				
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 002	8410131	May 22, 2025	DS DP U-1368			
	8410131*PED	Nov 22, 2025				
	8436010	Feb 22, 2022	DS DP U-1396			
	8436010*PED	Aug 22, 2022				
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 003	8410131	May 22, 2025	DS DP U-1368			
	8410131*PED	Nov 22, 2025				
	8436010	Feb 22, 2022	DS DP U-1396			
	8436010*PED	Aug 22, 2022				
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 004	8410131	May 22, 2025	DS DP U-1368			
	8410131*PED	Nov 22, 2025				
	8436010	Feb 22, 2022	DS DP U-1396			
	8436010*PED	Aug 22, 2022				
<u>EXENATIDE SYNTHETIC - BYDUREON</u>						
N 022200 001	8431685	Apr 13, 2025	DP U-412			
	8461105	Apr 13, 2025	DP U-412			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FAMOTIDINE; IBUPROFEN - DUEXIS</u>						
N 022519 001	8449910	Jul 18, 2026	DP			
	8501228	Jul 18, 2026	U-1196			
<u>FEBUXOSTAT - ULORIC</u>						
N 021856 001	5614520	Mar 25, 2019	DS DP	U-954		
	8372872	Sep 08, 2031	U-1346			
<u>FEBUXOSTAT - ULORIC</u>						
N 021856 002	5614520	Mar 25, 2019	DS DP	U-954		
	8372872	Sep 08, 2031	U-1346			
<u>FENOFIBRATE - ANTARA (MICRONIZED)</u>						
N 021695 004 >A>	8026281	Apr 22, 2025	U-1447			
	>A> 8026281	Apr 22, 2025	U-1448			
<u>FENOFIBRATE - ANTARA (MICRONIZED)</u>						
N 021695 005 >A>	8026281	Apr 22, 2025				
<u>FENOFIBRATE - FENOGLIDE</u>						
N 022118 001	8481078	Oct 01, 2024	DP	U-1416		
<u>FENOFIBRATE - FENOGLIDE</u>						
N 022118 002	8481078	Oct 01, 2024	DP	U-1416		
<u>FENTANYL - SUBSYS</u>						
N 020788 001	8486972	Apr 26, 2029	DP			
	8486973	Apr 26, 2029	U-55			
<u>FENTANYL - SUBSYS</u>						
N 020788 002	8486972	Apr 26, 2029	DP			
	8486973	Apr 26, 2029	U-55			
<u>FENTANYL - SUBSYS</u>						
N 020788 003	8486972	Apr 26, 2029	DP			
	8486973	Apr 26, 2029	U-55			
<u>FENTANYL - SUBSYS</u>						
N 020788 004	8486972	Apr 26, 2029	DP			
	8486973	Apr 26, 2029	U-55			
<u>FENTANYL - SUBSYS</u>						
N 020788 005	8486972	Apr 26, 2029	DP			
	8486973	Apr 26, 2029	U-55			
<u>FENTANYL - SUBSYS</u>						
N 020788 006	8486972	Apr 26, 2029	DP		NP	Jan 04, 2015
	8486973	Apr 26, 2029	U-55			
<u>FENTANYL - SUBSYS</u>						
N 020788 007	8486972	Apr 26, 2029	DP		NP	Jan 04, 2015
	8486973	Apr 26, 2029	U-55			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 020365 001	7612109	Feb 05, 2024	DS DP		NP	Jul 25, 2016
	7754702	Feb 13, 2027	DP	U-1432		
<u>FERUMOXYTOL - FERAHEME</u>						
N 022180 001	8501158	Mar 08, 2020	U-1422			
<u>FESOTERODINE FUMARATE - TOVIAZ</u>						
N 022030 001	8338478	May 11, 2019	DS DP	U-913		
	8501723	Jun 07, 2027	DP			
<u>FESOTERODINE FUMARATE - TOVIAZ</u>						
N 022030 002	8338478	May 11, 2019	DS DP	U-913		
	8501723	Jun 07, 2027	DP			
<u>FLORBETAPIR F-18 - AMYVID</u>						
N 020208 001	8506929	Apr 30, 2027	DS DP	U-1423		
<u>FLORBETAPIR F-18 - AMYVID</u>						
N 020208 002	8506929	Apr 30, 2027	DS DP	U-1423		
<u>FLORBETAPIR F-18 - AMYVID</u>						
N 020208 003	8506929	Apr 30, 2027	DS DP	U-1423		
<u>FLUNISOLIDE - AEROSPAN HFA</u>						
N 021247 001	5980867	Dec 20, 2013	DP		M-128	Aug 28, 2016

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUOXETINE HYDROCHLORIDE - PROZAC</u>						
N 018936 001					NPP	Jul 26, 2016
<u>FLUOXETINE HYDROCHLORIDE - PROZAC</u>						
N 018936 003					NPP	Jul 26, 2016
<u>FLUOXETINE HYDROCHLORIDE - PROZAC</u>						
N 018936 004					NPP	Jul 26, 2016
<u>FLUOXETINE HYDROCHLORIDE - PROZAC</u>						
N 018936 006					NPP	Jul 26, 2016
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>						
N 021520 001					NPP	Jul 26, 2016
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>						
N 021520 002					NPP	Jul 26, 2016
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>						
N 021520 003					NPP	Jul 26, 2016
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>						
N 021520 004					NPP	Jul 26, 2016
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>						
N 021520 005					NPP	Jul 26, 2016
<u>FLUTICASONE FUROATE - VERAMYST</u>						
N 022051 001	8347879	Apr 01, 2027	DP			
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 001	5873360	Feb 23, 2016	DP			
	6537983	Aug 03, 2021	DP U-1401			
	6759398	Aug 03, 2021	DP U-1401			
	6878698	Aug 03, 2021	U-1401			
	7101866	Aug 03, 2021	DS DP U-1401			
	7361787	Mar 23, 2023	DS DP U-1401			
	7439393	Sep 11, 2022	DS DP U-1401			
	7629335	Aug 03, 2021	DP			
	7776895	Sep 11, 2022	DP			
	8113199	Oct 23, 2027	DP			
	8161968	Feb 05, 2028	DP			
	8511304	Nov 11, 2025	DP U-1424			
	8534281	Aug 10, 2029	DP			
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N 021433 001	7107986	Jun 08, 2018	DP			
	7107986*PED	Dec 08, 2018				
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N 021433 002	7107986	Jun 08, 2018	DP			
	7107986*PED	Dec 08, 2018				
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N 021433 003	7107986	Jun 08, 2018	DP			
	7107986*PED	Dec 08, 2018				
<u>FLUVOXAMINE MALEATE - FLUVOXAMINE MALEATE</u>						
A 091476 002					PC	Sep 09, 2013
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N 021211 001	5929028	Jan 14, 2018	DP U-567			
	5929028	Jan 14, 2018	DP U-1366			
	7563763	Aug 23, 2019	U-993			
	7563763	Aug 23, 2019	U-1183			
	7563763	Aug 23, 2019	U-1367			
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N 021211 002	5929028	Jan 14, 2018	DP U-567			
	5929028	Jan 14, 2018	DP U-1366			
	7563763	Aug 23, 2019	U-993			
	7563763	Aug 23, 2019	U-1183			
	7563763	Aug 23, 2019	U-1367			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AO</u>						
N 021211 003	5929028	Jan 14, 2018	DP U-567			
	5929028	Jan 14, 2018	DP U-1366			
	7563763	Aug 23, 2019	U-993			
	7563763	Aug 23, 2019	U-1183			
	7563763	Aug 23, 2019	U-1367			
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AO</u>						
N 021211 004	5929028	Jan 14, 2018	DP U-567			
	5929028	Jan 14, 2018	DP U-1366			
	7563763	Aug 23, 2019	U-993			
	7563763	Aug 23, 2019	U-1183			
	7563763	Aug 23, 2019	U-1367			
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AO</u>						
N 021273 001	5767251	Jun 16, 2015	DS			
	5929028	Jan 14, 2018	DP U-1366			
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AO</u>						
N 021273 002	5767251	Jun 16, 2015	DS			
	5929028	Jan 14, 2018	DP U-1366			
<u>FORMOTEROL FUMARATE; MOMETASONE FUROATE - DULERA</u>						
N 022518 001	7566705	May 21, 2020	DP U-1068			
<u>FORMOTEROL FUMARATE; MOMETASONE FUROATE - DULERA</u>						
N 022518 002	7566705	May 21, 2020	DP U-1068			
<u>FULVESTRANT - FASLODEX</u>						
N 021344 001	8466139	Jan 09, 2021	U-596			
	8466139*PED	Jul 09, 2021				
<u>GABAPENTIN - GRALISE</u>						
N 022544 001	8333992	Oct 25, 2022	DP U-1114			
<u>GABAPENTIN - GRALISE</u>						
N 022544 002	8333992	Oct 25, 2022	DP U-1114			
<u>GADOFOSVESET TRISODIUM - ABLAVAR</u>						
N 021711 001	8394356	Feb 01, 2015	U-1112			
<u>GADOFOSVESET TRISODIUM - ABLAVAR</u>						
N 021711 002	8394356	Feb 01, 2015	U-1112			
<u>GADOTERATE MEGLUMINE - DOTAREM</u>						
N 0204781 001					NCE	Mar 20, 2018
<u>GADOTERATE MEGLUMINE - DOTAREM</u>						
N 0204781 002					NCE	Mar 20, 2018
<u>GADOTERATE MEGLUMINE - DOTAREM</u>						
N 0204781 003					NCE	Mar 20, 2018
<u>GADOTERATE MEGLUMINE - DOTAREM</u>						
N 0204781 004					NCE	Mar 20, 2018
<u>GADOXETATE DISODIUM - EOVI</u>						
N 022090 002					NCE	Jul 03, 2013
<u>GANIRELIX ACETATE - GANIRELIX ACETATE</u>						
N 021057 001	6653286	Jun 16, 2018	U-1354			
<u>GATIFLOXACIN - GATIFLOXACIN</u>						
A 202653 001					PC	Mar 30, 2014
<u>GLATIRAMER ACETATE - COPAXONE</u>						
N 020622 002	8367605	May 24, 2014	DS			
<u>GLIPIZIDE - GLUCOTROL XL</u>						
N 020329 001	RE44459	Mar 26, 2019	U-1431			
<u>GLIPIZIDE - GLUCOTROL XL</u>						
N 020329 002	RE44459	Mar 26, 2019	U-1431			
<u>GLIPIZIDE - GLUCOTROL XL</u>						
N 020329 003	RE44459	Mar 26, 2019	U-1431			
<u>GLYCEROL PHENYLBUTYRATE - RAVICTI</u>						
N 203284 001	5968979	Feb 07, 2015	DS DP U-1378		NE	Feb 01, 2016
	8404215	Mar 09, 2032	U-1383		ODE	Feb 01, 2020

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>GLYCOPYRROLATE - ROBINUL</u>						
N 012827 001	7091236	Apr 24, 2024	U-877	Y		
<u>GLYCOPYRROLATE - ROBINUL FORTE</u>						
N 012827 002	7091236	Apr 24, 2024	U-877	Y		
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 001					>A> NP	Oct 25, 2016
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 002					>A> NP	Oct 25, 2016
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 003					>A> NP	Oct 25, 2016
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 004					>A> NP	Oct 25, 2016
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 005					>A> NP	Oct 25, 2016
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 006					>A> NP	Oct 25, 2016
<u>IBUPROFEN LYSINE - NEOPROFEN</u>						
N 021903 001	8415337	Mar 02, 2032	DS DP			
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 001	8357677	Feb 09, 2030	U-1287			
	8367652	Feb 09, 2030	U-1287			
	8377920	Feb 09, 2030	U-1287			
	8399446	Feb 09, 2030	U-1287			
	8415335	Feb 09, 2030	U-1287			
	8426399	Feb 09, 2030	U-1287			
	8431560	Feb 09, 2030	U-1287			
	8440650	Feb 09, 2030	U-1287			
	8445003	Apr 29, 2030	U-1287			
	8445013	Apr 29, 2030	U-1287			
	8501225	Apr 29, 2030	U-1287			
	8518929	Apr 29, 2030	U-1287			
	8524698	Apr 29, 2030	U-1287			
	8546372	Apr 29, 2030	U-1287			
	8551521	Apr 29, 2030	U-1287			
>A>	8563608	Apr 29, 2030	U-1287			
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021588 001	7544799	Jan 16, 2019	DS DP	Y	I-666	Jan 25, 2016
	7544799*PED	Jul 16, 2019			ODE	Jan 25, 2020
	RE43932	Jan 16, 2019	DS DP			
	RE43932*PED	Jul 16, 2019				
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021588 002	7544799	Jan 16, 2019	DS DP	Y	I-666	Jan 25, 2016
	7544799*PED	Jul 16, 2019			ODE	Jan 25, 2020
	RE43932	Jan 16, 2019	DS DP			
	RE43932*PED	Jul 16, 2019				
<u>INDACATEROL MALEATE - ARCAPTA NEOHALER</u>						
N 022383 001	8067437	Jun 02, 2020	U-1168			
	8479730	Oct 11, 2028	DP			
<u>INDIUM IN-111 PENTETREOTIDE KIT - OCTREOSCAN</u>						
N 020314 001	6123916	Sep 26, 2017	U-1125			
<u>INGENOL MEBUTATE - PICATO</u>						
N 202833 001	6844013	Dec 13, 2018	DS DP	U-1221		
	8372827	Dec 18, 2026	DS DP			
	8372828	Dec 18, 2026	DS DP			
	8377919	Dec 18, 2026	DS DP			
	8536163	Dec 18, 2026	U-1440			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>INGENOL MEBUTATE - PICATO</u>						
N 202833 002	6844013	Dec 13, 2018	DS DP U-1221			
	8372827	Dec 18, 2026	DS DP			
	8372828	Dec 18, 2026	DS DP			
	8377919	Dec 18, 2026	DS DP			
	8536163	Dec 18, 2026	U-1440			
<u>INSULIN GLARGINE RECOMBINANT - LANTUS SOLOSTAR</u>						
N 021081 002	8512297	Sep 15, 2024	DP			
	>A> 8556864	Mar 03, 2024	DP			
<u>INSULIN GLULISINE RECOMBINANT - APIDRA SOLOSTAR</u>						
N 021629 003	8512297	Sep 15, 2024	DP			
	>A> 8556864	Mar 03, 2024	DP			
<u>INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT - HUMALOG MIX 75/25 KWIKPEN</u>						
N 021017 002	7291132	Aug 09, 2024	DP			
<u>INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT - HUMALOG MIX 50/50 KWIKPEN</u>						
N 021018 002	7291132	Aug 09, 2024	DP			
<u>INSULIN LISPRO RECOMBINANT - HUMALOG KWIKPEN</u>						
N 020563 003	7291132	Aug 09, 2024	DP			
<u>IOBENGUANE SULFATE I-123 - ADREVIEW</u>						
N 022290 001					I-669	Mar 20, 2016
<u>IRON SUCROSE - VENOFER</u>						
N 021135 005					NPP	Sep 21, 2015
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 001	8367102	Sep 21, 2021	U-1347			
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 002	8367102	Sep 21, 2021	U-1347			
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 003	8367102	Sep 21, 2021	U-1347			
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 004	8367102	Sep 21, 2021	U-1347			
<u>ITRACONAZOLE - ONMEL</u>						
N 022484 001	8486456	Oct 03, 2028	DP U-1054			
<u>IVACAFTOR - KALYDECO</u>						
N 203188 001	8410274	Dec 28, 2026	DP			
<u>KETOROLAC TROMETHAMINE - ACULAR LS</u>						
N 021528 001	8377982	May 28, 2024	U-1363			
	8377982*PED	Nov 28, 2024				
	>A> 8541463	May 28, 2024	U-1441			
	>A> 8541463*PED	Nov 28, 2024				
<u>KETOROLAC TROMETHAMINE - ACUVAIL</u>						
N 022427 001	8512717	Mar 07, 2028	DP			
<u>LAPATINIB DITOSYLATE - TYKERB</u>						
N 022059 001	6391874	Jul 11, 2017	DS DP U-800			
	6391874	Jul 11, 2017	DS DP U-1429			
	6713485	Sep 29, 2020	DS DP U-800			
	6713485	Sep 29, 2020	DS DP U-1429			
	6727256	Jan 08, 2019	DS DP U-800			
	6727256	Jan 08, 2019	DS DP U-1429			
	6828320	Jul 11, 2017	U-800			
	6828320	Jul 11, 2017	U-1429			
	>A> 7157466	Nov 19, 2021	DS DP			
	8513262	Jan 08, 2019	DS DP			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 001	6281230	Jul 24, 2016	U-1212		I-672	Jun 05, 2016
	6281230	Jul 24, 2016	U-1414		ODE	Jun 05, 2020
	7468363	Oct 07, 2023	U-1414			
	8404717	Apr 11, 2023	U-1215			
	8530498	May 15, 2023	U-1216			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 002	6281230	Jul 24, 2016	U-1212		I-672	Jun 05, 2016
	6281230	Jul 24, 2016	U-1414		ODE	Jun 05, 2020
	7468363	Oct 07, 2023	U-1414			
	8404717	Apr 11, 2023	U-1215			
	8530498	May 15, 2023	U-1216			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 003	6281230	Jul 24, 2016	U-1212		I-672	Jun 05, 2016
	6281230	Jul 24, 2016	U-1414		ODE	Jun 05, 2020
	7468363	Oct 07, 2023	U-1414			
	8404717	Apr 11, 2023	U-1215			
	8530498	May 15, 2023	U-1216			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 004	6281230	Jul 24, 2016	U-1212		I-672	Jun 05, 2016
	6281230	Jul 24, 2016	U-1414		ODE	Jun 05, 2020
	7468363	Oct 07, 2023	U-1414			
	8404717	Apr 11, 2023	U-1215			
	8530498	May 15, 2023	U-1216			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 005	6281230	Jul 24, 2016	U-1212		I-672	Jun 05, 2016
	6281230	Jul 24, 2016	U-1414		ODE	Jun 05, 2020
	7468363	Oct 07, 2023	U-1414			
	8404717	Apr 11, 2023	U-1215			
	8530498	May 15, 2023	U-1216			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 006	5635517	Oct 04, 2019	DS DP U-1211		I-672	Jun 05, 2016
	6045501	Aug 28, 2018	U-1210		NS	Jun 05, 2016
	6281230	Jul 24, 2016	U-1212		ODE	Jun 05, 2020
	6281230	Jul 24, 2016	U-1414			
	6315720	Oct 23, 2020	U-1210			
	6555554	Jul 24, 2016	DP U-1211			
	6561976	Aug 28, 2018	U-1210			
	6561977	Oct 23, 2020	U-1210			
	6755784	Oct 23, 2020	U-1210			
	6908432	Aug 28, 2018	U-1210			
	7119106	Jul 24, 2016	DP			
	7189740	Apr 11, 2023	U-1215			
	7465800	Apr 27, 2027	DS DP			
	7468363	Oct 07, 2023	U-1414			
	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023	U-1216			
	8204763	Aug 28, 2018	U-1249			
	8288415	Jul 24, 2016	DS DP			
	8315886	Oct 23, 2020	U-1249			
	8404717	Apr 11, 2023	U-1215			
	8530498	May 15, 2023	U-1216			
<u>LEVALBUTEROL HYDROCHLORIDE - LEVALBUTEROL HYDROCHLORIDE</u>						
A 077756 001					PC	Feb 16, 2013
<u>LEVALBUTEROL HYDROCHLORIDE - LEVALBUTEROL HYDROCHLORIDE</u>						
A 077756 002					PC	Feb 16, 2013
<u>LEVALBUTEROL HYDROCHLORIDE - LEVALBUTEROL HYDROCHLORIDE</u>						
A 077756 003					PC	Feb 16, 2013
<u>LEVOLEUCOVORIN CALCIUM - FUSILEV</u>						
N 020140 001	6500829	Mar 07, 2022	DS DP			
<u>LEVOLEUCOVORIN CALCIUM - FUSILEV</u>						
N 020140 002	6500829	Mar 07, 2022	DS DP			
<u>LEVOLEUCOVORIN CALCIUM - FUSILEV</u>						
N 020140 003	6500829	Mar 07, 2022	DS DP			
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168 001	8481598	Mar 02, 2031	U-839		NCE*	Jul 25, 2018
	RE43879	Jun 03, 2023	U-839			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168 002	8481598 RE43879	Mar 02, 2031 Jun 03, 2023	U-839 U-839		NCE*	Jul 25, 2018
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168 003	8481598 RE43879	Mar 02, 2031 Jun 03, 2023	U-839 U-839		NCE*	Jul 25, 2018
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168 004	8481598 RE43879	Mar 02, 2031 Jun 03, 2023	U-839 U-839		NCE*	Jul 25, 2018
<u>LEVONORGESTREL - PLAN B ONE-STEP</u>						
N 021998 001					RTO* RTO**	Apr 30, 2016 Apr 30, 2016
<u>LEVONORGESTREL - SKYLA</u>						
N 203159 001	5785053 7252839	Dec 05, 2015 Nov 13, 2023	DP DP		NP	Jan 09, 2016
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 001	7101569	Oct 02, 2023	U-759			
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 002	7101569	Oct 02, 2023	U-759			
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 003	7101569	Oct 02, 2023	U-759			
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 004	7101569	Oct 02, 2023	U-759			
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 005	7101569	Oct 02, 2023	U-759			
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 006	7101569	Oct 02, 2023	U-759			
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 007	7101569	Oct 02, 2023	U-759			
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 008	7101569	Oct 02, 2023	U-759			
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 009	7101569	Oct 02, 2023	U-759			
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 010	7101569	Oct 02, 2023	U-759			
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 011	7101569	Oct 02, 2023	U-759			
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 012	7101569	Oct 02, 2023	U-759			
<u>LIDOCAINE HYDROCHLORIDE - ZINGO</u>						
N 022114 001	8540665	Oct 22, 2029	U-1438			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 001	5712279 7932268	Feb 21, 2015 Aug 19, 2027	DS U-1317 U-1316		ODE	Dec 21, 2019
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 002	5712279 7932268	Feb 21, 2015 Aug 19, 2027	DS U-1317 U-1316		ODE	Dec 21, 2019
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 003	5712279 7932268	Feb 21, 2015 Aug 19, 2027	DS U-1317 U-1316		ODE	Dec 21, 2019
<u>LOPINAVIR; RITONAVIR - KALETRA</u>						
N 021251 001	8501219	Nov 28, 2021	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LOPINAVIR; RITONAVIR - KALETRA</u>						
N 021906 001	8025899	Dec 14, 2027	DP			
	8025899*PED	Jun 14, 2028				
	8377952	Oct 22, 2027	U-1372			
	8377952*PED	Apr 22, 2028				
	8399015	Aug 25, 2024	DP			
	8399015*PED	Feb 25, 2025				
	8470347	Sep 17, 2026	DP			
	8470347*PED	Mar 17, 2027				
<u>LOPINAVIR; RITONAVIR - KALETRA</u>						
N 021906 002	8025899	Dec 14, 2027	DP			
	8025899*PED	Jun 14, 2028				
	8377952	Oct 22, 2027	U-1372			
	8377952*PED	Apr 22, 2028				
	8399015	Aug 25, 2024	DP			
	8399015*PED	Feb 25, 2025				
	8470347	Sep 17, 2026	DP			
	8470347*PED	Mar 17, 2027				
<u>LORCASERIN HYDROCHLORIDE - BELVIO</u>						
N 022529 001	8367657	Apr 10, 2023	DS DP U-1252			
	8367657	Apr 10, 2023	DS DP U-1253			
	8367657	Apr 10, 2023	DS DP U-1254			
	8367657	Apr 10, 2023	DS DP U-1255			
	>A> 8546379	Apr 10, 2023	DS DP U-1252			
	>A> 8546379	Apr 10, 2023	DS DP U-1253			
	>A> 8546379	Apr 10, 2023	DS DP U-1254			
	>A> 8546379	Apr 10, 2023	DS DP U-1255			
<u>LOTEPREDNOL ETABONATE - LOTEMAX</u>						
N 202872 001	5800807	Jan 29, 2017	DP			
<u>LOXAPINE - ADASUVE</u>						
N 022549 001	6716416	May 20, 2022	DP			
	7052679	Mar 20, 2022	DP			
	7078020	Oct 26, 2021	DP U-1375			
	7090830	Oct 26, 2021	DP			
	7458374	Aug 18, 2024	DP			
	7537009	Oct 26, 2021	DP			
	7585493	Oct 26, 2021	DP			
	7601337	Oct 26, 2021	DP			
	8074644	Oct 26, 2021	DP			
	8173107	Oct 26, 2021	DP			
	8235037	Oct 26, 2021	DP			
	8387612	Oct 23, 2026	DP			
<u>LUBIPROSTONE - AMITIZA</u>						
N 021908 001	6414016	Sep 05, 2020	U-717		I-670	Apr 19, 2016
	6414016	Sep 05, 2020	U-1392			
	6982283	Dec 04, 2022	U-1391			
	7064148	Aug 30, 2022	U-739			
	7064148	Aug 30, 2022	U-1404			
	8026393	Oct 25, 2027	DP			
	8071613	Sep 05, 2020	U-1203			
	8071613	Sep 05, 2020	U-1393			
	8097653	Nov 14, 2022	U-1214			
	8097653	Nov 14, 2022	U-1394			
	8389542	Nov 14, 2022	DP U-1345			
	8389542	Nov 14, 2022	DP U-1395			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 001	5532372	Jul 02, 2018	DS		I-674	Jun 28, 2016
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 002	5532372	Jul 02, 2018	DS		I-674	Jun 28, 2016
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 003	5532372	Jul 02, 2018	DS		I-674	Jun 28, 2016
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 004	5532372	Jul 02, 2018	DS		I-674	Jun 28, 2016

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603	005				D-134 I-674 NCE	Apr 26, 2015 Jun 28, 2016 Oct 28, 2015
<u>MACITENTAN - OPSUMIT</u>						
N 204410	001	>A> 7094781	Oct 12, 2022	DS	>A> NCE	Oct 18, 2018
		>A> 8268847	Apr 18, 2029	U-1446	>A> ODE	Oct 18, 2020
		>A> 8367685	Oct 04, 2028	DP		
<u>MAGNESIUM SULFATE; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; POTASSIUM SULFATE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE - SUCLEAR</u>						
N 203595	001				NC	Jan 18, 2016
<u>MECHLORETHAMINE HYDROCHLORIDE - VALCHLOR</u>						
N 202317	001	7838564	Mar 07, 2026	DP	NDF	Aug 23, 2016
		7872050	Jul 08, 2029	U-1427		
		8450375	Mar 07, 2026	DP		
		8501818	Mar 07, 2026	DP		
		8501819	Mar 07, 2026	U-1427		
<u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u>						
N 022525	001	8168209	Nov 22, 2025	DP		
		8173708	Nov 22, 2025	U-539		
		8283379	Nov 22, 2025	U-539		
		8329752	Nov 22, 2025	DP		
		8362085	Nov 22, 2025	U-539		
<u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u>						
N 022525	002	8168209	Nov 22, 2025	DP		
		8173708	Nov 22, 2025	U-539		
		8283379	Nov 22, 2025	U-539		
		8329752	Nov 22, 2025	DP		
		8362085	Nov 22, 2025	U-539		
<u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u>						
N 022525	003	8168209	Nov 22, 2025	DP		
		8173708	Nov 22, 2025	U-539		
		8283379	Nov 22, 2025	U-539		
		8329752	Nov 22, 2025	DP		
		8362085	Nov 22, 2025	U-539		
<u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u>						
N 022525	004	8168209	Nov 22, 2025	DP		
		8173708	Nov 22, 2025	U-539		
		8283379	Nov 22, 2025	U-539		
		8329752	Nov 22, 2025	DP		
		8362085	Nov 22, 2025	U-539		
<u>MESALAMINE - CANASA</u>						
N 021252	002	8217083	Jun 06, 2028	DP		
		8436051	Jun 06, 2028	DP		
<u>MESALAMINE - ASACOL HD</u>						
N 021830	001	>A> 8580302	Nov 15, 2021	DP		
<u>MESALAMINE - APRISO</u>						
N 022301	001	8496965	Apr 20, 2018	DP		
<u>MESALAMINE - DELZICOL</u>						
N 204412	001	5541170	Jul 30, 2013	DP	U-141	
		5541171	Jul 30, 2013	DP	U-141	
		6649180	Apr 13, 2020	DP		
<u>METFORMIN HYDROCHLORIDE - FORTAMET</u>						
N 021574	001	8475841	Mar 20, 2018	U-604		
<u>METFORMIN HYDROCHLORIDE - FORTAMET</u>						
N 021574	002	8475841	Mar 20, 2018	U-604		
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR</u>						
N 022024	001	8470368	Sep 19, 2023	DP		
		8475841	Mar 20, 2018	U-973		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR</u>						
N 022024 002	8470368	Sep 19, 2023	DP			
	8475841	Mar 20, 2018	U-973			
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 001	RE44186	Jul 31, 2023	DS DP U-1097			
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 002	RE44186	Jul 31, 2023	DS DP U-1097			
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 003	RE44186	Jul 31, 2023	DS DP U-1097			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N 022044 001	7459428	Feb 02, 2019	U-1036			
	8414921	Jul 21, 2028	DP U-1036			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N 022044 002	7459428	Feb 02, 2019	U-1036			
	8414921	Jul 21, 2028	DP U-1036			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 001	>A> 6746429	Apr 12, 2020	DP			
	>A> 7744582	Aug 10, 2019	DP			
	>A> 7776015	Aug 10, 2019	DP			
	>A> 8021335	Oct 04, 2026	DP			
	>A> 8480631	Mar 19, 2030	DP U-1442			
	>A> 8562564	Jan 24, 2026	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 002	>A> 6746429	Apr 12, 2020	DP			
	>A> 7744582	Aug 10, 2019	DP U-1442			
	>A> 7776015	Aug 10, 2019	DP			
	>A> 8021335	Oct 04, 2026	DP			
	>A> 8480631	Mar 19, 2030	DP U-1442			
	>A> 8562564	Jan 24, 2026	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 003	>A> 6746429	Apr 12, 2020	DP			
	>A> 7744582	Aug 10, 2019	DP			
	>A> 7776015	Aug 10, 2019	DP			
	>A> 8021335	Oct 04, 2026	DP			
	>A> 8480631	Mar 19, 2030	DP U-1442			
	>A> 8562564	Jan 24, 2026	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 004	>A> 6746429	Apr 12, 2020	DP			
	>A> 7744582	Aug 10, 2019	DP			
	>A> 7776015	Aug 10, 2019	DP			
	>A> 8021335	Oct 04, 2026	DP			
	>A> 8480631	Mar 19, 2030	DP U-1442			
	>A> 8562564	Jan 24, 2026	DP			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 021964 001	8420663	Sep 30, 2029	U-1185			
	>A> 8552025	Apr 08, 2024	DP			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 021964 002	8420663	Sep 30, 2029	U-1185			
	>A> 8552025	Apr 08, 2024	DP			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 021964 003	8420663	Sep 30, 2029	U-1185			
	>A> 8552025	Apr 08, 2024	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLIVANT XR</u>						
N 202100 001	8062667	Mar 29, 2029	DP			
	8287903	Feb 15, 2031	DP			
	8465765	Feb 15, 2031	DP U-1415			
<u>METRONIDAZOLE - METRONIDAZOLE</u>						
A 090903 001					PC	Dec 28, 2013
<u>MICONAZOLE - ORAVIG</u>						
N 022404 001	8518442	Sep 11, 2022	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MICONAZOLE NITRATE; PETROLATUM, WHITE; ZINC OXIDE - VUSION</u>						
N 021026 001	8147852	Mar 30, 2028	U-1426			
<u>MINOCYCLINE HYDROCHLORIDE - XIMINO</u>						
N 201922 001	5908838	Feb 19, 2018	U-1376			
	7541347	Apr 02, 2027	U-917			
	7544373	Apr 02, 2027	DP			
	7790705	Jun 24, 2025	U-124			
	7919483	Mar 07, 2027	U-124			
	8252776	Jun 24, 2025	U-124			
	8268804	Jun 24, 2025	U-124			
<u>MINOCYCLINE HYDROCHLORIDE - XIMINO</u>						
N 201922 003	5908838	Feb 19, 2018	U-1376			
	7541347	Apr 02, 2027	U-917			
	7544373	Apr 02, 2027	DP			
	7790705	Jun 24, 2025	U-124			
	7919483	Mar 07, 2027	U-124			
	8252776	Jun 24, 2025	U-124			
	8268804	Jun 24, 2025	U-124			
<u>MINOCYCLINE HYDROCHLORIDE - XIMINO</u>						
N 201922 005	5908838	Feb 19, 2018	U-1376			
	7541347	Apr 02, 2027	U-917			
	7544373	Apr 02, 2027	DP			
	7790705	Jun 24, 2025	U-124			
	7919483	Mar 07, 2027	U-124			
	8252776	Jun 24, 2025	U-124			
	8268804	Jun 24, 2025	U-124			
<u>MIPOMERSEN SODIUM - KYNAMRO</u>						
N 203568 001	5914396	Jun 22, 2016	DS		NCE	Jan 29, 2018
	6166197	Dec 26, 2017	DS		ODE	Jan 29, 2020
	6222025	Mar 06, 2015	DS			
	6451991	Feb 11, 2017	DS			
	7015315	Mar 21, 2023	DS			
	7101993	Sep 05, 2023	DS			
	7407943	Aug 01, 2021	U-1353			
	7511131	Dec 13, 2025	DS			
<u>MOMETASONE FUROATE - ELOCON</u>						
N 019625 002					NP	Apr 19, 2016
<u>MOXIFLOXACIN HYDROCHLORIDE - MOXEZA</u>						
N 022428 001	8450311	May 29, 2029	DP			
<u>MUPIROCIN CALCIUM - BACTROBAN</u>						
N 050703 001	5569672	Oct 29, 2013	U-1358			
<u>MUPIROCIN CALCIUM - BACTROBAN</u>						
N 050746 001	5569672	Oct 29, 2013	U-1358			
<u>MYCOPHENOLIC ACID - MYFORTIC</u>						
N 050791 001	6306900	Feb 27, 2018	DP			
<u>MYCOPHENOLIC ACID - MYFORTIC</u>						
N 050791 002	6306900	Feb 27, 2018	DP			
<u>NAFTIFINE HYDROCHLORIDE - NAFTIN</u>						
N 204286 001					NP	Jun 27, 2016
<u>NEPAFENAC - ILEVRO</u>						
N 203491 001	5475034	Jun 06, 2014	U-100			
	6403609	Jul 17, 2018	DP			
	7947295	Jun 08, 2024	DP			
<u>NEVIRAPINE - VIRAMUNE XR</u>						
N 201152 001	8460704	Mar 12, 2029	U-1409			
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER</u>						
N 019734 002	8455524	Apr 18, 2027	U-1029			
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER</u>						
N 019734 003	8455524	Apr 18, 2027	U-1029			
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER</u>						
N 019734 004	8455524	Apr 18, 2027	U-1029			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER</u>						
N 019734 005	8455524	Apr 18, 2027	U-1029			
<u>NICOTINE POLACRILEX - NICORETTE</u>						
N 022360 001	8501164	Jun 14, 2029	DP			
<u>NICOTINE POLACRILEX - NICORETTE</u>						
N 022360 002	8501164	Jun 14, 2029	DP			
<u>NILOTINIB HYDROCHLORIDE MONOHYDRATE - TASIGNA</u>						
N 022068 001	8389537	Jul 18, 2026	DS DP U-1374			
	8415363	Jul 18, 2026	DS DP U-1407			
	8501760	Jul 18, 2026	DS DP			
<u>NILOTINIB HYDROCHLORIDE MONOHYDRATE - TASIGNA</u>						
N 022068 002	8389537	Jul 18, 2026	DS DP U-1374			
	8415363	Jul 18, 2026	DS DP U-1407			
	8501760	Jul 18, 2026	DS DP			
<u>NIMODIPINE - NYMALIZE</u>						
N 203340 001					ODE	May 10, 2020
<u>NITRIC OXIDE - INOMAX</u>						
N 020845 002	8431163	Jun 30, 2029	U-1286			
	8431163*PED	Dec 30, 2029				
<u>NITRIC OXIDE - INOMAX</u>						
N 020845 003	8431163	Jun 30, 2029	U-1286			
	8431163*PED	Dec 30, 2029				
<u>OLANZAPINE - ZYPREXA</u>						
N 020592 001					NPP	Jul 26, 2016
<u>OLANZAPINE - ZYPREXA</u>						
N 020592 002					NPP	Jul 26, 2016
<u>OLANZAPINE - ZYPREXA</u>						
N 020592 003					NPP	Jul 26, 2016
<u>OLANZAPINE - ZYPREXA</u>						
N 020592 004					NPP	Jul 26, 2016
<u>OLANZAPINE - ZYPREXA</u>						
N 020592 005					NPP	Jul 26, 2016
<u>OLANZAPINE - ZYPREXA</u>						
N 020592 006					NPP	Jul 26, 2016
<u>OLANZAPINE - ZYPREXA ZYDIS</u>						
N 021086 001					NPP	Jul 26, 2016
<u>OLANZAPINE - ZYPREXA ZYDIS</u>						
N 021086 002					NPP	Jul 26, 2016
<u>OLANZAPINE - ZYPREXA ZYDIS</u>						
N 021086 003					NPP	Jul 26, 2016
<u>OLANZAPINE - ZYPREXA ZYDIS</u>						
N 021086 004					NPP	Jul 26, 2016
<u>OLOPATADINE HYDROCHLORIDE - PATANASE</u>						
N 021861 001	8399508	Sep 17, 2022	U-726			
	8399508*PED	Mar 17, 2023				
<u>OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID</u>						
N 021636 001	6489346	Jul 16, 2016	DS DP U-588	Y		
	6645988	Jul 16, 2016	DS DP	Y		
	6699885	Jul 16, 2016	U-588	Y		
<u>OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID</u>						
N 021636 002	6489346	Jul 16, 2016	DS DP U-623	Y		
	6489346	Jul 16, 2016	DS DP U-624	Y		
	6645988	Jul 16, 2016	DS DP	Y		
	6699885	Jul 16, 2016	U-623	Y		
	6699885	Jul 16, 2016	U-624	Y		
<u>OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID OTC</u>						
N 022281 001	6489346	Jul 15, 2016	DP U-1025	Y		
	6645988	Jul 15, 2016	DP	Y		
	6699885	Jul 15, 2016	DP	Y		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OMEPRazole; SODIUM BICARBONATE - ZEGERID OTC</u>						
N 022283 001	5840737	Jul 16, 2016	U-1025			
	6780882	Jul 16, 2016	DP			
	7399772	Jul 16, 2016	U-1025			
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N 021087 001					NPP	Dec 21, 2015
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N 021087 002					NPP	Dec 21, 2015
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N 021087 003					NPP	Dec 21, 2015
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N 021246 001					NPP	Dec 21, 2015
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N 021246 002					NPP	Dec 21, 2015
<u>OSPEMIFENE - OSPHENA</u>						
N 203505 001	6245819	Jul 21, 2020	U-1369		NCE	Feb 26, 2018
	8236861	Aug 11, 2026	U-1369			
	8236861	Aug 11, 2026	U-1370			
	8470890	Feb 13, 2024	U-1369			
	8470890	Feb 13, 2024	U-1370			
<u>OXYBUTYNIN - OXYTROL FOR WOMEN</u>						
N 202211 001	5601839	Apr 26, 2015	DP U-1329		NP	Jan 25, 2016
	5834010	Apr 26, 2015	DP U-1329			
	6743441	Apr 26, 2020	DP U-1329			
	7081249	Apr 26, 2020	DP U-1329			
	7081250	Apr 26, 2020	DP U-1329			
	7081251	Apr 26, 2020	DP U-1329			
	7081252	Apr 26, 2020	DP U-1329			
	7179483	Apr 26, 2020	U-1329			
<u>OXYCODONE HYDROCHLORIDE - OXECTA</u>						
N 202080 001	8409616	Nov 26, 2023	DP			
<u>OXYCODONE HYDROCHLORIDE - OXECTA</u>						
N 202080 002	8409616	Nov 26, 2023	DP			
<u>OXYMORPHONE HYDROCHLORIDE - OXYMORPHONE HYDROCHLORIDE</u>						
A 079087 006					PC	Jul 07, 2013
<u>PACLITAXEL - ABRAXANE</u>						
N 021660 001	7758891	Feb 21, 2026	U-1434		I-676	Sep 06, 2016
	7820788	Mar 03, 2024	DP U-1092		ODE	Sep 06, 2020
	7820788	Mar 03, 2024	DP U-1290			
	7820788	Mar 03, 2024	DP U-1434			
	7923536	Dec 09, 2023	U-1117			
	7923536	Dec 09, 2023	U-1290			
	7923536	Dec 09, 2023	U-1434			
	8138229	Dec 09, 2023	DP U-1092			
	8138229	Dec 09, 2023	DP U-1290			
	8138229	Dec 09, 2023	DP U-1434			
	8314156	Dec 09, 2023	U-1290			
	8314156	Dec 09, 2023	U-1434			
	RE41884	Aug 14, 2016	U-1117			
	RE41884	Aug 14, 2016	U-1290			
	RE41884	Aug 14, 2016	U-1434			
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 021372 001	8518981	Jan 30, 2024	DP			
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 021372 002	8518981	Jan 30, 2024	DP			
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - CREON</u>						
N 020725 005					M-93 NCE	Jul 29, 2019 Apr 30, 2014
<u>PARICALCITOL - PARICALCITOL</u>						
A 090829 001					PC	Dec 24, 2013

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PARICALCITOL - PARICALCITOL</u>						
A 090829 002					PC	Dec 24, 2013
<u>PARICALCITOL - PARICALCITOL</u>						
A 090829 003					PC	Dec 24, 2013
<u>PAROXETINE MESYLATE - BRISDELLE</u>						
N 204516 001	5874447	Jun 10, 2017	DS		NP	Jun 28, 2016
	7598271	Feb 12, 2023	DS			
<u>PHENTERMINE HYDROCHLORIDE - SUPRENZA</u>						
N 202088 001	8440170	Mar 14, 2029	DP			
<u>PHENTERMINE HYDROCHLORIDE - SUPRENZA</u>						
N 202088 002	8440170	Mar 14, 2029	DP			
<u>PHENTERMINE HYDROCHLORIDE - SUPRENZA</u>						
N 202088 003	8440170	Mar 14, 2029	DP			
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - OSYMIA</u>						
N 022580 001	>A> 8580298	May 15, 2029	DP			
	>A> 8580299	Jun 14, 2029		U-1262		
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - OSYMIA</u>						
N 022580 002	>A> 8580298	May 15, 2029	DP			
	>A> 8580299	Jun 14, 2029		U-1262		
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - OSYMIA</u>						
N 022580 003	>A> 8580298	May 15, 2029	DP			
	>A> 8580299	Jun 14, 2029				
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - OSYMIA</u>						
N 022580 004	>A> 8580298	May 15, 2029	DP			
	>A> 8580299	Jun 14, 2029				
<u>PITAVASTATIN CALCIUM - LIVALO</u>						
N 022363 001	5856336	Dec 25, 2020	DS	U-998		
	>A> 8557993	Feb 02, 2024		DP		
<u>PITAVASTATIN CALCIUM - LIVALO</u>						
N 022363 002	5856336	Dec 25, 2020	DS	U-998		
	>A> 8557993	Feb 02, 2024		DP		
<u>PITAVASTATIN CALCIUM - LIVALO</u>						
N 022363 003	5856336	Dec 25, 2020	DS	U-998		
	>A> 8557993	Feb 02, 2024		DP		
<u>PLERIXAFOR - MOZOBIL</u>						
N 022311 001	RE42152	Dec 10, 2018	DP			
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 001	5635517	Jul 24, 2016		U-1359	NCE	Feb 08, 2018
	6045501	Aug 28, 2018		U-1361	ODE	Feb 08, 2020
	6315720	Oct 23, 2020		U-1361		
	6316471	Aug 10, 2016	DP	U-1360		
	6476052	Jul 24, 2016	DP	U-1360		
	6561976	Aug 28, 2018		U-1361		
	6561977	Oct 23, 2020		U-1361		
	6755784	Oct 23, 2020		U-1361		
	6908432	Aug 28, 2018		U-1361		
	8158653	Aug 10, 2016	DP			
	8198262	Oct 19, 2024		U-1360		
	8204763	Aug 28, 2018		U-1361		
	8315886	Oct 23, 2020		U-1361		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 002	5635517	Jul 24, 2016	U-1359		NCE	Feb 08, 2018
	6045501	Aug 28, 2018	U-1361		ODE	Feb 08, 2020
	6315720	Oct 23, 2020	U-1361			
	6316471	Aug 10, 2016	DP U-1360			
	6476052	Jul 24, 2016	DP U-1360			
	6561976	Aug 28, 2018	U-1361			
	6561977	Oct 23, 2020	U-1361			
	6755784	Oct 23, 2020	U-1361			
	6908432	Aug 28, 2018	U-1361			
	8158653	Aug 10, 2016	DP			
	8198262	Oct 19, 2024	U-1360			
	8204763	Aug 28, 2018	U-1361			
	8315886	Oct 23, 2020	U-1361			
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 003	5635517	Jul 24, 2016	U-1359		NCE	Feb 08, 2018
	6045501	Aug 28, 2018	U-1361		ODE	Feb 08, 2020
	6315720	Oct 23, 2020	U-1361			
	6316471	Aug 10, 2016	DP U-1360			
	6476052	Jul 24, 2016	DP U-1360			
	6561976	Aug 28, 2018	U-1361			
	6561977	Oct 23, 2020	U-1361			
	6755784	Oct 23, 2020	U-1361			
	6908432	Aug 28, 2018	U-1361			
	8158653	Aug 10, 2016	DP			
	8198262	Oct 19, 2024	U-1360			
	8204763	Aug 28, 2018	U-1361			
	8315886	Oct 23, 2020	U-1361			
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 004	5635517	Jul 24, 2016	U-1359		NCE	Feb 08, 2018
	6045501	Aug 28, 2018	U-1361		ODE	Feb 08, 2020
	6315720	Oct 23, 2020	U-1361			
	6316471	Aug 10, 2016	DP U-1360			
	6476052	Jul 24, 2016	DP U-1360			
	6561976	Aug 28, 2018	U-1361			
	6561977	Oct 23, 2020	U-1361			
	6755784	Oct 23, 2020	U-1361			
	6908432	Aug 28, 2018	U-1361			
	8158653	Aug 10, 2016	DP			
	8198262	Oct 19, 2024	U-1360			
	8204763	Aug 28, 2018	U-1361			
	8315886	Oct 23, 2020	U-1361			
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 001					ODE	Dec 14, 2019
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 002					ODE	Dec 14, 2019
<u>PRALATREXATE - FOLOTYN</u>						
N 022468 001	6028071	Jul 16, 2022	DS DP U-1004			
<u>PRALATREXATE - FOLOTYN</u>						
N 022468 002	6028071	Jul 16, 2022	DS DP U-1004			
<u>PRASUGREL HYDROCHLORIDE - EFFIENT</u>						
N 022307 001	>A> 8404703	Nov 12, 2022				
	>A> 8569325	Nov 12, 2022	U-1381			
<u>PRASUGREL HYDROCHLORIDE - EFFIENT</u>						
N 022307 002	>A> 8404703	Nov 12, 2022				
	>A> 8569325	Nov 12, 2022	U-1381			
<u>PREDNISONE - RAYOS</u>						
N 202020 001	8394407	Apr 23, 2024	DP U-1362		M-128	Jul 26, 2015
<u>PREDNISONE - RAYOS</u>						
N 202020 002	8394407	Apr 23, 2024	DP U-1362		M-128	Jul 26, 2015
<u>PREDNISONE - RAYOS</u>						
N 202020 003	8394407	Apr 23, 2024	DP U-1362		M-128	Jul 26, 2015

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PREGABALIN - LYRICA</u>						
N 022488 001					I-651	Jun 20, 2015
<u>PROPOFOL - DIPRIVAN</u>						
N 019627 002	8476010	Dec 01, 2024	DS DP			
	8476010*PED	Jun 01, 2025				
<u>RABEPRAZOLE SODIUM - ACIPHEX SPRINKLE</u>						
N 204736 001	5045552	May 08, 2013	DS DP U-385		NDF	Mar 26, 2016
	5045552*PED	Nov 08, 2013			PED	Sep 26, 2016
<u>RABEPRAZOLE SODIUM - ACIPHEX SPRINKLE</u>						
N 204736 002	5045552	May 08, 2013	DS DP U-385		NDF	Mar 26, 2016
	5045552*PED	Nov 08, 2013			PED	Sep 26, 2016
<u>RADIUM RA-223 DICHLORIDE - XOFIGO</u>						
N 203971 001	6635234	Jan 03, 2020	U-1405		NCE	May 15, 2018
<u>REGADENOSON - LEXISCAN</u>						
N 022161 001	8470801	Jun 22, 2019	U-116			
	>A> 8536150	Jun 22, 2019	U-116			
<u>REGORAFENIB - STIVARGA</u>						
N 203085 001					I-667 ODE	Feb 25, 2016 Feb 25, 2020
<u>REPAGLINIDE - REPAGLINIDE</u>						
A 077571 002					PC	Jan 20, 2014
<u>REPAGLINIDE - REPAGLINIDE</u>						
A 077571 003					PC	Jan 20, 2014
<u>REPAGLINIDE - PRANDIN</u>						
N 020741 002	6677358	Jun 12, 2018	DS DP U-1265	Y		
<u>REPAGLINIDE - PRANDIN</u>						
N 020741 003	6677358	Jun 12, 2018	DP U-1265	Y		
<u>RIFAXIMIN - XIFAXAN</u>						
N 021361 001	8518949	Mar 27, 2026	DP			
<u>RIFAXIMIN - XIFAXAN</u>						
N 022554 001	8518949	Mar 27, 2026	DP			
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 001	>A> 6743798	Jul 16, 2019	DS DP		>A> NCE	Oct 08, 2018
	>A> 7173037	Apr 25, 2023	DS DP		>A> ODE	Oct 08, 2020
					>A> ODE	Oct 08, 2020
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 002	>A> 6743798	Jul 16, 2019	DS DP		>A> NCE	Oct 08, 2018
	>A> 7173037	Apr 25, 2023	DS DP		>A> ODE	Oct 08, 2020
					>A> ODE	Oct 08, 2020
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 003	>A> 6743798	Jul 16, 2019	DS DP		>A> NCE	Oct 08, 2018
	>A> 7173037	Apr 25, 2023	DS DP		>A> ODE	Oct 08, 2020
					>A> ODE	Oct 08, 2020
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 004	>A> 6743798	Jul 16, 2019	DS DP		>A> NCE	Oct 08, 2018
	>A> 7173037	Apr 25, 2023	DS DP		>A> ODE	Oct 08, 2020
					>A> ODE	Oct 08, 2020
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 005	>A> 6743798	Jul 16, 2019	DS DP		>A> NCE	Oct 08, 2018
	>A> 7173037	Apr 25, 2023	DS DP		>A> ODE	Oct 08, 2020
					>A> ODE	Oct 08, 2020
<u>RITONAVIR - NORVIR</u>						
N 022417 001	8399015	Aug 25, 2024	DP			
	8399015*PED	Feb 25, 2025				
	8470347	Sep 17, 2026	DP			
	8470347*PED	Mar 17, 2027				
<u>RIVASTIGMINE - EXELON</u>						
N 022083 005					NPP	Jun 27, 2016

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RIZATRIPTAN BENZOATE - RIZATRIPTAN BENZOATE</u>						
A 078173 001					PC	Jun 29, 2013
<u>RIZATRIPTAN BENZOATE - RIZATRIPTAN BENZOATE</u>						
A 078173 002					PC	Jun 29, 2013
<u>ROFLUMILAST - DALIRESP</u>						
N 022522 001	8431154	Feb 19, 2023	DP			
	8536206	Mar 08, 2024	U-1115			
<u>ROPIVACAINE HYDROCHLORIDE - NAROPIN</u>						
N 020533 001	5670524	Sep 23, 2014	DS DP U-833			
<u>ROPIVACAINE HYDROCHLORIDE - NAROPIN</u>						
N 020533 003	5670524	Sep 23, 2014	DS DP U-833			
<u>ROPIVACAINE HYDROCHLORIDE - NAROPIN</u>						
N 020533 004	5670524	Sep 23, 2014	DS DP U-833			
<u>ROPIVACAINE HYDROCHLORIDE - NAROPIN</u>						
N 020533 005	5670524	Sep 23, 2014	DS DP U-833			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 001	8415362	Dec 24, 2027	DS DP			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 002	8415362	Dec 24, 2027	DS DP			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 003	8415362	Dec 24, 2027	DS DP			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 004	8415362	Dec 24, 2027	DS DP			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 005	8415362	Dec 24, 2027	DS DP			
<u>SAPROPTERIN DIHYDROCHLORIDE - KUVAN</u>						
N 022181 001	8318745	Nov 17, 2024	DP			
<u>SAQUINAVIR MESYLATE - INVIRASE</u>						
N 020628 001					M-61 PED	Nov 30, 2015 May 30, 2016
<u>SAQUINAVIR MESYLATE - INVIRASE</u>						
N 021785 001					M-61 PED	Nov 30, 2015 May 30, 2016
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
N 022350 001	RE44186	Jul 31, 2023	DS DP U-995			
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
N 022350 002	RE44186	Jul 31, 2023	DS DP U-995			
<u>SERTRALINE HYDROCHLORIDE - ZOLOFT</u>						
N 020990 001	7067555	Oct 11, 2019	DP			
	7067555*PED	Apr 11, 2020				
<u>SODIUM NITRITE - SODIUM NITRITE</u>						
N 203922 001	>A> 8568793	Dec 24, 2031	DS DP			
<u>SODIUM NITRITE; SODIUM THIOSULFATE - NITHIODOTE</u>						
N 201444 001	8496973	Mar 29, 2031	DS DP U-1419			
	>A> 8568793	Dec 24, 2031	DS DP			
<u>SODIUM OXYBATE - XYREM</u>						
N 021196 001	8457988	Dec 17, 2022	U-1110			
<u>SODIUM THIOSULFATE - SODIUM THIOSULFATE</u>						
N 203923 001	8496973	Mar 29, 2031	DS DP U-1419			
<u>SUMATRIPTAN SUCCINATE - SUMAVEL DOSEPRO</u>						
N 022239 001	8343130	Oct 18, 2022	DP			
<u>SUMATRIPTAN SUCCINATE - ZECUITY</u>						
N 202278 001	6745071	Feb 21, 2023	DP		NDF	Jan 17, 2016
	7973058	Apr 12, 2027	U-1328			
	8155737	Apr 12, 2027	U-1328			
	8366600	Apr 21, 2029	U-1327			
	8470853	Apr 12, 2027	U-1328			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TACROLIMUS - ASTAGRAF XL</u>						
N 204096 001	6440458	Mar 25, 2019	DP		NDF	Jul 19, 2016
	6576259	Mar 25, 2019	DP U-1420			
	6884433	Mar 25, 2019	DP U-1420			
	>A> 8551522	Mar 25, 2019	DP			
<u>TACROLIMUS - ASTAGRAF XL</u>						
N 204096 002	6440458	Mar 25, 2019	DP		NDF	Jul 19, 2016
	6576259	Mar 25, 2019	DP U-1420			
	6884433	Mar 25, 2019	DP U-1420			
	>A> 8551522	Mar 25, 2019	DP			
<u>TACROLIMUS - ASTAGRAF XL</u>						
N 204096 003	6440458	Mar 25, 2019	DP		NDF	Jul 19, 2016
	6576259	Mar 25, 2019	DP U-1420			
	6884433	Mar 25, 2019	DP U-1420			
	>A> 8551522	Mar 25, 2019	DP			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 001	8114383	Oct 10, 2024	DP	Y		
	8420056	Nov 20, 2023	DP			
	8536130	Sep 22, 2028	U-1276			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 002	8114383	Oct 10, 2024	DP	Y		
	8420056	Nov 20, 2023	DP			
	8536130	Sep 22, 2028	U-1276			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 003	8114383	Oct 10, 2024	DP	Y		
	8420056	Nov 20, 2023	DP			
	8536130	Sep 22, 2028	U-1276			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 004	8114383	Oct 10, 2024	DP	Y		
	8420056	Nov 20, 2023	DP			
	8536130	Sep 22, 2028	U-1276			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 005	8114383	Oct 10, 2024	DP	Y		
	8420056	Nov 20, 2023	DP			
	8536130	Sep 22, 2028	U-1276			
<u>TECHNETIUM TC-99M TILMANOCEPT - LYMPHOSEEK KIT</u>						
N 202207 001					NCE	Mar 13, 2018
<u>TEDUGLUTIDE RECOMBINANT - GATTEX KIT</u>						
N 203441 001	5789379	Apr 14, 2015	DS DP U-1320		ODE	Dec 21, 2019
	7056886	Sep 18, 2022	DP U-1320			
	7847061	Nov 01, 2025	U-1320			
<u>TELAPREVIR - INCIVEK</u>						
N 201917 001	8431615	May 30, 2028	U-1398			
	8529882	Aug 31, 2021	U-1398			
<u>TELAVANCIN HYDROCHLORIDE - VIBATIV</u>						
N 022110 001	6635618	Sep 11, 2023	DS DP U-728		I-673	Jun 21, 2016
<u>TELAVANCIN HYDROCHLORIDE - VIBATIV</u>						
N 022110 002	6635618	Sep 11, 2023	DS DP U-728		I-673	Jun 21, 2016
<u>TELBIVUDINE - TYZEKA</u>						
N 022011 001					M-124	Jan 28, 2016
<u>TELBIVUDINE - TYZEKA</u>						
N 022154 001					M-124	Jan 28, 2016
<u>TEMSIROLIMUS - TORISEL</u>						
N 022088 001	8455539	Jul 25, 2023	DP			
	8455539*PED	Jan 25, 2024				
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N 021356 001					M-128	Jul 24, 2016
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N 021356 002					M-128	Jul 24, 2016

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N 021356 003					M-128	Jul 24, 2016
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N 021356 004					M-128	Jul 24, 2016
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N 022577 001					M-128	Jul 24, 2016
<u>TERIFLUNOMIDE - AUBAGIO</u>						
N 202992 001	6794410	Apr 15, 2022	U-1285			
<u>TERIFLUNOMIDE - AUBAGIO</u>						
N 202992 002	6794410	Apr 15, 2022	U-1285			
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 001	8466136	Oct 12, 2026	DP			
	8466137	Oct 12, 2026	U-1103			
	8466138	Oct 12, 2026	U-1103			
	8486925	Oct 12, 2026	DP			
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 002	8466136	Oct 12, 2026	DP			
	8466137	Oct 12, 2026	U-1103			
	8466138	Oct 12, 2026	U-1103			
	8486925	Oct 12, 2026	DP			
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 003	8466136	Oct 12, 2026	DP			
	8466137	Oct 12, 2026	U-1103			
	8466138	Oct 12, 2026	U-1103			
	8486925	Oct 12, 2026	DP			
<u>TESTOSTERONE - AXIRON</u>						
N 022504 001	8419307	Feb 26, 2027	U-1386			
	8435944	Jul 05, 2027	U-1390			
<u>TESTOSTERONE - TESTOSTERONE</u>						
N 203098 001					NP	Jan 31, 2016
<u>TESTOSTERONE - TESTOSTERONE</u>						
N 203098 002					NP	Jan 31, 2016
<u>TESTOSTERONE - TESTOSTERONE</u>						
N 203098 003					NP	Jan 31, 2016
<u>TICAGRELOR - BRILINTA</u>						
N 022433 001	8425934	Dec 18, 2029	DP			
<u>TIGECYCLINE - TYGACIL</u>						
N 021821 001	8372995	Oct 08, 2030	DP			
<u>TIMOLOL MALEATE - ISTALOL</u>						
N 021516 001	6645963	Nov 02, 2018	DP			
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N 020912 001	>A> 6770660	May 01, 2023				
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N 020913 001	>A> 6770660	Jun 01, 2023				
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N 020913 002	>A> 6770660	Jun 01, 2023				
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N 020913 003	>A> 6770660	Jun 01, 2023				
<u>TOBRAMYCIN - TOBI PODHALER</u>						
N 201688 001	7097827	Apr 16, 2016	DP		NP	Mar 22, 2016
	7368102	Dec 19, 2022	DP U-909			
	7442388	May 10, 2020	DP			
	7516741	Jan 11, 2024	DP			
	7559325	Oct 27, 2025	DP			
	8069851	Sep 24, 2024	DP			
	8349294	May 10, 2020	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TOBRAMYCIN - BETHKIS</u>						
N 201820 001	6987094	Sep 22, 2022	DP			
	7696178	Mar 17, 2023	DP			
	7939502	Jun 14, 2022	U-1324			
<u>TOLTERODINE TARTRATE - DETROL LA</u>						
N 021228 001	6911217	Nov 11, 2019	DP U-544			
	6911217*PED	May 11, 2020				
<u>TOLTERODINE TARTRATE - DETROL LA</u>						
N 021228 002	6911217	Nov 11, 2019	DP U-544			
	6911217*PED	May 11, 2020				
<u>TOLVAPTAN - SAMSCA</u>						
N 022275 001	5258510	Nov 02, 2013	DS DP			
	8501730	Sep 01, 2026	DS			
<u>TOLVAPTAN - SAMSCA</u>						
N 022275 002	5258510	Nov 02, 2013	DS DP			
	8501730	Sep 01, 2026	DS			
<u>TOLVAPTAN - SAMSCA</u>						
N 022275 003	5258510	Nov 02, 2013	DS DP			
	8501730	Sep 01, 2026	DS			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 001	8298576	Mar 18, 2029	DP U-106			
	8298580	Nov 16, 2027	DP U-106			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 002	8298576	Mar 18, 2029	DP U-106			
	8298580	Nov 16, 2027	DP U-106			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 003	8298576	Mar 18, 2029	DP U-106			
	8298580	Nov 16, 2027	DP U-106			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 004	8298576	Mar 18, 2029	DP U-106			
	8298580	Nov 16, 2027	DP U-106			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 001	7378423	Sep 13, 2025	DS DP		NCE ODE	May 29, 2018 May 29, 2020
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 002	7378423	Sep 13, 2025	DS DP		NCE ODE	May 29, 2018 May 29, 2020
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 003	7378423	Sep 13, 2025	DS DP		NCE ODE	May 29, 2018 May 29, 2020
<u>TRANEXAMIC ACID - TRANEXAMIC ACID</u>						
A 202093 001					PC	Jul 02, 2013
<u>TRANEXAMIC ACID - LYSTEDA</u>						
N 022430 001	8487005	Mar 04, 2025	DP U-1182			
<u>TRAVOPROST - TRAVATAN Z</u>						
N 021994 001	8388941	Sep 20, 2027	DP			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 001	7999007	Mar 29, 2029	DP U-1437			
	8497393	Dec 15, 2028	DS			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 002	7999007	Mar 29, 2029	DP U-1437			
	8497393	Dec 15, 2028	DS			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 003	7999007	Mar 29, 2029	DP U-1437			
	8497393	Dec 15, 2028	DS			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 004	7999007	Mar 29, 2029	DP U-1437			
	8497393	Dec 15, 2028	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TREPROSTINIL - TYVASO</u>						
N 022387 001	8497393	Dec 15, 2028	DS			
<u>TROSPIMUM CHLORIDE - TROSPIMUM CHLORIDE</u>						
A 091289 001					PC	Apr 10, 2013
<u>ULIPRISTAL ACETATE - ELLA</u>						
N 022474 001	8426392	Jun 12, 2030	U-1389			
	8512745	Feb 14, 2030	DP			
<u>UNOPROSTONE ISOPROPYL - RESCULA</u>						
N 021214 001	6770675	Nov 24, 2018	DP U-1322			
<u>VEMURAFENIB - ZELBORAF</u>						
N 202429 001	8470818	Aug 02, 2026	U-1418			
<u>VIGABATRIN - SABRIL</u>						
N 020427 001					NCE PED	Aug 21, 2014 Feb 21, 2015
<u>VIGABATRIN - SABRIL</u>						
N 022006 001					NCE ODE PED PED	Aug 21, 2014 Aug 21, 2016 Feb 21, 2015 Feb 21, 2017
<u>VORICONAZOLE - VORICONAZOLE</u>						
A 202361 001					PC	Mar 24, 2014
<u>VORINOSTAT - ZOLINZA</u>						
N 021991 001	>A> RE38506	Jul 07, 2015	DS DP			
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 001	7144884	Jan 09, 2023	DS DP U-1439		NCE	Sep 30, 2018
	8476279	Oct 02, 2022	DP U-1439			
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 002	7144884	Jan 09, 2023	DS DP U-1439		NCE	Sep 30, 2018
	8476279	Oct 02, 2022	DP U-1439			
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 003	7144884	Jan 09, 2023	DS DP U-1439		NCE	Sep 30, 2018
	8476279	Oct 02, 2022	DP U-1439			
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 004	7144884	Jan 09, 2023	DS DP U-1439		NCE	Sep 30, 2018
	8476279	Oct 02, 2022	DP U-1439			
<u>ZOLEDRONIC ACID - RECLAST</u>						
N 021817 001	8052987	Oct 27, 2023	U-1199			
<u>ZOLPIDEM TARTRATE - EDLUAR</u>						
N 021997 001	8512747	Sep 24, 2019	U-674			
<u>ZOLPIDEM TARTRATE - EDLUAR</u>						
N 021997 002	8512747	Sep 24, 2019	U-674			

Footnote:

1. Patents are published upon receipt by the Orange book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).

2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 33rd Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at
<http://www.accessdata.fda.gov/scripts/cder/ob/docs/pattermsall.cfm>

The current complete list of patent terms is available at
<http://www.accessdata.fda.gov/scripts/cder/ob/docs/excltermsall.cfm>